<SEC-DOCUMENT>0001615219-23-000038.txt : 20230511
<SEC-HEADER>0001615219-23-000038.hdr.sgml : 20230511
<ACCEPTANCE-DATETIME>20230511082959
ACCESSION NUMBER:		0001615219-23-000038
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		44
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230511
DATE AS OF CHANGE:		20230511

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Salarius Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001615219
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				465087339
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36812
		FILM NUMBER:		23909001

	BUSINESS ADDRESS:	
		STREET 1:		2450 HOLCOMBE BLVD
		STREET 2:		SUITE J-608
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77021
		BUSINESS PHONE:		346-772-0346

	MAIL ADDRESS:	
		STREET 1:		2450 HOLCOMBE BLVD
		STREET 2:		SUITE J-608
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Flex Pharma, Inc.
		DATE OF NAME CHANGE:	20140730
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>flks-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:3bcb0391-ae28-4064-946d-9955ab3b15fb,g:a3263b3f-ee17-40f5-9314-e2273145249f,d:db19952ac17e43b5923fbedddc424393--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:flks="http://www.flex-pharma.com/20230331" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>flks-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180L2ZyYWc6M2M5ZTQ3YjRmZTE2NGM4ZTg1MDMwYWQ4NWU5MmY0YWYvdGFibGU6YWU3NGQyZTFmODI3NDAxM2JhZTQwNWI3MjI1Mjk5YWEvdGFibGVyYW5nZTphZTc0ZDJlMWY4Mjc0MDEzYmFlNDA1YjcyMjUyOTlhYV80LTEtMS0xLTM2ODI1_4af6c2fc-a492-421c-bb1c-f39b98492939">0001615219</ix:nonNumeric><ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180L2ZyYWc6M2M5ZTQ3YjRmZTE2NGM4ZTg1MDMwYWQ4NWU5MmY0YWYvdGFibGU6YWU3NGQyZTFmODI3NDAxM2JhZTQwNWI3MjI1Mjk5YWEvdGFibGVyYW5nZTphZTc0ZDJlMWY4Mjc0MDEzYmFlNDA1YjcyMjUyOTlhYV81LTEtMS0xLTM2ODI1_0eda17e0-f290-492c-beee-02a700a05df7">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180L2ZyYWc6M2M5ZTQ3YjRmZTE2NGM4ZTg1MDMwYWQ4NWU5MmY0YWYvdGFibGU6YWU3NGQyZTFmODI3NDAxM2JhZTQwNWI3MjI1Mjk5YWEvdGFibGVyYW5nZTphZTc0ZDJlMWY4Mjc0MDEzYmFlNDA1YjcyMjUyOTlhYV84LTEtMS0xLTM2ODI1_2c7372de-39dc-4304-9bb3-3d25b768f941">2023</ix:nonNumeric><ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180L2ZyYWc6M2M5ZTQ3YjRmZTE2NGM4ZTg1MDMwYWQ4NWU5MmY0YWYvdGFibGU6YWU3NGQyZTFmODI3NDAxM2JhZTQwNWI3MjI1Mjk5YWEvdGFibGVyYW5nZTphZTc0ZDJlMWY4Mjc0MDEzYmFlNDA1YjcyMjUyOTlhYV85LTEtMS0xLTM2ODI1_96103c31-47cc-4b11-9021-835d9286338f">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180L2ZyYWc6M2M5ZTQ3YjRmZTE2NGM4ZTg1MDMwYWQ4NWU5MmY0YWYvdGFibGU6YWU3NGQyZTFmODI3NDAxM2JhZTQwNWI3MjI1Mjk5YWEvdGFibGVyYW5nZTphZTc0ZDJlMWY4Mjc0MDEzYmFlNDA1YjcyMjUyOTlhYV8xMC0xLTEtMS0zNjgyNQ_8a5e7984-febb-4f1e-97f8-139d8c046960">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfMy0wLTEtMS0zNjgyNQ_4b3d7717-e9ff-4348-887b-6722ded66434">http://fasb.org/us-gaap/2022#GrantMember</ix:nonNumeric><ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfMy0wLTEtMS0zNjgyNQ_6fcee171-08bd-4be6-be8b-a55dbaaf7bed">http://fasb.org/us-gaap/2022#GrantMember</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="iebbb26c017234bd7878b9c40342ac167_D20221014-20221014" decimals="2" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M184NTgvZnJhZzo4NGU4ZjhkNGFhOTI0YzRmYTBiNjBhN2I0MjU1MjI4Mi90YWJsZTo2NjNhMjNhN2JlOTI0OWE1ODFjNjA2MTA2YWE0ZTEzMy90YWJsZXJhbmdlOjY2M2EyM2E3YmU5MjQ5YTU4MWM2MDYxMDZhYTRlMTMzXzAtMS0xLTEtMzg5MzY_c7134f6f-cc33-46fb-8be2-4b4cc0c7b67a">0.04</ix:nonFraction><ix:nonNumeric contextRef="i222ce181634a4cce9e9e36ac4ca82e0f_I20220430" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M181OC9mcmFnOmI0NjdiMTY2YzQ1ZjQ2OTNiOWQ5ODYzZWVkNDI2YjI1L3RhYmxlOjFlOTQ3YjNjMDI5MzQ2NWFiYzBmMGIwOTE1NzRmYjViL3RhYmxlcmFuZ2U6MWU5NDdiM2MwMjkzNDY1YWJjMGYwYjA5MTU3NGZiNWJfMS0xLTEtMS0zNjgyNQ_4880c436-ba91-4a2e-9728-b882c6b2d9b1">5.5</ix:nonNumeric><ix:nonNumeric contextRef="ic371e0e769f84d71a5a8b6aca305b5b2_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfODI0NjMzNzIxMTc2Ng_92999dea-8fe6-44eb-b277-ca85e4d4df2d">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="ie7eaf576725847c490d0015dcd98067e_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfMTAyMQ_c80ce869-a2e6-4296-953f-d1a3e4d42122">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="flks-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c058905dd194d4e8196eb0ec2edca27_I20230505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i21d8870425a246ecaa7e4fe2677a54c4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i99580c61c8454190b396ed58334ece96_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bb28550232b40a6a710d558583695ab_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5a306ceedd2446d93819bfd4e8afbe8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bd45e30d3c0413c9f0cdd01c63fbe3a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i182fe90a35fa46a4bee4ab0ee69ad6c0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55a4dc73d8734260b84dd299d02b0bea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9aac0bd35674eb4b2fe9319ccc12b17_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecc8902a9a25417493c9a87bcde49e28_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie373d68e8a8744798cfdbc196f59d0be_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafffc62468c54cae91120ea9c81a1bd5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4db7a89251f499c92610b04658dc2ae_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie574cf86bfc040409286776e93e62abd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6abf49e74f3942af9362b2fc6b6e5ee0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ideb363b95bd54426b36e8a3e499e28b9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7787220731c9412bb479d54b491fd7eb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib594d10fbc6146ba8590e1d37595ffc7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibca39c224c4d4c48a68e09a78c6cc957_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf6f50e29050415c8e6980f25eeba947_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i867fe0652a284dfa8c10e8eea406a8db_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80002a83141a4ef6a0ff3d67ce2967b1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf1223a5e90f40a8b60ebbab5dbe9e78_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c04e18316394009b6153f59ba41f585_D20230404-20230511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">flks:SalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-04</xbrli:startDate><xbrli:endDate>2023-05-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib514cd02604141cba330abbb11971983_I20221014"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-10-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a151b2cc8444c79aee3f783063d9279_D20220112-20220112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-12</xbrli:startDate><xbrli:endDate>2022-01-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6b59e45b64342c89f3426880dc1103d_D20220112-20220112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-12</xbrli:startDate><xbrli:endDate>2022-01-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebbb26c017234bd7878b9c40342ac167_D20221014-20221014"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-14</xbrli:startDate><xbrli:endDate>2022-10-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i939615b57778416faf3eff53296b4db2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if54e5126787f42138fb230f8a7f23b49_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib62a51e0853048ae9069dab610776a5d_I20111231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">flks:UniversityOfUtahResearchFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2011-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a9d75c4f5bd48619d14c8ca1830a6c9_D20160601-20160630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2016-06-01</xbrli:startDate><xbrli:endDate>2016-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e86d1fdb89f494eb9ee243d58ff09cd_D20160701-20160701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2016-07-01</xbrli:startDate><xbrli:endDate>2016-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f25028dab374645ab8bd704715c06ac_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">flks:SalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0609f51e976346d69581a350de826fe9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i750c9de36c044f428d626093ca2e218b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i222ce181634a4cce9e9e36ac4ca82e0f_I20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib762f099224741f2a7a409f28e07d108_I20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">flks:PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4da1d17c34948158531999f1b199116_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">flks:EquityIncentivePlan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i057e962232c1423ba944409a49a5dbbe_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">flks:EmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i571227b74c3343649a8d063d182cb2fc_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">flks:OfficersAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0508e6c8ee6f431281f539250baa1ab9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">flks:RestrictedStockAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic371e0e769f84d71a5a8b6aca305b5b2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">flks:RestrictedStockAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ae8b02bb35841958964d4e4837cd194_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">flks:RestrictedStockAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7eaf576725847c490d0015dcd98067e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i576cab9bf4214c329f021a9b27484527_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15eb79ec74594262ac1ee2bbbcb2dc8b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63818b7d4b4049b2b5649dd59933606d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ca10793f84f44ba8ea25c255a1b8295_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8708a10429e4617bd4cd3efa5411eee_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f0d7863d02d4527b559355b990c8aac_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25aebc31ca484ab3b3cbb46087a9333b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="idb19952ac17e43b5923fbedddc424393_1"></div><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_7">Table of Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGV4dHJlZ2lvbjo3YTg1YWIwY2M4ZTA0MjE5YWY4MGU3NjFhOWM0YTI5ZV8xOTI2_c6caf845-871d-4ca8-b34f-cbb7aeb74f20">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Mark&#160;One)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGFibGU6MGMxOWQyYmNhMTUzNGY5YTlkMmFkMmFkOGFmOTk3NmIvdGFibGVyYW5nZTowYzE5ZDJiY2ExNTM0ZjlhOWQyYWQyYWQ4YWY5OTc2Yl8xLTAtMS0xLTM2ODI1_fdedb851-a63f-42f1-93ad-56adf074d228">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR&#160;15(d)&#160;OF&#160;THE SECURITIES&#160;EXCHANGE ACT OF&#160;1934</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the quarterly period ended <ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGFibGU6MGMxOWQyYmNhMTUzNGY5YTlkMmFkMmFkOGFmOTk3NmIvdGFibGVyYW5nZTowYzE5ZDJiY2ExNTM0ZjlhOWQyYWQyYWQ4YWY5OTc2Yl8yLTAtMS0xLTM2ODI1L3RleHRyZWdpb246YTJjNmU1NGEzY2FjNDM1N2IwODU5MmQ4NzdiM2E1ZmZfMzU_a2a612c1-f258-4040-ab03-4cb891251524">March&#160;31, 2023</ix:nonNumeric></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">OR</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGFibGU6MGMxOWQyYmNhMTUzNGY5YTlkMmFkMmFkOGFmOTk3NmIvdGFibGVyYW5nZTowYzE5ZDJiY2ExNTM0ZjlhOWQyYWQyYWQ4YWY5OTc2Yl80LTAtMS0xLTM2ODI1_d2681490-3a84-411e-9a4f-7bee0d0e7baa">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR&#160;15(d)&#160;OF&#160;THE SECURITIES&#160;EXCHANGE ACT OF&#160;1934</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Transition Period from      to</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGV4dHJlZ2lvbjo3YTg1YWIwY2M4ZTA0MjE5YWY4MGU3NjFhOWM0YTI5ZV8xMTY_50c6119a-1739-45cf-89b7-8bcd4b38be57">001-36812</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGV4dHJlZ2lvbjo3YTg1YWIwY2M4ZTA0MjE5YWY4MGU3NjFhOWM0YTI5ZV8xMjA_160dfe47-0bf6-4002-aeb9-98e9878b56b1">SALARIUS PHARMACEUTICALS,&#160;INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"><tr><td style="width:1.0%"></td><td style="width:15.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.499%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.323%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGFibGU6MmVhNWUyODNjZWYyNDZlYWFjMzMzNWI5MjgxYWU3YTMvdGFibGVyYW5nZToyZWE1ZTI4M2NlZjI0NmVhYWMzMzM1YjkyODFhZTdhM18wLTEtMS0xLTM2ODI1_b022c420-25a4-4771-a76c-64f60c4833fb">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGFibGU6MmVhNWUyODNjZWYyNDZlYWFjMzMzNWI5MjgxYWU3YTMvdGFibGVyYW5nZToyZWE1ZTI4M2NlZjI0NmVhYWMzMzM1YjkyODFhZTdhM18wLTMtMS0xLTM2ODI1_e438d119-0f43-4250-87bc-07f901a491f2">46-5087339</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Identification Number)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGV4dHJlZ2lvbjo3YTg1YWIwY2M4ZTA0MjE5YWY4MGU3NjFhOWM0YTI5ZV8xODA_81af9d38-e6ae-4cd2-a72f-a66f3deb6941">2450 Holcombe Blvd</ix:nonNumeric>., <ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGV4dHJlZ2lvbjo3YTg1YWIwY2M4ZTA0MjE5YWY4MGU3NjFhOWM0YTI5ZV8xOTI4_532e09de-1fd2-408c-9b42-60c795a7af12">Suite X</ix:nonNumeric>, <ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGV4dHJlZ2lvbjo3YTg1YWIwY2M4ZTA0MjE5YWY4MGU3NjFhOWM0YTI5ZV8xOTQ_e02bf3d5-27df-4526-aa61-33c64426bd9d">Houston</ix:nonNumeric>, <ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGV4dHJlZ2lvbjo3YTg1YWIwY2M4ZTA0MjE5YWY4MGU3NjFhOWM0YTI5ZV8xOTg_48ac46c8-1237-4bff-b147-0e774d89fb43">TX</ix:nonNumeric> <ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGV4dHJlZ2lvbjo3YTg1YWIwY2M4ZTA0MjE5YWY4MGU3NjFhOWM0YTI5ZV8yMDE_7f20c9e6-8594-4885-b9e5-2dad974917a3">77021</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(Address of principal executive offices)(Zip Code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGV4dHJlZ2lvbjo3YTg1YWIwY2M4ZTA0MjE5YWY4MGU3NjFhOWM0YTI5ZV8yNTg_0898c24c-43e2-4ad0-b128-62c5c452a0bd">832</ix:nonNumeric>)<ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGV4dHJlZ2lvbjo3YTg1YWIwY2M4ZTA0MjE5YWY4MGU3NjFhOWM0YTI5ZV8xOTI5_8bd98203-9a44-42eb-9491-4d0e3c29ca60">804-9144</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Registrant's telephone number, including area code</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(Former name, former address and former fiscal year, If changed since last report)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.479%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:13.5pt"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.914%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.772%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGFibGU6NDM3YzRjMjk4YmE4NDhlYWE0ZDA0ZmVmMWFjYmE1ZmUvdGFibGVyYW5nZTo0MzdjNGMyOThiYTg0OGVhYTRkMDRmZWYxYWNiYTVmZV8xLTAtMS0xLTM2ODI1_ba472e46-4401-454d-880f-6f7c1a86b1e7">Common Stock, $0.0001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGFibGU6NDM3YzRjMjk4YmE4NDhlYWE0ZDA0ZmVmMWFjYmE1ZmUvdGFibGVyYW5nZTo0MzdjNGMyOThiYTg0OGVhYTRkMDRmZWYxYWNiYTVmZV8xLTItMS0xLTM2ODI1_37af43a8-d793-4d32-8681-f8f4b34aa7dd">SLRX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGFibGU6NDM3YzRjMjk4YmE4NDhlYWE0ZDA0ZmVmMWFjYmE1ZmUvdGFibGVyYW5nZTo0MzdjNGMyOThiYTg0OGVhYTRkMDRmZWYxYWNiYTVmZV8xLTQtMS0xLTM2ODI1_c979b05d-342f-48c6-81d0-f03c6412c999">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to the filing requirements for the past 90&#160;days.&#160;<ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGV4dHJlZ2lvbjo3YTg1YWIwY2M4ZTA0MjE5YWY4MGU3NjFhOWM0YTI5ZV84MTI_ad9c2dd6-4a13-4ec6-8a7f-e785499c208a">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;&#160;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;<ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGV4dHJlZ2lvbjo3YTg1YWIwY2M4ZTA0MjE5YWY4MGU3NjFhOWM0YTI5ZV8xMTMy_ce087016-8f18-4ccf-94c0-c63a414309b5">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:16.156%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.336%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.159%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.221%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.298%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Large Accelerated Filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated Filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGFibGU6NjJhNjM5ZjUzOGE3NGRjMThjMjJkNGU0YjAzMzBkZTEvdGFibGVyYW5nZTo2MmE2MzlmNTM4YTc0ZGMxOGMyMmQ0ZTRiMDMzMGRlMV8wLTQtMS0xLTM2ODI1_e8df8803-e848-4624-ba79-c83ca08b6136">Non-accelerated Filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller Reporting Company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGFibGU6NjJhNjM5ZjUzOGE3NGRjMThjMjJkNGU0YjAzMzBkZTEvdGFibGVyYW5nZTo2MmE2MzlmNTM4YTc0ZGMxOGMyMmQ0ZTRiMDMzMGRlMV8wLTctMS0xLTM2ODI1_86a97d90-42d6-4822-bbb5-ddbdeb07c4d7">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Emerging Growth Company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGFibGU6NjJhNjM5ZjUzOGE3NGRjMThjMjJkNGU0YjAzMzBkZTEvdGFibGVyYW5nZTo2MmE2MzlmNTM4YTc0ZGMxOGMyMmQ0ZTRiMDMzMGRlMV8wLTktMS0xLTM2ODI1_ac73ea01-c59e-45dc-8323-e8a083503f74">&#9744;</ix:nonNumeric></span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act.)&#160;Yes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGV4dHJlZ2lvbjo3YTg1YWIwY2M4ZTA0MjE5YWY4MGU3NjFhOWM0YTI5ZV8xODU2_e3048810-49fa-4e48-b6f9-7b1f8e5e7aa0">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">As of May&#160;5, 2023, there were  <ix:nonFraction unitRef="shares" contextRef="i7c058905dd194d4e8196eb0ec2edca27_I20230505" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGV4dHJlZ2lvbjo3YTg1YWIwY2M4ZTA0MjE5YWY4MGU3NjFhOWM0YTI5ZV8xODg3_f04097d5-ae3d-4b9e-bdba-12dd665f7b2f">2,491,428</ix:nonFraction>  shares of common stock outstanding.</span></div><div style="margin-bottom:3pt;margin-top:3pt"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt"><span><br/></span></div><div style="height:22.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="idb19952ac17e43b5923fbedddc424393_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SALARIUS PHARMACEUTICALS,&#160;INC.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.855%"><tr><td style="width:1.0%"></td><td style="width:12.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.287%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:17pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_13">PART I. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_13">Financial Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_16">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_13">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_16">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_19">Condensed </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_19">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_19">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_22">Condensed </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_22">Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_22">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_25">Condensed </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_25">Consolidated Statements of Cash Flows </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_25">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_28">Condensed </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_28">Consolidated Statement</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_28">s</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_28"> of Stockholders' Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_28">8</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_31">Notes to</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_31"> Condensed </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_31">Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_31">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_70">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_70">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_70">17</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_79">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_79">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_79">20</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_82">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_82">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_82">21</a></span></div></td></tr><tr style="height:17pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_85">PART II.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_85">Other Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_88">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_88">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_88">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_91">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_91">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_91">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_94">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_94">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_94">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_97">SIGNATURES</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_97">23</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="idb19952ac17e43b5923fbedddc424393_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Various statements made in this Quarterly Report on Form 10-Q are forward-looking and involve risks and uncertainties. All statements that address activities, events or developments that we intend, expect or believe may occur in the future are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements give our current expectations or forecasts of future events and are not statements of historical or current facts. These statements include, among others, statements about:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:13.8pt">the Company's ability to continue as a going concern and its ability to obtain additional capital to support its operations beyond the fourth quarter of 2023;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the Company's planned strategy; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">the Company's clinical trials, including expected costs, goals, timing and other expectations related thereto; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">the potential advantages of its lead compound, seclidemstat or SP-2577, as a treatment for Ewing sarcoma, and other cancers and its ability to improve the life of patients;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">the potential for seclidemstat to target the epigenetic dysregulation underlying Ewing sarcoma and advanced solid tumors; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:13.8pt">the future of the company&#8217;s Phase 1/2 trial of seclidemstat as a treatment for Ewing sarcoma and FET-rearranged sarcomas following the FDA's conclusion that the clinical trial may be resumed;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">the potential advantages of protein degraders including the value of SP-3164 as a cancer treatment; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">the expected impact that the addition of new clinical sites will have on the development of the Company&#8217;s product candidates; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">the commercial or market opportunity and expansion for each therapeutic option, including the availability and value of a pediatric priority review voucher for in-clinic treatments and potential for accelerated approval;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">the Company&#8217;s expectations as to revenue, cash flow, and expenses; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">the Company's liquidity position, the expected sufficiency of such position to support anticipated operating and capital requirements; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">the ability of the Company to access additional financing under the Cancer Research Grant Contract with Cancer Prevention and Research Institute of Texas ("CPRIT").</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Forward-looking statements also include statements other than statements of current or historical fact, including, without limitation, all statements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">related to any expectations of revenues, expenses, cash flows, earnings or losses from operations, cash required to maintain current and planned operations, capital or other financial items; any statements of the plans, strategies and objectives of management for future operations; any plans or expectations with respect to product research, development and commercialization, including regulatory approvals; any other statements of expectations, plans, intentions or beliefs; and any statements of assumptions underlying any of the foregoing. We often, although not always, identify forward-looking statements by using words or phrases such as &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;expect,&#8221; &#8220;indicate,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;would,&#8221;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;target&#8221;,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;potential,&#8221; &#8220;evaluate,&#8221; &#8220;proceeding.&#8221;</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following are some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:13.8pt">Our ability to raise additional capital;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to resume enrollment in the Phase 1/2 trial of seclidemstat following the clinical trial hold is removed; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">the effectiveness and timeliness of our preclinical studies and clinical trials, and the usefulness of the data;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">the adequacy of our capital to support our future operations and our ability to successfully initiate and complete clinical trials and regulatory submissions; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">fluctuations in our operating results;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">the success of current and future license and collaboration agreements;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">our dependence on contract research organizations, vendors and investigators;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">effects of competition and other developments affecting development of products;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">market acceptance of our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">protection of intellectual property and avoiding intellectual property infringement;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">product liability; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">other factors described in our filings with the SEC. </span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. The risks set forth under Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, describe major risks to our business, and you should read and interpret any forward-looking statements together with these risks. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="idb19952ac17e43b5923fbedddc424393_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I - FINANCIAL INFORMATION</span></div><div style="text-align:center"><span><br/></span></div><div id="idb19952ac17e43b5923fbedddc424393_16"></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td></tr></table></div><div><span><br/></span></div><div id="idb19952ac17e43b5923fbedddc424393_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SALARIUS PHARMACEUTICALS,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3/31/2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Audited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfNC0xLTEtMS0zNjgyNQ_0dcaf4b5-148b-4076-a8b2-2550c1126e46">9,273,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99580c61c8454190b396ed58334ece96_I20221231" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfNC0zLTEtMS0zNjgyNQ_7b23a26e-f56e-4a32-ae56-2d34b31f9932">12,106,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Grants receivable from CPRIT</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331" decimals="0" name="us-gaap:GrantsReceivableCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfNi0xLTEtMS0zODM2MQ_06186e9e-8df1-4be6-90b0-06b0b86d16b9">130,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99580c61c8454190b396ed58334ece96_I20221231" decimals="0" name="us-gaap:GrantsReceivableCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfNi0zLTEtMS0zODM2NQ_9ba3029d-9d03-43e5-8a12-961b4144bb0d">1,610,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfNi0xLTEtMS0zNjgyNQ_3c60b26b-ae59-40b2-902d-b705dab116bf">536,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99580c61c8454190b396ed58334ece96_I20221231" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfNi0zLTEtMS0zNjgyNQ_00e059ac-0c4d-4f33-a9d5-9af6b3ca1c7a">803,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfNy0xLTEtMS0zNjgyNQ_73acb16a-6412-467a-a289-b30bb2316ead">9,940,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99580c61c8454190b396ed58334ece96_I20221231" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfNy0zLTEtMS0zNjgyNQ_1be66ffc-1402-46a8-8904-f60a4d72830e">14,520,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfOS0xLTEtMS0zNjgyNQ_20634ca1-bbb4-4717-95e0-f2b6e83d7ab1">114,852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99580c61c8454190b396ed58334ece96_I20221231" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfOS0zLTEtMS0zNjgyNQ_f281ebe4-732d-4b91-9a1a-4478ada11e21">130,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMTEtMS0xLTEtMzY4MjU_b9a46feb-36c5-4f41-9bee-c6f977608903">10,055,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99580c61c8454190b396ed58334ece96_I20221231" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMTEtMy0xLTEtMzY4MjU_725e933e-271e-4840-8954-9c8d61cae9bf">14,650,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders' equity </span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331" decimals="0" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMTQtMS0xLTEtMzY4MjU_9f9d0fb4-5f28-4844-a63c-f9c3ceb0e94b">3,510,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99580c61c8454190b396ed58334ece96_I20221231" decimals="0" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMTQtMy0xLTEtMzY4MjU_632afad3-c422-4369-8e03-5b3c82a64299">2,858,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331" decimals="0" name="flks:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMTUtMS0xLTEtMzY4MjU_f67e04a0-251a-4079-8d62-693ca2b267ef">985,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99580c61c8454190b396ed58334ece96_I20221231" decimals="0" name="flks:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMTUtMy0xLTEtMzY4MjU_58a28c27-851e-48e9-92bf-be0b5c73fc86">1,407,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMTgtMS0xLTEtMzY4MjU_084a1487-0d47-441a-b9e5-ec5c7f458ece">4,496,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99580c61c8454190b396ed58334ece96_I20221231" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMTgtMy0xLTEtMzY4MjU_40c2b79a-0afd-468e-8e30-76e840d899bd">4,266,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 5)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjItMS0xLTEtMzY4MjU_88e348a7-837f-41d4-996b-c6aae0540e1a"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i99580c61c8454190b396ed58334ece96_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjItMy0xLTEtMzY4MjU_078ac024-032a-498c-a370-5c85f7e75187"></ix:nonFraction></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i99580c61c8454190b396ed58334ece96_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjUtMC0xLTEtMzY4MjUvdGV4dHJlZ2lvbjphZDUwYzdiMzg2ZjQ0Y2I2YmZmNjRiNTdkYTQyODhhZF8yMQ_69abaf8c-ae4a-4152-ac89-876ef52f0acd"><ix:nonFraction unitRef="usdPerShare" contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjUtMC0xLTEtMzY4MjUvdGV4dHJlZ2lvbjphZDUwYzdiMzg2ZjQ0Y2I2YmZmNjRiNTdkYTQyODhhZF8yMQ_ecb37091-ae89-4701-94f7-e89172d9f53e">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjUtMC0xLTEtMzY4MjUvdGV4dHJlZ2lvbjphZDUwYzdiMzg2ZjQ0Y2I2YmZmNjRiNTdkYTQyODhhZF8zNQ_0100eb51-d0c7-4544-88fb-3dc4e0718f9f"><ix:nonFraction unitRef="shares" contextRef="i99580c61c8454190b396ed58334ece96_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjUtMC0xLTEtMzY4MjUvdGV4dHJlZ2lvbjphZDUwYzdiMzg2ZjQ0Y2I2YmZmNjRiNTdkYTQyODhhZF8zNQ_0d53f117-b616-47ec-a470-f7ee2c719568">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjUtMC0xLTEtMzY4MjUvdGV4dHJlZ2lvbjphZDUwYzdiMzg2ZjQ0Y2I2YmZmNjRiNTdkYTQyODhhZF81Nw_0e8731e6-f745-456d-bb11-376d9425c956"><ix:nonFraction unitRef="shares" contextRef="i99580c61c8454190b396ed58334ece96_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjUtMC0xLTEtMzY4MjUvdGV4dHJlZ2lvbjphZDUwYzdiMzg2ZjQ0Y2I2YmZmNjRiNTdkYTQyODhhZF81Nw_390b9b27-a6e9-4227-ac39-f526d10267d1"><ix:nonFraction unitRef="shares" contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjUtMC0xLTEtMzY4MjUvdGV4dHJlZ2lvbjphZDUwYzdiMzg2ZjQ0Y2I2YmZmNjRiNTdkYTQyODhhZF81Nw_5818a1e2-d6ba-431e-bdf6-0784aca9ada8"><ix:nonFraction unitRef="shares" contextRef="i99580c61c8454190b396ed58334ece96_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjUtMC0xLTEtMzY4MjUvdGV4dHJlZ2lvbjphZDUwYzdiMzg2ZjQ0Y2I2YmZmNjRiNTdkYTQyODhhZF81Nw_e71c47ba-0a29-48a8-8240-8dca1455c391">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> issued and outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331" decimals="0" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjUtMS0xLTEtMzY4MjU_f001e72d-0ed7-45e2-8270-4d35e87a4924">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99580c61c8454190b396ed58334ece96_I20221231" decimals="0" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjUtMy0xLTEtMzY4MjU_6033c137-6cc2-4c78-8a88-c7a5d3eeffc2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjYtMC0xLTEtMzY4MjUvdGV4dHJlZ2lvbjpiNTkxMGU0YWQzYjM0NTM4OTViMmQ2ZGZmOGRjODM2M18xOA_19bcc498-702d-4775-9548-d890d7f31fa1"><ix:nonFraction unitRef="usdPerShare" contextRef="i99580c61c8454190b396ed58334ece96_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjYtMC0xLTEtMzY4MjUvdGV4dHJlZ2lvbjpiNTkxMGU0YWQzYjM0NTM4OTViMmQ2ZGZmOGRjODM2M18xOA_75508ff2-7716-42d3-8418-5c393ea7a6d4">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjYtMC0xLTEtMzY4MjUvdGV4dHJlZ2lvbjpiNTkxMGU0YWQzYjM0NTM4OTViMmQ2ZGZmOGRjODM2M18zMg_47f3a6ff-f44a-4667-970b-c46680fa0f9e"><ix:nonFraction unitRef="shares" contextRef="i99580c61c8454190b396ed58334ece96_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjYtMC0xLTEtMzY4MjUvdGV4dHJlZ2lvbjpiNTkxMGU0YWQzYjM0NTM4OTViMmQ2ZGZmOGRjODM2M18zMg_ac5670f8-11d8-4b39-a810-7041e4484b5f">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjYtMC0xLTEtMzY4MjUvdGV4dHJlZ2lvbjpiNTkxMGU0YWQzYjM0NTM4OTViMmQ2ZGZmOGRjODM2M181NA_3f99e8af-b27e-43f3-8d0f-06fb5640c88c"><ix:nonFraction unitRef="shares" contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjYtMC0xLTEtMzY4MjUvdGV4dHJlZ2lvbjpiNTkxMGU0YWQzYjM0NTM4OTViMmQ2ZGZmOGRjODM2M181NA_5b49987b-b84e-4451-bdbc-a9e951686f73">2,468,297</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i99580c61c8454190b396ed58334ece96_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjYtMC0xLTEtMzY4MjUvdGV4dHJlZ2lvbjpiNTkxMGU0YWQzYjM0NTM4OTViMmQ2ZGZmOGRjODM2M182MQ_4cb09d52-3082-4d78-a873-27679b523ac4"><ix:nonFraction unitRef="shares" contextRef="i99580c61c8454190b396ed58334ece96_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjYtMC0xLTEtMzY4MjUvdGV4dHJlZ2lvbjpiNTkxMGU0YWQzYjM0NTM4OTViMmQ2ZGZmOGRjODM2M182MQ_f3bef47e-b57b-4e54-947b-3019f75e1ba3">2,255,899</ix:nonFraction></ix:nonFraction> shares issued and outstanding at March&#160;31, 2023 and December&#160;31, 2022, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331" decimals="0" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjYtMS0xLTEtMzY4MjU_c021a303-1c68-4506-8819-027018bd0556">246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99580c61c8454190b396ed58334ece96_I20221231" decimals="0" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjYtMy0xLTEtMzY4MjU_6a3dd152-131a-4bad-9f7e-a767271b92b1">225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331" decimals="0" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjctMS0xLTEtMzY4MjU_7f245b8b-b370-416c-8fe5-db7ae017f8a4">74,704,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99580c61c8454190b396ed58334ece96_I20221231" decimals="0" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjctMy0xLTEtMzY4MjU_a298baaf-cbfc-4fe5-9cbb-ed71b5b6445b">74,189,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjktMS0xLTEtMzY4MjU_32673a74-5408-4521-98fd-20183edc80e4">69,145,921</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99580c61c8454190b396ed58334ece96_I20221231" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjktMy0xLTEtMzY4MjU_2e4e5a2e-c402-404f-bf73-9c4017633de0">63,805,148</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMzAtMS0xLTEtMzY4MjU_d41d40f3-b60a-43b1-b890-7762a868944c">5,558,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99580c61c8454190b396ed58334ece96_I20221231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMzAtMy0xLTEtMzY4MjU_0aaf85cd-14b3-4120-91d0-b83353b98a8d">10,384,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMzEtMS0xLTEtMzY4MjU_db58e8c2-a0e3-4610-a6f1-bd7963a56f44">10,055,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99580c61c8454190b396ed58334ece96_I20221231" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMzEtMy0xLTEtMzY4MjU_56ed4258-d795-4c23-a47b-ab047ab46248">14,650,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="idb19952ac17e43b5923fbedddc424393_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SALARIUS PHARMACEUTICALS,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.005%"><tr><td style="width:1.0%"></td><td style="width:54.196%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.650%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three Months Ended March 31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfMy0wLTEtMS0zNjgyNQ_4b3d7717-e9ff-4348-887b-6722ded66434"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfMy0wLTEtMS0zNjgyNQ_6fcee171-08bd-4be6-be8b-a55dbaaf7bed">Grant revenue</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfMy0xLTEtMS0zNjgyNQ_119e9212-6bde-41a5-bf82-90e096e891db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfMy0zLTEtMS0zNjgyNQ_5769b7a3-1a9d-4fb6-87ba-6149da2178f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfNS0xLTEtMS0zNjgyNQ_5592c5dc-eb0e-48df-8c4b-1b0873c338ed">3,725,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfNS0zLTEtMS0zNjgyNQ_0bf72a77-fdcc-4297-909f-0ae6c9a3b6df">4,439,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfNi0xLTEtMS0zNjgyNQ_c9a56d69-f6f5-4240-a37e-4d1e362ed1b9">1,695,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfNi0zLTEtMS0zNjgyNQ_dfabdec3-37ed-4872-9ae2-7bda44adb733">1,677,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfOC0xLTEtMS0zNjgyNQ_45ae5744-a6f7-409b-8304-2dd00def5c05">5,420,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfOC0zLTEtMS0zNjgyNQ_fe2a4a74-91bf-4bce-8329-87aeca2eefdb">6,117,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before other income (expense)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfOS0xLTEtMS0zNjgyNQ_b9a06cac-cfa3-4a19-851b-9db6cfa888c6">5,420,663</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfOS0zLTEtMS0zNjgyNQ_53a1d7bd-4104-4f16-9bfc-0715b6a078a3">6,117,229</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="0" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfMTEtMS0xLTEtMzY4MjU_5b1f65e8-826c-4c0d-a308-05e25411e17f">79,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" decimals="0" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfMTEtMy0xLTEtMzY4MjU_dab66988-a8ea-41ef-aba4-6fc116d8f843">8,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfMTItMS0xLTEtMzY4MjU_9b195427-e735-4b3a-a265-d2a74627ffc2">5,340,773</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfMTItMy0xLTEtMzY4MjU_9408af47-cea8-4df6-9c68-ef0989674d17">6,109,225</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfMTMtMS0xLTEtMzY4MjU_6f52e1ac-be09-4f01-9284-f21bf99c5324">5,340,773</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfMTMtMy0xLTEtMzY4MjU_b25d223d-4fcf-46a1-a1a1-66699d2d0998">6,109,225</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss per common share&#160;&#8212; basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfMTUtMS0xLTEtMzY4MjU_41fa3ba4-ccfc-43f1-a86b-28fb46b38d72"><ix:nonFraction unitRef="usdPerShare" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfMTUtMS0xLTEtMzY4MjU_9cfcddbe-2cbd-4f26-a7cb-ab2e4c11c1e0">2.23</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfMTUtMy0xLTEtMzY4MjU_200935ae-7ba3-4cc3-a092-38c50b7f2459"><ix:nonFraction unitRef="usdPerShare" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfMTUtMy0xLTEtMzY4MjU_934d44cd-bd37-47cb-9d3b-b0a6dd9255d8">3.30</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares outstanding&#160;&#8212; basic and diluted</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfMTYtMS0xLTEtMzY4MjU_57f9ffb0-d59c-4a32-8eb5-c53dd812839b"><ix:nonFraction unitRef="shares" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfMTYtMS0xLTEtMzY4MjU_e8c05c72-a9d5-4b63-af6f-23084f2d4113">2,391,964</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfMTYtMy0xLTEtMzY4MjU_16c21590-b943-496d-87ff-2639f9ace60d"><ix:nonFraction unitRef="shares" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfMTYtMy0xLTEtMzY4MjU_4e58fa0c-6e91-4b02-ada5-f60f8879d087">1,850,208</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="idb19952ac17e43b5923fbedddc424393_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SALARIUS PHARMACEUTICALS,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended&#160;<br/>March 31</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMy0xLTEtMS0zNjgyNQ_b05bd498-b667-4b2c-befb-14482087b109">5,340,773</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMy0zLTEtMS0zNjgyNQ_757ecd4a-c441-41e4-916b-c0960c4328f7">6,109,225</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="0" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfNS0xLTEtMS0zNjgyNQ_3bc10c8f-f73c-4242-9f2a-63c4feb0f055">1,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" decimals="0" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfNS0zLTEtMS0zNjgyNQ_bdbec665-099f-4452-a8b5-95bbd1134884">4,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfNy0xLTEtMS0zNjgyNQ_ab7cd923-7c9f-40e5-8fbf-988856d905d0">203,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfNy0zLTEtMS0zNjgyNQ_ea6d501b-ae8b-4a58-a200-4adcedc7a526">313,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="0" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfOS0xLTEtMS0zNjgyNQ_97958b40-f818-4915-947e-8d7e79e85d37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" decimals="0" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfOS0zLTEtMS0zNjgyNQ_34bc80c0-380e-4cbf-8ea5-926541f89208">1,987,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grants receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherReceivables" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMTItMS0xLTEtMzY4MjU_92cfbb66-93b4-4975-9677-69ab1356e484">1,480,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" decimals="0" name="us-gaap:IncreaseDecreaseInOtherReceivables" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMTItMy0xLTEtMzY4MjU_de123168-292e-48de-9b2d-c1419446321a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMTMtMS0xLTEtMzY4MjU_82755912-9323-44a6-8e3d-089073ee9769">280,728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMTMtMy0xLTEtMzY4MjU_1f305717-b855-40dc-997c-97e969ceaff6">300,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMTUtMS0xLTEtMzY4MjU_6ee8bd10-3a14-4444-9803-8c90a4ccb101">627,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMTUtMy0xLTEtMzY4MjU_6800ebc1-77db-465a-9472-4bb635d708a4">150,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMTYtMS0xLTEtMzY4MjU_a68a411c-e4e3-4246-9d79-6be332e9de14">422,470</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMTYtMy0xLTEtMzY4MjU_1e887590-fb98-4c69-ab6e-cd980e95bf3c">168,845</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMTctMS0xLTEtMzY4MjU_c71cf7b0-d12f-431c-b257-d8464ee2e679">3,169,435</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMTctMy0xLTEtMzY4MjU_c83e8216-0ab0-4aa4-bdca-68c0d5347847">3,520,826</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase in-process research and development technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="0" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMjAtMS0xLTEtMzY4MjU_ae1daa10-ab85-41dd-aea8-1e382715cb1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" decimals="0" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMjAtMy0xLTEtMzY4MjU_ae8df7eb-3e02-4646-8f39-88bb39bf55dc">1,500,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="0" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMjEtMS0xLTEtMzY4MjU_fceadf02-74e3-4318-aa72-18024df895ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMjEtMy0xLTEtMzY4MjU_aa3cead3-f4da-41a3-86f9-57f9c1307008">1,500,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of equity securities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="0" name="us-gaap:ProceedsFromOtherEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMjUtMS0xLTEtMzY4MjU_7506e7ba-86aa-4e82-a50f-7a15d093e393">336,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" decimals="0" name="us-gaap:ProceedsFromOtherEquity" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMjUtMy0xLTEtMzY4MjU_443081e2-7687-48b2-88e3-ec3c5a770a74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMjktMS0xLTEtMzY4MjU_655fc132-135d-4c41-b10a-c3dc1d16dc2e">336,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMjktMy0xLTEtMzY4MjU_88efe075-acba-45db-be73-7561c05753ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="0" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMzEtMS0xLTEtMzY4MjU_c8ceae8c-5609-4f7c-9077-0aef1767f3da">2,832,753</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" decimals="0" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMzEtMy0xLTEtMzY4MjU_9adb05e1-8fe8-4161-abee-30413b87ad3e">5,020,826</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99580c61c8454190b396ed58334ece96_I20221231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMzItMS0xLTEtMzY4MjU_0d8cf51a-9600-4b9c-b99b-a310e54d3fd5">12,106,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bb28550232b40a6a710d558583695ab_I20211231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMzItMy0xLTEtMzY4MjU_1a3d29b4-9684-4233-8db2-2ed9ea33854d">29,214,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMzMtMS0xLTEtMzY4MjU_3b1fb1f1-bf59-493b-ac16-76f83fefea69">9,273,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5a306ceedd2446d93819bfd4e8afbe8_I20220331" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMzMtMy0xLTEtMzY4MjU_f39696a6-92db-4cee-8536-0807a5a459ef">24,193,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issued for in-process research and development technology</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="0" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMzgtMS0xLTEtMzY4MjU_086122a7-b23c-4567-aa43-86f0fe690ddc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" decimals="0" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMzgtMy0xLTEtMzY4MjU_2e13adab-662e-4ffe-a1f5-9e039cd0775f">487,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued issuance costs for public offering</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="0" name="flks:StockIssuanceCostsAccruedAndAmortized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMzktMS0xLTEtMzY4MjU_7b44c74b-a341-4e8b-be35-ec2b9773797f">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" decimals="0" name="flks:StockIssuanceCostsAccruedAndAmortized" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMzktMy0xLTEtMzY4MjU_59e7a595-ac5b-405b-af2d-bb14574989a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="idb19952ac17e43b5923fbedddc424393_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SALARIUS PHARMACEUTICALS,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.530%"><tr><td style="width:1.0%"></td><td style="width:36.734%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.564%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.970%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.286%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.015%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Stockholders' Equity (Deficit)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2bd45e30d3c0413c9f0cdd01c63fbe3a_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMy0xLTEtMS0zNjgyNQ_2a1366b5-2d3f-4996-ad00-b7ad95faefd7">1,809,593</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bd45e30d3c0413c9f0cdd01c63fbe3a_I20211231" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMy0zLTEtMS0zNjgyNQ_69fd9a8a-9250-4243-912e-430c55c3f8fb">181</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i182fe90a35fa46a4bee4ab0ee69ad6c0_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMy01LTEtMS0zNjgyNQ_32b25822-2b8a-436b-bac1-cdff7813811f">70,919,996</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55a4dc73d8734260b84dd299d02b0bea_I20211231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMy03LTEtMS0zNjgyNQ_4ad0240f-e7cf-4af5-bd85-ca955260f8eb">32,197,192</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bb28550232b40a6a710d558583695ab_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMy05LTEtMS0zNjgyNQ_e372c722-0636-4945-aef8-912b293a794f">38,722,985</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issued for in-process research and development technology</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id9aac0bd35674eb4b2fe9319ccc12b17_D20220101-20220331" decimals="INF" name="flks:StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologySharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfNC0xLTEtMS0zNjgyNQ_36ccc04f-ed53-4bc7-8afb-63ee0e690cf9">40,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9aac0bd35674eb4b2fe9319ccc12b17_D20220101-20220331" decimals="0" name="flks:StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfNC0zLTEtMS0zNjgyNQ_01929904-d7e7-4548-ac3f-d8508194d487">4</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc8902a9a25417493c9a87bcde49e28_D20220101-20220331" decimals="0" name="flks:StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfNC01LTEtMS0zNjgyNQ_456b167d-73f9-4e42-97d6-dbc80de71035">487,896</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" decimals="0" name="flks:StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfNC05LTEtMS0zNjgyNQ_df416357-45d8-41f0-ba4c-23b2ac447055">487,900</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id9aac0bd35674eb4b2fe9319ccc12b17_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfNS0xLTEtMS0zNjgyNQ_da1e8637-23a1-4776-a948-afe9051b6ae2">18,215</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9aac0bd35674eb4b2fe9319ccc12b17_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfNS0zLTEtMS0zNjgyNQ_7c994ccd-3b52-4008-b021-c2ccabb527d9">2</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc8902a9a25417493c9a87bcde49e28_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfNS01LTEtMS0zNjgyNQ_c508f97f-7c4c-405f-a92a-0a8695c1b0b5">313,901</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfNS05LTEtMS0zNjgyNQ_7d0f4a55-660c-43ab-9965-2a1ccdeb29c5">313,903</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie373d68e8a8744798cfdbc196f59d0be_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfNi03LTEtMS0zNjgyNQ_378a173c-6a19-4c34-bfb9-cae9fbbf688d">6,109,225</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfNi05LTEtMS0zNjgyNQ_4e340998-0917-4984-b5f9-d5787c9d5293">6,109,225</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iafffc62468c54cae91120ea9c81a1bd5_I20220331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfNy0xLTEtMS0zNjgyNQ_a40ceaf2-5c03-4ba6-807c-28f418f68747">1,867,808</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafffc62468c54cae91120ea9c81a1bd5_I20220331" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfNy0zLTEtMS0zNjgyNQ_75310ced-4d4e-4ce8-b66f-b5845ed95ef4">187</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4db7a89251f499c92610b04658dc2ae_I20220331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfNy01LTEtMS0zNjgyNQ_f37f9484-7768-4734-a163-fa053b77ddc4">71,721,793</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie574cf86bfc040409286776e93e62abd_I20220331" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfNy03LTEtMS0zNjgyNQ_8d25991f-b38d-4b49-94dc-ad886880643b">38,306,417</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5a306ceedd2446d93819bfd4e8afbe8_I20220331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfNy05LTEtMS0zNjgyNQ_8439201c-e981-45a9-bdb2-d708bd4b0df2">33,415,563</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6abf49e74f3942af9362b2fc6b6e5ee0_I20221231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMTgtMS0xLTEtMzY4MjU_3f05a607-9226-427f-80f7-9dc8f28403bd">2,255,899</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6abf49e74f3942af9362b2fc6b6e5ee0_I20221231" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMTgtMy0xLTEtMzY4MjU_0a3b9e55-2ef3-440f-848e-e3d28a956d7e">225</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideb363b95bd54426b36e8a3e499e28b9_I20221231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMTgtNS0xLTEtMzY4MjU_249b3027-b6dd-4b72-a989-328cca13a4b3">74,189,531</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7787220731c9412bb479d54b491fd7eb_I20221231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMTgtNy0xLTEtMzY4MjU_9995341b-ac04-4253-b80f-8ae80a4b7750">63,805,148</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99580c61c8454190b396ed58334ece96_I20221231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMTgtOS0xLTEtMzY4MjU_710f4b9a-feb3-4d7e-9673-23011ea93f30">10,384,608</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of equity securities, net</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib594d10fbc6146ba8590e1d37595ffc7_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMTktMS0xLTEtMzY4MjU_6d2015f8-0a20-4572-97b1-c4e22fa499f7">142,499</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib594d10fbc6146ba8590e1d37595ffc7_D20230101-20230331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMTktMy0xLTEtMzY4MjU_5809fb5d-1d2d-4e4c-b599-cbc5eb809c27">14</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibca39c224c4d4c48a68e09a78c6cc957_D20230101-20230331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMTktNS0xLTEtMzY4MjU_22505180-6f0b-4891-a5aa-6cf2d6544f4f">311,667</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMTktOS0xLTEtMzY4MjU_851f7328-f3f7-4723-ac1b-8436a6d116a1">311,681</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib594d10fbc6146ba8590e1d37595ffc7_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMjAtMS0xLTEtMzY4MjU_8f02d4e1-ff89-4f14-9f8d-b004858ba7af">69,899</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib594d10fbc6146ba8590e1d37595ffc7_D20230101-20230331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMjAtMy0xLTEtMzY4MjU_4bed415c-3e98-410b-8770-da8ebd11d574">7</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibca39c224c4d4c48a68e09a78c6cc957_D20230101-20230331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMjAtNS0xLTEtMzY4MjU_7641ff5a-667f-4c52-9776-938fccc05a2f">203,338</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMjAtOS0xLTEtMzY4MjU_9251802f-d864-404d-b30b-808d802bf3c8">203,345</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf6f50e29050415c8e6980f25eeba947_D20230101-20230331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMjEtNy0xLTEtMzY4MjU_3ab3b152-c6e2-4d13-a8b2-24269e6f226e">5,340,773</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMjEtOS0xLTEtMzY4MjU_ed502bf7-3591-426a-8a54-f2e6c5cda689">5,340,773</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i867fe0652a284dfa8c10e8eea406a8db_I20230331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMjItMS0xLTEtMzY4MjU_9f348723-8078-4d5f-8eb3-fffb0626e5bd">2,468,297</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i867fe0652a284dfa8c10e8eea406a8db_I20230331" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMjItMy0xLTEtMzY4MjU_0bc79dd4-498a-4442-83b0-be68f38c8ef4">246</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80002a83141a4ef6a0ff3d67ce2967b1_I20230331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMjItNS0xLTEtMzY4MjU_38f641e0-b237-4018-a136-714d3298b716">74,704,536</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf1223a5e90f40a8b60ebbab5dbe9e78_I20230331" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMjItNy0xLTEtMzY4MjU_9aff9a25-76b1-465d-a84a-bbf69a9828a9">69,145,921</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMjItOS0xLTEtMzY4MjU_88ebd7a6-9301-4b7e-bf8a-57585f1d116b">5,558,861</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="idb19952ac17e43b5923fbedddc424393_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_7">Table of Contents</a></span></div></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SALARIUS PHARMACEUTICALS,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="idb19952ac17e43b5923fbedddc424393_34"></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. <ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18zNC9mcmFnOjE1Mzk4YWVmNzU0MjQ1YjE5MzAyZmFiYTZmMGU5NDg1L3RleHRyZWdpb246MTUzOThhZWY3NTQyNDViMTkzMDJmYWJhNmYwZTk0ODVfNjMxNw_efc108d8-fe1e-4036-877c-e6a639db2bda" continuedAt="iae3676941f6c4c4494e25fc7ccfbe62f" escape="true">ORGANIZATION AND OPERATIONS</ix:nonNumeric></span></div><div style="margin-bottom:1pt"><span><br/></span></div><ix:continuation id="iae3676941f6c4c4494e25fc7ccfbe62f" continuedAt="icdc21a08ad3040c8af05f1ac3736ce4a"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nature of Business</span></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Salarius Pharmaceuticals, Inc. (&#8220;Salarius&#8221; or the &#8220;Company&#8221;), together with its subsidiaries, Salarius Pharmaceuticals, LLC, Flex Innovation Group LLC, and TK Pharma, Inc., is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical need. Specifically, the Company is developing treatments for cancers caused by dysregulated gene expression, i.e., genes that are incorrectly turned on or off. The Company is developing two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degraders. The Company's technologies have the potential to work in both liquid and solid tumors. The Company's current pipeline consists of two small molecule drugs: 1) SP-3164, a targeted protein degrader, and 2)  seclidemstat (SP-2577), a targeted protein inhibitor. The Company is located in Houston, Texas. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Salarius has no products approved for commercial sale, has not generated any revenue from product sales to date and has suffered recurring losses from operations since its inception. The lack of revenue from product sales to date and recurring losses from operations since its inception raise substantial doubt as to the Company's ability to continue as a going concern. The accompanying financial statements are prepared using accounting principles generally accepted in the United States applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities should the Company be unable to continue as a going concern. Salarius will require substantial additional capital to fund its research and development expenses related to its pipeline including SP-3164 and seclidemstat. Based on Salarius&#8217; expected cash requirements, Salarius believes that there is substantial doubt that its existing cash and cash equivalents, will be sufficient to fund its operations through one year from the financial statements' issuance date. The Company intends to obtain additional capital through the sale of equity securities in one or more offerings or through issuances of debt instruments, and may also consider new collaborations or selectively partnering its technology. However, the Company cannot provide any assurance that it will be successful in accomplishing any of its plans. </span></div><div style="margin-bottom:12pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recent Developments</span></div><div style="margin-bottom:12pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Partial Clinical Hold Lifted</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 19, 2022, the Company voluntarily paused new patient enrollment in its Phase 1/2 trial of seclidemstat as a treatment for Ewing sarcoma and FET-rearranged sarcomas per protocol design. The pause in new patient enrollment was due to a metastatic FET-rearranged sarcoma patient death that was classified as a suspected unexpected serious adverse reaction (SUSAR). Upon review of the SUSAR and available information by the Company&#8217;s independent Safety Review Committee for the clinical trial, patients currently receiving seclidemstat treatment may continue treatment after consulting with their physician. During a conference call with the U.S. Food and Drug Administration (FDA) on November 1, 2022, the FDA informed the Company that the agency agreed with the voluntary enrollment pause and, as an administrative action, the FDA provided verbal notification that the Ewing sarcoma and FET-rearranged sarcoma trial was on partial clinical hold. While on partial clinical hold, FDA informed the Company that the pause in patient enrollment shall remain in place and patients currently receiving seclidemstat treatment may continue treatment after consulting with their physician. FDA&#8217;s clinical hold procedures provide the Company with an administrative process to work with the FDA to analyze the available data, adjust clinical protocols, and make other changes that may be needed in order to restart patient enrollment. The Company adhered to this administrative process and submitted its findings during early April, 2023. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">On May 5, 2023, the Company was notified by FDA that they have completed the review of our submission and have concluded that the clinical trial may be resumed.</span></div><div style="margin-bottom:12pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Common Stock Issued Under At the Market Offering Agreement </span></div></ix:continuation><div style="margin-bottom:12pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:8pt;text-align:justify"><ix:continuation id="icdc21a08ad3040c8af05f1ac3736ce4a" continuedAt="id9182d338e7640ea83124805441bf693"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 5, 2021, the Company entered into an At the Market Offering Agreement (the &#8220;Sales Agreement&#8221;) with Ladenburg Thalmann &amp; Co. Inc. (&#8220;Ladenburg&#8221;). Under the Sales Agreement the Company was able to issue and sell, from time to time, shares of its common stock (the &#8220;ATM Shares&#8221;) with Ladenburg acting as an agent for sales. Sales of the ATM Shares may be made by any method permitted by law deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended, including, without limitation, sales made directly on or through the Nasdaq Capital Market. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">From April 4, 2023 to May 11, 2023, the Company sold <ix:nonFraction unitRef="shares" contextRef="i1c04e18316394009b6153f59ba41f585_D20230404-20230511" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18zNC9mcmFnOjE1Mzk4YWVmNzU0MjQ1YjE5MzAyZmFiYTZmMGU5NDg1L3RleHRyZWdpb246MTUzOThhZWY3NTQyNDViMTkzMDJmYWJhNmYwZTk0ODVfODI0NjMzNzIyNjMyNw_26e445fc-80a2-44e0-b433-90a91f11fb19">527,672</ix:nonFraction> ATM shares of its common shares with gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i1c04e18316394009b6153f59ba41f585_D20230404-20230511" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18zNC9mcmFnOjE1Mzk4YWVmNzU0MjQ1YjE5MzAyZmFiYTZmMGU5NDg1L3RleHRyZWdpb246MTUzOThhZWY3NTQyNDViMTkzMDJmYWJhNmYwZTk0ODVfODI0NjMzNzIyNjMzNg_b48baef0-d44a-455a-a96b-deb81778be7a">1.3</ix:nonFraction>&#160;million </span></ix:continuation><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id9182d338e7640ea83124805441bf693">under the Sales Agreement.</ix:continuation> </span></div><div style="margin-bottom:12pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div id="idb19952ac17e43b5923fbedddc424393_40"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. <ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfMTI4OTg_54aee388-f299-48c9-9dc8-761bb1ae34b1" continuedAt="i8c0d921ded784da8a3d4837f58e6955e" escape="true">BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i8c0d921ded784da8a3d4837f58e6955e" continuedAt="i219719ec36ee4a958fd6e94c4a923381"><ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfMTI4OTk_b4ecafec-b940-458f-bbe4-9efeba698aa7" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standard Codification ("ASC") and Accounting Standards Update ("ASU") of the Financial Accounting Standards Board ("FASB").</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 14, 2022, the Company filed a Certificate of Amendment to the Company&#8217;s restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-25 reverse stock split of the Company&#8217;s issued and outstanding shares of common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="ib514cd02604141cba330abbb11971983_I20221014" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfMTA5OTUxMTY0NjEyMQ_c0cdb240-f6ce-4e0f-9dc6-afaa43e5bc41">0.0001</ix:nonFraction> per share (the &#8220;Reverse Stock Split&#8221;), which became effective on October 14, 2022. All historical share and per share amounts reflected throughout this report have been adjusted to reflect the Reverse Stock Split.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfMTI5MTQ_f8a53db1-9a54-453a-a5dc-d6163779f163" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim financial statements are unaudited. These unaudited interim financial statements have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial information. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. These unaudited interim financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended December&#160;31, 2022 included elsewhere in the Company's Annual Report on Form 10-K filed with the SEC on March 27, 2023. In the opinion of management, the unaudited interim financial statements reflect all the adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company&#8217;s financial position as of March&#160;31, 2023 and the results of operations for the three months ended March&#160;31, 2023 and 2022. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. The December&#160;31, 2022 balance sheet included herein was derived from the audited financial statements, but does not include all disclosures, including notes, required by GAAP for complete financial statements.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfMTI5MDU_d6ac7d4d-0ce6-4ef7-a0ec-2a54121a9354" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America as defined by the FASB ASC requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfMTI5MDY_27cc9e68-0e9b-446d-8fa1-3b7ed63e89ce" continuedAt="i89fa58e6cd88404abd0a7faac97ac5a3" escape="true">Cash and Cash Equivalents</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i89fa58e6cd88404abd0a7faac97ac5a3">Salarius considers all highly liquid investments with original maturities of three months or less to be cash equivalents.</ix:continuation> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfMTI5MTY_464ec7dc-0c00-43e7-a938-e26425d7080b" continuedAt="ib8b6f45677d34f4e94496158003f8bc7" escape="true">Impairment of Long-Lived Assets</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_7">Table of Contents</a></span></div></div><div><span><br/></span></div><ix:continuation id="i219719ec36ee4a958fd6e94c4a923381" continuedAt="ib7c1e7b977dc4570aa9c20f427bb3dde"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib8b6f45677d34f4e94496158003f8bc7">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that their carrying value may not be recoverable. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset.</ix:continuation> There were <ix:nonFraction unitRef="usd" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfMTA5OTUxMTY0MzQxMA_52c07baf-5a9e-4289-ac0e-02b2abb580c8"><ix:nonFraction unitRef="usd" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfMTA5OTUxMTY0MzQxMA_bd56aa26-1d19-4766-b626-c5cef5fd9ae5">no</ix:nonFraction></ix:nonFraction> impairment charges related to long-lived assets for the three months ended March&#160;31, 2023 and 2022.</span></div><div><span><br/></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfMTI5MDc_b188e384-0a96-45cc-aee3-77926d3584cb" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments and Credit Risks</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk include cash and cash equivalents and restricted cash. Cash is deposited in demand accounts in federally insured domestic institutions to minimize risk. Insurance is provided through the Federal Deposit Insurance Corporation. Although the balances in these accounts exceed the federally insured limit from time to time, the Company has not incurred losses related to these deposits.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfMTI5MTA_9390f09a-7a12-4fa9-b5a6-9131e88b1849" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether warrants should be classified as a liability or equity. For warrants classified as liabilities, the Company estimates the fair value of the warrants at each reporting period using Level 3 inputs with changes in fair value recorded in the Condensed Consolidated Statement of Operations within change in fair value of warrant liability. The estimates in valuation models are based, in part, on subjective assumptions, including but not limited to stock price volatility, the expected life of the warrants, the risk-free interest rate and the fair value of the common stock underlying the warrants, and could differ materially in the future. The Company will continue to adjust the fair value of the warrant liability at the end of each reporting period for changes in fair value from the prior period until the earlier of the exercise or expiration of the applicable warrant. For warrants classified as equity contracts, the Company allocates the transaction proceeds to the warrants and any other free-standing instruments issued in the transaction based on an allowable allocation method.</span></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Trial Accruals</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s preclinical and clinical trials are performed by third party contract research organizations ("CROs") and/or clinical investigators, and clinical supplies are manufactured by contract manufacturing organizations ("CMOs"). Invoicing from these third parties may be monthly based upon services performed or based upon milestones achieved. The Company accrues these expenses based upon its assessment of the status of each clinical trial and the work completed, and upon information obtained from the CROs and CMOs. The Company&#8217;s estimates are dependent upon the timeliness and accuracy of data provided by the CROs and CMOs regarding the status and cost of the studies, and may not match the actual services performed by the organizations. This could result in adjustments to the Company&#8217;s research and development expenses in future periods. To date the Company has had no significant adjustments.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfMTI5MDE_e6f4f27d-a91d-4042-9259-9d2d1bcf725e" continuedAt="ibbc630c2e12b42639139e1f87a8f1279" escape="true">Grants Receivable and Revenue </ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="ibbc630c2e12b42639139e1f87a8f1279">Salarius&#8217; source of revenue has been from a grant received from CPRIT. Grant revenue is recognized when qualifying costs are incurred and there is reasonable assurance that conditions of the grant have been met. Cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred.</ix:continuation> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfMTI5MTc_137ebf48-ddbd-45f2-bd28-7e73980d4602" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development costs consist of expenses incurred in performing research and development activities, including pre-clinical studies and clinical trials. Research and development costs include salaries and personnel-related costs, consulting fees, fees paid for contract research services, the costs of laboratory equipment and facilities, license fees and other external costs. Research and development costs are expensed when incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs incurred in obtaining in-process research and development ("IPRD") that has no alternative future use are charged to research and development expense as acquired, and presented as investing activity cash outflows on the Statement of Cash Flow.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_7">Table of Contents</a></span></div></div><ix:continuation id="ib7c1e7b977dc4570aa9c20f427bb3dde" continuedAt="if2333af9c381499f94e18f25562af60a"><ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfMTI5MTI_091069de-46da-45c4-9ab5-c97c841d15c4" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Equity-Based Compensation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salarius measures equity-based compensation based on the grant date fair value of the awards and recognizes the associated expense in the financial statements over the requisite service period of the award, which is generally the vesting period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option valuation model to estimate the fair value of stock options granted to employees and directors. Assumptions utilized in these models including expected volatility calculated based on implied volatility from traded stocks of peer companies, dividend yield and risk-free interest rate. Additionally, forfeitures are accounted for in compensation cost as they occur. Restricted stock and restricted stock units granted to employees and directors are measured at fair value based upon the closing price of the Company's common stock on the grant date.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfMTI5MTg_7fbdaf78-93db-47c8-8aaa-86ddcc74aa9b" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss Per Share</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods, as the inclusion of all potential common shares outstanding is anti-dilutive.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of anti-dilutive shares, consisting of common shares underlying (i) common stock options, (ii) stock purchase warrants, (iii) rights entitling holders to receive warrants to purchase the Company's common shares, and (iv) restricted stock units which have been excluded from the computation of diluted loss per share, was approximately <ix:nonFraction unitRef="shares" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfNjA0NzMxMzk2NzQ1OQ_7c349615-c9bd-4a95-89ed-299d23165d66">716,840</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfNjA0NzMxMzk2NzQ2Mw_bfa0afc9-3693-46ce-ac83-ea7125fe3436">431,407</ix:nonFraction> shares as of March&#160;31, 2023 and 2022, respectively.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfMTI5MDI_4e064b26-5d0f-4bac-aacf-0a368d05015a" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are recorded in accordance with FASB ASC Topic 740, Income Taxes ("ASC 740"), which provides for deferred taxes using an asset and liability approach. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and the tax reporting basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized. The Company has evaluated available evidence and concluded that the Company may not realize the benefit of its deferred tax assets; therefore, a valuation allowance has been established for the full amount of the deferred tax assets.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. As of March&#160;31, 2023 and December&#160;31, 2022, the Company did not have any significant uncertain tax positions and no interest or penalties have been charged. The Company's practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company is subject to routine audits by taxing jurisdictions.</span></div></ix:nonNumeric><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition and Strategic Collaboration Agreement</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_7">Table of Contents</a></span></div></div><ix:continuation id="if2333af9c381499f94e18f25562af60a"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 12, 2022, the Company entered into an Acquisition and Strategic Collaboration Agreement (the &#8220;ASCA&#8221;), with DeuteRx, LLC, a Delaware limited liability company (the &#8220;DeuteRx&#8221;), pursuant to which DeuteRx agreed to sell, and the Company agreed to purchase and assume from DeuteRx, all of DeuteRx&#8217;s rights, title, and interest in and to certain assets of DeuteRx, including SP-3164, DeuteRx&#8217;s intellectual property, information and data related to SP-3164, tangible materials or reagents related to SP-3164, goodwill, rights and claims, other than certain excluded assets (collectively, the &#8220;Purchased Assets&#8221;), all as more specifically set forth in the ASCA, and assume certain assumed liabilities, upon the terms and subject to the conditions set forth in the ASCA. The Aggregate purchase price paid under the ASCA was $<ix:nonFraction unitRef="usd" contextRef="i5a151b2cc8444c79aee3f783063d9279_D20220112-20220112" decimals="-5" name="flks:PaymentsForAcquisitionAndStrategicCollaborationAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfNTQ5NzU1ODE1NTQ1NA_68380c53-89cb-497f-97fd-ed79c527c30d">2.0</ix:nonFraction>&#160;million consisting of $<ix:nonFraction unitRef="usd" contextRef="i5a151b2cc8444c79aee3f783063d9279_D20220112-20220112" decimals="-5" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfNTQ5NzU1ODE1NTQ3Mg_1244dc2b-a144-4b42-9009-f35cfb09a1f1">1.5</ix:nonFraction> million cash payment and the delivery of <ix:nonFraction unitRef="shares" contextRef="ie6b59e45b64342c89f3426880dc1103d_D20220112-20220112" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfNTQ5NzU1ODE1NTUxNw_bb7226e2-e862-496e-9e6a-948f1a6f348b">40,000</ix:nonFraction> shares of the Company's common stock, valued at $<ix:nonFraction unitRef="usd" contextRef="i5a151b2cc8444c79aee3f783063d9279_D20220112-20220112" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfNTQ5NzU1ODE1NTU2OQ_81501b6d-79a7-4ab4-abf6-e4f787749a2f">0.5</ix:nonFraction> million. Total cost incurred in obtaining IPRD that has no alternative future use are charged to research and development expense as acquired, and presented as investing activity cash outflow on the Statement of Cash Flow. In addition, the Company agreed to pay to DeuteRx potential future milestone payments upon the occurrence of an applicable Milestone Event (as defined in the ASCA) and potential future royalty payments. A member of the Company&#8217;s Board of Directors also serves as a consultant to DeuteRx and is employed by an affiliate of DeuteRx.</span></div><ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfMTI5MDM_83152e3a-47c1-4041-b41a-63b7ae292718" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recently Adopted Accounting Standard</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments &#8212; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires the measurement of all expected credit losses for financial assets including trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Subsequent to the issuance of ASU 2016-13, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments - Credit Losses. This ASU does not change the core principle of the guidance in ASU 2016-13, instead these amendments are intended to clarify and improve operability of certain topics included within the credit losses guidance. The FASB also subsequently issued ASU No. 2019-04, Codification Improvements to Topic 326, Financial Instruments&#8212;Credit Losses, Derivatives and Hedging (Topic 815), and Financial Instruments (Topic 825), which did not change the core principle of the guidance in ASU 2016-13 but clarified that expected recoveries of amounts previously written off and expected to be written off should be included in the valuation account and should not exceed amounts previously written off and expected to be written off. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019 for public business entities, excluding smaller reporting companies. Early adoption is permitted. As a smaller reporting company, the guidance was effective for the Company on January 1, 2023. The adoption of this standard did not have a material impact to this Company's consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="idb19952ac17e43b5923fbedddc424393_43"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3. <ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180My9mcmFnOmYzMmU2MjZkZGQzYzQ5MDNiOTRlNzRlNTA4Y2EwYzg5L3RleHRyZWdpb246ZjMyZTYyNmRkZDNjNDkwM2I5NGU3NGU1MDhjYTBjODlfMzEx_e96ed984-46bf-45f0-b025-a282d4b7dafd" continuedAt="i291837716a72465398ba2dec399da4c9" escape="true">GRANT RECEIVABLE FROM CPRIT</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:justify"><ix:continuation id="i291837716a72465398ba2dec399da4c9" continuedAt="i7ba51a1c70804245a21854e08849bc8a"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grants receivable represents qualifying costs incurred where there is reasonable assurance that conditions of the grant have been met but the corresponding funds have not been received as of the reporting date. Grants receivable balances are $<ix:nonFraction unitRef="usd" contextRef="i939615b57778416faf3eff53296b4db2_I20230331" decimals="-5" name="us-gaap:GrantsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180My9mcmFnOmYzMmU2MjZkZGQzYzQ5MDNiOTRlNzRlNTA4Y2EwYzg5L3RleHRyZWdpb246ZjMyZTYyNmRkZDNjNDkwM2I5NGU3NGU1MDhjYTBjODlfMjgz_77206f02-d560-483c-84e5-7a68dd643701">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if54e5126787f42138fb230f8a7f23b49_I20221231" decimals="-5" name="us-gaap:GrantsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180My9mcmFnOmYzMmU2MjZkZGQzYzQ5MDNiOTRlNzRlNTA4Y2EwYzg5L3RleHRyZWdpb246ZjMyZTYyNmRkZDNjNDkwM2I5NGU3NGU1MDhjYTBjODlfNjA0NzMxMzk1MzA4Nw_3a87a6b2-eb52-4c59-b659-9a616cd76fcc">1.6</ix:nonFraction> million  at both March&#160;31, 2023 and December&#160;31, 2022. During the three</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended March&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the </span></ix:continuation><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7ba51a1c70804245a21854e08849bc8a">Company received $<ix:nonFraction unitRef="usd" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180My9mcmFnOmYzMmU2MjZkZGQzYzQ5MDNiOTRlNzRlNTA4Y2EwYzg5L3RleHRyZWdpb246ZjMyZTYyNmRkZDNjNDkwM2I5NGU3NGU1MDhjYTBjODlfODI0NjMzNzIwODgwMA_f80161ef-bab2-4e5a-8380-aefa9856ba58">1.5</ix:nonFraction> million from CPRIT.</ix:continuation> </span></div><div id="idb19952ac17e43b5923fbedddc424393_46"></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4. <ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="us-gaap:OtherCurrentAssetsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180Ni9mcmFnOjM0NGIyMDE3MGM3MjQzOGFiZTQ5NmQ4ZTYxZmQzNmZhL3RleHRyZWdpb246MzQ0YjIwMTcwYzcyNDM4YWJlNDk2ZDhlNjFmZDM2ZmFfMjI2_d6ca2b65-8ea8-4c86-851c-c5d2a4f7fb63" continuedAt="id9f70bf2242b47ee8f791c56accd8ba6" escape="true">PREPAID EXPENSES AND OTHER CURRENT ASSETS</ix:nonNumeric></span></div><ix:continuation id="id9f70bf2242b47ee8f791c56accd8ba6"><div style="margin-bottom:8pt;margin-top:8pt"><ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180Ni9mcmFnOjM0NGIyMDE3MGM3MjQzOGFiZTQ5NmQ4ZTYxZmQzNmZhL3RleHRyZWdpb246MzQ0YjIwMTcwYzcyNDM4YWJlNDk2ZDhlNjFmZDM2ZmFfMjMx_9d2efd0c-8765-4210-bef1-5190f78876ca" escape="true"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets at March&#160;31, 2023 and December&#160;31, 2022 consisted of the following: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.323%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical trial expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331" decimals="0" name="flks:PrepaidClinicalTrialExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180Ni9mcmFnOjM0NGIyMDE3MGM3MjQzOGFiZTQ5NmQ4ZTYxZmQzNmZhL3RhYmxlOjYzMzBlYmUxMDg5ZTRiNDNiMDIxMDFlOGRmNWJmZWNlL3RhYmxlcmFuZ2U6NjMzMGViZTEwODllNGI0M2IwMjEwMWU4ZGY1YmZlY2VfMS0xLTEtMS0zNjgyNQ_7c241052-623e-4dbe-a21f-d17541ae51b3">11,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99580c61c8454190b396ed58334ece96_I20221231" decimals="0" name="flks:PrepaidClinicalTrialExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180Ni9mcmFnOjM0NGIyMDE3MGM3MjQzOGFiZTQ5NmQ4ZTYxZmQzNmZhL3RhYmxlOjYzMzBlYmUxMDg5ZTRiNDNiMDIxMDFlOGRmNWJmZWNlL3RhYmxlcmFuZ2U6NjMzMGViZTEwODllNGI0M2IwMjEwMWU4ZGY1YmZlY2VfMS0zLTEtMS0zNjgyNQ_09cd75ce-0261-4b5b-84c9-9747c0b0c5b7">11,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331" decimals="0" name="us-gaap:PrepaidInsurance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180Ni9mcmFnOjM0NGIyMDE3MGM3MjQzOGFiZTQ5NmQ4ZTYxZmQzNmZhL3RhYmxlOjYzMzBlYmUxMDg5ZTRiNDNiMDIxMDFlOGRmNWJmZWNlL3RhYmxlcmFuZ2U6NjMzMGViZTEwODllNGI0M2IwMjEwMWU4ZGY1YmZlY2VfMi0xLTEtMS0zNjgyNQ_e4aad881-5cec-4338-a4f6-bbdd101ea1ea">368,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99580c61c8454190b396ed58334ece96_I20221231" decimals="0" name="us-gaap:PrepaidInsurance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180Ni9mcmFnOjM0NGIyMDE3MGM3MjQzOGFiZTQ5NmQ4ZTYxZmQzNmZhL3RhYmxlOjYzMzBlYmUxMDg5ZTRiNDNiMDIxMDFlOGRmNWJmZWNlL3RhYmxlcmFuZ2U6NjMzMGViZTEwODllNGI0M2IwMjEwMWU4ZGY1YmZlY2VfMi0zLTEtMS0zNjgyNQ_1714bad1-d378-40fd-b172-c1dd2266c6c7">624,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid and current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331" decimals="0" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180Ni9mcmFnOjM0NGIyMDE3MGM3MjQzOGFiZTQ5NmQ4ZTYxZmQzNmZhL3RhYmxlOjYzMzBlYmUxMDg5ZTRiNDNiMDIxMDFlOGRmNWJmZWNlL3RhYmxlcmFuZ2U6NjMzMGViZTEwODllNGI0M2IwMjEwMWU4ZGY1YmZlY2VfNC0xLTEtMS0zNjgyNQ_d98addee-a02c-4969-97e7-d0c3a7649f57">156,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99580c61c8454190b396ed58334ece96_I20221231" decimals="0" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180Ni9mcmFnOjM0NGIyMDE3MGM3MjQzOGFiZTQ5NmQ4ZTYxZmQzNmZhL3RhYmxlOjYzMzBlYmUxMDg5ZTRiNDNiMDIxMDFlOGRmNWJmZWNlL3RhYmxlcmFuZ2U6NjMzMGViZTEwODllNGI0M2IwMjEwMWU4ZGY1YmZlY2VfNC0zLTEtMS0zNjgyNQ_0d0d1d66-b980-4361-a4f8-ce52586159ad">167,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180Ni9mcmFnOjM0NGIyMDE3MGM3MjQzOGFiZTQ5NmQ4ZTYxZmQzNmZhL3RhYmxlOjYzMzBlYmUxMDg5ZTRiNDNiMDIxMDFlOGRmNWJmZWNlL3RhYmxlcmFuZ2U6NjMzMGViZTEwODllNGI0M2IwMjEwMWU4ZGY1YmZlY2VfNS0xLTEtMS0zNjgyNQ_0f0de2e5-4ab8-4777-9cbe-37ec66ae092c">536,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99580c61c8454190b396ed58334ece96_I20221231" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180Ni9mcmFnOjM0NGIyMDE3MGM3MjQzOGFiZTQ5NmQ4ZTYxZmQzNmZhL3RhYmxlOjYzMzBlYmUxMDg5ZTRiNDNiMDIxMDFlOGRmNWJmZWNlL3RhYmxlcmFuZ2U6NjMzMGViZTEwODllNGI0M2IwMjEwMWU4ZGY1YmZlY2VfNS0zLTEtMS0zNjgyNQ_901aee96-3045-4e3e-8cd7-578142791e10">803,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid insurance is mainly comprised of prepaid directors' and officers' insurance.</span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div id="idb19952ac17e43b5923fbedddc424393_49"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. <ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180OS9mcmFnOjVjZGJkOTYzOWNiYjRlZjdhMTM3ZWZkMDY5Y2M1NDdmL3RleHRyZWdpb246NWNkYmQ5NjM5Y2JiNGVmN2ExMzdlZmQwNjljYzU0N2ZfMjI2Ng_4c63fa5d-bc3b-4fd4-bfaf-b94043aa817e" continuedAt="ie3a1f99cc74e41e699223bec9d0fce4c" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_7">Table of Contents</a></span></div></div><div><span><br/></span></div><ix:continuation id="ie3a1f99cc74e41e699223bec9d0fce4c"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License Agreement with the University of Utah Research Foundation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2011, the Company entered into a license agreement with the University of Utah, under which, the Company acquired an exclusive license to an epigenetic enzyme lysine specific demethylase 1 ("LSD1"). In exchange for the license, the Company issued <ix:nonFraction unitRef="number" contextRef="ib62a51e0853048ae9069dab610776a5d_I20111231" decimals="INF" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180OS9mcmFnOjVjZGJkOTYzOWNiYjRlZjdhMTM3ZWZkMDY5Y2M1NDdmL3RleHRyZWdpb246NWNkYmQ5NjM5Y2JiNGVmN2ExMzdlZmQwNjljYzU0N2ZfMzYx_f89c88a0-7817-4a0d-829d-e1893a5d3e11">2</ix:nonFraction>% equity ownership in the Company based on a fully diluted basis at the effective date of the agreement subject to certain adjustments specified in the agreement, such as granted revenue sharing rights on any resulting products or processes to commence on first commercial sale, and milestone payments based upon regulatory approval of any resulting product or process as well as on the second anniversary of first commercial sale.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cancer Prevention and Research Institute of Texas</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company entered into a Cancer Research Grant Contract with CPRIT. Pursuant to the contract, CPRIT awarded the Company a grant up to $<ix:nonFraction unitRef="usd" contextRef="i3a9d75c4f5bd48619d14c8ca1830a6c9_D20160601-20160630" decimals="-5" name="flks:RevenueFromGrantsMaximumAward" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180OS9mcmFnOjVjZGJkOTYzOWNiYjRlZjdhMTM3ZWZkMDY5Y2M1NDdmL3RleHRyZWdpb246NWNkYmQ5NjM5Y2JiNGVmN2ExMzdlZmQwNjljYzU0N2ZfNjA0NzMxMzk1Nzk1MA_f3a5f303-96a7-4be7-a28a-041a7afc7ab8">18.7</ix:nonFraction> million further modified to $<ix:nonFraction unitRef="usd" contextRef="i2e86d1fdb89f494eb9ee243d58ff09cd_D20160701-20160701" decimals="-5" name="flks:RevenueFromGrantsMaximumAward" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180OS9mcmFnOjVjZGJkOTYzOWNiYjRlZjdhMTM3ZWZkMDY5Y2M1NDdmL3RleHRyZWdpb246NWNkYmQ5NjM5Y2JiNGVmN2ExMzdlZmQwNjljYzU0N2ZfNjA0NzMxMzk1Nzk4MQ_ec206740-ff9c-4260-bc50-28e51749b0cb">16.1</ix:nonFraction>&#160;million to fund development of LSD 1 inhibitor. This is a <ix:nonNumeric contextRef="i3a9d75c4f5bd48619d14c8ca1830a6c9_D20160601-20160630" name="flks:RevenueFromGrantsAwardTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180OS9mcmFnOjVjZGJkOTYzOWNiYjRlZjdhMTM3ZWZkMDY5Y2M1NDdmL3RleHRyZWdpb246NWNkYmQ5NjM5Y2JiNGVmN2ExMzdlZmQwNjljYzU0N2ZfMTA5OTUxMTYzMzA0Mg_b635d594-0748-4724-b3f6-f45401cab2f1">3-year</ix:nonNumeric> grant award originally expired on May 31, 2019. The Company applied for a no cost extension through November 30, 2023. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will retain ownership over any intellectual property developed under the contract ("Project Result"). With respect to non-commercial use of any Project Result, the Company agreed to grant to CPRIT a nonexclusive, irrevocable, royalty-free, perpetual, worldwide license with right to sublicense any necessary additional intellectual property rights to exploit all Project Results by CPRIT, other governmental entities and agencies of the State of Texas, and private or independent institutions of higher education located in Texas, for education, research and other non-commercial purposes.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is obligated to make revenue-sharing payments to CPRIT with respect to net sales of any product covered by the contract, up to a maximum repayment of certain percentage of the aggregate amount paid to the Company by CPRIT under the CPRIT contract. The payments are determined as a percentage of net sales, which may be reduced if the Company is required to obtain a license from a third party to sell any such product. In addition, upon meeting the foregoing limitation on revenue-sharing payments, the Company agreed to make continued revenue-sharing payments to CPRIT of less than <ix:nonFraction unitRef="number" contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331" decimals="INF" name="flks:RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180OS9mcmFnOjVjZGJkOTYzOWNiYjRlZjdhMTM3ZWZkMDY5Y2M1NDdmL3RleHRyZWdpb246NWNkYmQ5NjM5Y2JiNGVmN2ExMzdlZmQwNjljYzU0N2ZfNjA0NzMxMzk1ODAzMg_09ee84d6-73cd-459e-98a7-45473ab0c2cf">1</ix:nonFraction>% of net sales.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease Agreement</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company presently leases office space under operating lease agreements on a month-to-month basis.</span></div></ix:continuation><div><span><br/></span></div><div id="idb19952ac17e43b5923fbedddc424393_52"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6. <ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M181Mi9mcmFnOjNkZGYzYjk2OTE1ODQyODE4NmU0NTk0NmY2OWFkNDUyL3RleHRyZWdpb246M2RkZjNiOTY5MTU4NDI4MTg2ZTQ1OTQ2ZjY5YWQ0NTJfMTcwNA_82d7faba-57ea-4e23-b340-e9496ddf122e" continuedAt="i3a002a5a8f3549d9bf0f5cc009b674f9" escape="true">FAIR VALUE OF FINANCIAL INSTRUMENTS </ix:nonNumeric></span></div><ix:continuation id="i3a002a5a8f3549d9bf0f5cc009b674f9"><ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M181Mi9mcmFnOjNkZGYzYjk2OTE1ODQyODE4NmU0NTk0NmY2OWFkNDUyL3RleHRyZWdpb246M2RkZjNiOTY5MTU4NDI4MTg2ZTQ1OTQ2ZjY5YWQ0NTJfNTQ5NzU1ODE1NTk0_73a0ff38-243b-4064-8857-580240723e78" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last is considered unobservable, are used to measure fair value:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:3pt;padding-left:76.5pt;text-align:justify;text-indent:-40.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Significant unobservable inputs including Salarius&#8217; own assumptions in determining fair value.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes the recorded values of its financial instruments, including cash and cash equivalents, accounts payable and note payable approximate their fair values due to the short-term nature of these instruments.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div id="idb19952ac17e43b5923fbedddc424393_55"></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7. <ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M181NS9mcmFnOjc2NzhiZjQ2MGYyYjRmYmU4N2UxODRkMzljMWRhN2Q0L3RleHRyZWdpb246NzY3OGJmNDYwZjJiNGZiZTg3ZTE4NGQzOWMxZGE3ZDRfMzU5MA_324ce3d5-e900-46c8-9789-15bcdbdc84b2" continuedAt="i81f639f15bee4b29be4b59498b59cd38" escape="true">STOCKHOLDERS' EQUITY</ix:nonNumeric></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_7">Table of Contents</a></span></div></div><ix:continuation id="i81f639f15bee4b29be4b59498b59cd38" continuedAt="i586628c5d0b14ad4b6f08625d25c0794"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock  Issuances</span></div><div style="margin-bottom:12pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, the Company sold <ix:nonFraction unitRef="shares" contextRef="i5f25028dab374645ab8bd704715c06ac_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M181NS9mcmFnOjc2NzhiZjQ2MGYyYjRmYmU4N2UxODRkMzljMWRhN2Q0L3RleHRyZWdpb246NzY3OGJmNDYwZjJiNGZiZTg3ZTE4NGQzOWMxZGE3ZDRfODI0NjMzNzIxNTU4Mg_87031922-e027-490c-8464-7076c00177bc">142,499</ix:nonFraction> ATM shares under the Sales Agreement, with gross proceeds of  $<ix:nonFraction unitRef="usd" contextRef="i5f25028dab374645ab8bd704715c06ac_D20230101-20230331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M181NS9mcmFnOjc2NzhiZjQ2MGYyYjRmYmU4N2UxODRkMzljMWRhN2Q0L3RleHRyZWdpb246NzY3OGJmNDYwZjJiNGZiZTg3ZTE4NGQzOWMxZGE3ZDRfODI0NjMzNzIxNTU4Ng_e8e72359-bd05-4202-a8d0-0460c0314489">0.3</ix:nonFraction> million.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 12, 2022, the Company issued <ix:nonFraction unitRef="shares" contextRef="ie6b59e45b64342c89f3426880dc1103d_D20220112-20220112" decimals="INF" name="flks:StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologySharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M181NS9mcmFnOjc2NzhiZjQ2MGYyYjRmYmU4N2UxODRkMzljMWRhN2Q0L3RleHRyZWdpb246NzY3OGJmNDYwZjJiNGZiZTg3ZTE4NGQzOWMxZGE3ZDRfNjA3_190f20b9-6f82-4400-a6a6-a89caf043a5d">40,000</ix:nonFraction> shares of the Company's common stock, valued at $<ix:nonFraction unitRef="usd" contextRef="ie6b59e45b64342c89f3426880dc1103d_D20220112-20220112" decimals="-5" name="flks:StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M181NS9mcmFnOjc2NzhiZjQ2MGYyYjRmYmU4N2UxODRkMzljMWRhN2Q0L3RleHRyZWdpb246NzY3OGJmNDYwZjJiNGZiZTg3ZTE4NGQzOWMxZGE3ZDRfNjU4_245e7b0b-7c04-4336-b34e-6b5a511f5975">0.5</ix:nonFraction> million to purchase in-process research and development technology SP-3164, please refer to NOTE 2 for further discussion. </span></div><div style="margin-bottom:12pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants Exercised for Cash </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonNumeric contextRef="i0609f51e976346d69581a350de826fe9_I20201231" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M181NS9mcmFnOjc2NzhiZjQ2MGYyYjRmYmU4N2UxODRkMzljMWRhN2Q0L3RleHRyZWdpb246NzY3OGJmNDYwZjJiNGZiZTg3ZTE4NGQzOWMxZGE3ZDRfMzU4NQ_4c203b81-3a23-43a0-b782-10008cc49498">five-year</ix:nonNumeric> warrants outstanding that were issued in February 2020 and subsequently modified in December 2020 in connection with the issuance of additional inducement warrants. The warrants are exercisable at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i750c9de36c044f428d626093ca2e218b_I20201231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M181NS9mcmFnOjc2NzhiZjQ2MGYyYjRmYmU4N2UxODRkMzljMWRhN2Q0L3RleHRyZWdpb246NzY3OGJmNDYwZjJiNGZiZTg3ZTE4NGQzOWMxZGE3ZDRfMjkxOQ_2b00b63a-e8a6-40fe-82ac-7ad131475c11">28.75</ix:nonFraction>. The inducement warrants expire on June 11, 2026, and are exercisable at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i0609f51e976346d69581a350de826fe9_I20201231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M181NS9mcmFnOjc2NzhiZjQ2MGYyYjRmYmU4N2UxODRkMzljMWRhN2Q0L3RleHRyZWdpb246NzY3OGJmNDYwZjJiNGZiZTg3ZTE4NGQzOWMxZGE3ZDRfMzAxNg_13e24570-c01e-4c6b-b89b-24e03519f830">29.55</ix:nonFraction>. The Company has <ix:nonNumeric contextRef="i222ce181634a4cce9e9e36ac4ca82e0f_I20220430" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M181NS9mcmFnOjc2NzhiZjQ2MGYyYjRmYmU4N2UxODRkMzljMWRhN2Q0L3RleHRyZWdpb246NzY3OGJmNDYwZjJiNGZiZTg3ZTE4NGQzOWMxZGE3ZDRfMzAzNg_f8bf928f-28f5-46c4-b227-d4f396d2b5ac">5.5</ix:nonNumeric> year warrants outstanding that were issued in April 2022, with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib762f099224741f2a7a409f28e07d108_I20220430" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M181NS9mcmFnOjc2NzhiZjQ2MGYyYjRmYmU4N2UxODRkMzljMWRhN2Q0L3RleHRyZWdpb246NzY3OGJmNDYwZjJiNGZiZTg3ZTE4NGQzOWMxZGE3ZDRfMzExOQ_247ae3af-9512-4d3e-9fa7-53ef4d822000">8.4975</ix:nonFraction> per share. The warrants will be exercisable <ix:nonNumeric contextRef="i222ce181634a4cce9e9e36ac4ca82e0f_I20220430" name="flks:WarrantsAndRightsExercisableTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M181NS9mcmFnOjc2NzhiZjQ2MGYyYjRmYmU4N2UxODRkMzljMWRhN2Q0L3RleHRyZWdpb246NzY3OGJmNDYwZjJiNGZiZTg3ZTE4NGQzOWMxZGE3ZDRfMzE2Ng_7cd87de0-3034-4414-b0be-f23dde496d35">six months</ix:nonNumeric> following the issuance date and will expire five and one-half years from the issuance date. </span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i586628c5d0b14ad4b6f08625d25c0794"> As of March&#160;31, 2023 and 2022, approximately <ix:nonFraction unitRef="shares" contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M181NS9mcmFnOjc2NzhiZjQ2MGYyYjRmYmU4N2UxODRkMzljMWRhN2Q0L3RleHRyZWdpb246NzY3OGJmNDYwZjJiNGZiZTg3ZTE4NGQzOWMxZGE3ZDRfNzA3NQ_e5dab0a4-6c5c-4f43-b2ea-09da21f82338">597,512</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ie5a306ceedd2446d93819bfd4e8afbe8_I20220331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M181NS9mcmFnOjc2NzhiZjQ2MGYyYjRmYmU4N2UxODRkMzljMWRhN2Q0L3RleHRyZWdpb246NzY3OGJmNDYwZjJiNGZiZTg3ZTE4NGQzOWMxZGE3ZDRfODI0NjMzNzIxNTM5OA_b68c59d6-9649-4a6d-bd25-24a1e6c282a2">317,329</ix:nonFraction>  warrants remain outstanding</ix:continuation>.</span></div><div id="idb19952ac17e43b5923fbedddc424393_61"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. <ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfMjM3Mg_7ce09831-72c3-4c65-b2b0-c8f8dad4ec0e" continuedAt="i0bbdf0cdc2554cb2bbdddd4c928202dd" escape="true">EQUITY-BASED COMPENSATION </ix:nonNumeric></span></div><ix:continuation id="i0bbdf0cdc2554cb2bbdddd4c928202dd" continuedAt="i47e3dfbadf9842bc9597eb1d8b7ed9b4"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Incentive Plans</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has granted options to employees, directors, and consultants under the 2015 Equity Incentive Plan (the "2015 Plan"). The 2015 Plan provides for the grant of incentive stock options ("ISOs"), nonstatutory stock options, restricted stock awards, restricted stock units, stock appreciation rights, performance-based stock awards and other stock-based awards. Additionally, the 2015 Plan provides for the grant of performance-based cash awards. ISOs may be granted only to the Company's employees. All other awards may be granted to the Company's employees, including officers, and to non-employee directors and consultants. As of March&#160;31, 2023, there were approximately <ix:nonFraction unitRef="shares" contextRef="ic4da1d17c34948158531999f1b199116_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfNzMx_30221af4-bbb6-4e7c-9871-3a53e5ac0c66">55,365</ix:nonFraction> shares remaining available for the grant of option awards under the 2015 Plan.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, the Company awarded <ix:nonFraction unitRef="shares" contextRef="i057e962232c1423ba944409a49a5dbbe_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfODI0NjMzNzIxMTU5MQ_ef75b123-8ddd-4982-8609-1f078f339a2c">12,220</ix:nonFraction> restricted stock units to its employees and <ix:nonFraction unitRef="shares" contextRef="i571227b74c3343649a8d063d182cb2fc_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfODI0NjMzNzIxMTYwOA_8d570bba-ccf3-4adf-8f02-78ea884d5052">36,640</ix:nonFraction> restricted stock awards to its officers and directors, pursuant to the plan described above. Both the restricted stock units and restricted stock awards are valued at the closing price $<ix:nonFraction unitRef="usdPerShare" contextRef="i0508e6c8ee6f431281f539250baa1ab9_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfODI0NjMzNzIxMTYxNg_de8bb705-0163-4c68-9918-49cf85ec1bf7">1.57</ix:nonFraction> of the Company's common stock on the grant date, and generally vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfODI0NjMzNzIxMTc2Ng_92999dea-8fe6-44eb-b277-ca85e4d4df2d">one</span> to <ix:nonNumeric contextRef="i2ae8b02bb35841958964d4e4837cd194_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfODI0NjMzNzIxMTc4NQ_5ee748a0-f35e-4684-abe1-9535a0e10292">four years</ix:nonNumeric>. Total fair value of the restricted stock awards and restricted stock units awarded during the  three months periods ended March&#160;31, 2023 is $<ix:nonFraction unitRef="usd" contextRef="i0508e6c8ee6f431281f539250baa1ab9_D20230101-20230331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfODI0NjMzNzIxMTU5OQ_94ac3c29-9acb-4db4-b720-44b1e5cef86d">76,679</ix:nonFraction>. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three-month periods ended March&#160;31, 2023 and 2022, the Company awarded <ix:nonFraction unitRef="shares" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfODc4_178060ce-2435-44fe-b491-9dd286246549">0</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfMTA5OTUxMTYzMTIxMQ_5804e9fc-3530-472e-84fb-b0f4cbb27571">50,160</ix:nonFraction> stock options, to its employees and directors, pursuant to the plan described above. Stock options generally vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfMTAyMQ_c80ce869-a2e6-4296-953f-d1a3e4d42122">one</span> to <ix:nonNumeric contextRef="i576cab9bf4214c329f021a9b27484527_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfMTAyNw_cf93f03d-f28b-49f2-ac6f-e094e362e9ba">four years</ix:nonNumeric> and have a contractual term of <ix:nonNumeric contextRef="i15eb79ec74594262ac1ee2bbbcb2dc8b_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfMTA2MQ_67d7a525-386e-4df0-a449-de8371444e1c">ten years</ix:nonNumeric>. Stock options are valued using the Black-Scholes option pricing model and compensation cost is recognized based on the resulting value over the service period. Expected volatilities utilized in the model are based on implied volatilities from traded stocks of peer companies. Similarly, the dividend yield is based on historical experience and the estimate of future dividend yields. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The expected term of the options is based on the average period the stock options are expected to remain outstanding. The fair value of the option grants awarded during the three months periods ended March&#160;31, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfMTc3NA_3a4fb6fd-a47a-4954-85c5-63a7991c6378">0.5</ix:nonFraction> million, which has been estimated with the following assumptions on the grant date.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfMjM2NQ_97c75e52-5d6d-4ee9-bf98-2bd1df7f4d0a" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.128%"><tr><td style="width:1.0%"></td><td style="width:59.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.171%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.952%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjczMzQ4MWQwMjg0ZjRmOGU4MWUxZWQ1NDA1MTRkMDk1L3RhYmxlcmFuZ2U6NzMzNDgxZDAyODRmNGY4ZTgxZTFlZDU0MDUxNGQwOTVfMi0xLTEtMS0zNjgyNS90ZXh0cmVnaW9uOjE0MTg0YmU2MzFiOTQ3MTI5NzQyMGNjYjQwMGI4NGYyXzQ_caf70a3b-2045-4c03-87fe-934ab09d748a">1.62</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjczMzQ4MWQwMjg0ZjRmOGU4MWUxZWQ1NDA1MTRkMDk1L3RhYmxlcmFuZ2U6NzMzNDgxZDAyODRmNGY4ZTgxZTFlZDU0MDUxNGQwOTVfMi0xLTEtMS0zNjgyNS90ZXh0cmVnaW9uOjE0MTg0YmU2MzFiOTQ3MTI5NzQyMGNjYjQwMGI4NGYyXzc_3c157b2e-a044-48ec-ac9b-523765276284">1.70</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjczMzQ4MWQwMjg0ZjRmOGU4MWUxZWQ1NDA1MTRkMDk1L3RhYmxlcmFuZ2U6NzMzNDgxZDAyODRmNGY4ZTgxZTFlZDU0MDUxNGQwOTVfMy0xLTEtMS0zNjgyNS90ZXh0cmVnaW9uOmM0MjdhZjhiNjYzYTQyNDE5ZDk3YTdkMzVlZjU1OWQ4XzQ_ae511a0e-40ad-4201-baa8-bca14893f428">125.19</ix:nonFraction>% <ix:nonFraction unitRef="number" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjczMzQ4MWQwMjg0ZjRmOGU4MWUxZWQ1NDA1MTRkMDk1L3RhYmxlcmFuZ2U6NzMzNDgxZDAyODRmNGY4ZTgxZTFlZDU0MDUxNGQwOTVfMy0xLTEtMS0zNjgyNS90ZXh0cmVnaW9uOmM0MjdhZjhiNjYzYTQyNDE5ZDk3YTdkMzVlZjU1OWQ4Xzc_f72b1c67-8a7a-478d-b06f-b8874879511d">126.42</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i63818b7d4b4049b2b5649dd59933606d_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjczMzQ4MWQwMjg0ZjRmOGU4MWUxZWQ1NDA1MTRkMDk1L3RhYmxlcmFuZ2U6NzMzNDgxZDAyODRmNGY4ZTgxZTFlZDU0MDUxNGQwOTVfNC0xLTEtMS0zNjgyNS90ZXh0cmVnaW9uOjFlODZiOWIyNTZkMTRmOGQ5ZWM3NmI2ZmY5ODJhMmE4XzQ_fe678a6b-ba10-4e93-8b81-bfc14dd344a3">5.00</ix:nonNumeric>-<ix:nonNumeric contextRef="i6ca10793f84f44ba8ea25c255a1b8295_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjczMzQ4MWQwMjg0ZjRmOGU4MWUxZWQ1NDA1MTRkMDk1L3RhYmxlcmFuZ2U6NzMzNDgxZDAyODRmNGY4ZTgxZTFlZDU0MDUxNGQwOTVfNC0xLTEtMS0zNjgyNS90ZXh0cmVnaW9uOjFlODZiOWIyNTZkMTRmOGQ5ZWM3NmI2ZmY5ODJhMmE4Xzc_63220191-fb5f-4aaf-9df2-ee6d010afec9">6.00</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjczMzQ4MWQwMjg0ZjRmOGU4MWUxZWQ1NDA1MTRkMDk1L3RhYmxlcmFuZ2U6NzMzNDgxZDAyODRmNGY4ZTgxZTFlZDU0MDUxNGQwOTVfNS0xLTEtMS0zNjgyNQ_4df3f292-d27b-4e4b-a482-93f884d71ca4">0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><ix:continuation id="i47e3dfbadf9842bc9597eb1d8b7ed9b4"><div style="margin-bottom:8pt;margin-top:8pt"><ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfMjM2Ng_ac78d169-47af-4c7b-a5d4-c919463baeb6" escape="true"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for employees and non-employees for the three months ended March&#160;31, 2023 and 2022: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:44.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.755%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual<br/>Term (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9bb28550232b40a6a710d558583695ab_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfOS0xLTEtMS0zNjgyNQ_d688b2dc-fed4-4b10-92b0-aba4709719fc">63,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9bb28550232b40a6a710d558583695ab_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfOS0zLTEtMS0zNjgyNQ_0fec19b0-4379-43a4-b9bb-6df1cc4a357c">68.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib8708a10429e4617bd4cd3efa5411eee_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfOS01LTEtMS0zNjgyNQ_8465303d-1dd6-4b12-899c-bf041c8ba2f1">8.50</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bb28550232b40a6a710d558583695ab_I20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfOS03LTEtMS0zNjgyNQ_22cd097a-83ee-4823-bef6-f28641a3e324">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTAtMS0xLTEtMzY4MjU_403ee475-90d5-4ff2-b036-600cdd1866b0">50,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTAtMy0xLTEtMzY4MjU_be478a31-4151-493c-8b84-0d7c2c84968f">12.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTEtMS0xLTEtMzY4MjU_adcfb4f5-99bb-4e3e-817e-8067f38cdd41">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usdPerShare" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" xsi:nil="true" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTEtMy0xLTEtMzY5MDY_06280a48-1228-4663-bc5d-c242d19f89e1"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTItMS0xLTEtMzY4MjU_ba3fbe45-8b97-42a5-9440-333540157403">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usdPerShare" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" xsi:nil="true" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTItMy0xLTEtMzY5MDg_4dd005ec-898a-4b91-a042-ebd3a2deb555"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTMtMS0xLTEtMzY4MjU_8e7901b4-7ecf-4d23-a351-dccb1105c887">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usdPerShare" contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" xsi:nil="true" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTMtMy0xLTEtMzY5MTA_a5bac9fb-559f-44cd-8acb-9be0cb2c66f6"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie5a306ceedd2446d93819bfd4e8afbe8_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTQtMS0xLTEtMzY4MjU_d634954f-b89a-46b2-b11e-c75f2ddf7949">114,079</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie5a306ceedd2446d93819bfd4e8afbe8_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTQtMy0xLTEtMzY4MjU_764b5861-8ab5-41f6-9966-7dbc88c1d28b">43.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTQtNS0xLTEtMzY4MjU_af6e2997-97c3-4f8e-aa98-c33173145db9">8.94</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5a306ceedd2446d93819bfd4e8afbe8_I20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTQtNy0xLTEtMzY4MjU_cbc48583-a7a4-446c-b5db-b277f749ed06">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie5a306ceedd2446d93819bfd4e8afbe8_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTUtMS0xLTEtMzY4MjU_1de4159a-b56f-4fb0-861a-4325e81532bf">30,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie5a306ceedd2446d93819bfd4e8afbe8_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTUtMy0xLTEtMzY4MjU_ada3b842-f1e5-4ac9-a565-cb2206492a79">111.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTUtNS0xLTEtMzY4MjU_b3b6543e-83aa-4bdf-9735-1817ca834891">8.01</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5a306ceedd2446d93819bfd4e8afbe8_I20220331" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTUtNy0xLTEtMzY4MjU_7a30506d-a89b-4e78-adad-97b3e85f3cd9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i99580c61c8454190b396ed58334ece96_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfOS0xLTEtMS0zODY5OA_81cb637e-8121-499e-bb11-1282b45919be">107,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i99580c61c8454190b396ed58334ece96_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfOS0zLTEtMS0zODY5OA_9341ee5c-40df-4c3f-967b-1cf902b0309f">23.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9f0d7863d02d4527b559355b990c8aac_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfOS01LTEtMS0zODY5OA_3b397999-bc5e-4fa9-b3b7-621e8f0ecc6d">8.29</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99580c61c8454190b396ed58334ece96_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfOS03LTEtMS0zODcxOA_5848f233-15d4-4b09-b278-1208f90a1265">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTAtMS0xLTEtMzg3MDg_dbaa1876-c2b0-4624-97c6-425650f2c645">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usdPerShare" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" xsi:nil="true" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTAtMy0xLTEtMzg3MDg_d7b9d377-230f-4a2a-8580-4d9033b8a6dc"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTEtMS0xLTEtMzg3MDg_5c0ff0e1-c895-43d3-96aa-d22d8b783759">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usdPerShare" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" xsi:nil="true" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTEtMy0xLTEtMzg3MDg_a753d084-e56e-469e-9d9d-2a12453bfb7a"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTItMS0xLTEtMzg3MDg_6224086d-2b81-49a0-b925-be0f9fa4c3b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usdPerShare" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" xsi:nil="true" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTItMy0xLTEtMzg3MDg_bef44e12-2177-43cb-b4a5-0ac95227d4cd"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTMtMS0xLTEtMzg3MDg_3cfb4f6a-28df-45c7-a789-f804cbb7f37d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usdPerShare" contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" xsi:nil="true" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTMtMy0xLTEtMzg3MDg_b5296253-d955-4e67-a6ec-015e6b7cb751"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTQtMS0xLTEtMzg3MDI_3a837d2f-bbe8-4020-b535-b978d681c506">107,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTQtMy0xLTEtMzg3MDI_2b56327f-8187-4d70-bc09-16ecdd09cf13">23.67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTQtNS0xLTEtMzg3MDI_177b4b3c-682a-4b93-86c2-95c1d63dc0e0">8.04</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTQtNy0xLTEtMzg3MDY_1f02f320-7b8b-4197-aefe-55434743d2c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTUtMS0xLTEtMzg3MDI_25da84ec-dc72-44eb-a9b7-92f4991fec4e">59,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTUtMy0xLTEtMzg3MDI_5949319b-5ca6-4801-a416-4628b203dc96">28.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTUtNS0xLTEtMzg3MDI_064e8e2c-8c9a-40cc-b1ae-91ab99124a50">7.83</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTUtNy0xLTEtMzg3MDY_6774884d-9364-4f2f-bc2d-a1e83a9e6178">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of both March&#160;31, 2023 and 2022, there was approximately $<ix:nonFraction unitRef="usd" contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfMTA5OTUxMTYzMTA3OQ_fe39487c-08a0-4d72-b729-ed6d16673a11">0.7</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie5a306ceedd2446d93819bfd4e8afbe8_I20220331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfMjA2NA_cae0ae14-b8f0-4d17-9c9e-338f1e4b4d1a">1.0</ix:nonFraction> million of total unrecognized compensation cost related to unvested stock options,. Total unrecognized compensation cost will be adjusted for future changes in employee and non-employee forfeitures, if any. The Company expects to recognize that cost over a remaining weighted-average period of <ix:nonNumeric contextRef="i25aebc31ca484ab3b3cbb46087a9333b_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfMjM2MA_127f69c1-7e61-4712-897e-8ad6a2d7b5af">1.9</ix:nonNumeric> years.</span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div id="idb19952ac17e43b5923fbedddc424393_64"></div><div style="margin-bottom:12pt"><span><br/></span></div><div id="idb19952ac17e43b5923fbedddc424393_67"></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10 <ix:nonNumeric contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182Ny9mcmFnOmVjNjY0NGVmNjJmMzQ4OTU4NmE3MmQ4Njk2NzExZmRmL3RleHRyZWdpb246ZWM2NjQ0ZWY2MmYzNDg5NTg2YTcyZDg2OTY3MTFmZGZfMjQw_4b9fe734-3478-42f8-bdba-0c98021bac2e" continuedAt="i767f12879c0547bc9e2b66fefb5c5325" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:justify"><ix:continuation id="i767f12879c0547bc9e2b66fefb5c5325" continuedAt="i4e4e747318a04af59af814c2242403f7"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5, 2023, the Company was notified by FDA that they have completed the review of the Company's submission and have concluded that the clinical trial may be resumed. See Recent Developments for further discussion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">. </span></ix:continuation></div><div style="margin-bottom:12pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="i4e4e747318a04af59af814c2242403f7" continuedAt="ie8a0929e884f4bf780d02f9967b47388">From April 4, 2023 to May 11, 2023, the Company sold <ix:nonFraction unitRef="shares" contextRef="i1c04e18316394009b6153f59ba41f585_D20230404-20230511" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182Ny9mcmFnOmVjNjY0NGVmNjJmMzQ4OTU4NmE3MmQ4Njk2NzExZmRmL3RleHRyZWdpb246ZWM2NjQ0ZWY2MmYzNDg5NTg2YTcyZDg2OTY3MTFmZGZfODI0NjMzNzIxMDM0OA_b80f7dd0-71fe-45a9-aa61-57d209508be3">527,672</ix:nonFraction> ATM shares of its common shares with gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i1c04e18316394009b6153f59ba41f585_D20230404-20230511" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182Ny9mcmFnOmVjNjY0NGVmNjJmMzQ4OTU4NmE3MmQ4Njk2NzExZmRmL3RleHRyZWdpb246ZWM2NjQ0ZWY2MmYzNDg5NTg2YTcyZDg2OTY3MTFmZGZfODI0NjMzNzIxMDM1Nw_b3dbb691-d290-4f8b-a345-29f56642dde1">1.3</ix:nonFraction>&#160;million </ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie8a0929e884f4bf780d02f9967b47388">under the Sales Agreement.</ix:continuation> </span></div><div><span><br/></span></div><div style="margin-bottom:12pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="idb19952ac17e43b5923fbedddc424393_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:8.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.342%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The following discussion and analysis should be read in conjunction with the unaudited financial information and the notes thereto included herein, as well as our audited financial statements and notes thereto contained in our </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Annual Report</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 27, 2023. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under "Part I - Item 1A - Risk Factors" discussed in our </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Annual Report</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> on Form 10-K for the year ended December 31, 2022, in other subsequent filings with the SEC, and elsewhere in this Quarterly Report on Form 10-Q. These statements, like all statements in this report, speak only as of the date of this Quarterly Report on Form 10-Q (unless another date is indicated), and we undertake no obligation to update or revise these statements in light of future developments.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are a clinical-stage biopharmaceutical company focused on developing treatments for cancers with high, unmet medical need</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Specifically, we are developing treatments for cancers caused by dysregulated gene expression, i.e., genes which are incorrectly turned on or off. We are developing two classes of drugs that address gene dysregulation: protein inhibitors and targeted protein degraders. Our technologies have the potential to work in both liquid and solid tumors. Our current pipeline consists of: 1) SP-3164, a targeted protein degrader, and 2) seclidemstat (SP-2577), a targeted protein inhibitor. </span></div><div style="margin-bottom:12pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have no products approved for commercial sale and have not generated any revenue from product sales. We have never been profitable and have incurred operating losses in each year since inception. We had an accumulated deficit of $69.1 million as of March&#160;31, 2023. Substantially all of our operating losses resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations. As of March&#160;31, 2023, we had cash and cash equivalents of $9.3 million.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial statements are prepared using Generally Accepted Accounting Principles in the United States of America (&#8220;GAAP&#8221;) applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Our financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities should we be unable to continue as a going concern.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant expenses and increasing operating losses for at least the next several years as we initiate and continue the clinical development of, and seek regulatory approval for, our product candidate, add personnel necessary to continue to operate as a public company, and work to develop an advanced clinical pipeline of product candidates. We expect that our operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of clinical development programs and efforts to achieve regulatory approval.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The lack of revenue from product sales to date and recurring losses from operations since our inception raise substantial doubt as to our ability to continue as a going concern. We will continue to require substantial additional capital to continue our clinical development activities will likely need such additional capital sooner than 12 months and will need to raise substantial additional capital in the future to continue to fund our operations. The amount and timing of our future funding requirements will depend on many factors, including the pace and results of our development, regulatory approvals and authorizations, commercialization efforts and market conditions. Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on our financial condition and our ability to develop and commercialize our product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We intend to obtain additional capital through the sale of equity securities in one or more offerings or through issuances of debt instruments, which will likely cause significant dilution to our existing shareholders. We may also consider new collaborations or selectively partnering our technology. However, we cannot provide any assurance that we will be successful in accomplishing any of our plans to obtain additional capital or be able to do so on terms acceptable to us.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Program Development</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to develop SP-3164 and SP-2577 for treatment of cancers while attempting to maximize return for investors. To achieve this goal, our strategy consists of a two-pronged approach: 1) speed-to-market by developing SP-3164 and SP-2577 in high unmet need indications and 2) expand the market by developing SP-3164 and SP-2577 in larger market indications. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">SP-3164 &#8211; Targeted Protein Degradation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">SP-3164 is a next-generation cereblon-binding molecular glue. Molecular glues are small molecules that commandeer the body&#8217;s normal protein degradation processes by causing proteins to stick to one another thereby inducing selective degradation of cancer-causing proteins. Derived from avadomide, SP-3164 is engineered using DECS (deuterium-enabled chiral switching), a process that replaces hydrogen atoms with deuterium to stabilize the molecule&#8217;s active enantiomer, resulting in a novel molecular entity with the potential for increased efficacy and improved safety compared to the 1st generation compound. SP-3164 degrades transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), resulting in both direct anti-cancer activity and immune-modulating properties.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">SP-3164 has potential to treat both hematologic and solid tumors and is currently in IND-enabling studies. We have presented preclinical data of SP-3164 in hematological cancers at several scientific conferences. Last year, we completed the pre-IND meeting process with the FDA and plan to submit an IND application in the first half of 2023.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Seclidemstat - Targeted Protein Inhibition</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our lead compound, seclidemstat (SP-2577), is a small molecule that inhibits the epigenetic enzyme lysine specific demethylase 1 (LSD1). LSD1 is an enzyme that removes mono- and di-methyl marks on histones (core protein of chromatin) to alter gene expression. LSD1&#8217;s enzymatic activity can cause genes to turn on or off and thereby affect the cell&#8217;s gene expression and overall activity. In addition, LSD1 can act via its scaffolding properties, independently of its enzymatic function, to alter gene expression and modulate cell fate. In healthy cells, LSD1 is necessary for stem cell maintenance and cell development processes. However, in several cancers LSD1 is highly expressed and acts aberrantly to incorrectly silence or activate genes leading to disease progression. High levels of LSD1 expression are often associated with aggressive cancer phenotypes and poor patient prognosis. Hence, development of targeted LSD1 inhibitors is of interest for the treatment of various cancers. SP-2577 uses a novel, reversible mechanism to effectively inhibit LSD1&#8217;s enzymatic and scaffolding properties and thereby treat and prevent cancer progression.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">SP-2577 is being developed for both solid and liquid tumors. Our lead indication for SP-2577 is a devastating bone and soft-tissue cancer called Ewing sarcoma, which has a median age of diagnosis of 15. We are currently in a Phase 1/2 trial to treat relapsed/refractory Ewing sarcoma patients in combination with topotecan and cyclophosphamide. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, as part of our market expansion strategy, in 2021 an Investigator Initiated Trial with the MD Anderson Cancer Center was initiated to study SP-2577 in combination with azacitidine for the treatment of patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). MDS and CMML can progress into Acute Myeloid Leukemia (AML), which the American Cancer Society estimates there were almost 20,000 new cases of AML in the US alone in 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div id="idb19952ac17e43b5923fbedddc424393_73"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Results of Operations</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"> Three months ended March 31, 2023 Compared to the Three months ended March 31, 2022</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the condensed consolidated results of our operations for the three months ended March&#160;31, 2023 compared to March&#160;31, 2022. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.064%"><tr><td style="width:1.0%"></td><td style="width:39.943%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.117%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.117%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.034%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,725,588&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,439,475&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(713,887)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,695,075&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,677,754&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,321&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net and other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,890&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,004&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,886&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,340,773)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,109,225)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">768,452</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Research and development expenses decreased during the three months ended March&#160;31, 2023 compared to the same period in 2022 primarily due  to lower spending on SP-2577. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:41.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.943%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.484%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">SP-2577</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">SP-3164</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Research and development costs by candidates and by categories:</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outsourced research and development costs</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712,825&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,270,309&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,770,124&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,603&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee-related costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,376&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605,818&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,974&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,059&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and laboratory costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,822&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390,419&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,467&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,367&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In process research and development costs</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,987,900</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total research and development costs</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,344,023</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,266,546</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,381,565</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,171,929</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative expenses is $1.7 million during the three months ended March&#160;31, 2023, consistent with the three months ended March&#160;31, 2022, resulting from higher legal and business development cost offsetting by lower proxy service expense and overall compensation and benefit costs. </span></div><div id="idb19952ac17e43b5923fbedddc424393_76"></div><div style="margin-bottom:12pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred operating losses and we anticipate that we will continue to incur losses for the foreseeable future.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we had $5.4 million of working capital and our cash and cash equivalents totaled $9.3 million, which were held in bank deposit accounts and a money market account. Our cash and cash equivalents balance decreased during the three months ended March&#160;31, 2023, primarily due to cash used in operating activities, partially offset by the cash received from financing activities. We believe that our $9.3 million in cash and cash equivalents on hand as of March&#160;31, 2023, is sufficient to fund our anticipated operations through the third quarter of 2023.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect to generate any revenue from product sales unless and until we obtain regulatory approval for and commercialize our product candidate. At the same time, we expect to continue to incur significant expenses and increasing operating losses for at least the next several years as we initiate and continue the clinical development of, and seek regulatory approval for, our product candidate, add personnel necessary to continue to operate as a public company, and work to develop an advanced clinical pipeline of product candidates. We expect that our operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of clinical development programs and efforts to achieve regulatory approval.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have secured capital from the sale of equity and grant revenue. Until we can generate a sufficient amount of revenue from our products, if ever, we intend, when required, to obtain additional capital through the sale of equity securities in one or more offerings or through issuances of debt instruments. We may also consider new </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaborations or selectively partnering our technology. However, we cannot provide any assurance that we will be successful in accomplishing any of our plans to obtain additional capital or be able to do so on favorable terms acceptable to us. If we are unable to obtain additional financing, we may be required to significantly delay, scale back or discontinue the development or commercialization of our product candidate.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we may be unable to complete a collaboration, or if we do, we may be forced to relinquish valuable future product rights. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:56.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.812%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.838%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by in:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,169,435)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,520,826)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,500,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,832,753)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,020,826)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net cash used in operating activities was $3.2 million in the current period, a decrease of approximately $0.4 million from the same period a year ago. The decrease is primarily due to lower research and development cost incurred in current year and $1.5 million cash received from CPRIT.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net cash used in investing activities was $1.5 million in the prior period, for the cash portion of the purchase price for the acquisition of in-process research and development technology SP-3164. There was no such transaction during the same period in 2023.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net cash provided by financing activities for the three months ended March&#160;31, 2023 was $0.3 million, compared to $0.0 million for the same period of the year 2022. This is due to the Company's sale of 142,499 common shares under is ATM offering during the three months ended March 31, 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Critical Accounting Policies and Estimates</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our management's discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities as of the date of the condensed consolidated balance sheet and the reported amounts of expenses during the reporting period. In accordance with GAAP, we base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances at the time such estimates are made. Actual results may differ materially from our estimates and judgments under different assumptions or conditions. We periodically review our estimates in light of changes in circumstances, facts and experience. The effects of material revisions in estimates are reflected in our condensed consolidated financial statements prospectively from the date of the change in estimate.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There have been no material changes to our critical accounting policies from those described in "Management's Discussion and Analysis of Financial Condition and Results of Operations" included in our Annual Report on Form 10-K filed with SEC on March 27, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Readers should refer to our Annual Report on Form10-K filed with SEC on March 27, 2023, Note 2, Basis of Presentation and Significant Accounting Policies to the accompanying financial statements for descriptions of these policies and estimates.</span></div><div id="idb19952ac17e43b5923fbedddc424393_79"></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:8.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.342%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quantitative and Qualitative Disclosures about Market Risk</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_7">Table of Contents</a></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, and are not required to provide the information under this item.</span></div><div><span><br/></span></div><div id="idb19952ac17e43b5923fbedddc424393_82"></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:8.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.342%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 4. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Controls and Procedures</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of March&#160;31, 2023. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of March&#160;31, 2023, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the  three months ended March&#160;31, 2023, there was no significant change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div><span><br/></span></div><div id="idb19952ac17e43b5923fbedddc424393_85"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II - OTHER INFORMATION</span></div><div id="idb19952ac17e43b5923fbedddc424393_88"></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:8.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.342%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 1. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Proceedings</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are not a party to any material legal proceedings on the date of this report. We may from time to time become involved in legal proceedings arising in the ordinary course of business, and the resolution of any such claims could be material.</span></div><div><span><br/></span></div><div id="idb19952ac17e43b5923fbedddc424393_91"></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:8.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.342%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Risk Factors</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For a discussion of certain factors that could materially affect our business, financial condition, and operating results, you should carefully review and consider the information under &#8220;Part I, Item 1A- Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 27, 2023</span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="idb19952ac17e43b5923fbedddc424393_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary;margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.701%"><tr><td style="width:1.0%"></td><td style="width:8.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.342%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibits</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.670%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.676%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit<br/>number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description of Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1615219/000110465915007801/a15-4061_1ex3d1.htm">Amended and Restated Certificate Amended and Restated Certificate of Incorporation </a></span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1615219/000119312519199074/d754556dex31.htm">Certificate of Amendment to Certificate of Incorporation filed with the Secretary of State of Delaware on July 18, 2019</a></span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1615219/000161521922000135/exhibit31.htm">Certificate of Amendment to Certificate of Incorporation filed with the Secretary of State of Delaware on October 14, 2022</a></span></div><div><span><br/></span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1615219/000119312519199074/d754556dex32.htm">Amended and Restated Bylaws, effective July 19, 2019</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="slrx20230331ex-311.htm">Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.</a></span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="slrx20230331ex-312.htm">Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="slrx20230331ex-321.htm">Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rule 13a-14(b) or 15d-14(b) of the Exchange Act and 18 U.S.C. Section 1350.</a></span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following materials from Salarius Pharmaceuticals, Inc.'s Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2023, formatted in XBRL (eXtensible Business Reporting Language):(i) Unaudited Condensed Consolidated Balance Sheets, (ii) Unaudited Condensed Consolidated Statements of Operations (iii) Unaudited Condensed Consolidated Statements of Stockholders' Equity (Deficit), (iv) Unaudited Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed Unaudited Consolidated Financial Statements.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:38.362%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">*   The material contained in Exhibit 32.1 is not deemed &#8220;filed&#8221; with the SEC and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language contained in such filing, except to the extent that the registrant specifically incorporates it by reference.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="idb19952ac17e43b5923fbedddc424393_97"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idb19952ac17e43b5923fbedddc424393_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:4.808%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.111%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SALARIUS PHARMACEUTICALS,&#160;INC.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David J. Arthur</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David J. Arthur</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Executive Officer (Principal Executive Officer)</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mark J. Rosenblum</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark J. Rosenblum</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Chief Financial Officer and Executive Vice President of Finance (Principal Financial Officer and Principal Accounting Officer)</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 11, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>2
<FILENAME>flks-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:3bcb0391-ae28-4064-946d-9955ab3b15fb,g:a3263b3f-ee17-40f5-9314-e2273145249f-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:flks="http://www.flex-pharma.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.flex-pharma.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="flks-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="flks-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="flks-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="flks-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="COVERPAGE" roleURI="http://www.flex-pharma.com/role/COVERPAGE">
        <link:definition>0000001 - Document - COVER PAGE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDOPERATIONS" roleURI="http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONS">
        <link:definition>0000007 - Disclosure - ORGANIZATION AND OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>0000008 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GRANTRECEIVABLEFROMCPRIT" roleURI="http://www.flex-pharma.com/role/GRANTRECEIVABLEFROMCPRIT">
        <link:definition>0000009 - Disclosure - GRANT RECEIVABLE FROM CPRIT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PREPAIDEXPENSESANDOTHERCURRENTASSETS" roleURI="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETS">
        <link:definition>0000010 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>0000011 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEOFFINANCIALINSTRUMENTS" roleURI="http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS">
        <link:definition>0000012 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITY">
        <link:definition>0000013 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYBASEDCOMPENSATION" roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATION">
        <link:definition>0000014 - Disclosure - EQUITY-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTS" roleURI="http://www.flex-pharma.com/role/SUBSEQUENTEVENTS">
        <link:definition>0000015 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>0000016 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PREPAIDEXPENSESANDOTHERCURRENTASSETSTables" roleURI="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSTables">
        <link:definition>0000017 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYBASEDCOMPENSATIONTables" roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONTables">
        <link:definition>0000018 - Disclosure - EQUITY-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDOPERATIONSDetails" roleURI="http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONSDetails">
        <link:definition>0000019 - Disclosure - ORGANIZATION AND OPERATIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails" roleURI="http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails">
        <link:definition>0000020 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GRANTRECEIVABLEFROMCPRITDetails" roleURI="http://www.flex-pharma.com/role/GRANTRECEIVABLEFROMCPRITDetails">
        <link:definition>0000021 - Disclosure - GRANT RECEIVABLE FROM CPRIT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" roleURI="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails">
        <link:definition>0000022 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS - Schedule of Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>0000023 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDetails" roleURI="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYDetails">
        <link:definition>0000024 - Disclosure - STOCKHOLDERS' EQUITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>0000025 - Disclosure - EQUITY-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails" roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails">
        <link:definition>0000026 - Disclosure - EQUITY-BASED COMPENSATION - Schedule of Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofStockOptionActivityDetails">
        <link:definition>0000027 - Disclosure - EQUITY-BASED COMPENSATION - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTSDetails" roleURI="http://www.flex-pharma.com/role/SUBSEQUENTEVENTSDetails">
        <link:definition>0000028 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales" abstract="false" name="RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="flks_RevenueFromGrantsMaximumAward" abstract="false" name="RevenueFromGrantsMaximumAward" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="flks_WarrantsAndRightsExercisableTerm" abstract="false" name="WarrantsAndRightsExercisableTerm" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologySharesNewIssues" abstract="false" name="StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologySharesNewIssues" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="flks_EmployeesMember" abstract="true" name="EmployeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="flks_OfficersAndDirectorsMember" abstract="true" name="OfficersAndDirectorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="flks_PrepaidClinicalTrialExpense" abstract="false" name="PrepaidClinicalTrialExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="flks_RestrictedStockAndRestrictedStockUnitsMember" abstract="true" name="RestrictedStockAndRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="flks_EquityIncentivePlan2015Member" abstract="true" name="EquityIncentivePlan2015Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="flks_PaymentsForAcquisitionAndStrategicCollaborationAgreement" abstract="false" name="PaymentsForAcquisitionAndStrategicCollaborationAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="flks_RevenueFromGrantsAwardTerm" abstract="false" name="RevenueFromGrantsAwardTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="flks_StockIssuanceCostsAccruedAndAmortized" abstract="false" name="StockIssuanceCostsAccruedAndAmortized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="flks_PurchaseAgreementMember" abstract="true" name="PurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="flks_SalesAgreementMember" abstract="true" name="SalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="flks_UniversityOfUtahResearchFoundationMember" abstract="true" name="UniversityOfUtahResearchFoundationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="flks_AccruedExpensesAndOtherCurrentLiabilities" abstract="false" name="AccruedExpensesAndOtherCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues" abstract="false" name="StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>3
<FILENAME>flks-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:3bcb0391-ae28-4064-946d-9955ab3b15fb,g:a3263b3f-ee17-40f5-9314-e2273145249f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="flks-20230331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9135e91c-cd3a-4f5c-9e3b-af3c173ee4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_452f7178-5d69-4e25-9748-9770307bf232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9135e91c-cd3a-4f5c-9e3b-af3c173ee4b4" xlink:to="loc_us-gaap_StockholdersEquity_452f7178-5d69-4e25-9748-9770307bf232" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7155fd3f-20c1-4496-9309-d3475a5b3e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9135e91c-cd3a-4f5c-9e3b-af3c173ee4b4" xlink:to="loc_us-gaap_Liabilities_7155fd3f-20c1-4496-9309-d3475a5b3e6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_14fea41d-cf24-4bb4-b5ca-e7baa34c580f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9135e91c-cd3a-4f5c-9e3b-af3c173ee4b4" xlink:to="loc_us-gaap_CommitmentsAndContingencies_14fea41d-cf24-4bb4-b5ca-e7baa34c580f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8cd5350b-20d3-4630-810f-2d04f10149f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_AccruedExpensesAndOtherCurrentLiabilities_af75163a-66f2-44b7-a070-27e2fcbfb579" xlink:href="flks-20230331.xsd#flks_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8cd5350b-20d3-4630-810f-2d04f10149f9" xlink:to="loc_flks_AccruedExpensesAndOtherCurrentLiabilities_af75163a-66f2-44b7-a070-27e2fcbfb579" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_22ca27d5-a894-4068-8755-8c7c978ee146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8cd5350b-20d3-4630-810f-2d04f10149f9" xlink:to="loc_us-gaap_AccountsPayableCurrent_22ca27d5-a894-4068-8755-8c7c978ee146" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d1a79852-5285-43c8-803a-9984dc7d6b37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_8b4d408d-64bd-4923-a838-4f175f2cf293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d1a79852-5285-43c8-803a-9984dc7d6b37" xlink:to="loc_us-gaap_PreferredStockValue_8b4d408d-64bd-4923-a838-4f175f2cf293" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ecd4e506-5097-4ed0-b4c0-6c1c757f294a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d1a79852-5285-43c8-803a-9984dc7d6b37" xlink:to="loc_us-gaap_CommonStockValue_ecd4e506-5097-4ed0-b4c0-6c1c757f294a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_a0346ed5-2835-46c3-b39d-86ebaa473284" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d1a79852-5285-43c8-803a-9984dc7d6b37" xlink:to="loc_us-gaap_AdditionalPaidInCapital_a0346ed5-2835-46c3-b39d-86ebaa473284" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6afafe25-ab50-4205-ac2d-2069656670cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d1a79852-5285-43c8-803a-9984dc7d6b37" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6afafe25-ab50-4205-ac2d-2069656670cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_01d08731-374a-46bf-b5b4-f2fa99b00e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_69721de1-2cf0-4859-819b-3e82ac24a2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_01d08731-374a-46bf-b5b4-f2fa99b00e8d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_69721de1-2cf0-4859-819b-3e82ac24a2f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_37566488-8391-447b-bec5-a4a44c76fd27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_01d08731-374a-46bf-b5b4-f2fa99b00e8d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_37566488-8391-447b-bec5-a4a44c76fd27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivableCurrent_64ea8453-08f9-4384-a407-51ac1f4d10e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantsReceivableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_01d08731-374a-46bf-b5b4-f2fa99b00e8d" xlink:to="loc_us-gaap_GrantsReceivableCurrent_64ea8453-08f9-4384-a407-51ac1f4d10e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d9e8335e-d1ef-4811-bd7a-3b0387bf6c02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_01f36bf5-01db-489b-8a3e-b492f4968e18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d9e8335e-d1ef-4811-bd7a-3b0387bf6c02" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_01f36bf5-01db-489b-8a3e-b492f4968e18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c936059a-bb5f-4da6-bf3d-12360a1e2330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d9e8335e-d1ef-4811-bd7a-3b0387bf6c02" xlink:to="loc_us-gaap_AssetsCurrent_c936059a-bb5f-4da6-bf3d-12360a1e2330" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="flks-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_2663b7d8-9ccb-4e3b-a511-d1117770a71c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_74f8d575-8dc0-4596-b396-d1d416977dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_2663b7d8-9ccb-4e3b-a511-d1117770a71c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_74f8d575-8dc0-4596-b396-d1d416977dd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_cb98e924-2364-4570-afce-384518927a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_2663b7d8-9ccb-4e3b-a511-d1117770a71c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_cb98e924-2364-4570-afce-384518927a2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_5f74a101-acfc-4ebf-b7c2-a7b9f29b488d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bfbd4254-9893-420d-b593-624d0bec7868" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_5f74a101-acfc-4ebf-b7c2-a7b9f29b488d" xlink:to="loc_us-gaap_OperatingIncomeLoss_bfbd4254-9893-420d-b593-624d0bec7868" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_807a412d-164b-48e0-9fbe-c0633f0d20ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_5f74a101-acfc-4ebf-b7c2-a7b9f29b488d" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_807a412d-164b-48e0-9fbe-c0633f0d20ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_29590003-68f2-46db-b5c5-641e4a3c83a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_a702270e-e269-46dd-a8cd-822ab8d0e625" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_29590003-68f2-46db-b5c5-641e4a3c83a1" xlink:to="loc_us-gaap_OperatingExpenses_a702270e-e269-46dd-a8cd-822ab8d0e625" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4dea874b-78f3-4357-be77-d8d32701be89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_29590003-68f2-46db-b5c5-641e4a3c83a1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4dea874b-78f3-4357-be77-d8d32701be89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d21c1018-94f9-4932-8059-8c6aae46ba50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_c5dac706-39cc-4356-b4ee-7bec39ead2b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d21c1018-94f9-4932-8059-8c6aae46ba50" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_c5dac706-39cc-4356-b4ee-7bec39ead2b8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="flks-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1f560530-341b-4084-a4cd-7286170f5f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromOtherEquity_21951f0f-c7d3-41cf-81b6-d80ea75fe261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1f560530-341b-4084-a4cd-7286170f5f9a" xlink:to="loc_us-gaap_ProceedsFromOtherEquity_21951f0f-c7d3-41cf-81b6-d80ea75fe261" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc11891c-a6e8-4305-9e98-2aae289debf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d26bc76d-b212-4b1f-9bb8-187141725fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc11891c-a6e8-4305-9e98-2aae289debf1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d26bc76d-b212-4b1f-9bb8-187141725fe5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_d8264db2-2e8b-4e9d-8838-dc550c215f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc11891c-a6e8-4305-9e98-2aae289debf1" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_d8264db2-2e8b-4e9d-8838-dc550c215f8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_93115d7b-85ae-459a-afb8-b9c681133915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc11891c-a6e8-4305-9e98-2aae289debf1" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_93115d7b-85ae-459a-afb8-b9c681133915" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3a9df890-4945-4a26-8e32-05f0311334db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc11891c-a6e8-4305-9e98-2aae289debf1" xlink:to="loc_us-gaap_NetIncomeLoss_3a9df890-4945-4a26-8e32-05f0311334db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_9dd8e19e-94f3-4c31-9280-71b0748e0dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc11891c-a6e8-4305-9e98-2aae289debf1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_9dd8e19e-94f3-4c31-9280-71b0748e0dc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_354a605b-d199-4f37-8edd-d1b29cedbf9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc11891c-a6e8-4305-9e98-2aae289debf1" xlink:to="loc_us-gaap_ShareBasedCompensation_354a605b-d199-4f37-8edd-d1b29cedbf9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_e4aef718-b8a0-440d-91fd-a73de9766e9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc11891c-a6e8-4305-9e98-2aae289debf1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_e4aef718-b8a0-440d-91fd-a73de9766e9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_79f9dc57-8b50-4186-a863-cc26a0d18858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc11891c-a6e8-4305-9e98-2aae289debf1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_79f9dc57-8b50-4186-a863-cc26a0d18858" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9859f45d-a112-4e06-8ac0-a3b6c1e69125" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_91abdd1a-fb8b-4243-a3d8-9cb29ac6bfe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9859f45d-a112-4e06-8ac0-a3b6c1e69125" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_91abdd1a-fb8b-4243-a3d8-9cb29ac6bfe0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0d6ada90-5b4a-4b93-a71e-2f00d2518050" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9859f45d-a112-4e06-8ac0-a3b6c1e69125" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0d6ada90-5b4a-4b93-a71e-2f00d2518050" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_39882945-b065-4b7d-8994-3288c2501d29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9859f45d-a112-4e06-8ac0-a3b6c1e69125" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_39882945-b065-4b7d-8994-3288c2501d29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_818a3d18-8dd2-4ce2-9bf0-ab818c3c9c36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_8d174f09-9e25-4daf-a9a2-ad2a598dea1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_818a3d18-8dd2-4ce2-9bf0-ab818c3c9c36" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_8d174f09-9e25-4daf-a9a2-ad2a598dea1e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="flks-20230331.xsd#PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_073c64a1-1047-41c9-918f-b1b4adbf0db2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_029f6115-9a74-4e5d-abf0-b68eba312a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_073c64a1-1047-41c9-918f-b1b4adbf0db2" xlink:to="loc_us-gaap_OtherAssetsCurrent_029f6115-9a74-4e5d-abf0-b68eba312a0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_PrepaidClinicalTrialExpense_abfdf5a9-2e56-4862-9820-3e4ddbca62df" xlink:href="flks-20230331.xsd#flks_PrepaidClinicalTrialExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_073c64a1-1047-41c9-918f-b1b4adbf0db2" xlink:to="loc_flks_PrepaidClinicalTrialExpense_abfdf5a9-2e56-4862-9820-3e4ddbca62df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_b0fa25e2-0c09-427c-bbe1-866596c2cf33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_073c64a1-1047-41c9-918f-b1b4adbf0db2" xlink:to="loc_us-gaap_PrepaidInsurance_b0fa25e2-0c09-427c-bbe1-866596c2cf33" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>flks-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:3bcb0391-ae28-4064-946d-9955ab3b15fb,g:a3263b3f-ee17-40f5-9314-e2273145249f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="flks-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="i76de8f11741c4c1396a0cdf2c6bbb7b6_CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_96809933-4e16-4e0d-b75b-e2952f1aa16a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c03b5a5b-fa02-40c6-ab9d-a67b454dbdf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_96809933-4e16-4e0d-b75b-e2952f1aa16a" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c03b5a5b-fa02-40c6-ab9d-a67b454dbdf0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_18548d6d-61c9-4950-b73f-336c123cade4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c03b5a5b-fa02-40c6-ab9d-a67b454dbdf0" xlink:to="loc_us-gaap_SharesOutstanding_18548d6d-61c9-4950-b73f-336c123cade4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3f6d2046-d7fc-4222-a118-5fa933a6f7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c03b5a5b-fa02-40c6-ab9d-a67b454dbdf0" xlink:to="loc_us-gaap_StockholdersEquity_3f6d2046-d7fc-4222-a118-5fa933a6f7b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologySharesNewIssues_8c756d2d-d685-4b31-963e-194043124dc0" xlink:href="flks-20230331.xsd#flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologySharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c03b5a5b-fa02-40c6-ab9d-a67b454dbdf0" xlink:to="loc_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologySharesNewIssues_8c756d2d-d685-4b31-963e-194043124dc0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues_4d418744-7127-41ce-909e-23dd0986d9fe" xlink:href="flks-20230331.xsd#flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c03b5a5b-fa02-40c6-ab9d-a67b454dbdf0" xlink:to="loc_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues_4d418744-7127-41ce-909e-23dd0986d9fe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_56b3f928-f561-49c4-b39a-b7d98630e2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c03b5a5b-fa02-40c6-ab9d-a67b454dbdf0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_56b3f928-f561-49c4-b39a-b7d98630e2d6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e0fa3b03-4021-44a2-bfec-d914f4e11c92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c03b5a5b-fa02-40c6-ab9d-a67b454dbdf0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e0fa3b03-4021-44a2-bfec-d914f4e11c92" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_ac2ea5a5-5ec5-46b6-b68f-ed66f4447cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c03b5a5b-fa02-40c6-ab9d-a67b454dbdf0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_ac2ea5a5-5ec5-46b6-b68f-ed66f4447cfc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6b01423e-d410-4494-a089-e9fb39e5f483" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c03b5a5b-fa02-40c6-ab9d-a67b454dbdf0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6b01423e-d410-4494-a089-e9fb39e5f483" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_279823a7-35af-4b5b-b53b-a96fd275be6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c03b5a5b-fa02-40c6-ab9d-a67b454dbdf0" xlink:to="loc_us-gaap_NetIncomeLoss_279823a7-35af-4b5b-b53b-a96fd275be6b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_8618a07c-b7d9-4baa-b419-66edf3f8ff0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5533b27d-4b32-494a-8630-f0181f4e3581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f14a9b41-2742-46a4-aafa-36ed85caaefe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_96809933-4e16-4e0d-b75b-e2952f1aa16a" xlink:to="loc_us-gaap_StatementTable_f14a9b41-2742-46a4-aafa-36ed85caaefe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_82961896-1160-42c0-8f0e-1a5927c57611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f14a9b41-2742-46a4-aafa-36ed85caaefe" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_82961896-1160-42c0-8f0e-1a5927c57611" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_82961896-1160-42c0-8f0e-1a5927c57611_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_82961896-1160-42c0-8f0e-1a5927c57611" xlink:to="loc_us-gaap_EquityComponentDomain_82961896-1160-42c0-8f0e-1a5927c57611_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e3d17a6f-7a9b-4b23-90f4-3ed7b3b204b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_82961896-1160-42c0-8f0e-1a5927c57611" xlink:to="loc_us-gaap_EquityComponentDomain_e3d17a6f-7a9b-4b23-90f4-3ed7b3b204b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1bf8cc40-b0df-4abd-a6b0-b9d81123e2be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e3d17a6f-7a9b-4b23-90f4-3ed7b3b204b1" xlink:to="loc_us-gaap_CommonStockMember_1bf8cc40-b0df-4abd-a6b0-b9d81123e2be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_935082a4-bd8e-46e6-9908-5bcf101e720a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e3d17a6f-7a9b-4b23-90f4-3ed7b3b204b1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_935082a4-bd8e-46e6-9908-5bcf101e720a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_cd9ab745-2794-45f6-8144-2801afd82e29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e3d17a6f-7a9b-4b23-90f4-3ed7b3b204b1" xlink:to="loc_us-gaap_RetainedEarningsMember_cd9ab745-2794-45f6-8144-2801afd82e29" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONSDetails" xlink:type="simple" xlink:href="flks-20230331.xsd#ORGANIZATIONANDOPERATIONSDetails"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONSDetails" xlink:type="extended" id="i039c71c22b3b4a26822f9bebf0bcf55b_ORGANIZATIONANDOPERATIONSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8af8bb3c-0ed3-4f59-bca9-1063db2b6f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f694e572-4cb7-4e01-881a-6ec1f8fe8a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8af8bb3c-0ed3-4f59-bca9-1063db2b6f4b" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f694e572-4cb7-4e01-881a-6ec1f8fe8a1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1bb9cb28-00df-4eb1-bf62-0bee050065e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8af8bb3c-0ed3-4f59-bca9-1063db2b6f4b" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1bb9cb28-00df-4eb1-bf62-0bee050065e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0acecb95-4e8c-4f98-9301-0f7772445f15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8af8bb3c-0ed3-4f59-bca9-1063db2b6f4b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0acecb95-4e8c-4f98-9301-0f7772445f15" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a327f4ce-3d18-4149-802d-237696f4d600" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0acecb95-4e8c-4f98-9301-0f7772445f15" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a327f4ce-3d18-4149-802d-237696f4d600" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a327f4ce-3d18-4149-802d-237696f4d600_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a327f4ce-3d18-4149-802d-237696f4d600" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a327f4ce-3d18-4149-802d-237696f4d600_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_bb798358-4a82-4b33-b98f-36d4410784b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a327f4ce-3d18-4149-802d-237696f4d600" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_bb798358-4a82-4b33-b98f-36d4410784b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_eb5414b5-2fcc-4dad-a91d-7ecbdca55d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_bb798358-4a82-4b33-b98f-36d4410784b2" xlink:to="loc_us-gaap_SubsequentEventMember_eb5414b5-2fcc-4dad-a91d-7ecbdca55d0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c9fd5852-c6dd-4962-8b20-5abd8fe61b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0acecb95-4e8c-4f98-9301-0f7772445f15" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c9fd5852-c6dd-4962-8b20-5abd8fe61b8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c9fd5852-c6dd-4962-8b20-5abd8fe61b8f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c9fd5852-c6dd-4962-8b20-5abd8fe61b8f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c9fd5852-c6dd-4962-8b20-5abd8fe61b8f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9aa220a3-812b-41ae-b5be-267f33e43e76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c9fd5852-c6dd-4962-8b20-5abd8fe61b8f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9aa220a3-812b-41ae-b5be-267f33e43e76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_SalesAgreementMember_dbccff10-af7e-40ed-8600-601fdf3276a6" xlink:href="flks-20230331.xsd#flks_SalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9aa220a3-812b-41ae-b5be-267f33e43e76" xlink:to="loc_flks_SalesAgreementMember_dbccff10-af7e-40ed-8600-601fdf3276a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8b63d062-d293-4fba-88d9-c86d7082149f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0acecb95-4e8c-4f98-9301-0f7772445f15" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8b63d062-d293-4fba-88d9-c86d7082149f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8b63d062-d293-4fba-88d9-c86d7082149f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8b63d062-d293-4fba-88d9-c86d7082149f" xlink:to="loc_us-gaap_EquityComponentDomain_8b63d062-d293-4fba-88d9-c86d7082149f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bc7c9519-9865-4074-9ec7-bce7aa67690f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8b63d062-d293-4fba-88d9-c86d7082149f" xlink:to="loc_us-gaap_EquityComponentDomain_bc7c9519-9865-4074-9ec7-bce7aa67690f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_599bbb63-e205-48af-b861-402202a6f591" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bc7c9519-9865-4074-9ec7-bce7aa67690f" xlink:to="loc_us-gaap_CommonStockMember_599bbb63-e205-48af-b861-402202a6f591" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="flks-20230331.xsd#BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="extended" id="id9d523279f994567af756f67f179dd84_BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be8793ca-0059-4845-9105-c08f69b59925" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_4ce5e7ef-7ec2-4f03-a4ed-18b61024229f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be8793ca-0059-4845-9105-c08f69b59925" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_4ce5e7ef-7ec2-4f03-a4ed-18b61024229f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_698642cb-ca3d-4d3f-aef8-1a6a37182e37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be8793ca-0059-4845-9105-c08f69b59925" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_698642cb-ca3d-4d3f-aef8-1a6a37182e37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_18631e0b-4515-4953-8016-257987cf3386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be8793ca-0059-4845-9105-c08f69b59925" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_18631e0b-4515-4953-8016-257987cf3386" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9c6ef4ab-ec8b-437c-a45d-50e776ba9629" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be8793ca-0059-4845-9105-c08f69b59925" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9c6ef4ab-ec8b-437c-a45d-50e776ba9629" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_PaymentsForAcquisitionAndStrategicCollaborationAgreement_fbd32e31-2204-4f66-8ef7-7fd0bc6392d4" xlink:href="flks-20230331.xsd#flks_PaymentsForAcquisitionAndStrategicCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be8793ca-0059-4845-9105-c08f69b59925" xlink:to="loc_flks_PaymentsForAcquisitionAndStrategicCollaborationAgreement_fbd32e31-2204-4f66-8ef7-7fd0bc6392d4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_4afbc15b-1b98-46a8-8fce-58d559d6b612" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be8793ca-0059-4845-9105-c08f69b59925" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_4afbc15b-1b98-46a8-8fce-58d559d6b612" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8cf04db8-625a-4072-8536-7a62696dd2dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be8793ca-0059-4845-9105-c08f69b59925" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8cf04db8-625a-4072-8536-7a62696dd2dd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_27270878-0967-4e55-bea2-30c404b72929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be8793ca-0059-4845-9105-c08f69b59925" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_27270878-0967-4e55-bea2-30c404b72929" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7c32d5a0-c622-4598-9510-d201d6f63d25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be8793ca-0059-4845-9105-c08f69b59925" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7c32d5a0-c622-4598-9510-d201d6f63d25" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5ff196d0-c569-4d2e-aae6-4c26ea1627b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7c32d5a0-c622-4598-9510-d201d6f63d25" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5ff196d0-c569-4d2e-aae6-4c26ea1627b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5ff196d0-c569-4d2e-aae6-4c26ea1627b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5ff196d0-c569-4d2e-aae6-4c26ea1627b7" xlink:to="loc_us-gaap_EquityComponentDomain_5ff196d0-c569-4d2e-aae6-4c26ea1627b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e91fcec2-d2fd-4e52-a839-3f5a3113d503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5ff196d0-c569-4d2e-aae6-4c26ea1627b7" xlink:to="loc_us-gaap_EquityComponentDomain_e91fcec2-d2fd-4e52-a839-3f5a3113d503" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_eb3c57ef-4e2d-44ca-89ba-399a2728cc9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e91fcec2-d2fd-4e52-a839-3f5a3113d503" xlink:to="loc_us-gaap_CommonStockMember_eb3c57ef-4e2d-44ca-89ba-399a2728cc9c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/GRANTRECEIVABLEFROMCPRITDetails" xlink:type="simple" xlink:href="flks-20230331.xsd#GRANTRECEIVABLEFROMCPRITDetails"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/GRANTRECEIVABLEFROMCPRITDetails" xlink:type="extended" id="i7c6f0f8d972b4a56a2219f83eedf2324_GRANTRECEIVABLEFROMCPRITDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_360d50b7-510e-415a-a8ca-3fc0b1a861a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivableCurrent_76a809af-5830-484d-a118-5565e49fae2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantsReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_360d50b7-510e-415a-a8ca-3fc0b1a861a5" xlink:to="loc_us-gaap_GrantsReceivableCurrent_76a809af-5830-484d-a118-5565e49fae2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_b229099c-4cec-4a12-8a47-a3bb9a39e0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_360d50b7-510e-415a-a8ca-3fc0b1a861a5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_b229099c-4cec-4a12-8a47-a3bb9a39e0e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_bb94c108-b418-4157-8636-0534f73e9b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_360d50b7-510e-415a-a8ca-3fc0b1a861a5" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_bb94c108-b418-4157-8636-0534f73e9b6d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8ddb9ed9-fc5d-4c37-afa9-b2a755c9b56f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_bb94c108-b418-4157-8636-0534f73e9b6d" xlink:to="loc_srt_ProductOrServiceAxis_8ddb9ed9-fc5d-4c37-afa9-b2a755c9b56f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8ddb9ed9-fc5d-4c37-afa9-b2a755c9b56f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8ddb9ed9-fc5d-4c37-afa9-b2a755c9b56f" xlink:to="loc_srt_ProductsAndServicesDomain_8ddb9ed9-fc5d-4c37-afa9-b2a755c9b56f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ea006abf-07fd-47d2-97bc-17dbc6b06887" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8ddb9ed9-fc5d-4c37-afa9-b2a755c9b56f" xlink:to="loc_srt_ProductsAndServicesDomain_ea006abf-07fd-47d2-97bc-17dbc6b06887" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_6a242024-602a-4a12-9d39-a463151c7ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ea006abf-07fd-47d2-97bc-17dbc6b06887" xlink:to="loc_us-gaap_GrantMember_6a242024-602a-4a12-9d39-a463151c7ce6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="flks-20230331.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended" id="ia7c39f1513de4cca8776fe28fe1db2e7_COMMITMENTSANDCONTINGENCIESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_b3f9574b-787c-4605-8099-15d6f5689a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_c57bf9f1-aa2f-4196-b5f6-0a5c238ca5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_b3f9574b-787c-4605-8099-15d6f5689a7b" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_c57bf9f1-aa2f-4196-b5f6-0a5c238ca5e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsMaximumAward_249446c3-a08e-48d7-a2af-2af58a6df72f" xlink:href="flks-20230331.xsd#flks_RevenueFromGrantsMaximumAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_b3f9574b-787c-4605-8099-15d6f5689a7b" xlink:to="loc_flks_RevenueFromGrantsMaximumAward_249446c3-a08e-48d7-a2af-2af58a6df72f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsAwardTerm_4ba82fd4-83d1-44fb-a911-6aab0dac7575" xlink:href="flks-20230331.xsd#flks_RevenueFromGrantsAwardTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_b3f9574b-787c-4605-8099-15d6f5689a7b" xlink:to="loc_flks_RevenueFromGrantsAwardTerm_4ba82fd4-83d1-44fb-a911-6aab0dac7575" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales_f0642a78-f5da-4492-a412-bb2d9749ad46" xlink:href="flks-20230331.xsd#flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_b3f9574b-787c-4605-8099-15d6f5689a7b" xlink:to="loc_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales_f0642a78-f5da-4492-a412-bb2d9749ad46" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_75c12df5-6edd-4371-a469-59f8d7d672ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_b3f9574b-787c-4605-8099-15d6f5689a7b" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_75c12df5-6edd-4371-a469-59f8d7d672ce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_f2a1b31b-16e7-463d-878a-e2f11eabe49b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_75c12df5-6edd-4371-a469-59f8d7d672ce" xlink:to="loc_srt_OwnershipAxis_f2a1b31b-16e7-463d-878a-e2f11eabe49b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_f2a1b31b-16e7-463d-878a-e2f11eabe49b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_f2a1b31b-16e7-463d-878a-e2f11eabe49b" xlink:to="loc_srt_OwnershipDomain_f2a1b31b-16e7-463d-878a-e2f11eabe49b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_5d5a6323-d2a3-4bab-883b-548a1dd43d1d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_f2a1b31b-16e7-463d-878a-e2f11eabe49b" xlink:to="loc_srt_OwnershipDomain_5d5a6323-d2a3-4bab-883b-548a1dd43d1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_UniversityOfUtahResearchFoundationMember_d5a8ef06-3b7a-4b5d-b667-d543d74b08ad" xlink:href="flks-20230331.xsd#flks_UniversityOfUtahResearchFoundationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_5d5a6323-d2a3-4bab-883b-548a1dd43d1d" xlink:to="loc_flks_UniversityOfUtahResearchFoundationMember_d5a8ef06-3b7a-4b5d-b667-d543d74b08ad" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYDetails" xlink:type="simple" xlink:href="flks-20230331.xsd#STOCKHOLDERSEQUITYDetails"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYDetails" xlink:type="extended" id="iab784e9fcaa146b98e7b37021e2d9e25_STOCKHOLDERSEQUITYDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_de29b87f-d7e5-4518-9f30-f67aa419678b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_630cdc0f-1010-4e2c-8d02-38a678e6b00f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_de29b87f-d7e5-4518-9f30-f67aa419678b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_630cdc0f-1010-4e2c-8d02-38a678e6b00f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1a8cd6e2-a34e-4966-91f3-af1fa7b6cbf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_de29b87f-d7e5-4518-9f30-f67aa419678b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1a8cd6e2-a34e-4966-91f3-af1fa7b6cbf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologySharesNewIssues_7e6d06b9-f585-4e6e-a246-84261b340f02" xlink:href="flks-20230331.xsd#flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologySharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_de29b87f-d7e5-4518-9f30-f67aa419678b" xlink:to="loc_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologySharesNewIssues_7e6d06b9-f585-4e6e-a246-84261b340f02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues_27defc67-8403-4108-8c03-531327108b02" xlink:href="flks-20230331.xsd#flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_de29b87f-d7e5-4518-9f30-f67aa419678b" xlink:to="loc_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues_27defc67-8403-4108-8c03-531327108b02" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_038f5fb3-1c74-425c-a6a6-58c286e9a40c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_de29b87f-d7e5-4518-9f30-f67aa419678b" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_038f5fb3-1c74-425c-a6a6-58c286e9a40c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ea3fe7dd-7b4b-46a2-8cbe-29701175fca4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_de29b87f-d7e5-4518-9f30-f67aa419678b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ea3fe7dd-7b4b-46a2-8cbe-29701175fca4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_WarrantsAndRightsExercisableTerm_2e4da748-9e9e-4237-a01f-dfe27fc4db7d" xlink:href="flks-20230331.xsd#flks_WarrantsAndRightsExercisableTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_de29b87f-d7e5-4518-9f30-f67aa419678b" xlink:to="loc_flks_WarrantsAndRightsExercisableTerm_2e4da748-9e9e-4237-a01f-dfe27fc4db7d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6ae787ea-fcd8-43b9-b406-ef5bd2aee501" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_de29b87f-d7e5-4518-9f30-f67aa419678b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6ae787ea-fcd8-43b9-b406-ef5bd2aee501" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_dfd9a9ae-a309-4d04-a969-7d3100d77053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_de29b87f-d7e5-4518-9f30-f67aa419678b" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_dfd9a9ae-a309-4d04-a969-7d3100d77053" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_d3888f03-93c3-4c01-bf23-0cbccdd6314e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_dfd9a9ae-a309-4d04-a969-7d3100d77053" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_d3888f03-93c3-4c01-bf23-0cbccdd6314e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d3888f03-93c3-4c01-bf23-0cbccdd6314e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d3888f03-93c3-4c01-bf23-0cbccdd6314e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d3888f03-93c3-4c01-bf23-0cbccdd6314e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fc1e17dd-1815-4f8f-985d-0c5808e32d64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d3888f03-93c3-4c01-bf23-0cbccdd6314e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fc1e17dd-1815-4f8f-985d-0c5808e32d64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_SalesAgreementMember_d2b6bc25-1c36-4ed7-b49a-c66b9d48c304" xlink:href="flks-20230331.xsd#flks_SalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fc1e17dd-1815-4f8f-985d-0c5808e32d64" xlink:to="loc_flks_SalesAgreementMember_d2b6bc25-1c36-4ed7-b49a-c66b9d48c304" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_PurchaseAgreementMember_fbf8373c-60b1-472f-be9f-6e864a534f2d" xlink:href="flks-20230331.xsd#flks_PurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fc1e17dd-1815-4f8f-985d-0c5808e32d64" xlink:to="loc_flks_PurchaseAgreementMember_fbf8373c-60b1-472f-be9f-6e864a534f2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1e4509b9-36d8-4024-ac73-4cbed73d885a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_dfd9a9ae-a309-4d04-a969-7d3100d77053" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1e4509b9-36d8-4024-ac73-4cbed73d885a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1e4509b9-36d8-4024-ac73-4cbed73d885a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1e4509b9-36d8-4024-ac73-4cbed73d885a" xlink:to="loc_us-gaap_EquityComponentDomain_1e4509b9-36d8-4024-ac73-4cbed73d885a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e823686e-16ac-467e-9e4a-584e5c3161aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1e4509b9-36d8-4024-ac73-4cbed73d885a" xlink:to="loc_us-gaap_EquityComponentDomain_e823686e-16ac-467e-9e4a-584e5c3161aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0011a88c-6952-4ae0-a318-16dba9d6bc08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e823686e-16ac-467e-9e4a-584e5c3161aa" xlink:to="loc_us-gaap_CommonStockMember_0011a88c-6952-4ae0-a318-16dba9d6bc08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_ce49d487-6420-43a4-baa9-4b1824a9401c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e823686e-16ac-467e-9e4a-584e5c3161aa" xlink:to="loc_us-gaap_WarrantMember_ce49d487-6420-43a4-baa9-4b1824a9401c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_76e3b248-4da4-44bc-a259-0f6611dc0bb1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_dfd9a9ae-a309-4d04-a969-7d3100d77053" xlink:to="loc_srt_RangeAxis_76e3b248-4da4-44bc-a259-0f6611dc0bb1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_76e3b248-4da4-44bc-a259-0f6611dc0bb1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_76e3b248-4da4-44bc-a259-0f6611dc0bb1" xlink:to="loc_srt_RangeMember_76e3b248-4da4-44bc-a259-0f6611dc0bb1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9968d703-b37b-4348-8e9d-eb92478e5a63" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_76e3b248-4da4-44bc-a259-0f6611dc0bb1" xlink:to="loc_srt_RangeMember_9968d703-b37b-4348-8e9d-eb92478e5a63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bd432809-c488-40ff-8a52-3656d9c738a2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9968d703-b37b-4348-8e9d-eb92478e5a63" xlink:to="loc_srt_MaximumMember_bd432809-c488-40ff-8a52-3656d9c738a2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="flks-20230331.xsd#EQUITYBASEDCOMPENSATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended" id="ia5dc574e50834d748434bc36d81eff4f_EQUITYBASEDCOMPENSATIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4945249b-2ce9-4fc8-b5d0-85d1023046b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d5ee4207-2951-470b-9ede-d10d120c8a72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4945249b-2ce9-4fc8-b5d0-85d1023046b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d5ee4207-2951-470b-9ede-d10d120c8a72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2e8ad411-077d-4103-b86e-3548bc430f27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4945249b-2ce9-4fc8-b5d0-85d1023046b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2e8ad411-077d-4103-b86e-3548bc430f27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8e9f84b6-eeb4-4d9c-aaca-b5ceafbcb297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4945249b-2ce9-4fc8-b5d0-85d1023046b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8e9f84b6-eeb4-4d9c-aaca-b5ceafbcb297" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b07e3587-9b74-4b92-b019-d724377309ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4945249b-2ce9-4fc8-b5d0-85d1023046b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b07e3587-9b74-4b92-b019-d724377309ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_7d2c6144-63df-4061-a531-0f9b39eba6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4945249b-2ce9-4fc8-b5d0-85d1023046b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_7d2c6144-63df-4061-a531-0f9b39eba6f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c145500a-b888-48be-adc5-d0bc82d8d5b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4945249b-2ce9-4fc8-b5d0-85d1023046b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c145500a-b888-48be-adc5-d0bc82d8d5b0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_380a1f50-2ed3-44f8-ba94-34650b494a27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4945249b-2ce9-4fc8-b5d0-85d1023046b4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_380a1f50-2ed3-44f8-ba94-34650b494a27" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_19345e54-ee12-4da9-bf2f-3f7b406a36aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4945249b-2ce9-4fc8-b5d0-85d1023046b4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_19345e54-ee12-4da9-bf2f-3f7b406a36aa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2fa9df19-40d7-4ac5-98c6-20a54ba1a344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4945249b-2ce9-4fc8-b5d0-85d1023046b4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2fa9df19-40d7-4ac5-98c6-20a54ba1a344" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a65624b8-6c09-41a6-a6e7-1f872e4156c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4945249b-2ce9-4fc8-b5d0-85d1023046b4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a65624b8-6c09-41a6-a6e7-1f872e4156c4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8b35c941-aa00-46f4-9a83-9c22bb25cbb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4945249b-2ce9-4fc8-b5d0-85d1023046b4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8b35c941-aa00-46f4-9a83-9c22bb25cbb4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_75d052ce-e38b-47ad-a09b-4f7b180e4c7e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8b35c941-aa00-46f4-9a83-9c22bb25cbb4" xlink:to="loc_srt_TitleOfIndividualAxis_75d052ce-e38b-47ad-a09b-4f7b180e4c7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_75d052ce-e38b-47ad-a09b-4f7b180e4c7e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_75d052ce-e38b-47ad-a09b-4f7b180e4c7e" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_75d052ce-e38b-47ad-a09b-4f7b180e4c7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_355782fd-60e1-4441-9cd9-ff9e73a69e2f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_75d052ce-e38b-47ad-a09b-4f7b180e4c7e" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_355782fd-60e1-4441-9cd9-ff9e73a69e2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_EmployeesMember_5fbe60e3-82cc-4197-9025-57a4e0baa591" xlink:href="flks-20230331.xsd#flks_EmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_355782fd-60e1-4441-9cd9-ff9e73a69e2f" xlink:to="loc_flks_EmployeesMember_5fbe60e3-82cc-4197-9025-57a4e0baa591" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_OfficersAndDirectorsMember_6f0a44ce-bdb4-4a55-9b3c-7794cdab2599" xlink:href="flks-20230331.xsd#flks_OfficersAndDirectorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_355782fd-60e1-4441-9cd9-ff9e73a69e2f" xlink:to="loc_flks_OfficersAndDirectorsMember_6f0a44ce-bdb4-4a55-9b3c-7794cdab2599" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b86a9189-b9e2-41ee-86b5-61f152c7d942" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8b35c941-aa00-46f4-9a83-9c22bb25cbb4" xlink:to="loc_us-gaap_PlanNameAxis_b86a9189-b9e2-41ee-86b5-61f152c7d942" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b86a9189-b9e2-41ee-86b5-61f152c7d942_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_b86a9189-b9e2-41ee-86b5-61f152c7d942" xlink:to="loc_us-gaap_PlanNameDomain_b86a9189-b9e2-41ee-86b5-61f152c7d942_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9194dfb8-dca3-40c4-b40b-264cb0b67ada" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_b86a9189-b9e2-41ee-86b5-61f152c7d942" xlink:to="loc_us-gaap_PlanNameDomain_9194dfb8-dca3-40c4-b40b-264cb0b67ada" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_EquityIncentivePlan2015Member_587ad5dc-3817-4160-8209-bbb741c86c76" xlink:href="flks-20230331.xsd#flks_EquityIncentivePlan2015Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9194dfb8-dca3-40c4-b40b-264cb0b67ada" xlink:to="loc_flks_EquityIncentivePlan2015Member_587ad5dc-3817-4160-8209-bbb741c86c76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b8c54c14-9e06-487b-b39b-45caf4e2f251" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8b35c941-aa00-46f4-9a83-9c22bb25cbb4" xlink:to="loc_us-gaap_AwardTypeAxis_b8c54c14-9e06-487b-b39b-45caf4e2f251" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8c54c14-9e06-487b-b39b-45caf4e2f251_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b8c54c14-9e06-487b-b39b-45caf4e2f251" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8c54c14-9e06-487b-b39b-45caf4e2f251_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59d4eecd-0c5e-4bca-9153-78173d99d2b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b8c54c14-9e06-487b-b39b-45caf4e2f251" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59d4eecd-0c5e-4bca-9153-78173d99d2b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ddc1f6ab-f208-47db-b7a9-50b2386f8f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59d4eecd-0c5e-4bca-9153-78173d99d2b5" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ddc1f6ab-f208-47db-b7a9-50b2386f8f7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_ebe49b64-86b7-4268-b868-117663c2183e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59d4eecd-0c5e-4bca-9153-78173d99d2b5" xlink:to="loc_us-gaap_RestrictedStockMember_ebe49b64-86b7-4268-b868-117663c2183e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RestrictedStockAndRestrictedStockUnitsMember_ec47581a-e56f-4a46-bfdb-044a8d92bee8" xlink:href="flks-20230331.xsd#flks_RestrictedStockAndRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59d4eecd-0c5e-4bca-9153-78173d99d2b5" xlink:to="loc_flks_RestrictedStockAndRestrictedStockUnitsMember_ec47581a-e56f-4a46-bfdb-044a8d92bee8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7831a01b-0b7d-4d05-922e-3de13330ca31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59d4eecd-0c5e-4bca-9153-78173d99d2b5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7831a01b-0b7d-4d05-922e-3de13330ca31" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7f3b4b95-9d9d-45ac-a8a1-eb6ee5f3b19a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8b35c941-aa00-46f4-9a83-9c22bb25cbb4" xlink:to="loc_srt_RangeAxis_7f3b4b95-9d9d-45ac-a8a1-eb6ee5f3b19a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7f3b4b95-9d9d-45ac-a8a1-eb6ee5f3b19a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7f3b4b95-9d9d-45ac-a8a1-eb6ee5f3b19a" xlink:to="loc_srt_RangeMember_7f3b4b95-9d9d-45ac-a8a1-eb6ee5f3b19a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ac23420a-4ecd-4bb6-b189-5080e83e42b9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7f3b4b95-9d9d-45ac-a8a1-eb6ee5f3b19a" xlink:to="loc_srt_RangeMember_ac23420a-4ecd-4bb6-b189-5080e83e42b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e02197ea-f4a0-4e03-883e-0a8e47afbf47" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ac23420a-4ecd-4bb6-b189-5080e83e42b9" xlink:to="loc_srt_MinimumMember_e02197ea-f4a0-4e03-883e-0a8e47afbf47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_08c639c1-da54-4140-8e6d-c016a5212db0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ac23420a-4ecd-4bb6-b189-5080e83e42b9" xlink:to="loc_srt_MaximumMember_08c639c1-da54-4140-8e6d-c016a5212db0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails" xlink:type="simple" xlink:href="flks-20230331.xsd#EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails" xlink:type="extended" id="i3d19eee1b2ba4afb8be30baa6c33bc6b_EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ab1219e-7f13-42b2-a4a0-bd5e5ed2962c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_f245bbd0-a500-479d-b9cd-c42688ac034f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ab1219e-7f13-42b2-a4a0-bd5e5ed2962c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_f245bbd0-a500-479d-b9cd-c42688ac034f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0aa1f66e-812c-48aa-b1fc-52f70237888b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ab1219e-7f13-42b2-a4a0-bd5e5ed2962c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0aa1f66e-812c-48aa-b1fc-52f70237888b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_8a28d3f2-c346-4a85-b815-a40bd3d7d704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ab1219e-7f13-42b2-a4a0-bd5e5ed2962c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_8a28d3f2-c346-4a85-b815-a40bd3d7d704" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_997b21d0-ecab-4819-a639-cb025ce51bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ab1219e-7f13-42b2-a4a0-bd5e5ed2962c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_997b21d0-ecab-4819-a639-cb025ce51bd3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f6ca5f0e-f835-488a-a99b-2411e5b8478a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ab1219e-7f13-42b2-a4a0-bd5e5ed2962c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f6ca5f0e-f835-488a-a99b-2411e5b8478a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2763d3ec-e8a8-4360-8c15-ffca17523a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ab1219e-7f13-42b2-a4a0-bd5e5ed2962c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2763d3ec-e8a8-4360-8c15-ffca17523a5a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_319f1835-1128-423a-9ba9-a0387ad13bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ab1219e-7f13-42b2-a4a0-bd5e5ed2962c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_319f1835-1128-423a-9ba9-a0387ad13bc7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b61f91a6-c3d4-4be0-b54d-8c7a9d0b6104" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_319f1835-1128-423a-9ba9-a0387ad13bc7" xlink:to="loc_srt_RangeAxis_b61f91a6-c3d4-4be0-b54d-8c7a9d0b6104" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b61f91a6-c3d4-4be0-b54d-8c7a9d0b6104_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b61f91a6-c3d4-4be0-b54d-8c7a9d0b6104" xlink:to="loc_srt_RangeMember_b61f91a6-c3d4-4be0-b54d-8c7a9d0b6104_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_de06cd6d-7712-497f-9198-eab58db6519e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b61f91a6-c3d4-4be0-b54d-8c7a9d0b6104" xlink:to="loc_srt_RangeMember_de06cd6d-7712-497f-9198-eab58db6519e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5b553ec2-9d2d-4ab3-b936-00145f8f2809" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_de06cd6d-7712-497f-9198-eab58db6519e" xlink:to="loc_srt_MinimumMember_5b553ec2-9d2d-4ab3-b936-00145f8f2809" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d5c649bb-b544-42be-901d-8f03bca8eeee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_de06cd6d-7712-497f-9198-eab58db6519e" xlink:to="loc_srt_MaximumMember_d5c649bb-b544-42be-901d-8f03bca8eeee" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="flks-20230331.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended" id="if7328f4beb414c079a9460f23e131521_SUBSEQUENTEVENTSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_626ed3c7-7e7c-497a-9dcb-00a87932b043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0dc686a1-59ef-49bf-a3b4-485e39b5d7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_626ed3c7-7e7c-497a-9dcb-00a87932b043" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0dc686a1-59ef-49bf-a3b4-485e39b5d7cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a08ac1c5-1ff2-40b8-a95c-6aca238c6776" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_626ed3c7-7e7c-497a-9dcb-00a87932b043" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a08ac1c5-1ff2-40b8-a95c-6aca238c6776" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_51b34232-4801-4ff9-8d82-20eb3ae17d44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_626ed3c7-7e7c-497a-9dcb-00a87932b043" xlink:to="loc_us-gaap_SubsequentEventTable_51b34232-4801-4ff9-8d82-20eb3ae17d44" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_83035b8f-e2d2-4a79-ac43-a3fffd8cc95a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_51b34232-4801-4ff9-8d82-20eb3ae17d44" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_83035b8f-e2d2-4a79-ac43-a3fffd8cc95a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_83035b8f-e2d2-4a79-ac43-a3fffd8cc95a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_83035b8f-e2d2-4a79-ac43-a3fffd8cc95a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_83035b8f-e2d2-4a79-ac43-a3fffd8cc95a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b5efb0ad-7165-494b-b096-6acf6af8c1c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_83035b8f-e2d2-4a79-ac43-a3fffd8cc95a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b5efb0ad-7165-494b-b096-6acf6af8c1c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_f8252275-b445-462b-8822-2789ab2bf667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b5efb0ad-7165-494b-b096-6acf6af8c1c7" xlink:to="loc_us-gaap_SubsequentEventMember_f8252275-b445-462b-8822-2789ab2bf667" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6f611dad-03c1-488d-a699-18e816008b83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_51b34232-4801-4ff9-8d82-20eb3ae17d44" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6f611dad-03c1-488d-a699-18e816008b83" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6f611dad-03c1-488d-a699-18e816008b83_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6f611dad-03c1-488d-a699-18e816008b83" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6f611dad-03c1-488d-a699-18e816008b83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_999c3b9a-5565-43a1-ae27-acf85efcc69c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6f611dad-03c1-488d-a699-18e816008b83" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_999c3b9a-5565-43a1-ae27-acf85efcc69c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_SalesAgreementMember_7e8d671e-1e2e-4ea8-ac4e-73e083a3cc68" xlink:href="flks-20230331.xsd#flks_SalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_999c3b9a-5565-43a1-ae27-acf85efcc69c" xlink:to="loc_flks_SalesAgreementMember_7e8d671e-1e2e-4ea8-ac4e-73e083a3cc68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c68e4905-bdb6-4c2f-bf78-ff30a7a883c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_51b34232-4801-4ff9-8d82-20eb3ae17d44" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c68e4905-bdb6-4c2f-bf78-ff30a7a883c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c68e4905-bdb6-4c2f-bf78-ff30a7a883c0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c68e4905-bdb6-4c2f-bf78-ff30a7a883c0" xlink:to="loc_us-gaap_EquityComponentDomain_c68e4905-bdb6-4c2f-bf78-ff30a7a883c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a1c4d3c1-b48c-4702-b327-fcc3f6152b07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c68e4905-bdb6-4c2f-bf78-ff30a7a883c0" xlink:to="loc_us-gaap_EquityComponentDomain_a1c4d3c1-b48c-4702-b327-fcc3f6152b07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0b8d44b0-8f7b-420d-962b-ae4ff98e28d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a1c4d3c1-b48c-4702-b327-fcc3f6152b07" xlink:to="loc_us-gaap_CommonStockMember_0b8d44b0-8f7b-420d-962b-ae4ff98e28d7" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>flks-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:3bcb0391-ae28-4064-946d-9955ab3b15fb,g:a3263b3f-ee17-40f5-9314-e2273145249f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_flks_RevenueFromGrantsMaximumAward_60ee4dcb-674e-4978-94a5-77ec21b524f8_terseLabel_en-US" xlink:label="lab_flks_RevenueFromGrantsMaximumAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award amount</link:label>
    <link:label id="lab_flks_RevenueFromGrantsMaximumAward_label_en-US" xlink:label="lab_flks_RevenueFromGrantsMaximumAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Maximum Award</link:label>
    <link:label id="lab_flks_RevenueFromGrantsMaximumAward_documentation_en-US" xlink:label="lab_flks_RevenueFromGrantsMaximumAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Maximum Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsMaximumAward" xlink:href="flks-20230331.xsd#flks_RevenueFromGrantsMaximumAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_RevenueFromGrantsMaximumAward" xlink:to="lab_flks_RevenueFromGrantsMaximumAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_082fa83e-1074-40e3-9301-f882b6c0a63d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e14af5c1-2df7-478e-8157-b85e3e0bb996_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_18f09f95-4fa4-413d-89c8-95a4c0586fc1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_8bbe996f-9c65-46aa-974c-114b19a8ff62_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollar per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_261cd291-bf13-412e-af49-775c22d5a971_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c3b18f51-da55-416e-8e0b-cc4d73ad90ca_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stock options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a1584493-8f00-4fb8-b682-f325ac38fb0f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_0ce271b2-b510-4297-ba15-c5eb9f6d9018_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_a3f85565-4d48-412f-853b-b40a52f021f1_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment charges of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_020e3e26-4cd0-4bc6-90fe-51f167954076_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_f0a17f20-651d-4387-b944-536f5dfe686c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_StockIssuanceCostsAccruedAndAmortized_78180254-e2c3-448d-9982-24e798c8306c_terseLabel_en-US" xlink:label="lab_flks_StockIssuanceCostsAccruedAndAmortized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued issuance costs for public offering</link:label>
    <link:label id="lab_flks_StockIssuanceCostsAccruedAndAmortized_label_en-US" xlink:label="lab_flks_StockIssuanceCostsAccruedAndAmortized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs Accrued and Amortized</link:label>
    <link:label id="lab_flks_StockIssuanceCostsAccruedAndAmortized_documentation_en-US" xlink:label="lab_flks_StockIssuanceCostsAccruedAndAmortized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs Accrued and Amortized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_StockIssuanceCostsAccruedAndAmortized" xlink:href="flks-20230331.xsd#flks_StockIssuanceCostsAccruedAndAmortized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_StockIssuanceCostsAccruedAndAmortized" xlink:to="lab_flks_StockIssuanceCostsAccruedAndAmortized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_402b0fbf-3318-4082-b438-3037de146206_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_4f710a09-deea-43d9-9a3d-4a3e1856e335_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_c25e0c84-453e-4b4d-a88d-5f1d84853a1c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_523d9c35-b2c6-428c-9e6a-a4c18603498b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_28e68795-783b-4ccb-99d5-866ec1aaa51d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from contract with customer, product and service</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_00e3d6f7-a8c8-4741-9cdf-5572c0438f11_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_4e3fabec-efe9-42d2-a83e-0ef7f9b29920_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 100,000,000 shares authorized; 2,468,297 and 2,255,899 shares issued and outstanding at March&#160;31, 2023 and December&#160;31, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_bde1345d-cf12-47ca-b9f6-672349ea13ac_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_bbaca1c6-9c7a-476c-ac97-e1426260603a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase in-process research and development technology</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_0615d3d9-a0e4-4d54-b97f-f70d4091e145_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase in-process research and development technology</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_23bcc91d-c9a8-4e3d-91a5-3a1171c3aa59_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued, weighted average grant date fair value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_40e5fb16-0469-4661-b55b-b63dc936d6e8_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a069b542-49d2-4020-82c7-d3154a4e3969_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_8c72a19b-62f0-4e34-8827-3a70a20fac66_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d288f95f-25cb-47f9-bcc4-f9cac6f1dfcc_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_f546c644-a222-4ba9-8e40-47cb8860be04_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9ce1c624-17b9-46fc-a7b0-711fb39fe9cb_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3650d705-c193-4fe7-bec8-384bc634012d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_fd974d25-27b1-4af8-b743-1c940f3cbfff_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_e6b545a6-6b7a-4505-8190-8ad94c7e7390_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_f9f23983-fa31-404f-b6f9-3b38c40ba912_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_c9a1a9bb-319a-4c9f-905d-b2ea798d4b13_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_82199ee2-756a-4fb2-92a1-15841ae6d9a8_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_670dd89d-ca53-4c46-8ab4-2cf871210656_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_adb7271e-fa59-4e70-806a-1650a9233639_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_497adb02-5bec-4cb4-8359-288ab1db30fb_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid insurance</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_3d8d1573-a1fc-4dc4-b482-8e224af5d7b8_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_be3a6cb8-4333-42a1-8e12-83f009d49f07_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_1613201f-4775-425c-b777-8f942a25cbcf_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]</link:label>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_label_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_86efdd02-5c99-4959-a249-5c90812fa1b1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_cd78a4df-abe5-4576-9891-f6f9e1c39081_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_54c4b171-b55d-431e-889e-95bc34a8bb17_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_RevenueFromGrantsAwardTerm_024b1d2d-a8c0-4195-9e4d-b6c2cb9de616_terseLabel_en-US" xlink:label="lab_flks_RevenueFromGrantsAwardTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award term</link:label>
    <link:label id="lab_flks_RevenueFromGrantsAwardTerm_label_en-US" xlink:label="lab_flks_RevenueFromGrantsAwardTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Award Term</link:label>
    <link:label id="lab_flks_RevenueFromGrantsAwardTerm_documentation_en-US" xlink:label="lab_flks_RevenueFromGrantsAwardTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Award Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsAwardTerm" xlink:href="flks-20230331.xsd#flks_RevenueFromGrantsAwardTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_RevenueFromGrantsAwardTerm" xlink:to="lab_flks_RevenueFromGrantsAwardTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_86c0fa1c-c449-40dc-92ae-fdaada8c6718_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_ea37ed77-6fe8-4402-b885-a57f438e11bb_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_c08af000-cefb-4b60-bc55-b47cc25ea339_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_51dc8066-c0b7-496a-8a70-f979c5676949_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Term (in years) and Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4dd02c1a-20de-450a-8d6f-eba7f67c520b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_1d68d76d-f811-48b2-8058-a4f6848a95ed_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_20eea675-d0ad-4c5f-a6ae-e0d9466d19c3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited, weighted-average exercise price (in dollar per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_974bad6d-a12f-4321-8a3a-c6c171853035_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_972c1001-02ff-446e-bc2b-5cca91f6046a_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_EmployeesMember_52100c92-9636-4dc2-b617-0d1532e50a9c_terseLabel_en-US" xlink:label="lab_flks_EmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees</link:label>
    <link:label id="lab_flks_EmployeesMember_label_en-US" xlink:label="lab_flks_EmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees [Member]</link:label>
    <link:label id="lab_flks_EmployeesMember_documentation_en-US" xlink:label="lab_flks_EmployeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_EmployeesMember" xlink:href="flks-20230331.xsd#flks_EmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_EmployeesMember" xlink:to="lab_flks_EmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_5c43b7c0-a69a-4412-803d-6997fa13b61a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_13156c95-2559-4c65-8112-ca020d7976c5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_22762895-e907-485d-897c-aea821e016f3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, weighted-average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f8b12dfb-dbb5-4b1b-b432-f1f948e4f67c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_59abae27-fd79-4da5-ab7f-6c1f9aa56411_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_7d7b806f-2012-4ea3-a010-b9bb035e6b11_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_84c5008c-7334-48e4-ae47-acdad29bc590_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_b4b74ab0-5fee-4a42-9c52-644824bd5596_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_8db719b9-b86a-4e5b-b494-aa207093e8c2_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_4cf7695d-e810-4d99-9b0d-c9a90ee7edbd_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a0fef57d-eb2c-4219-9b44-35ffcc769065_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_b991233d-b79b-4b4c-9456-0d99d44986d9_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_475d2e74-6a57-47ab-96c5-eec55998caf7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_2aa5e3a1-16ec-45ba-8fb1-4462a05d45bb_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_7b6a8ae1-1842-402e-b806-cabfb6b3d767_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3128866f-5f68-4291-8f31-dd31b8a73d0f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_fc369d6c-3f1f-4d92-827d-512241e0ac3d_terseLabel_en-US" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GRANT RECEIVABLE FROM CPRIT</link:label>
    <link:label id="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_0b993747-e0d6-410c-95d5-b3615baaa6e4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_2f71a7cd-adb5-42a3-a3a5-b133f1a77b03_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2897631f-06bc-43ba-9cee-eb0dcbe41bad_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_e56b60ba-c421-4f04-b620-c6d1611457e4_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_9b1b4114-94e2-4584-8f3f-0189a9377d7c_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_62d65b1e-6c0c-4082-aad3-9cd022126a19_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantMember_6f3287d6-b2bb-42af-a1c2-c79a153e348c_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant</link:label>
    <link:label id="lab_us-gaap_GrantMember_label_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_a589a148-29f5-467b-a41e-b66841983457_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of equity securities, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_e6d9755c-2070-41ac-947d-63fbf175eb93_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued, value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_f513c03a-0ea4-4e23-a20b-9d40495e08f3_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1ea45e45-5461-45cf-83e5-9584f957a315_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_8192e4b9-47e9-47c6-909c-5f12aecccbe5_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_PaymentsForAcquisitionAndStrategicCollaborationAgreement_9ab9b216-084d-4dca-bcc5-ed7ec85d021a_terseLabel_en-US" xlink:label="lab_flks_PaymentsForAcquisitionAndStrategicCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate payments under ASCA</link:label>
    <link:label id="lab_flks_PaymentsForAcquisitionAndStrategicCollaborationAgreement_label_en-US" xlink:label="lab_flks_PaymentsForAcquisitionAndStrategicCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Acquisition And Strategic Collaboration Agreement</link:label>
    <link:label id="lab_flks_PaymentsForAcquisitionAndStrategicCollaborationAgreement_documentation_en-US" xlink:label="lab_flks_PaymentsForAcquisitionAndStrategicCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Acquisition And Strategic Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_PaymentsForAcquisitionAndStrategicCollaborationAgreement" xlink:href="flks-20230331.xsd#flks_PaymentsForAcquisitionAndStrategicCollaborationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_PaymentsForAcquisitionAndStrategicCollaborationAgreement" xlink:to="lab_flks_PaymentsForAcquisitionAndStrategicCollaborationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_973d2b57-a6d2-4a1e-90c2-7144b6a7bd6f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_c320ba1f-856f-436a-aae1-d4c84cd1a3e3_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_895c8dab-ede1-481c-8720-da1531cc62eb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_99e5c69c-eb12-40ab-9a1b-2803f0c240df_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_fd932383-401d-4d4e-b364-edf8aaffa5cb_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_057a1410-c496-4798-9c2a-853b2f34cadd_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3dbf76b8-2b68-40af-a34f-b08f0d53248d_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_03f0da18-dbaf-4e90-9266-9d08a48a54ed_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_4922540e-71cf-43b4-b553-b3344bce0b39_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_1ed223cb-2264-4b18-a6db-d5e560bbe7cc_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_05322990-046e-4d64-b5ad-c18fe0846bf2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_459684f8-4316-4915-b0ec-d45e81efc030_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ca046db1-d256-4dac-96de-dd2feeb63750_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_163c719f-140e-425f-96b0-856e42098c68_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_8f50fb2d-5958-4061-86bc-daabd8a8dd33_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION AND OPERATIONS</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_5edb4e6a-f7f6-4fff-9b52-bb8317cf51a9_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage by noncontrolling owner</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_5f13deff-4252-45f2-924e-526f969bf5a6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_64816d3f-de84-46ef-8469-31be3b4d68df_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues_291d578d-315f-4c5c-ad86-76e168e62103_terseLabel_en-US" xlink:label="lab_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued for in-process research and development technology</link:label>
    <link:label id="lab_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues_label_en-US" xlink:label="lab_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period For In-Process Research and Development Technology, Value, New Issues</link:label>
    <link:label id="lab_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues_documentation_en-US" xlink:label="lab_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period For In-Process Research and Development Technology, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues" xlink:href="flks-20230331.xsd#flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues" xlink:to="lab_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_38bd0bea-409a-49ba-a764-00c99782c11e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_PurchaseAgreementMember_22ec5c4b-3614-407e-9017-a647036101f3_terseLabel_en-US" xlink:label="lab_flks_PurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement</link:label>
    <link:label id="lab_flks_PurchaseAgreementMember_label_en-US" xlink:label="lab_flks_PurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement [Member]</link:label>
    <link:label id="lab_flks_PurchaseAgreementMember_documentation_en-US" xlink:label="lab_flks_PurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_PurchaseAgreementMember" xlink:href="flks-20230331.xsd#flks_PurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_PurchaseAgreementMember" xlink:to="lab_flks_PurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_5194391e-a4b8-45c8-8d5b-ca33f935fd2c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:to="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_483c5d4f-90e2-47b6-bd86-098c808c5ef4_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_037914c6-55d4-47e6-a356-78450013b0fc_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation expense (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_833f387e-7c41-469f-bc7e-641326299ee2_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_ba01de0c-eb23-4568-a7a7-fa383de5ca7a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_32a07ec8-2cf1-4e7a-aced-4441b1fe53e4_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_RestrictedStockAndRestrictedStockUnitsMember_e706c800-52c2-496c-b9a6-18a7d3fbf751_terseLabel_en-US" xlink:label="lab_flks_RestrictedStockAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock and Restricted Stock Units</link:label>
    <link:label id="lab_flks_RestrictedStockAndRestrictedStockUnitsMember_label_en-US" xlink:label="lab_flks_RestrictedStockAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock and Restricted Stock Units [Member]</link:label>
    <link:label id="lab_flks_RestrictedStockAndRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_flks_RestrictedStockAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock and Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RestrictedStockAndRestrictedStockUnitsMember" xlink:href="flks-20230331.xsd#flks_RestrictedStockAndRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_RestrictedStockAndRestrictedStockUnitsMember" xlink:to="lab_flks_RestrictedStockAndRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4b6289d4-1c26-4ee7-af55-e392a1d626f1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted, weighted-average exercise price (in dollar per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_fce52777-0994-4b1c-9417-6e19e9c38f1d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised, weighted-average exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_80850568-90ec-481e-a526-ae60a67ebe7c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_EquityIncentivePlan2015Member_cdc39d80-f887-4d15-87a9-10a57f801a35_terseLabel_en-US" xlink:label="lab_flks_EquityIncentivePlan2015Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Plan</link:label>
    <link:label id="lab_flks_EquityIncentivePlan2015Member_label_en-US" xlink:label="lab_flks_EquityIncentivePlan2015Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2015 [Member]</link:label>
    <link:label id="lab_flks_EquityIncentivePlan2015Member_documentation_en-US" xlink:label="lab_flks_EquityIncentivePlan2015Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2015 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_EquityIncentivePlan2015Member" xlink:href="flks-20230331.xsd#flks_EquityIncentivePlan2015Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_EquityIncentivePlan2015Member" xlink:to="lab_flks_EquityIncentivePlan2015Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_92ac80c4-a3c7-4b76-b050-19be051aba71_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_39439fb6-ea4f-43da-b1bb-83bf54574b3c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_35262a5a-58a2-4086-aadc-24d205dbf466_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_0b378107-2ca7-4487-a5b7-d59a437ca815_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fae2e10f-deed-4a99-9764-0dfe67f555ea_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_570112ce-893c-4055-a16e-e736756d5d64_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_a3ae6573-86f0-4914-b744-8a6d4b6a4485_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8b973202-4419-4c5b-b491-ae05fc129bdf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_9a1840bd-f581-4008-977e-c93cedf3d99e_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_b3aea3df-2432-4245-8105-e7cd967581d5_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_2506b54b-0041-41c8-818a-da9bec1a5316_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_66705ced-bdd0-4346-b655-e95d3a512da1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_69ec86b2-0bb5-439e-9110-e1b0c82d0c25_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_86c7088e-5384-4a39-97e5-870a5a5b42b7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_cd097b48-1764-44f1-a8b9-906846134ce3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost, recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2b183abe-a970-49bc-a84a-5809e478c24a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, weighted-average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_b4cdbc2b-1b1a-401c-9716-6c47a86281c2_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 5)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_d67072c2-638c-43a1-bf40-7ab04ad1db3a_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_7a5bd116-b864-4062-87ca-2b0cd7b5309d_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_980a2c78-25ec-4b9d-9484-ee3955963eca_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, beginning balance (in dollar per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_bbdff267-eebc-4b01-a279-251b0aca6428_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, ending balance (in dollar per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6670fb97-4c57-4d0a-9f79-0fbf8b7df84b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of equity securities, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_cc7767fd-768b-4298-b06e-df210156ec09_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologySharesNewIssues_d4cfc4a9-b595-4e2c-ae8f-685af248e37a_terseLabel_en-US" xlink:label="lab_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologySharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued for in-process research and development technology (in shares)</link:label>
    <link:label id="lab_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologySharesNewIssues_label_en-US" xlink:label="lab_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologySharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period For In-Process Research and Development Technology, Shares, New Issues</link:label>
    <link:label id="lab_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologySharesNewIssues_documentation_en-US" xlink:label="lab_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologySharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period For In-Process Research and Development Technology, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologySharesNewIssues" xlink:href="flks-20230331.xsd#flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologySharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologySharesNewIssues" xlink:to="lab_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologySharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_74d332ec-078b-4fbf-bc30-40c78a0db087_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_43e58df7-0d07-4012-91f6-341a6204873d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued for in-process research and development technology</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_72835c5a-c538-43b6-b44d-6f416d419310_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 10,000,000 shares authorized; 0 issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b70614e0-158a-46cf-921c-d93d28a5462a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_546dcb82-df43-43f2-bd75-2c5f5e3b8d36_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_673590a5-aabe-4332-a36a-1149df983990_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_ed1ed9d9-9561-4d4a-aea5-1536e54b2cb7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_a515caf0-b33e-45f8-983a-b3a8f5bae3a1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_2914cfe1-9da4-4ccc-8884-6a93b7c65455_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f857b983-b0c3-42cf-ad5f-2dc5b1eded8c_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EQUITY-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_00ac6ba1-a190-4b24-a80e-827140d8fc78_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_3623f38e-380c-4add-8427-f38234317e8e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_9143f6f4-9e55-4e74-b409-b207c7c2a86f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_729f0040-2bee-41a8-b364-115c73505562_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_b55d87e9-d0ed-488e-98bb-038ac2538975_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollar per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_0cf9b169-917a-4a7a-91a4-acb7a373187d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE OF FINANCIAL INSTRUMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_f97f1f19-d291-4601-a5b9-5a004b88ff3b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_d3580d6b-d1e5-4874-88b1-5f0cc17a6758_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_108ee99e-3f89-421c-8605-ebb54ccd42d2_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_c2657256-11ed-4371-a090-810c85c96f88_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c1851e69-bc54-4c83-9724-fa11c627cd2c_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_5182841f-096b-462c-8958-4d060711bced_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_ce3210f1-1409-480d-89b9-c7c4090f46ae_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_59ff2bf0-f278-4b00-8103-ba550143c460_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_9d00fe15-dd39-40e5-9a43-0f0ac97127fb_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_3b2bbf37-c3ce-493c-8961-88346a853d9e_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_682536b9-7b67-4233-9cc0-1c5d1436794c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per common share, diluted ( in dollar per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_2def90ff-2757-4a9e-b4e6-3d0375456c4d_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_c2e7c72c-2740-47b2-9620-2fe97a0eea5c_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_3e4fc96f-6200-4e57-b212-d53138d57446_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b95157c6-9b53-469d-bf62-8462e5b6022a_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_e0df19b9-3a7e-4414-861d-ef6c537b1bc9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_f58baca1-95a3-4b86-96fb-8a89a7edc632_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_76f754c9-bb0d-4d8f-96f4-6c67f02d7674_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_30ce4139-cc2f-4f19-a7b6-52e11609252d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_fa97e43d-97a6-412d-80e2-45a93543ebfc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other prepaid and current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_454849d1-eef5-46c2-bfd0-8e8967a43901_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9a0f43db-66ec-488d-93a6-830cee97c7b8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (in dollar per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_984b2f8c-5f21-408b-b6f1-bedcc09b51ae_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per common share, basic ( in dollar per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_9bf1142e-f0ab-41fb-8120-d03fb0a0feae_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_9447faa2-2a0e-487d-aecc-11e934e73572_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_382949c1-b7dc-4f4b-8b72-84a468a35bab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of awards</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_3e824c74-1dd0-4e22-8f03-e68a0221becd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_6a69916d-c802-4e99-bc5b-b8180c223b82_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_1640aca9-5f42-4cba-9f95-5a90d2c26af2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_dfa65c06-3d97-47a8-bca7-32686e9bd6cb_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_bf0283e7-9165-4c2d-a649-f37e65987bc5_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_a1324002-1907-4799-8964-8274d35241ed_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_a753b9cc-7d47-4e98-9239-5806b53ad7c8_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_WarrantsAndRightsExercisableTerm_b0e6e42e-7c5d-4d49-9f5d-10a823da6190_terseLabel_en-US" xlink:label="lab_flks_WarrantsAndRightsExercisableTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and rights exercisable, term</link:label>
    <link:label id="lab_flks_WarrantsAndRightsExercisableTerm_label_en-US" xlink:label="lab_flks_WarrantsAndRightsExercisableTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Exercisable, Term</link:label>
    <link:label id="lab_flks_WarrantsAndRightsExercisableTerm_documentation_en-US" xlink:label="lab_flks_WarrantsAndRightsExercisableTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Exercisable, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_WarrantsAndRightsExercisableTerm" xlink:href="flks-20230331.xsd#flks_WarrantsAndRightsExercisableTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_WarrantsAndRightsExercisableTerm" xlink:to="lab_flks_WarrantsAndRightsExercisableTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_b68177c3-c878-4d8f-9ef1-41974c9705ab_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_7bde92c6-2e27-4a46-ab2d-b9a9b060bbab_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_1fd4eb6b-391d-4abe-83a4-3adca2ed1a37_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_PrepaidClinicalTrialExpense_c57ce218-1a35-42a4-bf56-31324c0a349a_terseLabel_en-US" xlink:label="lab_flks_PrepaidClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid clinical trial expenses</link:label>
    <link:label id="lab_flks_PrepaidClinicalTrialExpense_label_en-US" xlink:label="lab_flks_PrepaidClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Clinical Trial Expense</link:label>
    <link:label id="lab_flks_PrepaidClinicalTrialExpense_documentation_en-US" xlink:label="lab_flks_PrepaidClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Clinical Trial Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_PrepaidClinicalTrialExpense" xlink:href="flks-20230331.xsd#flks_PrepaidClinicalTrialExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_PrepaidClinicalTrialExpense" xlink:to="lab_flks_PrepaidClinicalTrialExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b29ea0b0-a174-408a-874f-66c93436648e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4d2e2f4c-8850-495b-a8ac-948e6862fd06_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_ba72cba0-c742-4eab-b977-a030333e3c86_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_2df8b7fd-74a9-4b0d-a16f-416c6c1c9ab3_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_2ca2ec28-13fe-4e93-9f16-01d0ced867cc_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c8914360-520c-4d37-bca2-52535d69ee03_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost, options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantsReceivableCurrent_c58bc3b8-cf5a-4d00-9632-96dc08ef0410_terseLabel_en-US" xlink:label="lab_us-gaap_GrantsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants receivable from CPRIT</link:label>
    <link:label id="lab_us-gaap_GrantsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_GrantsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantsReceivableCurrent" xlink:to="lab_us-gaap_GrantsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_00da2f3d-6231-47dd-b227-3e88bf9e46a2_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_aa2aab91-a208-4550-95bb-2ab12280ca2d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_7daaf890-4c18-43bb-a3c1-bfade0107317_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation expense</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_351c9215-119c-4d82-a7d4-263f807b4398_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares remaining available for grant of stock awards (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_1ba6e396-c308-4b3e-810a-92d09c1bc79a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_c6bad9aa-5d17-4330-9d1c-cc6d320d0051_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants Receivable and Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_1580c158-a8df-478e-bbaa-386b0ea2a6a1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_OfficersAndDirectorsMember_90e3f9e9-9a0b-40ec-9336-6baf5cbd6c50_terseLabel_en-US" xlink:label="lab_flks_OfficersAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Officers and Directors</link:label>
    <link:label id="lab_flks_OfficersAndDirectorsMember_label_en-US" xlink:label="lab_flks_OfficersAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Officers and Directors [Member]</link:label>
    <link:label id="lab_flks_OfficersAndDirectorsMember_documentation_en-US" xlink:label="lab_flks_OfficersAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Officers and Directors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_OfficersAndDirectorsMember" xlink:href="flks-20230331.xsd#flks_OfficersAndDirectorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_OfficersAndDirectorsMember" xlink:to="lab_flks_OfficersAndDirectorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_AccruedExpensesAndOtherCurrentLiabilities_f48b50e6-ae83-43e9-9007-22a39e93862d_terseLabel_en-US" xlink:label="lab_flks_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_flks_AccruedExpensesAndOtherCurrentLiabilities_label_en-US" xlink:label="lab_flks_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses And Other Current Liabilities</link:label>
    <link:label id="lab_flks_AccruedExpensesAndOtherCurrentLiabilities_documentation_en-US" xlink:label="lab_flks_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses And Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_AccruedExpensesAndOtherCurrentLiabilities" xlink:href="flks-20230331.xsd#flks_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="lab_flks_AccruedExpensesAndOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_98dbc51b-4b41-4cbe-b0dc-04b6d913fed1_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_58658757-0bf2-44fd-a9c5-138c8d9e3afb_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_SalesAgreementMember_03dde5b7-e95d-42f3-b65b-3dcdd2db559d_terseLabel_en-US" xlink:label="lab_flks_SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreement</link:label>
    <link:label id="lab_flks_SalesAgreementMember_label_en-US" xlink:label="lab_flks_SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreement [Member]</link:label>
    <link:label id="lab_flks_SalesAgreementMember_documentation_en-US" xlink:label="lab_flks_SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_SalesAgreementMember" xlink:href="flks-20230331.xsd#flks_SalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_SalesAgreementMember" xlink:to="lab_flks_SalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_f944ada8-142d-492b-9550-f6c57ef3bae4_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_273536c2-e330-4f46-b1af-52e8ce820d3f_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_3107634c-63e5-4a0d-8409-57535e579d7e_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_55b37424-4850-423f-9070-c90f56026ad6_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_label_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_c728630f-a761-4808-8fef-4c202af97145_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_7060bfce-d32e-4dd1-adff-513d52f9fce6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_3b5a0082-f508-4d58-a2e6-9d760006f124_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_ef33fad5-1127-40cf-8598-78786a172a2d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, weighted-average exercise price (in dollar per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7934644a-a87a-4334-b8ea-dd76b5942e98_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_d314233f-e8b1-40c8-bd2a-5ea36ecac861_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments and Credit Risks</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_762d7169-13a4-42a2-8f1d-4d37140742f6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired, weighted-average exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_2781dfed-cdc2-4ba5-bfc9-9953081a8239_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income, net and other</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_a79069ca-53da-45a8-952e-0bcc712ae936_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d70d950f-8075-4732-95e6-52f21cd80d15_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_ab8b7855-743d-4017-abf6-b0bb317aa4c9_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_84e06ab3-14d1-4a3a-b6c4-71019392bec9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_ba19e123-0411-4dbd-afe7-58d154e0aec9_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_83d12316-e096-4b22-82b6-e61aa7ffdf34_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_e4ebdf5c-1b2f-418a-bf67-cf3d60d5a101_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and rights outstanding, term</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_ecd532b7-3dfa-4053-b0d7-24e639c5184f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_cb1d0ca8-3cfd-468d-a020-0f37c9875fa5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_UniversityOfUtahResearchFoundationMember_45e341b0-f527-4a5b-a7d8-4b5b5d79c89b_terseLabel_en-US" xlink:label="lab_flks_UniversityOfUtahResearchFoundationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of Utah Research Foundation</link:label>
    <link:label id="lab_flks_UniversityOfUtahResearchFoundationMember_label_en-US" xlink:label="lab_flks_UniversityOfUtahResearchFoundationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of Utah Research Foundation [Member]</link:label>
    <link:label id="lab_flks_UniversityOfUtahResearchFoundationMember_documentation_en-US" xlink:label="lab_flks_UniversityOfUtahResearchFoundationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of Utah Research Foundation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_UniversityOfUtahResearchFoundationMember" xlink:href="flks-20230331.xsd#flks_UniversityOfUtahResearchFoundationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_UniversityOfUtahResearchFoundationMember" xlink:to="lab_flks_UniversityOfUtahResearchFoundationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e603307b-0e15-4864-987f-41ddadad498d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_ee025efe-e67f-4876-93f8-251103af4cfe_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development technology</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_56894f31-c323-410a-8e68-ebe883e5e180_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e90e95c5-4e82-4baf-990b-fc015f6f5706_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_6be16d3f-3845-4569-81dd-9543fd8d8b3a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_0e16d730-610e-4694-86de-236532851f8d_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_6b93113e-2ba8-4655-b72a-88a5f3520d32_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_9a697a19-6d7a-4434-b781-e4cad002d0ae_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_cc011a94-5801-42ca-82e4-3143b82463d6_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ecc73cca-7ff5-4076-90f9-25cf0aba9c25_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_3a7865e6-9877-4f1d-884a-406dbb4b3532_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before other income (expense)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_caaad23c-df47-4f92-8aa2-c81b2707a3f6_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Standard</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromOtherEquity_70927472-5184-4702-870e-f274ccaf7917_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromOtherEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of equity securities, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromOtherEquity_label_en-US" xlink:label="lab_us-gaap_ProceedsFromOtherEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Other Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromOtherEquity" xlink:to="lab_us-gaap_ProceedsFromOtherEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c79aa14c-1153-4682-ba7a-47decf428b21_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_6d0d337f-2ec9-4afe-85b8-3aed84d44ea6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales_6414017e-718c-4d11-9e79-e275bcc960ee_terseLabel_en-US" xlink:label="lab_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continued payments, percent of net sales</link:label>
    <link:label id="lab_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales_label_en-US" xlink:label="lab_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Revenue-sharing Payments, Continued Payments, Percent of Net Sales</link:label>
    <link:label id="lab_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales_documentation_en-US" xlink:label="lab_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Revenue-sharing Payments, Continued Payments, Percent of Net Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales" xlink:href="flks-20230331.xsd#flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales" xlink:to="lab_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>flks-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:3bcb0391-ae28-4064-946d-9955ab3b15fb,g:a3263b3f-ee17-40f5-9314-e2273145249f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.flex-pharma.com/role/COVERPAGE" xlink:type="simple" xlink:href="flks-20230331.xsd#COVERPAGE"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/COVERPAGE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_44e7bdd4-f71e-4cd7-9ed3-74ddda6ab380" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_66bce0b9-050c-4ee7-afde-a87dbfa998f5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44e7bdd4-f71e-4cd7-9ed3-74ddda6ab380" xlink:to="loc_dei_DocumentType_66bce0b9-050c-4ee7-afde-a87dbfa998f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_d0c107bf-1a98-479e-b5b3-548f9ab18e50" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44e7bdd4-f71e-4cd7-9ed3-74ddda6ab380" xlink:to="loc_dei_DocumentQuarterlyReport_d0c107bf-1a98-479e-b5b3-548f9ab18e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_4091e270-bef2-4126-a2fa-e69decfaf4e7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44e7bdd4-f71e-4cd7-9ed3-74ddda6ab380" xlink:to="loc_dei_DocumentPeriodEndDate_4091e270-bef2-4126-a2fa-e69decfaf4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_36137a0d-ac23-40df-b62d-9545bd9c4aae" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44e7bdd4-f71e-4cd7-9ed3-74ddda6ab380" xlink:to="loc_dei_DocumentTransitionReport_36137a0d-ac23-40df-b62d-9545bd9c4aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_7510b467-9a5d-4ae8-ba97-3ea4036babb9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44e7bdd4-f71e-4cd7-9ed3-74ddda6ab380" xlink:to="loc_dei_EntityFileNumber_7510b467-9a5d-4ae8-ba97-3ea4036babb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_aba96e99-6e7e-4ac0-a092-4f75e85fede5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44e7bdd4-f71e-4cd7-9ed3-74ddda6ab380" xlink:to="loc_dei_EntityRegistrantName_aba96e99-6e7e-4ac0-a092-4f75e85fede5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_5f18158e-4b8e-4b28-a6e8-463b65e2f6b2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44e7bdd4-f71e-4cd7-9ed3-74ddda6ab380" xlink:to="loc_dei_EntityIncorporationStateCountryCode_5f18158e-4b8e-4b28-a6e8-463b65e2f6b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_dae9e3a0-36f8-456c-aa38-9894e9721126" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44e7bdd4-f71e-4cd7-9ed3-74ddda6ab380" xlink:to="loc_dei_EntityTaxIdentificationNumber_dae9e3a0-36f8-456c-aa38-9894e9721126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_c1b2142d-6f27-4ce8-970e-6a7497ed300d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44e7bdd4-f71e-4cd7-9ed3-74ddda6ab380" xlink:to="loc_dei_EntityAddressAddressLine1_c1b2142d-6f27-4ce8-970e-6a7497ed300d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_009ac567-a55d-4e1b-9eda-813db04d34dd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44e7bdd4-f71e-4cd7-9ed3-74ddda6ab380" xlink:to="loc_dei_EntityAddressAddressLine2_009ac567-a55d-4e1b-9eda-813db04d34dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_749e19a3-2ef2-477b-b9ae-3a6c5e559c52" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44e7bdd4-f71e-4cd7-9ed3-74ddda6ab380" xlink:to="loc_dei_EntityAddressCityOrTown_749e19a3-2ef2-477b-b9ae-3a6c5e559c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_cb3b1ce5-8e06-40ba-a303-f44309f105c1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44e7bdd4-f71e-4cd7-9ed3-74ddda6ab380" xlink:to="loc_dei_EntityAddressStateOrProvince_cb3b1ce5-8e06-40ba-a303-f44309f105c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_4b48ab66-3056-47ff-8af2-e616ced370ff" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44e7bdd4-f71e-4cd7-9ed3-74ddda6ab380" xlink:to="loc_dei_EntityAddressPostalZipCode_4b48ab66-3056-47ff-8af2-e616ced370ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_348f1447-7ed7-42bf-818e-84e04566d595" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44e7bdd4-f71e-4cd7-9ed3-74ddda6ab380" xlink:to="loc_dei_CityAreaCode_348f1447-7ed7-42bf-818e-84e04566d595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_f907f9cd-06dd-470f-aae2-279f44badb2f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44e7bdd4-f71e-4cd7-9ed3-74ddda6ab380" xlink:to="loc_dei_LocalPhoneNumber_f907f9cd-06dd-470f-aae2-279f44badb2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f78e22c0-9198-4746-a634-69445bc93d85" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44e7bdd4-f71e-4cd7-9ed3-74ddda6ab380" xlink:to="loc_dei_Security12bTitle_f78e22c0-9198-4746-a634-69445bc93d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_27b94017-b7cd-413c-8bfd-cc94f9d72875" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44e7bdd4-f71e-4cd7-9ed3-74ddda6ab380" xlink:to="loc_dei_TradingSymbol_27b94017-b7cd-413c-8bfd-cc94f9d72875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c353edec-64b8-4197-abc7-454deb965419" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44e7bdd4-f71e-4cd7-9ed3-74ddda6ab380" xlink:to="loc_dei_SecurityExchangeName_c353edec-64b8-4197-abc7-454deb965419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_b1326e1a-6674-43b8-8ff1-679adbd90bda" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44e7bdd4-f71e-4cd7-9ed3-74ddda6ab380" xlink:to="loc_dei_EntityCurrentReportingStatus_b1326e1a-6674-43b8-8ff1-679adbd90bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_6f9e65f1-ea75-488d-a175-7c1dbd51a15c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44e7bdd4-f71e-4cd7-9ed3-74ddda6ab380" xlink:to="loc_dei_EntityInteractiveDataCurrent_6f9e65f1-ea75-488d-a175-7c1dbd51a15c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_4e52d3ea-a66b-4ee6-89fd-0d3bc4a47e7d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44e7bdd4-f71e-4cd7-9ed3-74ddda6ab380" xlink:to="loc_dei_EntityFilerCategory_4e52d3ea-a66b-4ee6-89fd-0d3bc4a47e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_060a51b7-2a3d-4451-a069-fb5e7da0d196" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44e7bdd4-f71e-4cd7-9ed3-74ddda6ab380" xlink:to="loc_dei_EntitySmallBusiness_060a51b7-2a3d-4451-a069-fb5e7da0d196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_a0bbd57c-a569-4d47-9b45-81e6088e96d8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44e7bdd4-f71e-4cd7-9ed3-74ddda6ab380" xlink:to="loc_dei_EntityEmergingGrowthCompany_a0bbd57c-a569-4d47-9b45-81e6088e96d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_daff9584-378c-4a65-aa95-1f9be4e46dff" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44e7bdd4-f71e-4cd7-9ed3-74ddda6ab380" xlink:to="loc_dei_EntityShellCompany_daff9584-378c-4a65-aa95-1f9be4e46dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_dfc83733-f4aa-4e3f-89cb-672e84347284" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44e7bdd4-f71e-4cd7-9ed3-74ddda6ab380" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_dfc83733-f4aa-4e3f-89cb-672e84347284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_f64f32aa-f2a4-4ae0-af58-fe36c442e9d5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44e7bdd4-f71e-4cd7-9ed3-74ddda6ab380" xlink:to="loc_dei_EntityCentralIndexKey_f64f32aa-f2a4-4ae0-af58-fe36c442e9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_9d0058d3-e240-4e7a-b8d7-f56b880c7595" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44e7bdd4-f71e-4cd7-9ed3-74ddda6ab380" xlink:to="loc_dei_CurrentFiscalYearEndDate_9d0058d3-e240-4e7a-b8d7-f56b880c7595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_932162e4-eca0-4ff4-a172-7b576983db21" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44e7bdd4-f71e-4cd7-9ed3-74ddda6ab380" xlink:to="loc_dei_DocumentFiscalYearFocus_932162e4-eca0-4ff4-a172-7b576983db21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_757e8eda-515b-4468-a5bb-d25cb1706195" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44e7bdd4-f71e-4cd7-9ed3-74ddda6ab380" xlink:to="loc_dei_DocumentFiscalPeriodFocus_757e8eda-515b-4468-a5bb-d25cb1706195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_c8871d42-817d-4125-842a-e14751e2bbc5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_44e7bdd4-f71e-4cd7-9ed3-74ddda6ab380" xlink:to="loc_dei_AmendmentFlag_c8871d42-817d-4125-842a-e14751e2bbc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="flks-20230331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_951b74be-ef7f-46a6-854d-c2ca4b755380" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_754f6f96-a0dc-4b1d-bf69-83ea9ab8cd75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_951b74be-ef7f-46a6-854d-c2ca4b755380" xlink:to="loc_us-gaap_AssetsAbstract_754f6f96-a0dc-4b1d-bf69-83ea9ab8cd75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_d175bcb8-e0b8-4b9c-80ce-7ed7adc1a757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_754f6f96-a0dc-4b1d-bf69-83ea9ab8cd75" xlink:to="loc_us-gaap_AssetsCurrentAbstract_d175bcb8-e0b8-4b9c-80ce-7ed7adc1a757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_30007f49-f759-4e66-96aa-48118322ac48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d175bcb8-e0b8-4b9c-80ce-7ed7adc1a757" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_30007f49-f759-4e66-96aa-48118322ac48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivableCurrent_c091888c-1d04-4a8f-99b8-c8e6637da31e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantsReceivableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d175bcb8-e0b8-4b9c-80ce-7ed7adc1a757" xlink:to="loc_us-gaap_GrantsReceivableCurrent_c091888c-1d04-4a8f-99b8-c8e6637da31e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f236dcab-d353-4d3c-b425-d118ad11ccf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d175bcb8-e0b8-4b9c-80ce-7ed7adc1a757" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f236dcab-d353-4d3c-b425-d118ad11ccf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1590876b-c662-403b-a7c1-8b10543e0b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d175bcb8-e0b8-4b9c-80ce-7ed7adc1a757" xlink:to="loc_us-gaap_AssetsCurrent_1590876b-c662-403b-a7c1-8b10543e0b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_94592161-8fa3-4e46-a3c9-92c65971a2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_754f6f96-a0dc-4b1d-bf69-83ea9ab8cd75" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_94592161-8fa3-4e46-a3c9-92c65971a2b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_319af8c0-a9d9-4339-91b0-dee703636c09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_754f6f96-a0dc-4b1d-bf69-83ea9ab8cd75" xlink:to="loc_us-gaap_Assets_319af8c0-a9d9-4339-91b0-dee703636c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3acb965e-14c2-475d-b900-da8174045993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_951b74be-ef7f-46a6-854d-c2ca4b755380" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3acb965e-14c2-475d-b900-da8174045993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_4389bafb-c4d4-4965-8377-b9194cbba65b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3acb965e-14c2-475d-b900-da8174045993" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_4389bafb-c4d4-4965-8377-b9194cbba65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_d642d0ee-b2ae-4aff-b77b-29b08d3050df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4389bafb-c4d4-4965-8377-b9194cbba65b" xlink:to="loc_us-gaap_AccountsPayableCurrent_d642d0ee-b2ae-4aff-b77b-29b08d3050df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_AccruedExpensesAndOtherCurrentLiabilities_74e6eccb-64d5-460c-8953-0d664a0b1cd2" xlink:href="flks-20230331.xsd#flks_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4389bafb-c4d4-4965-8377-b9194cbba65b" xlink:to="loc_flks_AccruedExpensesAndOtherCurrentLiabilities_74e6eccb-64d5-460c-8953-0d664a0b1cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f982e5f2-47a8-4d55-a2d3-a39a48e8b31a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3acb965e-14c2-475d-b900-da8174045993" xlink:to="loc_us-gaap_Liabilities_f982e5f2-47a8-4d55-a2d3-a39a48e8b31a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_c5c88337-a256-45ae-93ec-e0b732e84786" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3acb965e-14c2-475d-b900-da8174045993" xlink:to="loc_us-gaap_CommitmentsAndContingencies_c5c88337-a256-45ae-93ec-e0b732e84786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_635dc15a-fbf4-4960-8e2c-2fdc14720c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3acb965e-14c2-475d-b900-da8174045993" xlink:to="loc_us-gaap_StockholdersEquityAbstract_635dc15a-fbf4-4960-8e2c-2fdc14720c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_409b3e59-440a-4728-8fea-3f06a4fcfbeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_635dc15a-fbf4-4960-8e2c-2fdc14720c7d" xlink:to="loc_us-gaap_PreferredStockValue_409b3e59-440a-4728-8fea-3f06a4fcfbeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f0183ce8-e4a2-4a29-b831-231badcc24eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_635dc15a-fbf4-4960-8e2c-2fdc14720c7d" xlink:to="loc_us-gaap_CommonStockValue_f0183ce8-e4a2-4a29-b831-231badcc24eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_dff442ed-6a1d-4cf4-991b-5858287ab690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_635dc15a-fbf4-4960-8e2c-2fdc14720c7d" xlink:to="loc_us-gaap_AdditionalPaidInCapital_dff442ed-6a1d-4cf4-991b-5858287ab690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7d16700b-598a-45b7-b93c-f0787c94e493" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_635dc15a-fbf4-4960-8e2c-2fdc14720c7d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7d16700b-598a-45b7-b93c-f0787c94e493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a91e4970-c022-4942-a049-06408e97832b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_635dc15a-fbf4-4960-8e2c-2fdc14720c7d" xlink:to="loc_us-gaap_StockholdersEquity_a91e4970-c022-4942-a049-06408e97832b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1d0bea5f-c818-40b2-861c-e58c8954eefc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3acb965e-14c2-475d-b900-da8174045993" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_1d0bea5f-c818-40b2-861c-e58c8954eefc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="flks-20230331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_6e801794-26ee-4462-8c5e-6db492b2163a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7876fab0-92c5-4e89-bc93-cc72703aedf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6e801794-26ee-4462-8c5e-6db492b2163a" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7876fab0-92c5-4e89-bc93-cc72703aedf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_f3ee166b-7617-41ca-a1e2-05bd32116cad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6e801794-26ee-4462-8c5e-6db492b2163a" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_f3ee166b-7617-41ca-a1e2-05bd32116cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_66c85358-1744-418f-9f09-8eda5ae930c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6e801794-26ee-4462-8c5e-6db492b2163a" xlink:to="loc_us-gaap_PreferredStockSharesIssued_66c85358-1744-418f-9f09-8eda5ae930c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_475130cf-3bdd-41a5-9fdc-cfcbf030f523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6e801794-26ee-4462-8c5e-6db492b2163a" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_475130cf-3bdd-41a5-9fdc-cfcbf030f523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_d6c8d8b0-b6da-4468-86cc-c3ee7dde3f14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6e801794-26ee-4462-8c5e-6db492b2163a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_d6c8d8b0-b6da-4468-86cc-c3ee7dde3f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_e602dbf7-48a4-4953-a880-28b3e59e2837" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6e801794-26ee-4462-8c5e-6db492b2163a" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_e602dbf7-48a4-4953-a880-28b3e59e2837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_93a8db4f-c93d-42d1-84ed-67b29ea97322" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6e801794-26ee-4462-8c5e-6db492b2163a" xlink:to="loc_us-gaap_CommonStockSharesIssued_93a8db4f-c93d-42d1-84ed-67b29ea97322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4914cfff-d2e0-4e76-82a7-d74dac92ca6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6e801794-26ee-4462-8c5e-6db492b2163a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4914cfff-d2e0-4e76-82a7-d74dac92ca6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="flks-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_f68371f2-1e47-49a4-ac1b-9d080b168932" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_cc29f807-52d0-4ac3-a106-6f46735f8391" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f68371f2-1e47-49a4-ac1b-9d080b168932" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_cc29f807-52d0-4ac3-a106-6f46735f8391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d2c7ec9f-c124-4e2d-a9ab-8ae96ea2164c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f68371f2-1e47-49a4-ac1b-9d080b168932" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d2c7ec9f-c124-4e2d-a9ab-8ae96ea2164c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_d6784975-33f6-494b-8a42-f604fbdb26d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f68371f2-1e47-49a4-ac1b-9d080b168932" xlink:to="loc_us-gaap_OperatingExpensesAbstract_d6784975-33f6-494b-8a42-f604fbdb26d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_779fbba9-d8d0-42fb-b6fd-92fb38d82f40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d6784975-33f6-494b-8a42-f604fbdb26d2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_779fbba9-d8d0-42fb-b6fd-92fb38d82f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_267b481e-8b80-4022-9c4b-83c6cd371256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d6784975-33f6-494b-8a42-f604fbdb26d2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_267b481e-8b80-4022-9c4b-83c6cd371256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_11837a1d-71d7-4f7b-9fd7-453a4dbab6eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d6784975-33f6-494b-8a42-f604fbdb26d2" xlink:to="loc_us-gaap_OperatingExpenses_11837a1d-71d7-4f7b-9fd7-453a4dbab6eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_81deb61f-d3c1-4d68-b819-75a8f67b86cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f68371f2-1e47-49a4-ac1b-9d080b168932" xlink:to="loc_us-gaap_OperatingIncomeLoss_81deb61f-d3c1-4d68-b819-75a8f67b86cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_e7369c8d-ff08-4a50-ab90-4cdecd70c975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f68371f2-1e47-49a4-ac1b-9d080b168932" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_e7369c8d-ff08-4a50-ab90-4cdecd70c975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_bfe0c0cf-5fd1-4c9d-a35d-2628d743e28c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f68371f2-1e47-49a4-ac1b-9d080b168932" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_bfe0c0cf-5fd1-4c9d-a35d-2628d743e28c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8d780363-0aa0-47d7-8037-313d6aad7764" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f68371f2-1e47-49a4-ac1b-9d080b168932" xlink:to="loc_us-gaap_NetIncomeLoss_8d780363-0aa0-47d7-8037-313d6aad7764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b36fa812-c4d1-4c9a-a255-b4cbb528c40d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f68371f2-1e47-49a4-ac1b-9d080b168932" xlink:to="loc_us-gaap_EarningsPerShareBasic_b36fa812-c4d1-4c9a-a255-b4cbb528c40d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_44c30554-5649-4897-8683-1619ee0dacd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f68371f2-1e47-49a4-ac1b-9d080b168932" xlink:to="loc_us-gaap_EarningsPerShareDiluted_44c30554-5649-4897-8683-1619ee0dacd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f7930695-9247-4df1-b7a9-9744caf55ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f68371f2-1e47-49a4-ac1b-9d080b168932" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f7930695-9247-4df1-b7a9-9744caf55ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_436edce8-811a-424e-b3c6-0592bee9a4cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f68371f2-1e47-49a4-ac1b-9d080b168932" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_436edce8-811a-424e-b3c6-0592bee9a4cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="flks-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_44a08569-d27f-475e-a498-65fda5481fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b2fb9a16-8624-491c-88e6-ceb365efc06e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_44a08569-d27f-475e-a498-65fda5481fdc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b2fb9a16-8624-491c-88e6-ceb365efc06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_56655936-3daa-4f7e-a1fd-bd9b1da692ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b2fb9a16-8624-491c-88e6-ceb365efc06e" xlink:to="loc_us-gaap_NetIncomeLoss_56655936-3daa-4f7e-a1fd-bd9b1da692ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5c62b4d2-0b09-40f0-be03-05f79e97fc8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b2fb9a16-8624-491c-88e6-ceb365efc06e" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5c62b4d2-0b09-40f0-be03-05f79e97fc8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_312d59b9-c1bb-46ac-aef1-c0201e01822c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5c62b4d2-0b09-40f0-be03-05f79e97fc8a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_312d59b9-c1bb-46ac-aef1-c0201e01822c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_eb27ad76-af44-43bd-968e-ac2c721e4bab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5c62b4d2-0b09-40f0-be03-05f79e97fc8a" xlink:to="loc_us-gaap_ShareBasedCompensation_eb27ad76-af44-43bd-968e-ac2c721e4bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_aa4a4450-c9a2-428d-a169-8149d99d7a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5c62b4d2-0b09-40f0-be03-05f79e97fc8a" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_aa4a4450-c9a2-428d-a169-8149d99d7a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5a6c1443-df93-4c23-ab82-1da9d2dac262" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5c62b4d2-0b09-40f0-be03-05f79e97fc8a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5a6c1443-df93-4c23-ab82-1da9d2dac262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_e6292cfb-2c43-4f1b-9253-5775c6af39e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5a6c1443-df93-4c23-ab82-1da9d2dac262" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_e6292cfb-2c43-4f1b-9253-5775c6af39e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_70bed618-4a12-475e-b9ff-b7f77de117e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5a6c1443-df93-4c23-ab82-1da9d2dac262" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_70bed618-4a12-475e-b9ff-b7f77de117e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6b1b8783-1109-4d89-8a41-18362af86136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5a6c1443-df93-4c23-ab82-1da9d2dac262" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6b1b8783-1109-4d89-8a41-18362af86136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a8b7b822-35e7-47d8-8ae9-76b60c1d71b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5a6c1443-df93-4c23-ab82-1da9d2dac262" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a8b7b822-35e7-47d8-8ae9-76b60c1d71b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_660aee9a-cfd3-4266-8b80-30ef30bc3d18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b2fb9a16-8624-491c-88e6-ceb365efc06e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_660aee9a-cfd3-4266-8b80-30ef30bc3d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6239cea8-251e-4121-90a8-dfd88955afac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_44a08569-d27f-475e-a498-65fda5481fdc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6239cea8-251e-4121-90a8-dfd88955afac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_95b1d425-7b40-473a-8f8b-4bfefc1afe59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6239cea8-251e-4121-90a8-dfd88955afac" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_95b1d425-7b40-473a-8f8b-4bfefc1afe59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5c0c7da4-2f82-4e1c-bc0d-8a5ac6415047" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6239cea8-251e-4121-90a8-dfd88955afac" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5c0c7da4-2f82-4e1c-bc0d-8a5ac6415047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d552f2e2-d09d-4683-b3d7-c2fb445ee90c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_44a08569-d27f-475e-a498-65fda5481fdc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d552f2e2-d09d-4683-b3d7-c2fb445ee90c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromOtherEquity_332d0480-5c7a-4ac3-807a-641a37d54a34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d552f2e2-d09d-4683-b3d7-c2fb445ee90c" xlink:to="loc_us-gaap_ProceedsFromOtherEquity_332d0480-5c7a-4ac3-807a-641a37d54a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5e1653c3-86f2-4cc7-9e56-9977b0dea34e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d552f2e2-d09d-4683-b3d7-c2fb445ee90c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5e1653c3-86f2-4cc7-9e56-9977b0dea34e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1e8adef5-82c6-4dde-9e7a-58c18faf4a14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_44a08569-d27f-475e-a498-65fda5481fdc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1e8adef5-82c6-4dde-9e7a-58c18faf4a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_33acac79-7ade-400c-a6c1-ef88c4605a99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_44a08569-d27f-475e-a498-65fda5481fdc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_33acac79-7ade-400c-a6c1-ef88c4605a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d5dd8a47-f895-4332-8222-9fd94e75860e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_44a08569-d27f-475e-a498-65fda5481fdc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d5dd8a47-f895-4332-8222-9fd94e75860e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_9f2bc1cb-1d11-4912-becf-3aab9e9140b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_44a08569-d27f-475e-a498-65fda5481fdc" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_9f2bc1cb-1d11-4912-becf-3aab9e9140b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_05537a72-6ff6-4d6b-b2b3-0d0cf73878e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_9f2bc1cb-1d11-4912-becf-3aab9e9140b0" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_05537a72-6ff6-4d6b-b2b3-0d0cf73878e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_3b877541-c166-4136-b21a-d5b2fbcfbf3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_05537a72-6ff6-4d6b-b2b3-0d0cf73878e9" xlink:to="loc_us-gaap_StockIssued1_3b877541-c166-4136-b21a-d5b2fbcfbf3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_StockIssuanceCostsAccruedAndAmortized_a3bd460f-2c6b-405f-8994-6568913861be" xlink:href="flks-20230331.xsd#flks_StockIssuanceCostsAccruedAndAmortized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_05537a72-6ff6-4d6b-b2b3-0d0cf73878e9" xlink:to="loc_flks_StockIssuanceCostsAccruedAndAmortized_a3bd460f-2c6b-405f-8994-6568913861be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="flks-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_306861a4-cf66-4d4b-84f1-65c87214685a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f14a9b41-2742-46a4-aafa-36ed85caaefe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_306861a4-cf66-4d4b-84f1-65c87214685a" xlink:to="loc_us-gaap_StatementTable_f14a9b41-2742-46a4-aafa-36ed85caaefe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_82961896-1160-42c0-8f0e-1a5927c57611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f14a9b41-2742-46a4-aafa-36ed85caaefe" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_82961896-1160-42c0-8f0e-1a5927c57611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e3d17a6f-7a9b-4b23-90f4-3ed7b3b204b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_82961896-1160-42c0-8f0e-1a5927c57611" xlink:to="loc_us-gaap_EquityComponentDomain_e3d17a6f-7a9b-4b23-90f4-3ed7b3b204b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1bf8cc40-b0df-4abd-a6b0-b9d81123e2be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e3d17a6f-7a9b-4b23-90f4-3ed7b3b204b1" xlink:to="loc_us-gaap_CommonStockMember_1bf8cc40-b0df-4abd-a6b0-b9d81123e2be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_935082a4-bd8e-46e6-9908-5bcf101e720a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e3d17a6f-7a9b-4b23-90f4-3ed7b3b204b1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_935082a4-bd8e-46e6-9908-5bcf101e720a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_cd9ab745-2794-45f6-8144-2801afd82e29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e3d17a6f-7a9b-4b23-90f4-3ed7b3b204b1" xlink:to="loc_us-gaap_RetainedEarningsMember_cd9ab745-2794-45f6-8144-2801afd82e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_96809933-4e16-4e0d-b75b-e2952f1aa16a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f14a9b41-2742-46a4-aafa-36ed85caaefe" xlink:to="loc_us-gaap_StatementLineItems_96809933-4e16-4e0d-b75b-e2952f1aa16a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c03b5a5b-fa02-40c6-ab9d-a67b454dbdf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_96809933-4e16-4e0d-b75b-e2952f1aa16a" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c03b5a5b-fa02-40c6-ab9d-a67b454dbdf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_18548d6d-61c9-4950-b73f-336c123cade4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c03b5a5b-fa02-40c6-ab9d-a67b454dbdf0" xlink:to="loc_us-gaap_SharesOutstanding_18548d6d-61c9-4950-b73f-336c123cade4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3f6d2046-d7fc-4222-a118-5fa933a6f7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c03b5a5b-fa02-40c6-ab9d-a67b454dbdf0" xlink:to="loc_us-gaap_StockholdersEquity_3f6d2046-d7fc-4222-a118-5fa933a6f7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologySharesNewIssues_8c756d2d-d685-4b31-963e-194043124dc0" xlink:href="flks-20230331.xsd#flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologySharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c03b5a5b-fa02-40c6-ab9d-a67b454dbdf0" xlink:to="loc_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologySharesNewIssues_8c756d2d-d685-4b31-963e-194043124dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues_4d418744-7127-41ce-909e-23dd0986d9fe" xlink:href="flks-20230331.xsd#flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c03b5a5b-fa02-40c6-ab9d-a67b454dbdf0" xlink:to="loc_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues_4d418744-7127-41ce-909e-23dd0986d9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_56b3f928-f561-49c4-b39a-b7d98630e2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c03b5a5b-fa02-40c6-ab9d-a67b454dbdf0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_56b3f928-f561-49c4-b39a-b7d98630e2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e0fa3b03-4021-44a2-bfec-d914f4e11c92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c03b5a5b-fa02-40c6-ab9d-a67b454dbdf0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e0fa3b03-4021-44a2-bfec-d914f4e11c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_ac2ea5a5-5ec5-46b6-b68f-ed66f4447cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c03b5a5b-fa02-40c6-ab9d-a67b454dbdf0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_ac2ea5a5-5ec5-46b6-b68f-ed66f4447cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6b01423e-d410-4494-a089-e9fb39e5f483" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c03b5a5b-fa02-40c6-ab9d-a67b454dbdf0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6b01423e-d410-4494-a089-e9fb39e5f483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_279823a7-35af-4b5b-b53b-a96fd275be6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c03b5a5b-fa02-40c6-ab9d-a67b454dbdf0" xlink:to="loc_us-gaap_NetIncomeLoss_279823a7-35af-4b5b-b53b-a96fd275be6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_8618a07c-b7d9-4baa-b419-66edf3f8ff0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c03b5a5b-fa02-40c6-ab9d-a67b454dbdf0" xlink:to="loc_us-gaap_SharesOutstanding_8618a07c-b7d9-4baa-b419-66edf3f8ff0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5533b27d-4b32-494a-8630-f0181f4e3581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c03b5a5b-fa02-40c6-ab9d-a67b454dbdf0" xlink:to="loc_us-gaap_StockholdersEquity_5533b27d-4b32-494a-8630-f0181f4e3581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONS" xlink:type="simple" xlink:href="flks-20230331.xsd#ORGANIZATIONANDOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9b295fe9-7702-4e7b-87d0-cb9260026aea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_4f99357c-c319-4413-b90b-591db4457403" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9b295fe9-7702-4e7b-87d0-cb9260026aea" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_4f99357c-c319-4413-b90b-591db4457403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="flks-20230331.xsd#BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b868b5b7-4fcb-42fc-a955-7f71e9f8380b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_cd4a1b5d-0b7e-44b1-8ddb-adf20f50dba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b868b5b7-4fcb-42fc-a955-7f71e9f8380b" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_cd4a1b5d-0b7e-44b1-8ddb-adf20f50dba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/GRANTRECEIVABLEFROMCPRIT" xlink:type="simple" xlink:href="flks-20230331.xsd#GRANTRECEIVABLEFROMCPRIT"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/GRANTRECEIVABLEFROMCPRIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_0dfd2cf7-fb28-4e97-b8b3-5c75ae589043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_5958468b-c550-42e2-9781-a94c2a0402b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_0dfd2cf7-fb28-4e97-b8b3-5c75ae589043" xlink:to="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_5958468b-c550-42e2-9781-a94c2a0402b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETS" xlink:type="simple" xlink:href="flks-20230331.xsd#PREPAIDEXPENSESANDOTHERCURRENTASSETS"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_a970d4a0-ab7b-45ad-830e-5c3af8903966" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock_db7fa8f5-3b80-4cd6-a041-8688c2ade7e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_a970d4a0-ab7b-45ad-830e-5c3af8903966" xlink:to="loc_us-gaap_OtherCurrentAssetsTextBlock_db7fa8f5-3b80-4cd6-a041-8688c2ade7e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="flks-20230331.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7922eff5-d846-4238-90df-330d6b17be07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6321571e-0bfb-4667-99c9-1d68e9f693cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7922eff5-d846-4238-90df-330d6b17be07" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6321571e-0bfb-4667-99c9-1d68e9f693cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS" xlink:type="simple" xlink:href="flks-20230331.xsd#FAIRVALUEOFFINANCIALINSTRUMENTS"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e4545ef7-c23a-4113-8feb-c023360fdc92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_99019f6d-79ec-4ce8-8e26-7b4a973878dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e4545ef7-c23a-4113-8feb-c023360fdc92" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_99019f6d-79ec-4ce8-8e26-7b4a973878dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="flks-20230331.xsd#STOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_9ec002a7-01fe-4161-936c-63b897bfdad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_f1459427-4b53-42a5-b1f1-9a4133a93bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9ec002a7-01fe-4161-936c-63b897bfdad4" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_f1459427-4b53-42a5-b1f1-9a4133a93bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATION" xlink:type="simple" xlink:href="flks-20230331.xsd#EQUITYBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0ab58d36-4d29-4eef-a486-d195fc817381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_da16ad39-97c9-4413-9a22-8cda093de2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0ab58d36-4d29-4eef-a486-d195fc817381" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_da16ad39-97c9-4413-9a22-8cda093de2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="flks-20230331.xsd#SUBSEQUENTEVENTS"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_b0e2b5bb-9214-470c-92a1-a856bc7e5b38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_224be004-c13d-440d-a74d-d286d43402b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_b0e2b5bb-9214-470c-92a1-a856bc7e5b38" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_224be004-c13d-440d-a74d-d286d43402b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="flks-20230331.xsd#BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6806775a-f15c-44a0-8a5e-9b979dcb166f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_27e9b349-5ca8-43d9-82c1-8eeee9807d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6806775a-f15c-44a0-8a5e-9b979dcb166f" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_27e9b349-5ca8-43d9-82c1-8eeee9807d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_d6984850-2d39-41ea-ab4f-7f1f0baab878" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6806775a-f15c-44a0-8a5e-9b979dcb166f" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_d6984850-2d39-41ea-ab4f-7f1f0baab878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_411cbbf8-069a-4e2f-84c4-7bf26d56b134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6806775a-f15c-44a0-8a5e-9b979dcb166f" xlink:to="loc_us-gaap_UseOfEstimates_411cbbf8-069a-4e2f-84c4-7bf26d56b134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3145ec64-3111-4efb-8d34-d9d810eab822" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6806775a-f15c-44a0-8a5e-9b979dcb166f" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3145ec64-3111-4efb-8d34-d9d810eab822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_0cb27f9e-8e2c-4942-a029-64f4c3340aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6806775a-f15c-44a0-8a5e-9b979dcb166f" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_0cb27f9e-8e2c-4942-a029-64f4c3340aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_648ea09c-7ce2-433d-92e1-a17f8bebb6d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6806775a-f15c-44a0-8a5e-9b979dcb166f" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_648ea09c-7ce2-433d-92e1-a17f8bebb6d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_e8711c5d-0d28-4658-a711-411f6a341bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6806775a-f15c-44a0-8a5e-9b979dcb166f" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_e8711c5d-0d28-4658-a711-411f6a341bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_b36ab260-87ef-4264-921c-939b84bba090" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6806775a-f15c-44a0-8a5e-9b979dcb166f" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_b36ab260-87ef-4264-921c-939b84bba090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_436c2c5a-4381-4f3f-97ed-b5c927a17b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6806775a-f15c-44a0-8a5e-9b979dcb166f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_436c2c5a-4381-4f3f-97ed-b5c927a17b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_7f8ab7e4-7db7-4b55-b80f-f2dfa53b10bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6806775a-f15c-44a0-8a5e-9b979dcb166f" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_7f8ab7e4-7db7-4b55-b80f-f2dfa53b10bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_35ec8ef5-c210-469f-8f6c-a4016c4645d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6806775a-f15c-44a0-8a5e-9b979dcb166f" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_35ec8ef5-c210-469f-8f6c-a4016c4645d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_6bf02405-55d6-454d-9279-774d3b817bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6806775a-f15c-44a0-8a5e-9b979dcb166f" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_6bf02405-55d6-454d-9279-774d3b817bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8cc4ca1a-60bb-4ce0-bf5d-a6ea0a5d6381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6806775a-f15c-44a0-8a5e-9b979dcb166f" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8cc4ca1a-60bb-4ce0-bf5d-a6ea0a5d6381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_fdd803fb-eaab-446b-adc0-aeb206ccf11c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6806775a-f15c-44a0-8a5e-9b979dcb166f" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_fdd803fb-eaab-446b-adc0-aeb206ccf11c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSTables" xlink:type="simple" xlink:href="flks-20230331.xsd#PREPAIDEXPENSESANDOTHERCURRENTASSETSTables"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_93c62d53-ec05-4491-bc3f-d53f0a37ff27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_ce6c89dc-518a-4f28-adc5-286bd59e1780" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_93c62d53-ec05-4491-bc3f-d53f0a37ff27" xlink:to="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_ce6c89dc-518a-4f28-adc5-286bd59e1780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="flks-20230331.xsd#EQUITYBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4b778441-5d6b-4fe7-942b-2e74a7de5cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2c83e150-282c-4d0f-bbd1-e2fc87c21eee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4b778441-5d6b-4fe7-942b-2e74a7de5cbd" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2c83e150-282c-4d0f-bbd1-e2fc87c21eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7883f388-6960-4673-8d49-56745925330d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4b778441-5d6b-4fe7-942b-2e74a7de5cbd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7883f388-6960-4673-8d49-56745925330d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONSDetails" xlink:type="simple" xlink:href="flks-20230331.xsd#ORGANIZATIONANDOPERATIONSDetails"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b1cf3a21-bcb1-4ac7-b73c-a6e2a03d6ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0acecb95-4e8c-4f98-9301-0f7772445f15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b1cf3a21-bcb1-4ac7-b73c-a6e2a03d6ba5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0acecb95-4e8c-4f98-9301-0f7772445f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a327f4ce-3d18-4149-802d-237696f4d600" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0acecb95-4e8c-4f98-9301-0f7772445f15" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a327f4ce-3d18-4149-802d-237696f4d600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_bb798358-4a82-4b33-b98f-36d4410784b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a327f4ce-3d18-4149-802d-237696f4d600" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_bb798358-4a82-4b33-b98f-36d4410784b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_eb5414b5-2fcc-4dad-a91d-7ecbdca55d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_bb798358-4a82-4b33-b98f-36d4410784b2" xlink:to="loc_us-gaap_SubsequentEventMember_eb5414b5-2fcc-4dad-a91d-7ecbdca55d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c9fd5852-c6dd-4962-8b20-5abd8fe61b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0acecb95-4e8c-4f98-9301-0f7772445f15" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c9fd5852-c6dd-4962-8b20-5abd8fe61b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9aa220a3-812b-41ae-b5be-267f33e43e76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c9fd5852-c6dd-4962-8b20-5abd8fe61b8f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9aa220a3-812b-41ae-b5be-267f33e43e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_SalesAgreementMember_dbccff10-af7e-40ed-8600-601fdf3276a6" xlink:href="flks-20230331.xsd#flks_SalesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9aa220a3-812b-41ae-b5be-267f33e43e76" xlink:to="loc_flks_SalesAgreementMember_dbccff10-af7e-40ed-8600-601fdf3276a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8b63d062-d293-4fba-88d9-c86d7082149f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0acecb95-4e8c-4f98-9301-0f7772445f15" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8b63d062-d293-4fba-88d9-c86d7082149f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bc7c9519-9865-4074-9ec7-bce7aa67690f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8b63d062-d293-4fba-88d9-c86d7082149f" xlink:to="loc_us-gaap_EquityComponentDomain_bc7c9519-9865-4074-9ec7-bce7aa67690f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_599bbb63-e205-48af-b861-402202a6f591" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bc7c9519-9865-4074-9ec7-bce7aa67690f" xlink:to="loc_us-gaap_CommonStockMember_599bbb63-e205-48af-b861-402202a6f591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8af8bb3c-0ed3-4f59-bca9-1063db2b6f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0acecb95-4e8c-4f98-9301-0f7772445f15" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8af8bb3c-0ed3-4f59-bca9-1063db2b6f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f694e572-4cb7-4e01-881a-6ec1f8fe8a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8af8bb3c-0ed3-4f59-bca9-1063db2b6f4b" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f694e572-4cb7-4e01-881a-6ec1f8fe8a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1bb9cb28-00df-4eb1-bf62-0bee050065e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8af8bb3c-0ed3-4f59-bca9-1063db2b6f4b" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1bb9cb28-00df-4eb1-bf62-0bee050065e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="flks-20230331.xsd#BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e373a049-6c63-4ccb-b091-35245af067ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7c32d5a0-c622-4598-9510-d201d6f63d25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e373a049-6c63-4ccb-b091-35245af067ad" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7c32d5a0-c622-4598-9510-d201d6f63d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5ff196d0-c569-4d2e-aae6-4c26ea1627b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7c32d5a0-c622-4598-9510-d201d6f63d25" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5ff196d0-c569-4d2e-aae6-4c26ea1627b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e91fcec2-d2fd-4e52-a839-3f5a3113d503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5ff196d0-c569-4d2e-aae6-4c26ea1627b7" xlink:to="loc_us-gaap_EquityComponentDomain_e91fcec2-d2fd-4e52-a839-3f5a3113d503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_eb3c57ef-4e2d-44ca-89ba-399a2728cc9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e91fcec2-d2fd-4e52-a839-3f5a3113d503" xlink:to="loc_us-gaap_CommonStockMember_eb3c57ef-4e2d-44ca-89ba-399a2728cc9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be8793ca-0059-4845-9105-c08f69b59925" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7c32d5a0-c622-4598-9510-d201d6f63d25" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be8793ca-0059-4845-9105-c08f69b59925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_4ce5e7ef-7ec2-4f03-a4ed-18b61024229f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be8793ca-0059-4845-9105-c08f69b59925" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_4ce5e7ef-7ec2-4f03-a4ed-18b61024229f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_698642cb-ca3d-4d3f-aef8-1a6a37182e37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be8793ca-0059-4845-9105-c08f69b59925" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_698642cb-ca3d-4d3f-aef8-1a6a37182e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_18631e0b-4515-4953-8016-257987cf3386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be8793ca-0059-4845-9105-c08f69b59925" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_18631e0b-4515-4953-8016-257987cf3386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9c6ef4ab-ec8b-437c-a45d-50e776ba9629" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be8793ca-0059-4845-9105-c08f69b59925" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9c6ef4ab-ec8b-437c-a45d-50e776ba9629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_PaymentsForAcquisitionAndStrategicCollaborationAgreement_fbd32e31-2204-4f66-8ef7-7fd0bc6392d4" xlink:href="flks-20230331.xsd#flks_PaymentsForAcquisitionAndStrategicCollaborationAgreement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be8793ca-0059-4845-9105-c08f69b59925" xlink:to="loc_flks_PaymentsForAcquisitionAndStrategicCollaborationAgreement_fbd32e31-2204-4f66-8ef7-7fd0bc6392d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_4afbc15b-1b98-46a8-8fce-58d559d6b612" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be8793ca-0059-4845-9105-c08f69b59925" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_4afbc15b-1b98-46a8-8fce-58d559d6b612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8cf04db8-625a-4072-8536-7a62696dd2dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be8793ca-0059-4845-9105-c08f69b59925" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8cf04db8-625a-4072-8536-7a62696dd2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_27270878-0967-4e55-bea2-30c404b72929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be8793ca-0059-4845-9105-c08f69b59925" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_27270878-0967-4e55-bea2-30c404b72929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/GRANTRECEIVABLEFROMCPRITDetails" xlink:type="simple" xlink:href="flks-20230331.xsd#GRANTRECEIVABLEFROMCPRITDetails"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/GRANTRECEIVABLEFROMCPRITDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_69b08bf3-0c0b-4450-b725-2b81f65e4a99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_bb94c108-b418-4157-8636-0534f73e9b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_69b08bf3-0c0b-4450-b725-2b81f65e4a99" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_bb94c108-b418-4157-8636-0534f73e9b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8ddb9ed9-fc5d-4c37-afa9-b2a755c9b56f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_bb94c108-b418-4157-8636-0534f73e9b6d" xlink:to="loc_srt_ProductOrServiceAxis_8ddb9ed9-fc5d-4c37-afa9-b2a755c9b56f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ea006abf-07fd-47d2-97bc-17dbc6b06887" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8ddb9ed9-fc5d-4c37-afa9-b2a755c9b56f" xlink:to="loc_srt_ProductsAndServicesDomain_ea006abf-07fd-47d2-97bc-17dbc6b06887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_6a242024-602a-4a12-9d39-a463151c7ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ea006abf-07fd-47d2-97bc-17dbc6b06887" xlink:to="loc_us-gaap_GrantMember_6a242024-602a-4a12-9d39-a463151c7ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_360d50b7-510e-415a-a8ca-3fc0b1a861a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_bb94c108-b418-4157-8636-0534f73e9b6d" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_360d50b7-510e-415a-a8ca-3fc0b1a861a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivableCurrent_76a809af-5830-484d-a118-5565e49fae2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_360d50b7-510e-415a-a8ca-3fc0b1a861a5" xlink:to="loc_us-gaap_GrantsReceivableCurrent_76a809af-5830-484d-a118-5565e49fae2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_b229099c-4cec-4a12-8a47-a3bb9a39e0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_360d50b7-510e-415a-a8ca-3fc0b1a861a5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_b229099c-4cec-4a12-8a47-a3bb9a39e0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="flks-20230331.xsd#PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_52dbad92-e1ff-4b84-94ac-549cf3fb4faf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_PrepaidClinicalTrialExpense_ad23b977-572c-46bf-9f0f-a489e3ce94b8" xlink:href="flks-20230331.xsd#flks_PrepaidClinicalTrialExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_52dbad92-e1ff-4b84-94ac-549cf3fb4faf" xlink:to="loc_flks_PrepaidClinicalTrialExpense_ad23b977-572c-46bf-9f0f-a489e3ce94b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_07d4ca95-2446-4d5b-aba1-fcfc6c3838de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_52dbad92-e1ff-4b84-94ac-549cf3fb4faf" xlink:to="loc_us-gaap_PrepaidInsurance_07d4ca95-2446-4d5b-aba1-fcfc6c3838de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_adb80b8e-3d60-4807-bcce-d8cc28d7663d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_52dbad92-e1ff-4b84-94ac-549cf3fb4faf" xlink:to="loc_us-gaap_OtherAssetsCurrent_adb80b8e-3d60-4807-bcce-d8cc28d7663d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_84b4fdd0-76aa-41ac-980d-4eb7737be2ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_52dbad92-e1ff-4b84-94ac-549cf3fb4faf" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_84b4fdd0-76aa-41ac-980d-4eb7737be2ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="flks-20230331.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_430270fe-ff03-4f61-8f18-ad967e556585" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_75c12df5-6edd-4371-a469-59f8d7d672ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_430270fe-ff03-4f61-8f18-ad967e556585" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_75c12df5-6edd-4371-a469-59f8d7d672ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_f2a1b31b-16e7-463d-878a-e2f11eabe49b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_75c12df5-6edd-4371-a469-59f8d7d672ce" xlink:to="loc_srt_OwnershipAxis_f2a1b31b-16e7-463d-878a-e2f11eabe49b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_5d5a6323-d2a3-4bab-883b-548a1dd43d1d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_f2a1b31b-16e7-463d-878a-e2f11eabe49b" xlink:to="loc_srt_OwnershipDomain_5d5a6323-d2a3-4bab-883b-548a1dd43d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_UniversityOfUtahResearchFoundationMember_d5a8ef06-3b7a-4b5d-b667-d543d74b08ad" xlink:href="flks-20230331.xsd#flks_UniversityOfUtahResearchFoundationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_5d5a6323-d2a3-4bab-883b-548a1dd43d1d" xlink:to="loc_flks_UniversityOfUtahResearchFoundationMember_d5a8ef06-3b7a-4b5d-b667-d543d74b08ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_b3f9574b-787c-4605-8099-15d6f5689a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_75c12df5-6edd-4371-a469-59f8d7d672ce" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_b3f9574b-787c-4605-8099-15d6f5689a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_c57bf9f1-aa2f-4196-b5f6-0a5c238ca5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_b3f9574b-787c-4605-8099-15d6f5689a7b" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_c57bf9f1-aa2f-4196-b5f6-0a5c238ca5e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsMaximumAward_249446c3-a08e-48d7-a2af-2af58a6df72f" xlink:href="flks-20230331.xsd#flks_RevenueFromGrantsMaximumAward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_b3f9574b-787c-4605-8099-15d6f5689a7b" xlink:to="loc_flks_RevenueFromGrantsMaximumAward_249446c3-a08e-48d7-a2af-2af58a6df72f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsAwardTerm_4ba82fd4-83d1-44fb-a911-6aab0dac7575" xlink:href="flks-20230331.xsd#flks_RevenueFromGrantsAwardTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_b3f9574b-787c-4605-8099-15d6f5689a7b" xlink:to="loc_flks_RevenueFromGrantsAwardTerm_4ba82fd4-83d1-44fb-a911-6aab0dac7575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales_f0642a78-f5da-4492-a412-bb2d9749ad46" xlink:href="flks-20230331.xsd#flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_b3f9574b-787c-4605-8099-15d6f5689a7b" xlink:to="loc_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales_f0642a78-f5da-4492-a412-bb2d9749ad46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYDetails" xlink:type="simple" xlink:href="flks-20230331.xsd#STOCKHOLDERSEQUITYDetails"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a368ebc3-d61b-4f43-9c70-36109fc1680c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_dfd9a9ae-a309-4d04-a969-7d3100d77053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a368ebc3-d61b-4f43-9c70-36109fc1680c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_dfd9a9ae-a309-4d04-a969-7d3100d77053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_d3888f03-93c3-4c01-bf23-0cbccdd6314e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_dfd9a9ae-a309-4d04-a969-7d3100d77053" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_d3888f03-93c3-4c01-bf23-0cbccdd6314e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fc1e17dd-1815-4f8f-985d-0c5808e32d64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d3888f03-93c3-4c01-bf23-0cbccdd6314e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fc1e17dd-1815-4f8f-985d-0c5808e32d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_SalesAgreementMember_d2b6bc25-1c36-4ed7-b49a-c66b9d48c304" xlink:href="flks-20230331.xsd#flks_SalesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fc1e17dd-1815-4f8f-985d-0c5808e32d64" xlink:to="loc_flks_SalesAgreementMember_d2b6bc25-1c36-4ed7-b49a-c66b9d48c304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_PurchaseAgreementMember_fbf8373c-60b1-472f-be9f-6e864a534f2d" xlink:href="flks-20230331.xsd#flks_PurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fc1e17dd-1815-4f8f-985d-0c5808e32d64" xlink:to="loc_flks_PurchaseAgreementMember_fbf8373c-60b1-472f-be9f-6e864a534f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1e4509b9-36d8-4024-ac73-4cbed73d885a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_dfd9a9ae-a309-4d04-a969-7d3100d77053" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1e4509b9-36d8-4024-ac73-4cbed73d885a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e823686e-16ac-467e-9e4a-584e5c3161aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1e4509b9-36d8-4024-ac73-4cbed73d885a" xlink:to="loc_us-gaap_EquityComponentDomain_e823686e-16ac-467e-9e4a-584e5c3161aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0011a88c-6952-4ae0-a318-16dba9d6bc08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e823686e-16ac-467e-9e4a-584e5c3161aa" xlink:to="loc_us-gaap_CommonStockMember_0011a88c-6952-4ae0-a318-16dba9d6bc08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_ce49d487-6420-43a4-baa9-4b1824a9401c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e823686e-16ac-467e-9e4a-584e5c3161aa" xlink:to="loc_us-gaap_WarrantMember_ce49d487-6420-43a4-baa9-4b1824a9401c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_76e3b248-4da4-44bc-a259-0f6611dc0bb1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_dfd9a9ae-a309-4d04-a969-7d3100d77053" xlink:to="loc_srt_RangeAxis_76e3b248-4da4-44bc-a259-0f6611dc0bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9968d703-b37b-4348-8e9d-eb92478e5a63" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_76e3b248-4da4-44bc-a259-0f6611dc0bb1" xlink:to="loc_srt_RangeMember_9968d703-b37b-4348-8e9d-eb92478e5a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bd432809-c488-40ff-8a52-3656d9c738a2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9968d703-b37b-4348-8e9d-eb92478e5a63" xlink:to="loc_srt_MaximumMember_bd432809-c488-40ff-8a52-3656d9c738a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_de29b87f-d7e5-4518-9f30-f67aa419678b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_dfd9a9ae-a309-4d04-a969-7d3100d77053" xlink:to="loc_us-gaap_ClassOfStockLineItems_de29b87f-d7e5-4518-9f30-f67aa419678b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_630cdc0f-1010-4e2c-8d02-38a678e6b00f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_de29b87f-d7e5-4518-9f30-f67aa419678b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_630cdc0f-1010-4e2c-8d02-38a678e6b00f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1a8cd6e2-a34e-4966-91f3-af1fa7b6cbf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_de29b87f-d7e5-4518-9f30-f67aa419678b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1a8cd6e2-a34e-4966-91f3-af1fa7b6cbf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologySharesNewIssues_7e6d06b9-f585-4e6e-a246-84261b340f02" xlink:href="flks-20230331.xsd#flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologySharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_de29b87f-d7e5-4518-9f30-f67aa419678b" xlink:to="loc_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologySharesNewIssues_7e6d06b9-f585-4e6e-a246-84261b340f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues_27defc67-8403-4108-8c03-531327108b02" xlink:href="flks-20230331.xsd#flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_de29b87f-d7e5-4518-9f30-f67aa419678b" xlink:to="loc_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues_27defc67-8403-4108-8c03-531327108b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_038f5fb3-1c74-425c-a6a6-58c286e9a40c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_de29b87f-d7e5-4518-9f30-f67aa419678b" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_038f5fb3-1c74-425c-a6a6-58c286e9a40c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ea3fe7dd-7b4b-46a2-8cbe-29701175fca4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_de29b87f-d7e5-4518-9f30-f67aa419678b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ea3fe7dd-7b4b-46a2-8cbe-29701175fca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_WarrantsAndRightsExercisableTerm_2e4da748-9e9e-4237-a01f-dfe27fc4db7d" xlink:href="flks-20230331.xsd#flks_WarrantsAndRightsExercisableTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_de29b87f-d7e5-4518-9f30-f67aa419678b" xlink:to="loc_flks_WarrantsAndRightsExercisableTerm_2e4da748-9e9e-4237-a01f-dfe27fc4db7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6ae787ea-fcd8-43b9-b406-ef5bd2aee501" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_de29b87f-d7e5-4518-9f30-f67aa419678b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6ae787ea-fcd8-43b9-b406-ef5bd2aee501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="flks-20230331.xsd#EQUITYBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_71510fcd-80f4-4a10-8b18-93c1c74f88a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8b35c941-aa00-46f4-9a83-9c22bb25cbb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_71510fcd-80f4-4a10-8b18-93c1c74f88a6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8b35c941-aa00-46f4-9a83-9c22bb25cbb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_75d052ce-e38b-47ad-a09b-4f7b180e4c7e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8b35c941-aa00-46f4-9a83-9c22bb25cbb4" xlink:to="loc_srt_TitleOfIndividualAxis_75d052ce-e38b-47ad-a09b-4f7b180e4c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_355782fd-60e1-4441-9cd9-ff9e73a69e2f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_75d052ce-e38b-47ad-a09b-4f7b180e4c7e" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_355782fd-60e1-4441-9cd9-ff9e73a69e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_EmployeesMember_5fbe60e3-82cc-4197-9025-57a4e0baa591" xlink:href="flks-20230331.xsd#flks_EmployeesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_355782fd-60e1-4441-9cd9-ff9e73a69e2f" xlink:to="loc_flks_EmployeesMember_5fbe60e3-82cc-4197-9025-57a4e0baa591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_OfficersAndDirectorsMember_6f0a44ce-bdb4-4a55-9b3c-7794cdab2599" xlink:href="flks-20230331.xsd#flks_OfficersAndDirectorsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_355782fd-60e1-4441-9cd9-ff9e73a69e2f" xlink:to="loc_flks_OfficersAndDirectorsMember_6f0a44ce-bdb4-4a55-9b3c-7794cdab2599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b86a9189-b9e2-41ee-86b5-61f152c7d942" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8b35c941-aa00-46f4-9a83-9c22bb25cbb4" xlink:to="loc_us-gaap_PlanNameAxis_b86a9189-b9e2-41ee-86b5-61f152c7d942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9194dfb8-dca3-40c4-b40b-264cb0b67ada" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_b86a9189-b9e2-41ee-86b5-61f152c7d942" xlink:to="loc_us-gaap_PlanNameDomain_9194dfb8-dca3-40c4-b40b-264cb0b67ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_EquityIncentivePlan2015Member_587ad5dc-3817-4160-8209-bbb741c86c76" xlink:href="flks-20230331.xsd#flks_EquityIncentivePlan2015Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9194dfb8-dca3-40c4-b40b-264cb0b67ada" xlink:to="loc_flks_EquityIncentivePlan2015Member_587ad5dc-3817-4160-8209-bbb741c86c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b8c54c14-9e06-487b-b39b-45caf4e2f251" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8b35c941-aa00-46f4-9a83-9c22bb25cbb4" xlink:to="loc_us-gaap_AwardTypeAxis_b8c54c14-9e06-487b-b39b-45caf4e2f251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59d4eecd-0c5e-4bca-9153-78173d99d2b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b8c54c14-9e06-487b-b39b-45caf4e2f251" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59d4eecd-0c5e-4bca-9153-78173d99d2b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ddc1f6ab-f208-47db-b7a9-50b2386f8f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59d4eecd-0c5e-4bca-9153-78173d99d2b5" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ddc1f6ab-f208-47db-b7a9-50b2386f8f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_ebe49b64-86b7-4268-b868-117663c2183e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59d4eecd-0c5e-4bca-9153-78173d99d2b5" xlink:to="loc_us-gaap_RestrictedStockMember_ebe49b64-86b7-4268-b868-117663c2183e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RestrictedStockAndRestrictedStockUnitsMember_ec47581a-e56f-4a46-bfdb-044a8d92bee8" xlink:href="flks-20230331.xsd#flks_RestrictedStockAndRestrictedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59d4eecd-0c5e-4bca-9153-78173d99d2b5" xlink:to="loc_flks_RestrictedStockAndRestrictedStockUnitsMember_ec47581a-e56f-4a46-bfdb-044a8d92bee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7831a01b-0b7d-4d05-922e-3de13330ca31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59d4eecd-0c5e-4bca-9153-78173d99d2b5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7831a01b-0b7d-4d05-922e-3de13330ca31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7f3b4b95-9d9d-45ac-a8a1-eb6ee5f3b19a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8b35c941-aa00-46f4-9a83-9c22bb25cbb4" xlink:to="loc_srt_RangeAxis_7f3b4b95-9d9d-45ac-a8a1-eb6ee5f3b19a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ac23420a-4ecd-4bb6-b189-5080e83e42b9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7f3b4b95-9d9d-45ac-a8a1-eb6ee5f3b19a" xlink:to="loc_srt_RangeMember_ac23420a-4ecd-4bb6-b189-5080e83e42b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e02197ea-f4a0-4e03-883e-0a8e47afbf47" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ac23420a-4ecd-4bb6-b189-5080e83e42b9" xlink:to="loc_srt_MinimumMember_e02197ea-f4a0-4e03-883e-0a8e47afbf47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_08c639c1-da54-4140-8e6d-c016a5212db0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ac23420a-4ecd-4bb6-b189-5080e83e42b9" xlink:to="loc_srt_MaximumMember_08c639c1-da54-4140-8e6d-c016a5212db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4945249b-2ce9-4fc8-b5d0-85d1023046b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8b35c941-aa00-46f4-9a83-9c22bb25cbb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4945249b-2ce9-4fc8-b5d0-85d1023046b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d5ee4207-2951-470b-9ede-d10d120c8a72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4945249b-2ce9-4fc8-b5d0-85d1023046b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d5ee4207-2951-470b-9ede-d10d120c8a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2e8ad411-077d-4103-b86e-3548bc430f27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4945249b-2ce9-4fc8-b5d0-85d1023046b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2e8ad411-077d-4103-b86e-3548bc430f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8e9f84b6-eeb4-4d9c-aaca-b5ceafbcb297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4945249b-2ce9-4fc8-b5d0-85d1023046b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8e9f84b6-eeb4-4d9c-aaca-b5ceafbcb297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b07e3587-9b74-4b92-b019-d724377309ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4945249b-2ce9-4fc8-b5d0-85d1023046b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b07e3587-9b74-4b92-b019-d724377309ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_7d2c6144-63df-4061-a531-0f9b39eba6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4945249b-2ce9-4fc8-b5d0-85d1023046b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_7d2c6144-63df-4061-a531-0f9b39eba6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c145500a-b888-48be-adc5-d0bc82d8d5b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4945249b-2ce9-4fc8-b5d0-85d1023046b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c145500a-b888-48be-adc5-d0bc82d8d5b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_380a1f50-2ed3-44f8-ba94-34650b494a27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4945249b-2ce9-4fc8-b5d0-85d1023046b4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_380a1f50-2ed3-44f8-ba94-34650b494a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_19345e54-ee12-4da9-bf2f-3f7b406a36aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4945249b-2ce9-4fc8-b5d0-85d1023046b4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_19345e54-ee12-4da9-bf2f-3f7b406a36aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2fa9df19-40d7-4ac5-98c6-20a54ba1a344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4945249b-2ce9-4fc8-b5d0-85d1023046b4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2fa9df19-40d7-4ac5-98c6-20a54ba1a344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a65624b8-6c09-41a6-a6e7-1f872e4156c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4945249b-2ce9-4fc8-b5d0-85d1023046b4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a65624b8-6c09-41a6-a6e7-1f872e4156c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails" xlink:type="simple" xlink:href="flks-20230331.xsd#EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_79431f21-fd62-42ad-a270-445cc5794baf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_319f1835-1128-423a-9ba9-a0387ad13bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_79431f21-fd62-42ad-a270-445cc5794baf" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_319f1835-1128-423a-9ba9-a0387ad13bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b61f91a6-c3d4-4be0-b54d-8c7a9d0b6104" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_319f1835-1128-423a-9ba9-a0387ad13bc7" xlink:to="loc_srt_RangeAxis_b61f91a6-c3d4-4be0-b54d-8c7a9d0b6104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_de06cd6d-7712-497f-9198-eab58db6519e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b61f91a6-c3d4-4be0-b54d-8c7a9d0b6104" xlink:to="loc_srt_RangeMember_de06cd6d-7712-497f-9198-eab58db6519e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5b553ec2-9d2d-4ab3-b936-00145f8f2809" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_de06cd6d-7712-497f-9198-eab58db6519e" xlink:to="loc_srt_MinimumMember_5b553ec2-9d2d-4ab3-b936-00145f8f2809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d5c649bb-b544-42be-901d-8f03bca8eeee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_de06cd6d-7712-497f-9198-eab58db6519e" xlink:to="loc_srt_MaximumMember_d5c649bb-b544-42be-901d-8f03bca8eeee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ab1219e-7f13-42b2-a4a0-bd5e5ed2962c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_319f1835-1128-423a-9ba9-a0387ad13bc7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ab1219e-7f13-42b2-a4a0-bd5e5ed2962c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_f245bbd0-a500-479d-b9cd-c42688ac034f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ab1219e-7f13-42b2-a4a0-bd5e5ed2962c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_f245bbd0-a500-479d-b9cd-c42688ac034f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0aa1f66e-812c-48aa-b1fc-52f70237888b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ab1219e-7f13-42b2-a4a0-bd5e5ed2962c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0aa1f66e-812c-48aa-b1fc-52f70237888b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_8a28d3f2-c346-4a85-b815-a40bd3d7d704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ab1219e-7f13-42b2-a4a0-bd5e5ed2962c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_8a28d3f2-c346-4a85-b815-a40bd3d7d704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_997b21d0-ecab-4819-a639-cb025ce51bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ab1219e-7f13-42b2-a4a0-bd5e5ed2962c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_997b21d0-ecab-4819-a639-cb025ce51bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f6ca5f0e-f835-488a-a99b-2411e5b8478a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ab1219e-7f13-42b2-a4a0-bd5e5ed2962c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f6ca5f0e-f835-488a-a99b-2411e5b8478a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2763d3ec-e8a8-4360-8c15-ffca17523a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ab1219e-7f13-42b2-a4a0-bd5e5ed2962c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2763d3ec-e8a8-4360-8c15-ffca17523a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="flks-20230331.xsd#EQUITYBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4442be46-6849-471a-9e96-938ae85c00cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bae6a0c0-1450-475e-a5ed-cf370130aa99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4442be46-6849-471a-9e96-938ae85c00cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bae6a0c0-1450-475e-a5ed-cf370130aa99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8a021b32-a16a-478b-bdaa-44ea9092366b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bae6a0c0-1450-475e-a5ed-cf370130aa99" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8a021b32-a16a-478b-bdaa-44ea9092366b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1a804532-e745-4360-b8b2-f0c4ffd9bfd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bae6a0c0-1450-475e-a5ed-cf370130aa99" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1a804532-e745-4360-b8b2-f0c4ffd9bfd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2fdff78e-d0f3-483a-a24a-a25e7a3f96d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bae6a0c0-1450-475e-a5ed-cf370130aa99" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2fdff78e-d0f3-483a-a24a-a25e7a3f96d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4bf05c8c-7b06-4432-9384-befb5f1d04d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bae6a0c0-1450-475e-a5ed-cf370130aa99" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4bf05c8c-7b06-4432-9384-befb5f1d04d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_06b144ff-23f1-4f15-b9fd-ac09d1315712" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bae6a0c0-1450-475e-a5ed-cf370130aa99" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_06b144ff-23f1-4f15-b9fd-ac09d1315712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9853ec41-a8e2-4512-80bc-0559d1250332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bae6a0c0-1450-475e-a5ed-cf370130aa99" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9853ec41-a8e2-4512-80bc-0559d1250332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3f47f0a8-bacf-464c-a1a1-2a03079ea844" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4442be46-6849-471a-9e96-938ae85c00cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3f47f0a8-bacf-464c-a1a1-2a03079ea844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5a261126-a144-43da-ab08-67a04dba014c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4442be46-6849-471a-9e96-938ae85c00cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5a261126-a144-43da-ab08-67a04dba014c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1f8a629e-2aad-4a87-bd7c-5e0961f7ac80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5a261126-a144-43da-ab08-67a04dba014c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1f8a629e-2aad-4a87-bd7c-5e0961f7ac80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3edf880b-69a1-461f-8848-d68093782fec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5a261126-a144-43da-ab08-67a04dba014c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3edf880b-69a1-461f-8848-d68093782fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a7638e18-d42b-4df6-9860-00f40a2f4f76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5a261126-a144-43da-ab08-67a04dba014c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a7638e18-d42b-4df6-9860-00f40a2f4f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_79bbd908-d701-4ad0-9a9a-1d8132f13c54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5a261126-a144-43da-ab08-67a04dba014c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_79bbd908-d701-4ad0-9a9a-1d8132f13c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4f358c01-7809-4060-8b04-c2df6bf14dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5a261126-a144-43da-ab08-67a04dba014c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4f358c01-7809-4060-8b04-c2df6bf14dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4aaf07d6-5c39-4ee9-ab3d-47a2eab225be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5a261126-a144-43da-ab08-67a04dba014c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4aaf07d6-5c39-4ee9-ab3d-47a2eab225be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_dd0fb4e8-67a1-46d9-ba4c-18ad502e632f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4442be46-6849-471a-9e96-938ae85c00cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_dd0fb4e8-67a1-46d9-ba4c-18ad502e632f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e7dfc2b4-3e0f-49ac-8de9-3cc711f99567" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4442be46-6849-471a-9e96-938ae85c00cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e7dfc2b4-3e0f-49ac-8de9-3cc711f99567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_685ecf97-5ddb-48ce-a46c-f7d2a68e740b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e7dfc2b4-3e0f-49ac-8de9-3cc711f99567" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_685ecf97-5ddb-48ce-a46c-f7d2a68e740b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b2e64ba4-87c6-413b-b2e6-766c9fe39381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e7dfc2b4-3e0f-49ac-8de9-3cc711f99567" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b2e64ba4-87c6-413b-b2e6-766c9fe39381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f86924c2-4988-4fa6-b3ff-c611bcf18c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e7dfc2b4-3e0f-49ac-8de9-3cc711f99567" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f86924c2-4988-4fa6-b3ff-c611bcf18c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c3da4d71-45ca-4924-beca-5dae2d4614f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e7dfc2b4-3e0f-49ac-8de9-3cc711f99567" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c3da4d71-45ca-4924-beca-5dae2d4614f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="flks-20230331.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_aad32dd7-7c79-45c6-a673-2f15cc8812ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_51b34232-4801-4ff9-8d82-20eb3ae17d44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_aad32dd7-7c79-45c6-a673-2f15cc8812ef" xlink:to="loc_us-gaap_SubsequentEventTable_51b34232-4801-4ff9-8d82-20eb3ae17d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_83035b8f-e2d2-4a79-ac43-a3fffd8cc95a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_51b34232-4801-4ff9-8d82-20eb3ae17d44" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_83035b8f-e2d2-4a79-ac43-a3fffd8cc95a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b5efb0ad-7165-494b-b096-6acf6af8c1c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_83035b8f-e2d2-4a79-ac43-a3fffd8cc95a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b5efb0ad-7165-494b-b096-6acf6af8c1c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_f8252275-b445-462b-8822-2789ab2bf667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b5efb0ad-7165-494b-b096-6acf6af8c1c7" xlink:to="loc_us-gaap_SubsequentEventMember_f8252275-b445-462b-8822-2789ab2bf667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6f611dad-03c1-488d-a699-18e816008b83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_51b34232-4801-4ff9-8d82-20eb3ae17d44" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6f611dad-03c1-488d-a699-18e816008b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_999c3b9a-5565-43a1-ae27-acf85efcc69c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6f611dad-03c1-488d-a699-18e816008b83" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_999c3b9a-5565-43a1-ae27-acf85efcc69c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_SalesAgreementMember_7e8d671e-1e2e-4ea8-ac4e-73e083a3cc68" xlink:href="flks-20230331.xsd#flks_SalesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_999c3b9a-5565-43a1-ae27-acf85efcc69c" xlink:to="loc_flks_SalesAgreementMember_7e8d671e-1e2e-4ea8-ac4e-73e083a3cc68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c68e4905-bdb6-4c2f-bf78-ff30a7a883c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_51b34232-4801-4ff9-8d82-20eb3ae17d44" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c68e4905-bdb6-4c2f-bf78-ff30a7a883c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a1c4d3c1-b48c-4702-b327-fcc3f6152b07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c68e4905-bdb6-4c2f-bf78-ff30a7a883c0" xlink:to="loc_us-gaap_EquityComponentDomain_a1c4d3c1-b48c-4702-b327-fcc3f6152b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0b8d44b0-8f7b-420d-962b-ae4ff98e28d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a1c4d3c1-b48c-4702-b327-fcc3f6152b07" xlink:to="loc_us-gaap_CommonStockMember_0b8d44b0-8f7b-420d-962b-ae4ff98e28d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_626ed3c7-7e7c-497a-9dcb-00a87932b043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_51b34232-4801-4ff9-8d82-20eb3ae17d44" xlink:to="loc_us-gaap_SubsequentEventLineItems_626ed3c7-7e7c-497a-9dcb-00a87932b043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0dc686a1-59ef-49bf-a3b4-485e39b5d7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_626ed3c7-7e7c-497a-9dcb-00a87932b043" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0dc686a1-59ef-49bf-a3b4-485e39b5d7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a08ac1c5-1ff2-40b8-a95c-6aca238c6776" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_626ed3c7-7e7c-497a-9dcb-00a87932b043" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a08ac1c5-1ff2-40b8-a95c-6aca238c6776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>slrx20230331ex-311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i81a4512b5314488bb68c36f20eac2a9c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David J. Arthur, President and Chief Executive Officer, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q of Salarius Pharmaceuticals, Inc.&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="padding-left:47.25pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:19.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.199%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.074%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David J. Arthur</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David J. Arthur</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 11, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief&#160;Executive&#160;Officer (Principal&#160;Executive&#160;Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-33.2
<SEQUENCE>8
<FILENAME>slrx20230331ex-312.htm
<DESCRIPTION>EX-33.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i5cd72f6b030142958f781b78b38c84aa_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Mark J. Rosenblum, Executive Vice President and Interim Chief Financial Officer, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q of Salarius Pharmaceuticals, Inc.&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter  that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="padding-left:47.25pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.771%"><tr><td style="width:1.0%"></td><td style="width:23.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:59.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Mark J. Rosenblum</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark J. Rosenblum</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 11, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Interim Chief Financial Officer<br>(Principal&#160;Financial and Accounting&#160;Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>slrx20230331ex-321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ica037ab9a0824df7b29c7d4122d3410e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.1</font></div><div><font><br></font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Salarius Pharmaceuticals, Inc. (the &#34;Company&#34;) for the fiscal period ended March&#160;31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#34;Report&#34;), the undersigned hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of their knowledge&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:47.25pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:18.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.074%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David J. Arthur</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David J. Arthur</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May&#160;11, 2023</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief&#160;Executive&#160;Officer (Principal&#160;Executive&#160;Officer)</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:18.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.074%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Mark J. Rosenblum</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark J. Rosenblum</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May&#160;11, 2023</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Interim Chief Financial Officer<br>(Principal&#160;Financial Officer and Principal Accounting&#160;Officer)</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139960924512032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COVER PAGE - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 05, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SALARIUS PHARMACEUTICALS,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-5087339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2450 Holcombe Blvd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite X<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Houston<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">804-9144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SLRX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,491,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001615219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139960924581104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 9,273,682<span></span>
</td>
<td class="nump">$ 12,106,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Grants receivable from CPRIT</a></td>
<td class="nump">130,000<span></span>
</td>
<td class="nump">1,610,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">536,625<span></span>
</td>
<td class="nump">803,373<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">9,940,307<span></span>
</td>
<td class="nump">14,520,298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">114,852<span></span>
</td>
<td class="nump">130,501<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">10,055,159<span></span>
</td>
<td class="nump">14,650,799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,510,905<span></span>
</td>
<td class="nump">2,858,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flks_AccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">985,393<span></span>
</td>
<td class="nump">1,407,861<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">4,496,298<span></span>
</td>
<td class="nump">4,266,191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 5)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000,000 shares authorized; 0 issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 100,000,000 shares authorized; 2,468,297 and 2,255,899 shares issued and outstanding at March&#160;31, 2023 and December&#160;31, 2022, respectively</a></td>
<td class="nump">246<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">74,704,536<span></span>
</td>
<td class="nump">74,189,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(69,145,921)<span></span>
</td>
<td class="num">(63,805,148)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">5,558,861<span></span>
</td>
<td class="nump">10,384,608<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 10,055,159<span></span>
</td>
<td class="nump">$ 14,650,799<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Expenses And Other Current Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139960924488848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollar per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollar per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">2,468,297<span></span>
</td>
<td class="nump">2,255,899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">2,468,297<span></span>
</td>
<td class="nump">2,255,899<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139960927555888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList', window );">Revenue from contract with customer, product and service</a></td>
<td class="text">Grant<span></span>
</td>
<td class="text">Grant<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Grant revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">3,725,588<span></span>
</td>
<td class="nump">4,439,475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,695,075<span></span>
</td>
<td class="nump">1,677,754<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">5,420,663<span></span>
</td>
<td class="nump">6,117,229<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss before other income (expense)</a></td>
<td class="num">(5,420,663)<span></span>
</td>
<td class="num">(6,117,229)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income, net and other</a></td>
<td class="nump">79,890<span></span>
</td>
<td class="nump">8,004<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Loss from continuing operations</a></td>
<td class="num">(5,340,773)<span></span>
</td>
<td class="num">(6,109,225)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,340,773)<span></span>
</td>
<td class="num">$ (6,109,225)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per common share, basic ( in dollar per share)</a></td>
<td class="num">$ (2.23)<span></span>
</td>
<td class="num">$ (3.30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Loss per common share, diluted ( in dollar per share)</a></td>
<td class="num">$ (2.23)<span></span>
</td>
<td class="num">$ (3.30)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares outstanding, basic (in shares)</a></td>
<td class="nump">2,391,964<span></span>
</td>
<td class="nump">1,850,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares outstanding, diluted (in shares)</a></td>
<td class="nump">2,391,964<span></span>
</td>
<td class="nump">1,850,208<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920602&amp;loc=SL49130690-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139960928585152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,340,773)<span></span>
</td>
<td class="num">$ (6,109,225)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,669<span></span>
</td>
<td class="nump">4,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation expense</a></td>
<td class="nump">203,345<span></span>
</td>
<td class="nump">313,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development technology</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,987,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Grants receivable</a></td>
<td class="nump">1,480,490<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">280,728<span></span>
</td>
<td class="nump">300,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">627,576<span></span>
</td>
<td class="nump">150,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(422,470)<span></span>
</td>
<td class="num">(168,845)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(3,169,435)<span></span>
</td>
<td class="num">(3,520,826)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Purchase in-process research and development technology</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,500,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,500,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Proceeds from issuance of equity securities, net</a></td>
<td class="nump">336,682<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">336,682<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(2,832,753)<span></span>
</td>
<td class="num">(5,020,826)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">12,106,435<span></span>
</td>
<td class="nump">29,214,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">9,273,682<span></span>
</td>
<td class="nump">24,193,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Common stock issued for in-process research and development technology</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">487,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flks_StockIssuanceCostsAccruedAndAmortized', window );">Accrued issuance costs for public offering</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_StockIssuanceCostsAccruedAndAmortized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs Accrued and Amortized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_StockIssuanceCostsAccruedAndAmortized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the issuance of equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139960924536928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,809,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 38,722,985<span></span>
</td>
<td class="nump">$ 181<span></span>
</td>
<td class="nump">$ 70,919,996<span></span>
</td>
<td class="num">$ (32,197,192)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologySharesNewIssues', window );">Common stock issued for in-process research and development technology (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues', window );">Common stock issued for in-process research and development technology</a></td>
<td class="nump">487,900<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">487,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Equity-based compensation expense (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity-based compensation expense</a></td>
<td class="nump">313,903<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">313,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(6,109,225)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,109,225)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,867,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">33,415,563<span></span>
</td>
<td class="nump">$ 187<span></span>
</td>
<td class="nump">71,721,793<span></span>
</td>
<td class="num">(38,306,417)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,255,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">10,384,608<span></span>
</td>
<td class="nump">$ 225<span></span>
</td>
<td class="nump">74,189,531<span></span>
</td>
<td class="num">(63,805,148)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of equity securities, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of equity securities, net</a></td>
<td class="nump">311,681<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">311,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Equity-based compensation expense (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity-based compensation expense</a></td>
<td class="nump">203,345<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">203,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(5,340,773)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,340,773)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,468,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 5,558,861<span></span>
</td>
<td class="nump">$ 246<span></span>
</td>
<td class="nump">$ 74,704,536<span></span>
</td>
<td class="num">$ (69,145,921)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologySharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period For In-Process Research and Development Technology, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologySharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period For In-Process Research and Development Technology, Value, New Issues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139960927370928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND OPERATIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND OPERATIONS</a></td>
<td class="text">ORGANIZATION AND OPERATIONS<div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nature of Business</span></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Salarius Pharmaceuticals, Inc. (&#8220;Salarius&#8221; or the &#8220;Company&#8221;), together with its subsidiaries, Salarius Pharmaceuticals, LLC, Flex Innovation Group LLC, and TK Pharma, Inc., is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical need. Specifically, the Company is developing treatments for cancers caused by dysregulated gene expression, i.e., genes that are incorrectly turned on or off. The Company is developing two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degraders. The Company's technologies have the potential to work in both liquid and solid tumors. The Company's current pipeline consists of two small molecule drugs: 1) SP-3164, a targeted protein degrader, and 2)  seclidemstat (SP-2577), a targeted protein inhibitor. The Company is located in Houston, Texas. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Salarius has no products approved for commercial sale, has not generated any revenue from product sales to date and has suffered recurring losses from operations since its inception. The lack of revenue from product sales to date and recurring losses from operations since its inception raise substantial doubt as to the Company's ability to continue as a going concern. The accompanying financial statements are prepared using accounting principles generally accepted in the United States applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities should the Company be unable to continue as a going concern. Salarius will require substantial additional capital to fund its research and development expenses related to its pipeline including SP-3164 and seclidemstat. Based on Salarius&#8217; expected cash requirements, Salarius believes that there is substantial doubt that its existing cash and cash equivalents, will be sufficient to fund its operations through one year from the financial statements' issuance date. The Company intends to obtain additional capital through the sale of equity securities in one or more offerings or through issuances of debt instruments, and may also consider new collaborations or selectively partnering its technology. However, the Company cannot provide any assurance that it will be successful in accomplishing any of its plans. </span></div><div style="margin-bottom:12pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recent Developments</span></div><div style="margin-bottom:12pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Partial Clinical Hold Lifted</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 19, 2022, the Company voluntarily paused new patient enrollment in its Phase 1/2 trial of seclidemstat as a treatment for Ewing sarcoma and FET-rearranged sarcomas per protocol design. The pause in new patient enrollment was due to a metastatic FET-rearranged sarcoma patient death that was classified as a suspected unexpected serious adverse reaction (SUSAR). Upon review of the SUSAR and available information by the Company&#8217;s independent Safety Review Committee for the clinical trial, patients currently receiving seclidemstat treatment may continue treatment after consulting with their physician. During a conference call with the U.S. Food and Drug Administration (FDA) on November 1, 2022, the FDA informed the Company that the agency agreed with the voluntary enrollment pause and, as an administrative action, the FDA provided verbal notification that the Ewing sarcoma and FET-rearranged sarcoma trial was on partial clinical hold. While on partial clinical hold, FDA informed the Company that the pause in patient enrollment shall remain in place and patients currently receiving seclidemstat treatment may continue treatment after consulting with their physician. FDA&#8217;s clinical hold procedures provide the Company with an administrative process to work with the FDA to analyze the available data, adjust clinical protocols, and make other changes that may be needed in order to restart patient enrollment. The Company adhered to this administrative process and submitted its findings during early April, 2023. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">On May 5, 2023, the Company was notified by FDA that they have completed the review of our submission and have concluded that the clinical trial may be resumed.</span></div><div style="margin-bottom:12pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Common Stock Issued Under At the Market Offering Agreement </span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 5, 2021, the Company entered into an At the Market Offering Agreement (the &#8220;Sales Agreement&#8221;) with Ladenburg Thalmann &amp; Co. Inc. (&#8220;Ladenburg&#8221;). Under the Sales Agreement the Company was able to issue and sell, from time to time, shares of its common stock (the &#8220;ATM Shares&#8221;) with Ladenburg acting as an agent for sales. Sales of the ATM Shares may be made by any method permitted by law deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended, including, without limitation, sales made directly on or through the Nasdaq Capital Market. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">From April 4, 2023 to May 11, 2023, the Company sold 527,672 ATM shares of its common shares with gross proceeds of approximately $1.3&#160;million </span>under the Sales Agreement.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139960927417088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standard Codification ("ASC") and Accounting Standards Update ("ASU") of the Financial Accounting Standards Board ("FASB").</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 14, 2022, the Company filed a Certificate of Amendment to the Company&#8217;s restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-25 reverse stock split of the Company&#8217;s issued and outstanding shares of common stock, par value $0.0001 per share (the &#8220;Reverse Stock Split&#8221;), which became effective on October 14, 2022. All historical share and per share amounts reflected throughout this report have been adjusted to reflect the Reverse Stock Split.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim financial statements are unaudited. These unaudited interim financial statements have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial information. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. These unaudited interim financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended December&#160;31, 2022 included elsewhere in the Company's Annual Report on Form 10-K filed with the SEC on March 27, 2023. In the opinion of management, the unaudited interim financial statements reflect all the adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company&#8217;s financial position as of March&#160;31, 2023 and the results of operations for the three months ended March&#160;31, 2023 and 2022. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. The December&#160;31, 2022 balance sheet included herein was derived from the audited financial statements, but does not include all disclosures, including notes, required by GAAP for complete financial statements.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America as defined by the FASB ASC requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salarius considers all highly liquid investments with original maturities of three months or less to be cash equivalents. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that their carrying value may not be recoverable. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. There were no impairment charges related to long-lived assets for the three months ended March&#160;31, 2023 and 2022.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments and Credit Risks</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk include cash and cash equivalents and restricted cash. Cash is deposited in demand accounts in federally insured domestic institutions to minimize risk. Insurance is provided through the Federal Deposit Insurance Corporation. Although the balances in these accounts exceed the federally insured limit from time to time, the Company has not incurred losses related to these deposits.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether warrants should be classified as a liability or equity. For warrants classified as liabilities, the Company estimates the fair value of the warrants at each reporting period using Level 3 inputs with changes in fair value recorded in the Condensed Consolidated Statement of Operations within change in fair value of warrant liability. The estimates in valuation models are based, in part, on subjective assumptions, including but not limited to stock price volatility, the expected life of the warrants, the risk-free interest rate and the fair value of the common stock underlying the warrants, and could differ materially in the future. The Company will continue to adjust the fair value of the warrant liability at the end of each reporting period for changes in fair value from the prior period until the earlier of the exercise or expiration of the applicable warrant. For warrants classified as equity contracts, the Company allocates the transaction proceeds to the warrants and any other free-standing instruments issued in the transaction based on an allowable allocation method.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Trial Accruals</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s preclinical and clinical trials are performed by third party contract research organizations ("CROs") and/or clinical investigators, and clinical supplies are manufactured by contract manufacturing organizations ("CMOs"). Invoicing from these third parties may be monthly based upon services performed or based upon milestones achieved. The Company accrues these expenses based upon its assessment of the status of each clinical trial and the work completed, and upon information obtained from the CROs and CMOs. The Company&#8217;s estimates are dependent upon the timeliness and accuracy of data provided by the CROs and CMOs regarding the status and cost of the studies, and may not match the actual services performed by the organizations. This could result in adjustments to the Company&#8217;s research and development expenses in future periods. To date the Company has had no significant adjustments.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Grants Receivable and Revenue </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Salarius&#8217; source of revenue has been from a grant received from CPRIT. Grant revenue is recognized when qualifying costs are incurred and there is reasonable assurance that conditions of the grant have been met. Cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development costs consist of expenses incurred in performing research and development activities, including pre-clinical studies and clinical trials. Research and development costs include salaries and personnel-related costs, consulting fees, fees paid for contract research services, the costs of laboratory equipment and facilities, license fees and other external costs. Research and development costs are expensed when incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs incurred in obtaining in-process research and development ("IPRD") that has no alternative future use are charged to research and development expense as acquired, and presented as investing activity cash outflows on the Statement of Cash Flow.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Equity-Based Compensation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salarius measures equity-based compensation based on the grant date fair value of the awards and recognizes the associated expense in the financial statements over the requisite service period of the award, which is generally the vesting period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option valuation model to estimate the fair value of stock options granted to employees and directors. Assumptions utilized in these models including expected volatility calculated based on implied volatility from traded stocks of peer companies, dividend yield and risk-free interest rate. Additionally, forfeitures are accounted for in compensation cost as they occur. Restricted stock and restricted stock units granted to employees and directors are measured at fair value based upon the closing price of the Company's common stock on the grant date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss Per Share</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods, as the inclusion of all potential common shares outstanding is anti-dilutive.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of anti-dilutive shares, consisting of common shares underlying (i) common stock options, (ii) stock purchase warrants, (iii) rights entitling holders to receive warrants to purchase the Company's common shares, and (iv) restricted stock units which have been excluded from the computation of diluted loss per share, was approximately 716,840 and 431,407 shares as of March&#160;31, 2023 and 2022, respectively.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are recorded in accordance with FASB ASC Topic 740, Income Taxes ("ASC 740"), which provides for deferred taxes using an asset and liability approach. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and the tax reporting basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized. The Company has evaluated available evidence and concluded that the Company may not realize the benefit of its deferred tax assets; therefore, a valuation allowance has been established for the full amount of the deferred tax assets.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. As of March&#160;31, 2023 and December&#160;31, 2022, the Company did not have any significant uncertain tax positions and no interest or penalties have been charged. The Company's practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company is subject to routine audits by taxing jurisdictions.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition and Strategic Collaboration Agreement</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 12, 2022, the Company entered into an Acquisition and Strategic Collaboration Agreement (the &#8220;ASCA&#8221;), with DeuteRx, LLC, a Delaware limited liability company (the &#8220;DeuteRx&#8221;), pursuant to which DeuteRx agreed to sell, and the Company agreed to purchase and assume from DeuteRx, all of DeuteRx&#8217;s rights, title, and interest in and to certain assets of DeuteRx, including SP-3164, DeuteRx&#8217;s intellectual property, information and data related to SP-3164, tangible materials or reagents related to SP-3164, goodwill, rights and claims, other than certain excluded assets (collectively, the &#8220;Purchased Assets&#8221;), all as more specifically set forth in the ASCA, and assume certain assumed liabilities, upon the terms and subject to the conditions set forth in the ASCA. The Aggregate purchase price paid under the ASCA was $2.0&#160;million consisting of $1.5 million cash payment and the delivery of 40,000 shares of the Company's common stock, valued at $0.5 million. Total cost incurred in obtaining IPRD that has no alternative future use are charged to research and development expense as acquired, and presented as investing activity cash outflow on the Statement of Cash Flow. In addition, the Company agreed to pay to DeuteRx potential future milestone payments upon the occurrence of an applicable Milestone Event (as defined in the ASCA) and potential future royalty payments. A member of the Company&#8217;s Board of Directors also serves as a consultant to DeuteRx and is employed by an affiliate of DeuteRx.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recently Adopted Accounting Standard</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments &#8212; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires the measurement of all expected credit losses for financial assets including trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Subsequent to the issuance of ASU 2016-13, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments - Credit Losses. This ASU does not change the core principle of the guidance in ASU 2016-13, instead these amendments are intended to clarify and improve operability of certain topics included within the credit losses guidance. The FASB also subsequently issued ASU No. 2019-04, Codification Improvements to Topic 326, Financial Instruments&#8212;Credit Losses, Derivatives and Hedging (Topic 815), and Financial Instruments (Topic 825), which did not change the core principle of the guidance in ASU 2016-13 but clarified that expected recoveries of amounts previously written off and expected to be written off should be included in the valuation account and should not exceed amounts previously written off and expected to be written off. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019 for public business entities, excluding smaller reporting companies. Early adoption is permitted. As a smaller reporting company, the guidance was effective for the Company on January 1, 2023. The adoption of this standard did not have a material impact to this Company's consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139960925361504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GRANT RECEIVABLE FROM CPRIT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">GRANT RECEIVABLE FROM CPRIT</a></td>
<td class="text">GRANT RECEIVABLE FROM CPRIT<span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grants receivable represents qualifying costs incurred where there is reasonable assurance that conditions of the grant have been met but the corresponding funds have not been received as of the reporting date. Grants receivable balances are $0.1 million and $1.6 million  at both March&#160;31, 2023 and December&#160;31, 2022. During the three</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended March&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the </span>Company received $1.5 million from CPRIT.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -URI https://asc.fasb.org/subtopic&amp;trid=2196772<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139960926119136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
<td class="text">PREPAID EXPENSES AND OTHER CURRENT ASSETS<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets at March&#160;31, 2023 and December&#160;31, 2022 consisted of the following: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:65.322%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.323%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical trial expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368,931&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624,612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid and current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536,625&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803,373&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid insurance is mainly comprised of prepaid directors' and officers' insurance.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139960927388752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License Agreement with the University of Utah Research Foundation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2011, the Company entered into a license agreement with the University of Utah, under which, the Company acquired an exclusive license to an epigenetic enzyme lysine specific demethylase 1 ("LSD1"). In exchange for the license, the Company issued 2% equity ownership in the Company based on a fully diluted basis at the effective date of the agreement subject to certain adjustments specified in the agreement, such as granted revenue sharing rights on any resulting products or processes to commence on first commercial sale, and milestone payments based upon regulatory approval of any resulting product or process as well as on the second anniversary of first commercial sale.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cancer Prevention and Research Institute of Texas</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company entered into a Cancer Research Grant Contract with CPRIT. Pursuant to the contract, CPRIT awarded the Company a grant up to $18.7 million further modified to $16.1&#160;million to fund development of LSD 1 inhibitor. This is a 3-year grant award originally expired on May 31, 2019. The Company applied for a no cost extension through November 30, 2023. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will retain ownership over any intellectual property developed under the contract ("Project Result"). With respect to non-commercial use of any Project Result, the Company agreed to grant to CPRIT a nonexclusive, irrevocable, royalty-free, perpetual, worldwide license with right to sublicense any necessary additional intellectual property rights to exploit all Project Results by CPRIT, other governmental entities and agencies of the State of Texas, and private or independent institutions of higher education located in Texas, for education, research and other non-commercial purposes.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is obligated to make revenue-sharing payments to CPRIT with respect to net sales of any product covered by the contract, up to a maximum repayment of certain percentage of the aggregate amount paid to the Company by CPRIT under the CPRIT contract. The payments are determined as a percentage of net sales, which may be reduced if the Company is required to obtain a license from a third party to sell any such product. In addition, upon meeting the foregoing limitation on revenue-sharing payments, the Company agreed to make continued revenue-sharing payments to CPRIT of less than 1% of net sales.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease Agreement</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company presently leases office space under operating lease agreements on a month-to-month basis.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139960926691008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE OF FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE OF FINANCIAL INSTRUMENTS</a></td>
<td class="text">FAIR VALUE OF FINANCIAL INSTRUMENTS <div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last is considered unobservable, are used to measure fair value:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:3pt;padding-left:76.5pt;text-align:justify;text-indent:-40.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Significant unobservable inputs including Salarius&#8217; own assumptions in determining fair value.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes the recorded values of its financial instruments, including cash and cash equivalents, accounts payable and note payable approximate their fair values due to the short-term nature of these instruments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139960924477408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text">STOCKHOLDERS' EQUITY<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock  Issuances</span></div><div style="margin-bottom:12pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, the Company sold 142,499 ATM shares under the Sales Agreement, with gross proceeds of  $0.3 million.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 12, 2022, the Company issued 40,000 shares of the Company's common stock, valued at $0.5 million to purchase in-process research and development technology SP-3164, please refer to NOTE 2 for further discussion. </span></div><div style="margin-bottom:12pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants Exercised for Cash </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has five-year warrants outstanding that were issued in February 2020 and subsequently modified in December 2020 in connection with the issuance of additional inducement warrants. The warrants are exercisable at a price per share of $28.75. The inducement warrants expire on June 11, 2026, and are exercisable at a price per share of $29.55. The Company has 5.5 year warrants outstanding that were issued in April 2022, with an exercise price of $8.4975 per share. The warrants will be exercisable six months following the issuance date and will expire five and one-half years from the issuance date. </span></div> As of March&#160;31, 2023 and 2022, approximately 597,512 and 317,329  warrants remain outstanding<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139960926048000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">EQUITY-BASED COMPENSATION</a></td>
<td class="text">EQUITY-BASED COMPENSATION <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Incentive Plans</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has granted options to employees, directors, and consultants under the 2015 Equity Incentive Plan (the "2015 Plan"). The 2015 Plan provides for the grant of incentive stock options ("ISOs"), nonstatutory stock options, restricted stock awards, restricted stock units, stock appreciation rights, performance-based stock awards and other stock-based awards. Additionally, the 2015 Plan provides for the grant of performance-based cash awards. ISOs may be granted only to the Company's employees. All other awards may be granted to the Company's employees, including officers, and to non-employee directors and consultants. As of March&#160;31, 2023, there were approximately 55,365 shares remaining available for the grant of option awards under the 2015 Plan.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, the Company awarded 12,220 restricted stock units to its employees and 36,640 restricted stock awards to its officers and directors, pursuant to the plan described above. Both the restricted stock units and restricted stock awards are valued at the closing price $1.57 of the Company's common stock on the grant date, and generally vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfODI0NjMzNzIxMTc2Ng_92999dea-8fe6-44eb-b277-ca85e4d4df2d">one</span> to four years. Total fair value of the restricted stock awards and restricted stock units awarded during the  three months periods ended March&#160;31, 2023 is $76,679. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three-month periods ended March&#160;31, 2023 and 2022, the Company awarded 0 and 50,160 stock options, to its employees and directors, pursuant to the plan described above. Stock options generally vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfMTAyMQ_c80ce869-a2e6-4296-953f-d1a3e4d42122">one</span> to four years and have a contractual term of ten years. Stock options are valued using the Black-Scholes option pricing model and compensation cost is recognized based on the resulting value over the service period. Expected volatilities utilized in the model are based on implied volatilities from traded stocks of peer companies. Similarly, the dividend yield is based on historical experience and the estimate of future dividend yields. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The expected term of the options is based on the average period the stock options are expected to remain outstanding. The fair value of the option grants awarded during the three months periods ended March&#160;31, 2022 was $0.5 million, which has been estimated with the following assumptions on the grant date.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.128%"><tr><td style="width:1.0%"/><td style="width:59.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.171%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.952%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.62%-1.70%</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.19% 126.42%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00-6.00</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for employees and non-employees for the three months ended March&#160;31, 2023 and 2022: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:44.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.755%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual<br/>Term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,919&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.50</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,079&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.94</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.01</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.29</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,128&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.04</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.83</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of both March&#160;31, 2023 and 2022, there was approximately $0.7 and $1.0 million of total unrecognized compensation cost related to unvested stock options,. Total unrecognized compensation cost will be adjusted for future changes in employee and non-employee forfeitures, if any. The Company expects to recognize that cost over a remaining weighted-average period of 1.9 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139960926037408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">SUBSEQUENT EVENTS<span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5, 2023, the Company was notified by FDA that they have completed the review of the Company's submission and have concluded that the clinical trial may be resumed. See Recent Developments for further discussion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">. </span>From April 4, 2023 to May 11, 2023, the Company sold 527,672 ATM shares of its common shares with gross proceeds of approximately $1.3&#160;million under the Sales Agreement.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139960928584368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standard Codification ("ASC") and Accounting Standards Update ("ASU") of the Financial Accounting Standards Board ("FASB").</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 14, 2022, the Company filed a Certificate of Amendment to the Company&#8217;s restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-25 reverse stock split of the Company&#8217;s issued and outstanding shares of common stock, par value $0.0001 per share (the &#8220;Reverse Stock Split&#8221;), which became effective on October 14, 2022. All historical share and per share amounts reflected throughout this report have been adjusted to reflect the Reverse Stock Split.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America as defined by the FASB ASC requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">Cash and Cash EquivalentsSalarius considers all highly liquid investments with original maturities of three months or less to be cash equivalents.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">Impairment of Long-Lived AssetsLong-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that their carrying value may not be recoverable. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Financial Instruments and Credit Risks</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments and Credit Risks</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk include cash and cash equivalents and restricted cash. Cash is deposited in demand accounts in federally insured domestic institutions to minimize risk. Insurance is provided through the Federal Deposit Insurance Corporation. Although the balances in these accounts exceed the federally insured limit from time to time, the Company has not incurred losses related to these deposits.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether warrants should be classified as a liability or equity. For warrants classified as liabilities, the Company estimates the fair value of the warrants at each reporting period using Level 3 inputs with changes in fair value recorded in the Condensed Consolidated Statement of Operations within change in fair value of warrant liability. The estimates in valuation models are based, in part, on subjective assumptions, including but not limited to stock price volatility, the expected life of the warrants, the risk-free interest rate and the fair value of the common stock underlying the warrants, and could differ materially in the future. The Company will continue to adjust the fair value of the warrant liability at the end of each reporting period for changes in fair value from the prior period until the earlier of the exercise or expiration of the applicable warrant. For warrants classified as equity contracts, the Company allocates the transaction proceeds to the warrants and any other free-standing instruments issued in the transaction based on an allowable allocation method.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Grants Receivable and Revenue</a></td>
<td class="text">Grants Receivable and Revenue Salarius&#8217; source of revenue has been from a grant received from CPRIT. Grant revenue is recognized when qualifying costs are incurred and there is reasonable assurance that conditions of the grant have been met. Cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development costs consist of expenses incurred in performing research and development activities, including pre-clinical studies and clinical trials. Research and development costs include salaries and personnel-related costs, consulting fees, fees paid for contract research services, the costs of laboratory equipment and facilities, license fees and other external costs. Research and development costs are expensed when incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs incurred in obtaining in-process research and development ("IPRD") that has no alternative future use are charged to research and development expense as acquired, and presented as investing activity cash outflows on the Statement of Cash Flow.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Equity-Based Compensation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Equity-Based Compensation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salarius measures equity-based compensation based on the grant date fair value of the awards and recognizes the associated expense in the financial statements over the requisite service period of the award, which is generally the vesting period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option valuation model to estimate the fair value of stock options granted to employees and directors. Assumptions utilized in these models including expected volatility calculated based on implied volatility from traded stocks of peer companies, dividend yield and risk-free interest rate. Additionally, forfeitures are accounted for in compensation cost as they occur. Restricted stock and restricted stock units granted to employees and directors are measured at fair value based upon the closing price of the Company's common stock on the grant date.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss Per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss Per Share</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods, as the inclusion of all potential common shares outstanding is anti-dilutive.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are recorded in accordance with FASB ASC Topic 740, Income Taxes ("ASC 740"), which provides for deferred taxes using an asset and liability approach. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and the tax reporting basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized. The Company has evaluated available evidence and concluded that the Company may not realize the benefit of its deferred tax assets; therefore, a valuation allowance has been established for the full amount of the deferred tax assets.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. As of March&#160;31, 2023 and December&#160;31, 2022, the Company did not have any significant uncertain tax positions and no interest or penalties have been charged. The Company's practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company is subject to routine audits by taxing jurisdictions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Standard</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recently Adopted Accounting Standard</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments &#8212; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires the measurement of all expected credit losses for financial assets including trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Subsequent to the issuance of ASU 2016-13, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments - Credit Losses. This ASU does not change the core principle of the guidance in ASU 2016-13, instead these amendments are intended to clarify and improve operability of certain topics included within the credit losses guidance. The FASB also subsequently issued ASU No. 2019-04, Codification Improvements to Topic 326, Financial Instruments&#8212;Credit Losses, Derivatives and Hedging (Topic 815), and Financial Instruments (Topic 825), which did not change the core principle of the guidance in ASU 2016-13 but clarified that expected recoveries of amounts previously written off and expected to be written off should be included in the valuation account and should not exceed amounts previously written off and expected to be written off. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019 for public business entities, excluding smaller reporting companies. Early adoption is permitted. As a smaller reporting company, the guidance was effective for the Company on January 1, 2023. The adoption of this standard did not have a material impact to this Company's consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last is considered unobservable, are used to measure fair value:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:3pt;padding-left:76.5pt;text-align:justify;text-indent:-40.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Significant unobservable inputs including Salarius&#8217; own assumptions in determining fair value.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes the recorded values of its financial instruments, including cash and cash equivalents, accounts payable and note payable approximate their fair values due to the short-term nature of these instruments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139960926062496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets at March&#160;31, 2023 and December&#160;31, 2022 consisted of the following: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:65.322%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.323%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical trial expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368,931&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624,612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid and current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536,625&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803,373&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139960925336896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value Assumptions</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.128%"><tr><td style="width:1.0%"/><td style="width:59.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.171%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.952%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.62%-1.70%</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.19% 126.42%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00-6.00</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for employees and non-employees for the three months ended March&#160;31, 2023 and 2022: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:44.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.755%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual<br/>Term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,919&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.50</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,079&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.94</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.01</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.29</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,128&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.04</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.83</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139960927684976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND OPERATIONS (Details) - Subsequent Event - Sales Agreement - Common Stock<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>May 11, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued (in shares) | shares</a></td>
<td class="nump">527,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sale of stock | $</a></td>
<td class="nump">$ 1.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=flks_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=flks_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139960924539408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 14, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 12, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Conversion ratio</a></td>
<td class="nump">0.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollar per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment charges of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716,840<span></span>
</td>
<td class="nump">431,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flks_PaymentsForAcquisitionAndStrategicCollaborationAgreement', window );">Aggregate payments under ASCA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Purchase in-process research and development technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of equity securities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 311,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of equity securities, net (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">142,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of equity securities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_PaymentsForAcquisitionAndStrategicCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Acquisition And Strategic Collaboration Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_PaymentsForAcquisitionAndStrategicCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139960927649168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GRANT RECEIVABLE FROM CPRIT (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Grants receivable from CPRIT</a></td>
<td class="nump">$ 130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,610,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Grants receivable</a></td>
<td class="nump">1,480,490<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Grants receivable from CPRIT</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139960928642816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flks_PrepaidClinicalTrialExpense', window );">Prepaid clinical trial expenses</a></td>
<td class="nump">$ 11,185<span></span>
</td>
<td class="nump">$ 11,185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">368,931<span></span>
</td>
<td class="nump">624,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other prepaid and current assets</a></td>
<td class="nump">156,509<span></span>
</td>
<td class="nump">167,576<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 536,625<span></span>
</td>
<td class="nump">$ 803,373<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_PrepaidClinicalTrialExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Clinical Trial Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_PrepaidClinicalTrialExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139960927690288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2011</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems', window );"><strong>Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flks_RevenueFromGrantsMaximumAward', window );">Award amount</a></td>
<td class="nump">$ 16.1<span></span>
</td>
<td class="nump">$ 18.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flks_RevenueFromGrantsAwardTerm', window );">Award term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales', window );">Continued payments, percent of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=flks_UniversityOfUtahResearchFoundationMember', window );">University of Utah Research Foundation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems', window );"><strong>Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership percentage by noncontrolling owner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_RevenueFromGrantsAwardTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Award Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_RevenueFromGrantsAwardTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_RevenueFromGrantsMaximumAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Maximum Award</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_RevenueFromGrantsMaximumAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Revenue-sharing Payments, Continued Payments, Percent of Net Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=flks_UniversityOfUtahResearchFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=flks_UniversityOfUtahResearchFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139960924730672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 12, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued, value</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 311,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues', window );">Common stock issued for in-process research and development technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 487,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollar per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flks_WarrantsAndRightsExercisableTerm', window );">Warrants and rights exercisable, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597,512<span></span>
</td>
<td class="nump">317,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollar per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">142,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologySharesNewIssues', window );">Common stock issued for in-process research and development technology (in shares)</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues', window );">Common stock issued for in-process research and development technology</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=flks_SalesAgreementMember', window );">Sales Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=flks_PurchaseAgreementMember', window );">Purchase Agreement | Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollar per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.4975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologySharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period For In-Process Research and Development Technology, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologySharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period For In-Process Research and Development Technology, Value, New Issues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_WarrantsAndRightsExercisableTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants and Rights Exercisable, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_WarrantsAndRightsExercisableTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=flks_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=flks_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=flks_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=flks_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139960922360976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY-BASED COMPENSATION - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock options granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">50,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost, options</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=flks_RestrictedStockAndRestrictedStockUnitsMember', window );">Restricted Stock and Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Issued, weighted average grant date fair value (in usd per share)</a></td>
<td class="nump">$ 1.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of awards</a></td>
<td class="nump">$ 76,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=flks_RestrictedStockAndRestrictedStockUnitsMember', window );">Restricted Stock and Restricted Stock Units | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=flks_RestrictedStockAndRestrictedStockUnitsMember', window );">Restricted Stock and Restricted Stock Units | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options, contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, recognition period</a></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=flks_EquityIncentivePlan2015Member', window );">2015 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares remaining available for grant of stock awards (in shares)</a></td>
<td class="nump">55,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=flks_EmployeesMember', window );">Employees | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares granted (in shares)</a></td>
<td class="nump">12,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=flks_OfficersAndDirectorsMember', window );">Officers and Directors | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares granted (in shares)</a></td>
<td class="nump">36,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=flks_RestrictedStockAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=flks_RestrictedStockAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=flks_EquityIncentivePlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=flks_EquityIncentivePlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=flks_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=flks_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=flks_OfficersAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=flks_OfficersAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139960924584144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY-BASED COMPENSATION - Schedule of Fair Value Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">1.62%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, minimum</a></td>
<td class="nump">125.19%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, maximum</a></td>
<td class="nump">126.42%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139960927591040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY-BASED COMPENSATION - Schedule of Stock Option Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">107,128<span></span>
</td>
<td class="nump">63,919<span></span>
</td>
<td class="nump">63,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">50,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">107,128<span></span>
</td>
<td class="nump">114,079<span></span>
</td>
<td class="nump">107,128<span></span>
</td>
<td class="nump">63,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">59,870<span></span>
</td>
<td class="nump">30,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, beginning balance (in dollar per share)</a></td>
<td class="nump">$ 23.67<span></span>
</td>
<td class="nump">$ 68.75<span></span>
</td>
<td class="nump">$ 68.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, weighted-average exercise price (in dollar per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">12.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, weighted-average exercise price (in usd per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited, weighted-average exercise price (in dollar per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired, weighted-average exercise price (in usd per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, ending balance (in dollar per share)</a></td>
<td class="nump">23.67<span></span>
</td>
<td class="nump">43.75<span></span>
</td>
<td class="nump">$ 23.67<span></span>
</td>
<td class="nump">$ 68.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, weighted-average exercise price (in dollar per share)</a></td>
<td class="nump">$ 28.30<span></span>
</td>
<td class="nump">$ 111.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual Term (in years) and Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, weighted-average remaining contractual term</a></td>
<td class="text">8 years 14 days<span></span>
</td>
<td class="text">8 years 11 months 8 days<span></span>
</td>
<td class="text">8 years 3 months 14 days<span></span>
</td>
<td class="text">8 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, weighted-average remaining contractual term</a></td>
<td class="text">7 years 9 months 29 days<span></span>
</td>
<td class="text">8 years 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, aggregate intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, aggregate intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139960921604432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - Subsequent Event - Sales Agreement - Common Stock<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>May 11, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued (in shares) | shares</a></td>
<td class="nump">527,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sale of stock | $</a></td>
<td class="nump">$ 1.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=flks_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=flks_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>flks-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:flks="http://www.flex-pharma.com/20230331"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="flks-20230331.xsd" xlink:type="simple"/>
    <context id="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7c058905dd194d4e8196eb0ec2edca27_I20230505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <instant>2023-05-05</instant>
        </period>
    </context>
    <context id="i21d8870425a246ecaa7e4fe2677a54c4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i99580c61c8454190b396ed58334ece96_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9bb28550232b40a6a710d558583695ab_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie5a306ceedd2446d93819bfd4e8afbe8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2bd45e30d3c0413c9f0cdd01c63fbe3a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i182fe90a35fa46a4bee4ab0ee69ad6c0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i55a4dc73d8734260b84dd299d02b0bea_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id9aac0bd35674eb4b2fe9319ccc12b17_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iecc8902a9a25417493c9a87bcde49e28_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie373d68e8a8744798cfdbc196f59d0be_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iafffc62468c54cae91120ea9c81a1bd5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie4db7a89251f499c92610b04658dc2ae_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie574cf86bfc040409286776e93e62abd_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6abf49e74f3942af9362b2fc6b6e5ee0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ideb363b95bd54426b36e8a3e499e28b9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7787220731c9412bb479d54b491fd7eb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib594d10fbc6146ba8590e1d37595ffc7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibca39c224c4d4c48a68e09a78c6cc957_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iaf6f50e29050415c8e6980f25eeba947_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i867fe0652a284dfa8c10e8eea406a8db_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i80002a83141a4ef6a0ff3d67ce2967b1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="icf1223a5e90f40a8b60ebbab5dbe9e78_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1c04e18316394009b6153f59ba41f585_D20230404-20230511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">flks:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-04</startDate>
            <endDate>2023-05-11</endDate>
        </period>
    </context>
    <context id="ib514cd02604141cba330abbb11971983_I20221014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <instant>2022-10-14</instant>
        </period>
    </context>
    <context id="i5a151b2cc8444c79aee3f783063d9279_D20220112-20220112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <startDate>2022-01-12</startDate>
            <endDate>2022-01-12</endDate>
        </period>
    </context>
    <context id="ie6b59e45b64342c89f3426880dc1103d_D20220112-20220112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-12</startDate>
            <endDate>2022-01-12</endDate>
        </period>
    </context>
    <context id="iebbb26c017234bd7878b9c40342ac167_D20221014-20221014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <startDate>2022-10-14</startDate>
            <endDate>2022-10-14</endDate>
        </period>
    </context>
    <context id="i939615b57778416faf3eff53296b4db2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if54e5126787f42138fb230f8a7f23b49_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib62a51e0853048ae9069dab610776a5d_I20111231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">flks:UniversityOfUtahResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2011-12-31</instant>
        </period>
    </context>
    <context id="i3a9d75c4f5bd48619d14c8ca1830a6c9_D20160601-20160630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <startDate>2016-06-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="i2e86d1fdb89f494eb9ee243d58ff09cd_D20160701-20160701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <startDate>2016-07-01</startDate>
            <endDate>2016-07-01</endDate>
        </period>
    </context>
    <context id="i5f25028dab374645ab8bd704715c06ac_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">flks:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0609f51e976346d69581a350de826fe9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i750c9de36c044f428d626093ca2e218b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i222ce181634a4cce9e9e36ac4ca82e0f_I20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="ib762f099224741f2a7a409f28e07d108_I20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">flks:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="ic4da1d17c34948158531999f1b199116_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">flks:EquityIncentivePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i057e962232c1423ba944409a49a5dbbe_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">flks:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i571227b74c3343649a8d063d182cb2fc_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">flks:OfficersAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0508e6c8ee6f431281f539250baa1ab9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">flks:RestrictedStockAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic371e0e769f84d71a5a8b6aca305b5b2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">flks:RestrictedStockAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2ae8b02bb35841958964d4e4837cd194_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">flks:RestrictedStockAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie7eaf576725847c490d0015dcd98067e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i576cab9bf4214c329f021a9b27484527_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i15eb79ec74594262ac1ee2bbbcb2dc8b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i63818b7d4b4049b2b5649dd59933606d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6ca10793f84f44ba8ea25c255a1b8295_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib8708a10429e4617bd4cd3efa5411eee_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9f0d7863d02d4527b559355b990c8aac_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i25aebc31ca484ab3b3cbb46087a9333b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180L2ZyYWc6M2M5ZTQ3YjRmZTE2NGM4ZTg1MDMwYWQ4NWU5MmY0YWYvdGFibGU6YWU3NGQyZTFmODI3NDAxM2JhZTQwNWI3MjI1Mjk5YWEvdGFibGVyYW5nZTphZTc0ZDJlMWY4Mjc0MDEzYmFlNDA1YjcyMjUyOTlhYV80LTEtMS0xLTM2ODI1_4af6c2fc-a492-421c-bb1c-f39b98492939">0001615219</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180L2ZyYWc6M2M5ZTQ3YjRmZTE2NGM4ZTg1MDMwYWQ4NWU5MmY0YWYvdGFibGU6YWU3NGQyZTFmODI3NDAxM2JhZTQwNWI3MjI1Mjk5YWEvdGFibGVyYW5nZTphZTc0ZDJlMWY4Mjc0MDEzYmFlNDA1YjcyMjUyOTlhYV81LTEtMS0xLTM2ODI1_0eda17e0-f290-492c-beee-02a700a05df7">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180L2ZyYWc6M2M5ZTQ3YjRmZTE2NGM4ZTg1MDMwYWQ4NWU5MmY0YWYvdGFibGU6YWU3NGQyZTFmODI3NDAxM2JhZTQwNWI3MjI1Mjk5YWEvdGFibGVyYW5nZTphZTc0ZDJlMWY4Mjc0MDEzYmFlNDA1YjcyMjUyOTlhYV84LTEtMS0xLTM2ODI1_2c7372de-39dc-4304-9bb3-3d25b768f941">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180L2ZyYWc6M2M5ZTQ3YjRmZTE2NGM4ZTg1MDMwYWQ4NWU5MmY0YWYvdGFibGU6YWU3NGQyZTFmODI3NDAxM2JhZTQwNWI3MjI1Mjk5YWEvdGFibGVyYW5nZTphZTc0ZDJlMWY4Mjc0MDEzYmFlNDA1YjcyMjUyOTlhYV85LTEtMS0xLTM2ODI1_96103c31-47cc-4b11-9021-835d9286338f">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180L2ZyYWc6M2M5ZTQ3YjRmZTE2NGM4ZTg1MDMwYWQ4NWU5MmY0YWYvdGFibGU6YWU3NGQyZTFmODI3NDAxM2JhZTQwNWI3MjI1Mjk5YWEvdGFibGVyYW5nZTphZTc0ZDJlMWY4Mjc0MDEzYmFlNDA1YjcyMjUyOTlhYV8xMC0xLTEtMS0zNjgyNQ_8a5e7984-febb-4f1e-97f8-139d8c046960">false</dei:AmendmentFlag>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfMy0wLTEtMS0zNjgyNQ_4b3d7717-e9ff-4348-887b-6722ded66434">http://fasb.org/us-gaap/2022#GrantMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfMy0wLTEtMS0zNjgyNQ_6fcee171-08bd-4be6-be8b-a55dbaaf7bed">http://fasb.org/us-gaap/2022#GrantMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="iebbb26c017234bd7878b9c40342ac167_D20221014-20221014"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M184NTgvZnJhZzo4NGU4ZjhkNGFhOTI0YzRmYTBiNjBhN2I0MjU1MjI4Mi90YWJsZTo2NjNhMjNhN2JlOTI0OWE1ODFjNjA2MTA2YWE0ZTEzMy90YWJsZXJhbmdlOjY2M2EyM2E3YmU5MjQ5YTU4MWM2MDYxMDZhYTRlMTMzXzAtMS0xLTEtMzg5MzY_c7134f6f-cc33-46fb-8be2-4b4cc0c7b67a"
      unitRef="number">0.04</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i222ce181634a4cce9e9e36ac4ca82e0f_I20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M181OC9mcmFnOmI0NjdiMTY2YzQ1ZjQ2OTNiOWQ5ODYzZWVkNDI2YjI1L3RhYmxlOjFlOTQ3YjNjMDI5MzQ2NWFiYzBmMGIwOTE1NzRmYjViL3RhYmxlcmFuZ2U6MWU5NDdiM2MwMjkzNDY1YWJjMGYwYjA5MTU3NGZiNWJfMS0xLTEtMS0zNjgyNQ_4880c436-ba91-4a2e-9728-b882c6b2d9b1">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ic371e0e769f84d71a5a8b6aca305b5b2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfODI0NjMzNzIxMTc2Ng_92999dea-8fe6-44eb-b277-ca85e4d4df2d">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ie7eaf576725847c490d0015dcd98067e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfMTAyMQ_c80ce869-a2e6-4296-953f-d1a3e4d42122">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGV4dHJlZ2lvbjo3YTg1YWIwY2M4ZTA0MjE5YWY4MGU3NjFhOWM0YTI5ZV8xOTI2_c6caf845-871d-4ca8-b34f-cbb7aeb74f20">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGFibGU6MGMxOWQyYmNhMTUzNGY5YTlkMmFkMmFkOGFmOTk3NmIvdGFibGVyYW5nZTowYzE5ZDJiY2ExNTM0ZjlhOWQyYWQyYWQ4YWY5OTc2Yl8xLTAtMS0xLTM2ODI1_fdedb851-a63f-42f1-93ad-56adf074d228">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGFibGU6MGMxOWQyYmNhMTUzNGY5YTlkMmFkMmFkOGFmOTk3NmIvdGFibGVyYW5nZTowYzE5ZDJiY2ExNTM0ZjlhOWQyYWQyYWQ4YWY5OTc2Yl8yLTAtMS0xLTM2ODI1L3RleHRyZWdpb246YTJjNmU1NGEzY2FjNDM1N2IwODU5MmQ4NzdiM2E1ZmZfMzU_a2a612c1-f258-4040-ab03-4cb891251524">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGFibGU6MGMxOWQyYmNhMTUzNGY5YTlkMmFkMmFkOGFmOTk3NmIvdGFibGVyYW5nZTowYzE5ZDJiY2ExNTM0ZjlhOWQyYWQyYWQ4YWY5OTc2Yl80LTAtMS0xLTM2ODI1_d2681490-3a84-411e-9a4f-7bee0d0e7baa">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGV4dHJlZ2lvbjo3YTg1YWIwY2M4ZTA0MjE5YWY4MGU3NjFhOWM0YTI5ZV8xMTY_50c6119a-1739-45cf-89b7-8bcd4b38be57">001-36812</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGV4dHJlZ2lvbjo3YTg1YWIwY2M4ZTA0MjE5YWY4MGU3NjFhOWM0YTI5ZV8xMjA_160dfe47-0bf6-4002-aeb9-98e9878b56b1">SALARIUS PHARMACEUTICALS,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGFibGU6MmVhNWUyODNjZWYyNDZlYWFjMzMzNWI5MjgxYWU3YTMvdGFibGVyYW5nZToyZWE1ZTI4M2NlZjI0NmVhYWMzMzM1YjkyODFhZTdhM18wLTEtMS0xLTM2ODI1_b022c420-25a4-4771-a76c-64f60c4833fb">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGFibGU6MmVhNWUyODNjZWYyNDZlYWFjMzMzNWI5MjgxYWU3YTMvdGFibGVyYW5nZToyZWE1ZTI4M2NlZjI0NmVhYWMzMzM1YjkyODFhZTdhM18wLTMtMS0xLTM2ODI1_e438d119-0f43-4250-87bc-07f901a491f2">46-5087339</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGV4dHJlZ2lvbjo3YTg1YWIwY2M4ZTA0MjE5YWY4MGU3NjFhOWM0YTI5ZV8xODA_81af9d38-e6ae-4cd2-a72f-a66f3deb6941">2450 Holcombe Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGV4dHJlZ2lvbjo3YTg1YWIwY2M4ZTA0MjE5YWY4MGU3NjFhOWM0YTI5ZV8xOTI4_532e09de-1fd2-408c-9b42-60c795a7af12">Suite X</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGV4dHJlZ2lvbjo3YTg1YWIwY2M4ZTA0MjE5YWY4MGU3NjFhOWM0YTI5ZV8xOTQ_e02bf3d5-27df-4526-aa61-33c64426bd9d">Houston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGV4dHJlZ2lvbjo3YTg1YWIwY2M4ZTA0MjE5YWY4MGU3NjFhOWM0YTI5ZV8xOTg_48ac46c8-1237-4bff-b147-0e774d89fb43">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGV4dHJlZ2lvbjo3YTg1YWIwY2M4ZTA0MjE5YWY4MGU3NjFhOWM0YTI5ZV8yMDE_7f20c9e6-8594-4885-b9e5-2dad974917a3">77021</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGV4dHJlZ2lvbjo3YTg1YWIwY2M4ZTA0MjE5YWY4MGU3NjFhOWM0YTI5ZV8yNTg_0898c24c-43e2-4ad0-b128-62c5c452a0bd">832</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGV4dHJlZ2lvbjo3YTg1YWIwY2M4ZTA0MjE5YWY4MGU3NjFhOWM0YTI5ZV8xOTI5_8bd98203-9a44-42eb-9491-4d0e3c29ca60">804-9144</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGFibGU6NDM3YzRjMjk4YmE4NDhlYWE0ZDA0ZmVmMWFjYmE1ZmUvdGFibGVyYW5nZTo0MzdjNGMyOThiYTg0OGVhYTRkMDRmZWYxYWNiYTVmZV8xLTAtMS0xLTM2ODI1_ba472e46-4401-454d-880f-6f7c1a86b1e7">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGFibGU6NDM3YzRjMjk4YmE4NDhlYWE0ZDA0ZmVmMWFjYmE1ZmUvdGFibGVyYW5nZTo0MzdjNGMyOThiYTg0OGVhYTRkMDRmZWYxYWNiYTVmZV8xLTItMS0xLTM2ODI1_37af43a8-d793-4d32-8681-f8f4b34aa7dd">SLRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGFibGU6NDM3YzRjMjk4YmE4NDhlYWE0ZDA0ZmVmMWFjYmE1ZmUvdGFibGVyYW5nZTo0MzdjNGMyOThiYTg0OGVhYTRkMDRmZWYxYWNiYTVmZV8xLTQtMS0xLTM2ODI1_c979b05d-342f-48c6-81d0-f03c6412c999">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGV4dHJlZ2lvbjo3YTg1YWIwY2M4ZTA0MjE5YWY4MGU3NjFhOWM0YTI5ZV84MTI_ad9c2dd6-4a13-4ec6-8a7f-e785499c208a">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGV4dHJlZ2lvbjo3YTg1YWIwY2M4ZTA0MjE5YWY4MGU3NjFhOWM0YTI5ZV8xMTMy_ce087016-8f18-4ccf-94c0-c63a414309b5">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGFibGU6NjJhNjM5ZjUzOGE3NGRjMThjMjJkNGU0YjAzMzBkZTEvdGFibGVyYW5nZTo2MmE2MzlmNTM4YTc0ZGMxOGMyMmQ0ZTRiMDMzMGRlMV8wLTQtMS0xLTM2ODI1_e8df8803-e848-4624-ba79-c83ca08b6136">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGFibGU6NjJhNjM5ZjUzOGE3NGRjMThjMjJkNGU0YjAzMzBkZTEvdGFibGVyYW5nZTo2MmE2MzlmNTM4YTc0ZGMxOGMyMmQ0ZTRiMDMzMGRlMV8wLTctMS0xLTM2ODI1_86a97d90-42d6-4822-bbb5-ddbdeb07c4d7">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGFibGU6NjJhNjM5ZjUzOGE3NGRjMThjMjJkNGU0YjAzMzBkZTEvdGFibGVyYW5nZTo2MmE2MzlmNTM4YTc0ZGMxOGMyMmQ0ZTRiMDMzMGRlMV8wLTktMS0xLTM2ODI1_ac73ea01-c59e-45dc-8323-e8a083503f74">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGV4dHJlZ2lvbjo3YTg1YWIwY2M4ZTA0MjE5YWY4MGU3NjFhOWM0YTI5ZV8xODU2_e3048810-49fa-4e48-b6f9-7b1f8e5e7aa0">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i7c058905dd194d4e8196eb0ec2edca27_I20230505"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xL2ZyYWc6N2E4NWFiMGNjOGUwNDIxOWFmODBlNzYxYTljNGEyOWUvdGV4dHJlZ2lvbjo3YTg1YWIwY2M4ZTA0MjE5YWY4MGU3NjFhOWM0YTI5ZV8xODg3_f04097d5-ae3d-4b9e-bdba-12dd665f7b2f"
      unitRef="shares">2491428</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfNC0xLTEtMS0zNjgyNQ_0dcaf4b5-148b-4076-a8b2-2550c1126e46"
      unitRef="usd">9273682</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i99580c61c8454190b396ed58334ece96_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfNC0zLTEtMS0zNjgyNQ_7b23a26e-f56e-4a32-ae56-2d34b31f9932"
      unitRef="usd">12106435</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:GrantsReceivableCurrent
      contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfNi0xLTEtMS0zODM2MQ_06186e9e-8df1-4be6-90b0-06b0b86d16b9"
      unitRef="usd">130000</us-gaap:GrantsReceivableCurrent>
    <us-gaap:GrantsReceivableCurrent
      contextRef="i99580c61c8454190b396ed58334ece96_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfNi0zLTEtMS0zODM2NQ_9ba3029d-9d03-43e5-8a12-961b4144bb0d"
      unitRef="usd">1610490</us-gaap:GrantsReceivableCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfNi0xLTEtMS0zNjgyNQ_3c60b26b-ae59-40b2-902d-b705dab116bf"
      unitRef="usd">536625</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i99580c61c8454190b396ed58334ece96_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfNi0zLTEtMS0zNjgyNQ_00e059ac-0c4d-4f33-a9d5-9af6b3ca1c7a"
      unitRef="usd">803373</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfNy0xLTEtMS0zNjgyNQ_73acb16a-6412-467a-a289-b30bb2316ead"
      unitRef="usd">9940307</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i99580c61c8454190b396ed58334ece96_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfNy0zLTEtMS0zNjgyNQ_1be66ffc-1402-46a8-8904-f60a4d72830e"
      unitRef="usd">14520298</us-gaap:AssetsCurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfOS0xLTEtMS0zNjgyNQ_20634ca1-bbb4-4717-95e0-f2b6e83d7ab1"
      unitRef="usd">114852</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i99580c61c8454190b396ed58334ece96_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfOS0zLTEtMS0zNjgyNQ_f281ebe4-732d-4b91-9a1a-4478ada11e21"
      unitRef="usd">130501</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMTEtMS0xLTEtMzY4MjU_b9a46feb-36c5-4f41-9bee-c6f977608903"
      unitRef="usd">10055159</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i99580c61c8454190b396ed58334ece96_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMTEtMy0xLTEtMzY4MjU_725e933e-271e-4840-8954-9c8d61cae9bf"
      unitRef="usd">14650799</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMTQtMS0xLTEtMzY4MjU_9f9d0fb4-5f28-4844-a63c-f9c3ceb0e94b"
      unitRef="usd">3510905</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i99580c61c8454190b396ed58334ece96_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMTQtMy0xLTEtMzY4MjU_632afad3-c422-4369-8e03-5b3c82a64299"
      unitRef="usd">2858330</us-gaap:AccountsPayableCurrent>
    <flks:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMTUtMS0xLTEtMzY4MjU_f67e04a0-251a-4079-8d62-693ca2b267ef"
      unitRef="usd">985393</flks:AccruedExpensesAndOtherCurrentLiabilities>
    <flks:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="i99580c61c8454190b396ed58334ece96_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMTUtMy0xLTEtMzY4MjU_58a28c27-851e-48e9-92bf-be0b5c73fc86"
      unitRef="usd">1407861</flks:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:Liabilities
      contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMTgtMS0xLTEtMzY4MjU_084a1487-0d47-441a-b9e5-ec5c7f458ece"
      unitRef="usd">4496298</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i99580c61c8454190b396ed58334ece96_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMTgtMy0xLTEtMzY4MjU_40c2b79a-0afd-468e-8e30-76e840d899bd"
      unitRef="usd">4266191</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjItMS0xLTEtMzY4MjU_88e348a7-837f-41d4-996b-c6aae0540e1a"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i99580c61c8454190b396ed58334ece96_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjItMy0xLTEtMzY4MjU_078ac024-032a-498c-a370-5c85f7e75187"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i99580c61c8454190b396ed58334ece96_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjUtMC0xLTEtMzY4MjUvdGV4dHJlZ2lvbjphZDUwYzdiMzg2ZjQ0Y2I2YmZmNjRiNTdkYTQyODhhZF8yMQ_69abaf8c-ae4a-4152-ac89-876ef52f0acd"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjUtMC0xLTEtMzY4MjUvdGV4dHJlZ2lvbjphZDUwYzdiMzg2ZjQ0Y2I2YmZmNjRiNTdkYTQyODhhZF8yMQ_ecb37091-ae89-4701-94f7-e89172d9f53e"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjUtMC0xLTEtMzY4MjUvdGV4dHJlZ2lvbjphZDUwYzdiMzg2ZjQ0Y2I2YmZmNjRiNTdkYTQyODhhZF8zNQ_0100eb51-d0c7-4544-88fb-3dc4e0718f9f"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i99580c61c8454190b396ed58334ece96_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjUtMC0xLTEtMzY4MjUvdGV4dHJlZ2lvbjphZDUwYzdiMzg2ZjQ0Y2I2YmZmNjRiNTdkYTQyODhhZF8zNQ_0d53f117-b616-47ec-a470-f7ee2c719568"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjUtMC0xLTEtMzY4MjUvdGV4dHJlZ2lvbjphZDUwYzdiMzg2ZjQ0Y2I2YmZmNjRiNTdkYTQyODhhZF81Nw_0e8731e6-f745-456d-bb11-376d9425c956"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i99580c61c8454190b396ed58334ece96_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjUtMC0xLTEtMzY4MjUvdGV4dHJlZ2lvbjphZDUwYzdiMzg2ZjQ0Y2I2YmZmNjRiNTdkYTQyODhhZF81Nw_390b9b27-a6e9-4227-ac39-f526d10267d1"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjUtMC0xLTEtMzY4MjUvdGV4dHJlZ2lvbjphZDUwYzdiMzg2ZjQ0Y2I2YmZmNjRiNTdkYTQyODhhZF81Nw_5818a1e2-d6ba-431e-bdf6-0784aca9ada8"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i99580c61c8454190b396ed58334ece96_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjUtMC0xLTEtMzY4MjUvdGV4dHJlZ2lvbjphZDUwYzdiMzg2ZjQ0Y2I2YmZmNjRiNTdkYTQyODhhZF81Nw_e71c47ba-0a29-48a8-8240-8dca1455c391"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjUtMS0xLTEtMzY4MjU_f001e72d-0ed7-45e2-8270-4d35e87a4924"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i99580c61c8454190b396ed58334ece96_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjUtMy0xLTEtMzY4MjU_6033c137-6cc2-4c78-8a88-c7a5d3eeffc2"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjYtMC0xLTEtMzY4MjUvdGV4dHJlZ2lvbjpiNTkxMGU0YWQzYjM0NTM4OTViMmQ2ZGZmOGRjODM2M18xOA_19bcc498-702d-4775-9548-d890d7f31fa1"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i99580c61c8454190b396ed58334ece96_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjYtMC0xLTEtMzY4MjUvdGV4dHJlZ2lvbjpiNTkxMGU0YWQzYjM0NTM4OTViMmQ2ZGZmOGRjODM2M18xOA_75508ff2-7716-42d3-8418-5c393ea7a6d4"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjYtMC0xLTEtMzY4MjUvdGV4dHJlZ2lvbjpiNTkxMGU0YWQzYjM0NTM4OTViMmQ2ZGZmOGRjODM2M18zMg_47f3a6ff-f44a-4667-970b-c46680fa0f9e"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i99580c61c8454190b396ed58334ece96_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjYtMC0xLTEtMzY4MjUvdGV4dHJlZ2lvbjpiNTkxMGU0YWQzYjM0NTM4OTViMmQ2ZGZmOGRjODM2M18zMg_ac5670f8-11d8-4b39-a810-7041e4484b5f"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjYtMC0xLTEtMzY4MjUvdGV4dHJlZ2lvbjpiNTkxMGU0YWQzYjM0NTM4OTViMmQ2ZGZmOGRjODM2M181NA_3f99e8af-b27e-43f3-8d0f-06fb5640c88c"
      unitRef="shares">2468297</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjYtMC0xLTEtMzY4MjUvdGV4dHJlZ2lvbjpiNTkxMGU0YWQzYjM0NTM4OTViMmQ2ZGZmOGRjODM2M181NA_5b49987b-b84e-4451-bdbc-a9e951686f73"
      unitRef="shares">2468297</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i99580c61c8454190b396ed58334ece96_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjYtMC0xLTEtMzY4MjUvdGV4dHJlZ2lvbjpiNTkxMGU0YWQzYjM0NTM4OTViMmQ2ZGZmOGRjODM2M182MQ_4cb09d52-3082-4d78-a873-27679b523ac4"
      unitRef="shares">2255899</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i99580c61c8454190b396ed58334ece96_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjYtMC0xLTEtMzY4MjUvdGV4dHJlZ2lvbjpiNTkxMGU0YWQzYjM0NTM4OTViMmQ2ZGZmOGRjODM2M182MQ_f3bef47e-b57b-4e54-947b-3019f75e1ba3"
      unitRef="shares">2255899</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjYtMS0xLTEtMzY4MjU_c021a303-1c68-4506-8819-027018bd0556"
      unitRef="usd">246</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i99580c61c8454190b396ed58334ece96_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjYtMy0xLTEtMzY4MjU_6a3dd152-131a-4bad-9f7e-a767271b92b1"
      unitRef="usd">225</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjctMS0xLTEtMzY4MjU_7f245b8b-b370-416c-8fe5-db7ae017f8a4"
      unitRef="usd">74704536</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i99580c61c8454190b396ed58334ece96_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjctMy0xLTEtMzY4MjU_a298baaf-cbfc-4fe5-9cbb-ed71b5b6445b"
      unitRef="usd">74189531</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjktMS0xLTEtMzY4MjU_32673a74-5408-4521-98fd-20183edc80e4"
      unitRef="usd">-69145921</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i99580c61c8454190b396ed58334ece96_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMjktMy0xLTEtMzY4MjU_2e4e5a2e-c402-404f-bf73-9c4017633de0"
      unitRef="usd">-63805148</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMzAtMS0xLTEtMzY4MjU_d41d40f3-b60a-43b1-b890-7762a868944c"
      unitRef="usd">5558861</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i99580c61c8454190b396ed58334ece96_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMzAtMy0xLTEtMzY4MjU_0aaf85cd-14b3-4120-91d0-b83353b98a8d"
      unitRef="usd">10384608</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMzEtMS0xLTEtMzY4MjU_db58e8c2-a0e3-4610-a6f1-bd7963a56f44"
      unitRef="usd">10055159</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i99580c61c8454190b396ed58334ece96_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18xOS9mcmFnOmI0NWI5Y2RjYzUwOTRmYWJhODgzMjEwY2Q0OGYyYjgyL3RhYmxlOjZkNjJlOTM1ODE5NjQ1ODI4ZWI4OWViMjIxYzU5ZmJmL3RhYmxlcmFuZ2U6NmQ2MmU5MzU4MTk2NDU4MjhlYjg5ZWIyMjFjNTlmYmZfMzEtMy0xLTEtMzY4MjU_56ed4258-d795-4c23-a47b-ab047ab46248"
      unitRef="usd">14650799</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfMy0xLTEtMS0zNjgyNQ_119e9212-6bde-41a5-bf82-90e096e891db"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfMy0zLTEtMS0zNjgyNQ_5769b7a3-1a9d-4fb6-87ba-6149da2178f1"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfNS0xLTEtMS0zNjgyNQ_5592c5dc-eb0e-48df-8c4b-1b0873c338ed"
      unitRef="usd">3725588</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfNS0zLTEtMS0zNjgyNQ_0bf72a77-fdcc-4297-909f-0ae6c9a3b6df"
      unitRef="usd">4439475</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfNi0xLTEtMS0zNjgyNQ_c9a56d69-f6f5-4240-a37e-4d1e362ed1b9"
      unitRef="usd">1695075</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfNi0zLTEtMS0zNjgyNQ_dfabdec3-37ed-4872-9ae2-7bda44adb733"
      unitRef="usd">1677754</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfOC0xLTEtMS0zNjgyNQ_45ae5744-a6f7-409b-8304-2dd00def5c05"
      unitRef="usd">5420663</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfOC0zLTEtMS0zNjgyNQ_fe2a4a74-91bf-4bce-8329-87aeca2eefdb"
      unitRef="usd">6117229</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfOS0xLTEtMS0zNjgyNQ_b9a06cac-cfa3-4a19-851b-9db6cfa888c6"
      unitRef="usd">-5420663</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfOS0zLTEtMS0zNjgyNQ_53a1d7bd-4104-4f16-9bfc-0715b6a078a3"
      unitRef="usd">-6117229</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfMTEtMS0xLTEtMzY4MjU_5b1f65e8-826c-4c0d-a308-05e25411e17f"
      unitRef="usd">79890</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfMTEtMy0xLTEtMzY4MjU_dab66988-a8ea-41ef-aba4-6fc116d8f843"
      unitRef="usd">8004</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfMTItMS0xLTEtMzY4MjU_9b195427-e735-4b3a-a265-d2a74627ffc2"
      unitRef="usd">-5340773</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfMTItMy0xLTEtMzY4MjU_9408af47-cea8-4df6-9c68-ef0989674d17"
      unitRef="usd">-6109225</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:NetIncomeLoss
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfMTMtMS0xLTEtMzY4MjU_6f52e1ac-be09-4f01-9284-f21bf99c5324"
      unitRef="usd">-5340773</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfMTMtMy0xLTEtMzY4MjU_b25d223d-4fcf-46a1-a1a1-66699d2d0998"
      unitRef="usd">-6109225</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfMTUtMS0xLTEtMzY4MjU_41fa3ba4-ccfc-43f1-a86b-28fb46b38d72"
      unitRef="usdPerShare">-2.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfMTUtMS0xLTEtMzY4MjU_9cfcddbe-2cbd-4f26-a7cb-ab2e4c11c1e0"
      unitRef="usdPerShare">-2.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfMTUtMy0xLTEtMzY4MjU_200935ae-7ba3-4cc3-a092-38c50b7f2459"
      unitRef="usdPerShare">-3.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfMTUtMy0xLTEtMzY4MjU_934d44cd-bd37-47cb-9d3b-b0a6dd9255d8"
      unitRef="usdPerShare">-3.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfMTYtMS0xLTEtMzY4MjU_57f9ffb0-d59c-4a32-8eb5-c53dd812839b"
      unitRef="shares">2391964</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfMTYtMS0xLTEtMzY4MjU_e8c05c72-a9d5-4b63-af6f-23084f2d4113"
      unitRef="shares">2391964</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfMTYtMy0xLTEtMzY4MjU_16c21590-b943-496d-87ff-2639f9ace60d"
      unitRef="shares">1850208</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yMi9mcmFnOmM4YTgwODQxOTQyOTRkMGY4OTg5M2UwYzVkOGNiZjY3L3RhYmxlOjZmZWFmYjI4YmQ4YTQxN2Q5NWE1YzlmNTBhNmZlMjA5L3RhYmxlcmFuZ2U6NmZlYWZiMjhiZDhhNDE3ZDk1YTVjOWY1MGE2ZmUyMDlfMTYtMy0xLTEtMzY4MjU_4e58fa0c-6e91-4b02-ada5-f60f8879d087"
      unitRef="shares">1850208</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMy0xLTEtMS0zNjgyNQ_b05bd498-b667-4b2c-befb-14482087b109"
      unitRef="usd">-5340773</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMy0zLTEtMS0zNjgyNQ_757ecd4a-c441-41e4-916b-c0960c4328f7"
      unitRef="usd">-6109225</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfNS0xLTEtMS0zNjgyNQ_3bc10c8f-f73c-4242-9f2a-63c4feb0f055"
      unitRef="usd">1669</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfNS0zLTEtMS0zNjgyNQ_bdbec665-099f-4452-a8b5-95bbd1134884"
      unitRef="usd">4797</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfNy0xLTEtMS0zNjgyNQ_ab7cd923-7c9f-40e5-8fbf-988856d905d0"
      unitRef="usd">203345</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfNy0zLTEtMS0zNjgyNQ_ea6d501b-ae8b-4a58-a200-4adcedc7a526"
      unitRef="usd">313903</us-gaap:ShareBasedCompensation>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfOS0xLTEtMS0zNjgyNQ_97958b40-f818-4915-947e-8d7e79e85d37"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfOS0zLTEtMS0zNjgyNQ_34bc80c0-380e-4cbf-8ea5-926541f89208"
      unitRef="usd">1987900</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMTItMS0xLTEtMzY4MjU_92cfbb66-93b4-4975-9677-69ab1356e484"
      unitRef="usd">-1480490</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMTItMy0xLTEtMzY4MjU_de123168-292e-48de-9b2d-c1419446321a"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMTMtMS0xLTEtMzY4MjU_82755912-9323-44a6-8e3d-089073ee9769"
      unitRef="usd">-280728</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMTMtMy0xLTEtMzY4MjU_1f305717-b855-40dc-997c-97e969ceaff6"
      unitRef="usd">-300342</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMTUtMS0xLTEtMzY4MjU_6ee8bd10-3a14-4444-9803-8c90a4ccb101"
      unitRef="usd">627576</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMTUtMy0xLTEtMzY4MjU_6800ebc1-77db-465a-9472-4bb635d708a4"
      unitRef="usd">150302</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMTYtMS0xLTEtMzY4MjU_a68a411c-e4e3-4246-9d79-6be332e9de14"
      unitRef="usd">-422470</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMTYtMy0xLTEtMzY4MjU_1e887590-fb98-4c69-ab6e-cd980e95bf3c"
      unitRef="usd">-168845</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMTctMS0xLTEtMzY4MjU_c71cf7b0-d12f-431c-b257-d8464ee2e679"
      unitRef="usd">-3169435</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMTctMy0xLTEtMzY4MjU_c83e8216-0ab0-4aa4-bdca-68c0d5347847"
      unitRef="usd">-3520826</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMjAtMS0xLTEtMzY4MjU_ae1daa10-ab85-41dd-aea8-1e382715cb1f"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMjAtMy0xLTEtMzY4MjU_ae8df7eb-3e02-4646-8f39-88bb39bf55dc"
      unitRef="usd">1500000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMjEtMS0xLTEtMzY4MjU_fceadf02-74e3-4318-aa72-18024df895ea"
      unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMjEtMy0xLTEtMzY4MjU_aa3cead3-f4da-41a3-86f9-57f9c1307008"
      unitRef="usd">-1500000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMjUtMS0xLTEtMzY4MjU_7506e7ba-86aa-4e82-a50f-7a15d093e393"
      unitRef="usd">336682</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMjUtMy0xLTEtMzY4MjU_443081e2-7687-48b2-88e3-ec3c5a770a74"
      unitRef="usd">0</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMjktMS0xLTEtMzY4MjU_655fc132-135d-4c41-b10a-c3dc1d16dc2e"
      unitRef="usd">336682</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMjktMy0xLTEtMzY4MjU_88efe075-acba-45db-be73-7561c05753ef"
      unitRef="usd">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMzEtMS0xLTEtMzY4MjU_c8ceae8c-5609-4f7c-9077-0aef1767f3da"
      unitRef="usd">-2832753</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMzEtMy0xLTEtMzY4MjU_9adb05e1-8fe8-4161-abee-30413b87ad3e"
      unitRef="usd">-5020826</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i99580c61c8454190b396ed58334ece96_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMzItMS0xLTEtMzY4MjU_0d8cf51a-9600-4b9c-b99b-a310e54d3fd5"
      unitRef="usd">12106435</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9bb28550232b40a6a710d558583695ab_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMzItMy0xLTEtMzY4MjU_1a3d29b4-9684-4233-8db2-2ed9ea33854d"
      unitRef="usd">29214380</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMzMtMS0xLTEtMzY4MjU_3b1fb1f1-bf59-493b-ac16-76f83fefea69"
      unitRef="usd">9273682</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie5a306ceedd2446d93819bfd4e8afbe8_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMzMtMy0xLTEtMzY4MjU_f39696a6-92db-4cee-8536-0807a5a459ef"
      unitRef="usd">24193554</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:StockIssued1
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMzgtMS0xLTEtMzY4MjU_086122a7-b23c-4567-aa43-86f0fe690ddc"
      unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMzgtMy0xLTEtMzY4MjU_2e13adab-662e-4ffe-a1f5-9e039cd0775f"
      unitRef="usd">487900</us-gaap:StockIssued1>
    <flks:StockIssuanceCostsAccruedAndAmortized
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMzktMS0xLTEtMzY4MjU_7b44c74b-a341-4e8b-be35-ec2b9773797f"
      unitRef="usd">25000</flks:StockIssuanceCostsAccruedAndAmortized>
    <flks:StockIssuanceCostsAccruedAndAmortized
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yNS9mcmFnOjU4YzQ4YTFhNGIwZjQ2MzFiZDY5ZGM5OTNmNjFjZjZjL3RhYmxlOmY5ZWFmYjAyYTdiMTRmYTA5NzU2NjBmMGVjOWMzMGMzL3RhYmxlcmFuZ2U6ZjllYWZiMDJhN2IxNGZhMDk3NTY2MGYwZWM5YzMwYzNfMzktMy0xLTEtMzY4MjU_59e7a595-ac5b-405b-af2d-bb14574989a5"
      unitRef="usd">0</flks:StockIssuanceCostsAccruedAndAmortized>
    <us-gaap:SharesOutstanding
      contextRef="i2bd45e30d3c0413c9f0cdd01c63fbe3a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMy0xLTEtMS0zNjgyNQ_2a1366b5-2d3f-4996-ad00-b7ad95faefd7"
      unitRef="shares">1809593</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2bd45e30d3c0413c9f0cdd01c63fbe3a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMy0zLTEtMS0zNjgyNQ_69fd9a8a-9250-4243-912e-430c55c3f8fb"
      unitRef="usd">181</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i182fe90a35fa46a4bee4ab0ee69ad6c0_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMy01LTEtMS0zNjgyNQ_32b25822-2b8a-436b-bac1-cdff7813811f"
      unitRef="usd">70919996</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i55a4dc73d8734260b84dd299d02b0bea_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMy03LTEtMS0zNjgyNQ_4ad0240f-e7cf-4af5-bd85-ca955260f8eb"
      unitRef="usd">-32197192</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9bb28550232b40a6a710d558583695ab_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMy05LTEtMS0zNjgyNQ_e372c722-0636-4945-aef8-912b293a794f"
      unitRef="usd">38722985</us-gaap:StockholdersEquity>
    <flks:StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologySharesNewIssues
      contextRef="id9aac0bd35674eb4b2fe9319ccc12b17_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfNC0xLTEtMS0zNjgyNQ_36ccc04f-ed53-4bc7-8afb-63ee0e690cf9"
      unitRef="shares">40000</flks:StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologySharesNewIssues>
    <flks:StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues
      contextRef="id9aac0bd35674eb4b2fe9319ccc12b17_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfNC0zLTEtMS0zNjgyNQ_01929904-d7e7-4548-ac3f-d8508194d487"
      unitRef="usd">4</flks:StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues>
    <flks:StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues
      contextRef="iecc8902a9a25417493c9a87bcde49e28_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfNC01LTEtMS0zNjgyNQ_456b167d-73f9-4e42-97d6-dbc80de71035"
      unitRef="usd">487896</flks:StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues>
    <flks:StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfNC05LTEtMS0zNjgyNQ_df416357-45d8-41f0-ba4c-23b2ac447055"
      unitRef="usd">487900</flks:StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="id9aac0bd35674eb4b2fe9319ccc12b17_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfNS0xLTEtMS0zNjgyNQ_da1e8637-23a1-4776-a948-afe9051b6ae2"
      unitRef="shares">18215</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id9aac0bd35674eb4b2fe9319ccc12b17_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfNS0zLTEtMS0zNjgyNQ_7c994ccd-3b52-4008-b021-c2ccabb527d9"
      unitRef="usd">2</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iecc8902a9a25417493c9a87bcde49e28_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfNS01LTEtMS0zNjgyNQ_c508f97f-7c4c-405f-a92a-0a8695c1b0b5"
      unitRef="usd">313901</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfNS05LTEtMS0zNjgyNQ_7d0f4a55-660c-43ab-9965-2a1ccdeb29c5"
      unitRef="usd">313903</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="ie373d68e8a8744798cfdbc196f59d0be_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfNi03LTEtMS0zNjgyNQ_378a173c-6a19-4c34-bfb9-cae9fbbf688d"
      unitRef="usd">-6109225</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfNi05LTEtMS0zNjgyNQ_4e340998-0917-4984-b5f9-d5787c9d5293"
      unitRef="usd">-6109225</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="iafffc62468c54cae91120ea9c81a1bd5_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfNy0xLTEtMS0zNjgyNQ_a40ceaf2-5c03-4ba6-807c-28f418f68747"
      unitRef="shares">1867808</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iafffc62468c54cae91120ea9c81a1bd5_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfNy0zLTEtMS0zNjgyNQ_75310ced-4d4e-4ce8-b66f-b5845ed95ef4"
      unitRef="usd">187</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie4db7a89251f499c92610b04658dc2ae_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfNy01LTEtMS0zNjgyNQ_f37f9484-7768-4734-a163-fa053b77ddc4"
      unitRef="usd">71721793</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie574cf86bfc040409286776e93e62abd_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfNy03LTEtMS0zNjgyNQ_8d25991f-b38d-4b49-94dc-ad886880643b"
      unitRef="usd">-38306417</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie5a306ceedd2446d93819bfd4e8afbe8_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfNy05LTEtMS0zNjgyNQ_8439201c-e981-45a9-bdb2-d708bd4b0df2"
      unitRef="usd">33415563</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i6abf49e74f3942af9362b2fc6b6e5ee0_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMTgtMS0xLTEtMzY4MjU_3f05a607-9226-427f-80f7-9dc8f28403bd"
      unitRef="shares">2255899</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i6abf49e74f3942af9362b2fc6b6e5ee0_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMTgtMy0xLTEtMzY4MjU_0a3b9e55-2ef3-440f-848e-e3d28a956d7e"
      unitRef="usd">225</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ideb363b95bd54426b36e8a3e499e28b9_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMTgtNS0xLTEtMzY4MjU_249b3027-b6dd-4b72-a989-328cca13a4b3"
      unitRef="usd">74189531</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7787220731c9412bb479d54b491fd7eb_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMTgtNy0xLTEtMzY4MjU_9995341b-ac04-4253-b80f-8ae80a4b7750"
      unitRef="usd">-63805148</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i99580c61c8454190b396ed58334ece96_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMTgtOS0xLTEtMzY4MjU_710f4b9a-feb3-4d7e-9673-23011ea93f30"
      unitRef="usd">10384608</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ib594d10fbc6146ba8590e1d37595ffc7_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMTktMS0xLTEtMzY4MjU_6d2015f8-0a20-4572-97b1-c4e22fa499f7"
      unitRef="shares">142499</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib594d10fbc6146ba8590e1d37595ffc7_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMTktMy0xLTEtMzY4MjU_5809fb5d-1d2d-4e4c-b599-cbc5eb809c27"
      unitRef="usd">14</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ibca39c224c4d4c48a68e09a78c6cc957_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMTktNS0xLTEtMzY4MjU_22505180-6f0b-4891-a5aa-6cf2d6544f4f"
      unitRef="usd">311667</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMTktOS0xLTEtMzY4MjU_851f7328-f3f7-4723-ac1b-8436a6d116a1"
      unitRef="usd">311681</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ib594d10fbc6146ba8590e1d37595ffc7_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMjAtMS0xLTEtMzY4MjU_8f02d4e1-ff89-4f14-9f8d-b004858ba7af"
      unitRef="shares">69899</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib594d10fbc6146ba8590e1d37595ffc7_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMjAtMy0xLTEtMzY4MjU_4bed415c-3e98-410b-8770-da8ebd11d574"
      unitRef="usd">7</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ibca39c224c4d4c48a68e09a78c6cc957_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMjAtNS0xLTEtMzY4MjU_7641ff5a-667f-4c52-9776-938fccc05a2f"
      unitRef="usd">203338</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMjAtOS0xLTEtMzY4MjU_9251802f-d864-404d-b30b-808d802bf3c8"
      unitRef="usd">203345</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="iaf6f50e29050415c8e6980f25eeba947_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMjEtNy0xLTEtMzY4MjU_3ab3b152-c6e2-4d13-a8b2-24269e6f226e"
      unitRef="usd">-5340773</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMjEtOS0xLTEtMzY4MjU_ed502bf7-3591-426a-8a54-f2e6c5cda689"
      unitRef="usd">-5340773</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i867fe0652a284dfa8c10e8eea406a8db_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMjItMS0xLTEtMzY4MjU_9f348723-8078-4d5f-8eb3-fffb0626e5bd"
      unitRef="shares">2468297</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i867fe0652a284dfa8c10e8eea406a8db_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMjItMy0xLTEtMzY4MjU_0bc79dd4-498a-4442-83b0-be68f38c8ef4"
      unitRef="usd">246</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i80002a83141a4ef6a0ff3d67ce2967b1_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMjItNS0xLTEtMzY4MjU_38f641e0-b237-4018-a136-714d3298b716"
      unitRef="usd">74704536</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icf1223a5e90f40a8b60ebbab5dbe9e78_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMjItNy0xLTEtMzY4MjU_9aff9a25-76b1-465d-a84a-bbf69a9828a9"
      unitRef="usd">-69145921</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18yOC9mcmFnOmRjNWY1MGQ3YjcwZTRkZTY5NDcwNDA3NzgyODc2ZmIzL3RhYmxlOmQ1NWQ2YmJiNmU4ZjRlOGU4YTU3ZTliZWFhMGZlN2I3L3RhYmxlcmFuZ2U6ZDU1ZDZiYmI2ZThmNGU4ZThhNTdlOWJlYWEwZmU3YjdfMjItOS0xLTEtMzY4MjU_88ebd7a6-9301-4b7e-bf8a-57585f1d116b"
      unitRef="usd">5558861</us-gaap:StockholdersEquity>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18zNC9mcmFnOjE1Mzk4YWVmNzU0MjQ1YjE5MzAyZmFiYTZmMGU5NDg1L3RleHRyZWdpb246MTUzOThhZWY3NTQyNDViMTkzMDJmYWJhNmYwZTk0ODVfNjMxNw_efc108d8-fe1e-4036-877c-e6a639db2bda">ORGANIZATION AND OPERATIONS&lt;div style="margin-bottom:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Nature of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Salarius Pharmaceuticals, Inc. (&#x201c;Salarius&#x201d; or the &#x201c;Company&#x201d;), together with its subsidiaries, Salarius Pharmaceuticals, LLC, Flex Innovation Group LLC, and TK Pharma, Inc., is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical need. Specifically, the Company is developing treatments for cancers caused by dysregulated gene expression, i.e., genes that are incorrectly turned on or off. The Company is developing two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degraders. The Company's technologies have the potential to work in both liquid and solid tumors. The Company's current pipeline consists of two small molecule drugs: 1) SP-3164, a targeted protein degrader, and 2)  seclidemstat (SP-2577), a targeted protein inhibitor. The Company is located in Houston, Texas. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Going Concern&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Salarius has no products approved for commercial sale, has not generated any revenue from product sales to date and has suffered recurring losses from operations since its inception. The lack of revenue from product sales to date and recurring losses from operations since its inception raise substantial doubt as to the Company's ability to continue as a going concern. The accompanying financial statements are prepared using accounting principles generally accepted in the United States applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities should the Company be unable to continue as a going concern. Salarius will require substantial additional capital to fund its research and development expenses related to its pipeline including SP-3164 and seclidemstat. Based on Salarius&#x2019; expected cash requirements, Salarius believes that there is substantial doubt that its existing cash and cash equivalents, will be sufficient to fund its operations through one year from the financial statements' issuance date. The Company intends to obtain additional capital through the sale of equity securities in one or more offerings or through issuances of debt instruments, and may also consider new collaborations or selectively partnering its technology. However, the Company cannot provide any assurance that it will be successful in accomplishing any of its plans. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Recent Developments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%"&gt;Partial Clinical Hold Lifted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 19, 2022, the Company voluntarily paused new patient enrollment in its Phase 1/2 trial of seclidemstat as a treatment for Ewing sarcoma and FET-rearranged sarcomas per protocol design. The pause in new patient enrollment was due to a metastatic FET-rearranged sarcoma patient death that was classified as a suspected unexpected serious adverse reaction (SUSAR). Upon review of the SUSAR and available information by the Company&#x2019;s independent Safety Review Committee for the clinical trial, patients currently receiving seclidemstat treatment may continue treatment after consulting with their physician. During a conference call with the U.S. Food and Drug Administration (FDA) on November 1, 2022, the FDA informed the Company that the agency agreed with the voluntary enrollment pause and, as an administrative action, the FDA provided verbal notification that the Ewing sarcoma and FET-rearranged sarcoma trial was on partial clinical hold. While on partial clinical hold, FDA informed the Company that the pause in patient enrollment shall remain in place and patients currently receiving seclidemstat treatment may continue treatment after consulting with their physician. FDA&#x2019;s clinical hold procedures provide the Company with an administrative process to work with the FDA to analyze the available data, adjust clinical protocols, and make other changes that may be needed in order to restart patient enrollment. The Company adhered to this administrative process and submitted its findings during early April, 2023. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;On May 5, 2023, the Company was notified by FDA that they have completed the review of our submission and have concluded that the clinical trial may be resumed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%"&gt;Common Stock Issued Under At the Market Offering Agreement &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 5, 2021, the Company entered into an At the Market Offering Agreement (the &#x201c;Sales Agreement&#x201d;) with Ladenburg Thalmann &amp;amp; Co. Inc. (&#x201c;Ladenburg&#x201d;). Under the Sales Agreement the Company was able to issue and sell, from time to time, shares of its common stock (the &#x201c;ATM Shares&#x201d;) with Ladenburg acting as an agent for sales. Sales of the ATM Shares may be made by any method permitted by law deemed to be an &#x201c;at the market offering&#x201d; as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended, including, without limitation, sales made directly on or through the Nasdaq Capital Market. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;From April 4, 2023 to May 11, 2023, the Company sold 527,672 ATM shares of its common shares with gross proceeds of approximately $1.3&#160;million &lt;/span&gt;under the Sales Agreement.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i1c04e18316394009b6153f59ba41f585_D20230404-20230511"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18zNC9mcmFnOjE1Mzk4YWVmNzU0MjQ1YjE5MzAyZmFiYTZmMGU5NDg1L3RleHRyZWdpb246MTUzOThhZWY3NTQyNDViMTkzMDJmYWJhNmYwZTk0ODVfODI0NjMzNzIyNjMyNw_26e445fc-80a2-44e0-b433-90a91f11fb19"
      unitRef="shares">527672</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i1c04e18316394009b6153f59ba41f585_D20230404-20230511"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M18zNC9mcmFnOjE1Mzk4YWVmNzU0MjQ1YjE5MzAyZmFiYTZmMGU5NDg1L3RleHRyZWdpb246MTUzOThhZWY3NTQyNDViMTkzMDJmYWJhNmYwZTk0ODVfODI0NjMzNzIyNjMzNg_b48baef0-d44a-455a-a96b-deb81778be7a"
      unitRef="usd">1300000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfMTI4OTg_54aee388-f299-48c9-9dc8-761bb1ae34b1">BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standard Codification ("ASC") and Accounting Standards Update ("ASU") of the Financial Accounting Standards Board ("FASB").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 14, 2022, the Company filed a Certificate of Amendment to the Company&#x2019;s restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-25 reverse stock split of the Company&#x2019;s issued and outstanding shares of common stock, par value $0.0001 per share (the &#x201c;Reverse Stock Split&#x201d;), which became effective on October 14, 2022. All historical share and per share amounts reflected throughout this report have been adjusted to reflect the Reverse Stock Split.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Unaudited Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim financial statements are unaudited. These unaudited interim financial statements have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim financial information. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. These unaudited interim financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended December&#160;31, 2022 included elsewhere in the Company's Annual Report on Form 10-K filed with the SEC on March 27, 2023. In the opinion of management, the unaudited interim financial statements reflect all the adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company&#x2019;s financial position as of March&#160;31, 2023 and the results of operations for the three months ended March&#160;31, 2023 and 2022. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. The December&#160;31, 2022 balance sheet included herein was derived from the audited financial statements, but does not include all disclosures, including notes, required by GAAP for complete financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America as defined by the FASB ASC requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Salarius considers all highly liquid investments with original maturities of three months or less to be cash equivalents. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that their carrying value may not be recoverable. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. There were no impairment charges related to long-lived assets for the three months ended March&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial Instruments and Credit Risks&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to credit risk include cash and cash equivalents and restricted cash. Cash is deposited in demand accounts in federally insured domestic institutions to minimize risk. Insurance is provided through the Federal Deposit Insurance Corporation. Although the balances in these accounts exceed the federally insured limit from time to time, the Company has not incurred losses related to these deposits.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether warrants should be classified as a liability or equity. For warrants classified as liabilities, the Company estimates the fair value of the warrants at each reporting period using Level 3 inputs with changes in fair value recorded in the Condensed Consolidated Statement of Operations within change in fair value of warrant liability. The estimates in valuation models are based, in part, on subjective assumptions, including but not limited to stock price volatility, the expected life of the warrants, the risk-free interest rate and the fair value of the common stock underlying the warrants, and could differ materially in the future. The Company will continue to adjust the fair value of the warrant liability at the end of each reporting period for changes in fair value from the prior period until the earlier of the exercise or expiration of the applicable warrant. For warrants classified as equity contracts, the Company allocates the transaction proceeds to the warrants and any other free-standing instruments issued in the transaction based on an allowable allocation method.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Clinical Trial Accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s preclinical and clinical trials are performed by third party contract research organizations ("CROs") and/or clinical investigators, and clinical supplies are manufactured by contract manufacturing organizations ("CMOs"). Invoicing from these third parties may be monthly based upon services performed or based upon milestones achieved. The Company accrues these expenses based upon its assessment of the status of each clinical trial and the work completed, and upon information obtained from the CROs and CMOs. The Company&#x2019;s estimates are dependent upon the timeliness and accuracy of data provided by the CROs and CMOs regarding the status and cost of the studies, and may not match the actual services performed by the organizations. This could result in adjustments to the Company&#x2019;s research and development expenses in future periods. To date the Company has had no significant adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Grants Receivable and Revenue &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Salarius&#x2019; source of revenue has been from a grant received from CPRIT. Grant revenue is recognized when qualifying costs are incurred and there is reasonable assurance that conditions of the grant have been met. Cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Research and development costs consist of expenses incurred in performing research and development activities, including pre-clinical studies and clinical trials. Research and development costs include salaries and personnel-related costs, consulting fees, fees paid for contract research services, the costs of laboratory equipment and facilities, license fees and other external costs. Research and development costs are expensed when incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Costs incurred in obtaining in-process research and development ("IPRD") that has no alternative future use are charged to research and development expense as acquired, and presented as investing activity cash outflows on the Statement of Cash Flow.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Equity-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Salarius measures equity-based compensation based on the grant date fair value of the awards and recognizes the associated expense in the financial statements over the requisite service period of the award, which is generally the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the Black-Scholes option valuation model to estimate the fair value of stock options granted to employees and directors. Assumptions utilized in these models including expected volatility calculated based on implied volatility from traded stocks of peer companies, dividend yield and risk-free interest rate. Additionally, forfeitures are accounted for in compensation cost as they occur. Restricted stock and restricted stock units granted to employees and directors are measured at fair value based upon the closing price of the Company's common stock on the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing the net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods, as the inclusion of all potential common shares outstanding is anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The number of anti-dilutive shares, consisting of common shares underlying (i) common stock options, (ii) stock purchase warrants, (iii) rights entitling holders to receive warrants to purchase the Company's common shares, and (iv) restricted stock units which have been excluded from the computation of diluted loss per share, was approximately 716,840 and 431,407 shares as of March&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are recorded in accordance with FASB ASC Topic 740, Income Taxes ("ASC 740"), which provides for deferred taxes using an asset and liability approach. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and the tax reporting basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized. The Company has evaluated available evidence and concluded that the Company may not realize the benefit of its deferred tax assets; therefore, a valuation allowance has been established for the full amount of the deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. As of March&#160;31, 2023 and December&#160;31, 2022, the Company did not have any significant uncertain tax positions and no interest or penalties have been charged. The Company's practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company is subject to routine audits by taxing jurisdictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisition and Strategic Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 12, 2022, the Company entered into an Acquisition and Strategic Collaboration Agreement (the &#x201c;ASCA&#x201d;), with DeuteRx, LLC, a Delaware limited liability company (the &#x201c;DeuteRx&#x201d;), pursuant to which DeuteRx agreed to sell, and the Company agreed to purchase and assume from DeuteRx, all of DeuteRx&#x2019;s rights, title, and interest in and to certain assets of DeuteRx, including SP-3164, DeuteRx&#x2019;s intellectual property, information and data related to SP-3164, tangible materials or reagents related to SP-3164, goodwill, rights and claims, other than certain excluded assets (collectively, the &#x201c;Purchased Assets&#x201d;), all as more specifically set forth in the ASCA, and assume certain assumed liabilities, upon the terms and subject to the conditions set forth in the ASCA. The Aggregate purchase price paid under the ASCA was $2.0&#160;million consisting of $1.5 million cash payment and the delivery of 40,000 shares of the Company's common stock, valued at $0.5 million. Total cost incurred in obtaining IPRD that has no alternative future use are charged to research and development expense as acquired, and presented as investing activity cash outflow on the Statement of Cash Flow. In addition, the Company agreed to pay to DeuteRx potential future milestone payments upon the occurrence of an applicable Milestone Event (as defined in the ASCA) and potential future royalty payments. A member of the Company&#x2019;s Board of Directors also serves as a consultant to DeuteRx and is employed by an affiliate of DeuteRx.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Recently Adopted Accounting Standard&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments &#x2014; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires the measurement of all expected credit losses for financial assets including trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Subsequent to the issuance of ASU 2016-13, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments - Credit Losses. This ASU does not change the core principle of the guidance in ASU 2016-13, instead these amendments are intended to clarify and improve operability of certain topics included within the credit losses guidance. The FASB also subsequently issued ASU No. 2019-04, Codification Improvements to Topic 326, Financial Instruments&#x2014;Credit Losses, Derivatives and Hedging (Topic 815), and Financial Instruments (Topic 825), which did not change the core principle of the guidance in ASU 2016-13 but clarified that expected recoveries of amounts previously written off and expected to be written off should be included in the valuation account and should not exceed amounts previously written off and expected to be written off. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019 for public business entities, excluding smaller reporting companies. Early adoption is permitted. As a smaller reporting company, the guidance was effective for the Company on January 1, 2023. The adoption of this standard did not have a material impact to this Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfMTI4OTk_b4ecafec-b940-458f-bbe4-9efeba698aa7">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standard Codification ("ASC") and Accounting Standards Update ("ASU") of the Financial Accounting Standards Board ("FASB").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 14, 2022, the Company filed a Certificate of Amendment to the Company&#x2019;s restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-25 reverse stock split of the Company&#x2019;s issued and outstanding shares of common stock, par value $0.0001 per share (the &#x201c;Reverse Stock Split&#x201d;), which became effective on October 14, 2022. All historical share and per share amounts reflected throughout this report have been adjusted to reflect the Reverse Stock Split.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ib514cd02604141cba330abbb11971983_I20221014"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfMTA5OTUxMTY0NjEyMQ_c0cdb240-f6ce-4e0f-9dc6-afaa43e5bc41"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfMTI5MTQ_f8a53db1-9a54-453a-a5dc-d6163779f163">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfMTI5MDU_d6ac7d4d-0ce6-4ef7-a0ec-2a54121a9354">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America as defined by the FASB ASC requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfMTI5MDY_27cc9e68-0e9b-446d-8fa1-3b7ed63e89ce">Cash and Cash EquivalentsSalarius considers all highly liquid investments with original maturities of three months or less to be cash equivalents.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfMTI5MTY_464ec7dc-0c00-43e7-a938-e26425d7080b">Impairment of Long-Lived AssetsLong-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that their carrying value may not be recoverable. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfMTA5OTUxMTY0MzQxMA_52c07baf-5a9e-4289-ac0e-02b2abb580c8"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfMTA5OTUxMTY0MzQxMA_bd56aa26-1d19-4766-b626-c5cef5fd9ae5"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfMTI5MDc_b188e384-0a96-45cc-aee3-77926d3584cb">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial Instruments and Credit Risks&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to credit risk include cash and cash equivalents and restricted cash. Cash is deposited in demand accounts in federally insured domestic institutions to minimize risk. Insurance is provided through the Federal Deposit Insurance Corporation. Although the balances in these accounts exceed the federally insured limit from time to time, the Company has not incurred losses related to these deposits.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfMTI5MTA_9390f09a-7a12-4fa9-b5a6-9131e88b1849">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether warrants should be classified as a liability or equity. For warrants classified as liabilities, the Company estimates the fair value of the warrants at each reporting period using Level 3 inputs with changes in fair value recorded in the Condensed Consolidated Statement of Operations within change in fair value of warrant liability. The estimates in valuation models are based, in part, on subjective assumptions, including but not limited to stock price volatility, the expected life of the warrants, the risk-free interest rate and the fair value of the common stock underlying the warrants, and could differ materially in the future. The Company will continue to adjust the fair value of the warrant liability at the end of each reporting period for changes in fair value from the prior period until the earlier of the exercise or expiration of the applicable warrant. For warrants classified as equity contracts, the Company allocates the transaction proceeds to the warrants and any other free-standing instruments issued in the transaction based on an allowable allocation method.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfMTI5MDE_e6f4f27d-a91d-4042-9259-9d2d1bcf725e">Grants Receivable and Revenue Salarius&#x2019; source of revenue has been from a grant received from CPRIT. Grant revenue is recognized when qualifying costs are incurred and there is reasonable assurance that conditions of the grant have been met. Cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred.</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfMTI5MTc_137ebf48-ddbd-45f2-bd28-7e73980d4602">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Research and development costs consist of expenses incurred in performing research and development activities, including pre-clinical studies and clinical trials. Research and development costs include salaries and personnel-related costs, consulting fees, fees paid for contract research services, the costs of laboratory equipment and facilities, license fees and other external costs. Research and development costs are expensed when incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Costs incurred in obtaining in-process research and development ("IPRD") that has no alternative future use are charged to research and development expense as acquired, and presented as investing activity cash outflows on the Statement of Cash Flow.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfMTI5MTI_091069de-46da-45c4-9ab5-c97c841d15c4">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Equity-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Salarius measures equity-based compensation based on the grant date fair value of the awards and recognizes the associated expense in the financial statements over the requisite service period of the award, which is generally the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the Black-Scholes option valuation model to estimate the fair value of stock options granted to employees and directors. Assumptions utilized in these models including expected volatility calculated based on implied volatility from traded stocks of peer companies, dividend yield and risk-free interest rate. Additionally, forfeitures are accounted for in compensation cost as they occur. Restricted stock and restricted stock units granted to employees and directors are measured at fair value based upon the closing price of the Company's common stock on the grant date.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfMTI5MTg_7fbdaf78-93db-47c8-8aaa-86ddcc74aa9b">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing the net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods, as the inclusion of all potential common shares outstanding is anti-dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfNjA0NzMxMzk2NzQ1OQ_7c349615-c9bd-4a95-89ed-299d23165d66"
      unitRef="shares">716840</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfNjA0NzMxMzk2NzQ2Mw_bfa0afc9-3693-46ce-ac83-ea7125fe3436"
      unitRef="shares">431407</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfMTI5MDI_4e064b26-5d0f-4bac-aacf-0a368d05015a">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are recorded in accordance with FASB ASC Topic 740, Income Taxes ("ASC 740"), which provides for deferred taxes using an asset and liability approach. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and the tax reporting basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized. The Company has evaluated available evidence and concluded that the Company may not realize the benefit of its deferred tax assets; therefore, a valuation allowance has been established for the full amount of the deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. As of March&#160;31, 2023 and December&#160;31, 2022, the Company did not have any significant uncertain tax positions and no interest or penalties have been charged. The Company's practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company is subject to routine audits by taxing jurisdictions.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <flks:PaymentsForAcquisitionAndStrategicCollaborationAgreement
      contextRef="i5a151b2cc8444c79aee3f783063d9279_D20220112-20220112"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfNTQ5NzU1ODE1NTQ1NA_68380c53-89cb-497f-97fd-ed79c527c30d"
      unitRef="usd">2000000</flks:PaymentsForAcquisitionAndStrategicCollaborationAgreement>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="i5a151b2cc8444c79aee3f783063d9279_D20220112-20220112"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfNTQ5NzU1ODE1NTQ3Mg_1244dc2b-a144-4b42-9009-f35cfb09a1f1"
      unitRef="usd">1500000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ie6b59e45b64342c89f3426880dc1103d_D20220112-20220112"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfNTQ5NzU1ODE1NTUxNw_bb7226e2-e862-496e-9e6a-948f1a6f348b"
      unitRef="shares">40000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5a151b2cc8444c79aee3f783063d9279_D20220112-20220112"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfNTQ5NzU1ODE1NTU2OQ_81501b6d-79a7-4ab4-abf6-e4f787749a2f"
      unitRef="usd">500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180MC9mcmFnOmZjYzZlMTc3NGU2ZjRhN2Y5NmQ5ZTAyZDI5ZjhhNThkL3RleHRyZWdpb246ZmNjNmUxNzc0ZTZmNGE3Zjk2ZDllMDJkMjlmOGE1OGRfMTI5MDM_83152e3a-47c1-4041-b41a-63b7ae292718">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Recently Adopted Accounting Standard&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments &#x2014; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires the measurement of all expected credit losses for financial assets including trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Subsequent to the issuance of ASU 2016-13, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments - Credit Losses. This ASU does not change the core principle of the guidance in ASU 2016-13, instead these amendments are intended to clarify and improve operability of certain topics included within the credit losses guidance. The FASB also subsequently issued ASU No. 2019-04, Codification Improvements to Topic 326, Financial Instruments&#x2014;Credit Losses, Derivatives and Hedging (Topic 815), and Financial Instruments (Topic 825), which did not change the core principle of the guidance in ASU 2016-13 but clarified that expected recoveries of amounts previously written off and expected to be written off should be included in the valuation account and should not exceed amounts previously written off and expected to be written off. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019 for public business entities, excluding smaller reporting companies. Early adoption is permitted. As a smaller reporting company, the guidance was effective for the Company on January 1, 2023. The adoption of this standard did not have a material impact to this Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180My9mcmFnOmYzMmU2MjZkZGQzYzQ5MDNiOTRlNzRlNTA4Y2EwYzg5L3RleHRyZWdpb246ZjMyZTYyNmRkZDNjNDkwM2I5NGU3NGU1MDhjYTBjODlfMzEx_e96ed984-46bf-45f0-b025-a282d4b7dafd">GRANT RECEIVABLE FROM CPRIT&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Grants receivable represents qualifying costs incurred where there is reasonable assurance that conditions of the grant have been met but the corresponding funds have not been received as of the reporting date. Grants receivable balances are $0.1 million and $1.6 million  at both March&#160;31, 2023 and December&#160;31, 2022. During the three&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended March&#160;31, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the &lt;/span&gt;Company received $1.5 million from CPRIT.</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:GrantsReceivableCurrent
      contextRef="i939615b57778416faf3eff53296b4db2_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180My9mcmFnOmYzMmU2MjZkZGQzYzQ5MDNiOTRlNzRlNTA4Y2EwYzg5L3RleHRyZWdpb246ZjMyZTYyNmRkZDNjNDkwM2I5NGU3NGU1MDhjYTBjODlfMjgz_77206f02-d560-483c-84e5-7a68dd643701"
      unitRef="usd">100000</us-gaap:GrantsReceivableCurrent>
    <us-gaap:GrantsReceivableCurrent
      contextRef="if54e5126787f42138fb230f8a7f23b49_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180My9mcmFnOmYzMmU2MjZkZGQzYzQ5MDNiOTRlNzRlNTA4Y2EwYzg5L3RleHRyZWdpb246ZjMyZTYyNmRkZDNjNDkwM2I5NGU3NGU1MDhjYTBjODlfNjA0NzMxMzk1MzA4Nw_3a87a6b2-eb52-4c59-b659-9a616cd76fcc"
      unitRef="usd">1600000</us-gaap:GrantsReceivableCurrent>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180My9mcmFnOmYzMmU2MjZkZGQzYzQ5MDNiOTRlNzRlNTA4Y2EwYzg5L3RleHRyZWdpb246ZjMyZTYyNmRkZDNjNDkwM2I5NGU3NGU1MDhjYTBjODlfODI0NjMzNzIwODgwMA_f80161ef-bab2-4e5a-8380-aefa9856ba58"
      unitRef="usd">-1500000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:OtherCurrentAssetsTextBlock
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180Ni9mcmFnOjM0NGIyMDE3MGM3MjQzOGFiZTQ5NmQ4ZTYxZmQzNmZhL3RleHRyZWdpb246MzQ0YjIwMTcwYzcyNDM4YWJlNDk2ZDhlNjFmZDM2ZmFfMjI2_d6ca2b65-8ea8-4c86-851c-c5d2a4f7fb63">PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets at March&#160;31, 2023 and December&#160;31, 2022 consisted of the following: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.323%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid clinical trial expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;624,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid and current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;803,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid insurance is mainly comprised of prepaid directors' and officers' insurance.&lt;/span&gt;&lt;/div&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180Ni9mcmFnOjM0NGIyMDE3MGM3MjQzOGFiZTQ5NmQ4ZTYxZmQzNmZhL3RleHRyZWdpb246MzQ0YjIwMTcwYzcyNDM4YWJlNDk2ZDhlNjFmZDM2ZmFfMjMx_9d2efd0c-8765-4210-bef1-5190f78876ca">&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets at March&#160;31, 2023 and December&#160;31, 2022 consisted of the following: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.323%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid clinical trial expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;624,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid and current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;803,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <flks:PrepaidClinicalTrialExpense
      contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180Ni9mcmFnOjM0NGIyMDE3MGM3MjQzOGFiZTQ5NmQ4ZTYxZmQzNmZhL3RhYmxlOjYzMzBlYmUxMDg5ZTRiNDNiMDIxMDFlOGRmNWJmZWNlL3RhYmxlcmFuZ2U6NjMzMGViZTEwODllNGI0M2IwMjEwMWU4ZGY1YmZlY2VfMS0xLTEtMS0zNjgyNQ_7c241052-623e-4dbe-a21f-d17541ae51b3"
      unitRef="usd">11185</flks:PrepaidClinicalTrialExpense>
    <flks:PrepaidClinicalTrialExpense
      contextRef="i99580c61c8454190b396ed58334ece96_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180Ni9mcmFnOjM0NGIyMDE3MGM3MjQzOGFiZTQ5NmQ4ZTYxZmQzNmZhL3RhYmxlOjYzMzBlYmUxMDg5ZTRiNDNiMDIxMDFlOGRmNWJmZWNlL3RhYmxlcmFuZ2U6NjMzMGViZTEwODllNGI0M2IwMjEwMWU4ZGY1YmZlY2VfMS0zLTEtMS0zNjgyNQ_09cd75ce-0261-4b5b-84c9-9747c0b0c5b7"
      unitRef="usd">11185</flks:PrepaidClinicalTrialExpense>
    <us-gaap:PrepaidInsurance
      contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180Ni9mcmFnOjM0NGIyMDE3MGM3MjQzOGFiZTQ5NmQ4ZTYxZmQzNmZhL3RhYmxlOjYzMzBlYmUxMDg5ZTRiNDNiMDIxMDFlOGRmNWJmZWNlL3RhYmxlcmFuZ2U6NjMzMGViZTEwODllNGI0M2IwMjEwMWU4ZGY1YmZlY2VfMi0xLTEtMS0zNjgyNQ_e4aad881-5cec-4338-a4f6-bbdd101ea1ea"
      unitRef="usd">368931</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="i99580c61c8454190b396ed58334ece96_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180Ni9mcmFnOjM0NGIyMDE3MGM3MjQzOGFiZTQ5NmQ4ZTYxZmQzNmZhL3RhYmxlOjYzMzBlYmUxMDg5ZTRiNDNiMDIxMDFlOGRmNWJmZWNlL3RhYmxlcmFuZ2U6NjMzMGViZTEwODllNGI0M2IwMjEwMWU4ZGY1YmZlY2VfMi0zLTEtMS0zNjgyNQ_1714bad1-d378-40fd-b172-c1dd2266c6c7"
      unitRef="usd">624612</us-gaap:PrepaidInsurance>
    <us-gaap:OtherAssetsCurrent
      contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180Ni9mcmFnOjM0NGIyMDE3MGM3MjQzOGFiZTQ5NmQ4ZTYxZmQzNmZhL3RhYmxlOjYzMzBlYmUxMDg5ZTRiNDNiMDIxMDFlOGRmNWJmZWNlL3RhYmxlcmFuZ2U6NjMzMGViZTEwODllNGI0M2IwMjEwMWU4ZGY1YmZlY2VfNC0xLTEtMS0zNjgyNQ_d98addee-a02c-4969-97e7-d0c3a7649f57"
      unitRef="usd">156509</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i99580c61c8454190b396ed58334ece96_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180Ni9mcmFnOjM0NGIyMDE3MGM3MjQzOGFiZTQ5NmQ4ZTYxZmQzNmZhL3RhYmxlOjYzMzBlYmUxMDg5ZTRiNDNiMDIxMDFlOGRmNWJmZWNlL3RhYmxlcmFuZ2U6NjMzMGViZTEwODllNGI0M2IwMjEwMWU4ZGY1YmZlY2VfNC0zLTEtMS0zNjgyNQ_0d0d1d66-b980-4361-a4f8-ce52586159ad"
      unitRef="usd">167576</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180Ni9mcmFnOjM0NGIyMDE3MGM3MjQzOGFiZTQ5NmQ4ZTYxZmQzNmZhL3RhYmxlOjYzMzBlYmUxMDg5ZTRiNDNiMDIxMDFlOGRmNWJmZWNlL3RhYmxlcmFuZ2U6NjMzMGViZTEwODllNGI0M2IwMjEwMWU4ZGY1YmZlY2VfNS0xLTEtMS0zNjgyNQ_0f0de2e5-4ab8-4777-9cbe-37ec66ae092c"
      unitRef="usd">536625</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i99580c61c8454190b396ed58334ece96_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180Ni9mcmFnOjM0NGIyMDE3MGM3MjQzOGFiZTQ5NmQ4ZTYxZmQzNmZhL3RhYmxlOjYzMzBlYmUxMDg5ZTRiNDNiMDIxMDFlOGRmNWJmZWNlL3RhYmxlcmFuZ2U6NjMzMGViZTEwODllNGI0M2IwMjEwMWU4ZGY1YmZlY2VfNS0zLTEtMS0zNjgyNQ_901aee96-3045-4e3e-8cd7-578142791e10"
      unitRef="usd">803373</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180OS9mcmFnOjVjZGJkOTYzOWNiYjRlZjdhMTM3ZWZkMDY5Y2M1NDdmL3RleHRyZWdpb246NWNkYmQ5NjM5Y2JiNGVmN2ExMzdlZmQwNjljYzU0N2ZfMjI2Ng_4c63fa5d-bc3b-4fd4-bfaf-b94043aa817e">COMMITMENTS AND CONTINGENCIES&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;License Agreement with the University of Utah Research Foundation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2011, the Company entered into a license agreement with the University of Utah, under which, the Company acquired an exclusive license to an epigenetic enzyme lysine specific demethylase 1 ("LSD1"). In exchange for the license, the Company issued 2% equity ownership in the Company based on a fully diluted basis at the effective date of the agreement subject to certain adjustments specified in the agreement, such as granted revenue sharing rights on any resulting products or processes to commence on first commercial sale, and milestone payments based upon regulatory approval of any resulting product or process as well as on the second anniversary of first commercial sale.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cancer Prevention and Research Institute of Texas&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Company entered into a Cancer Research Grant Contract with CPRIT. Pursuant to the contract, CPRIT awarded the Company a grant up to $18.7 million further modified to $16.1&#160;million to fund development of LSD 1 inhibitor. This is a 3-year grant award originally expired on May 31, 2019. The Company applied for a no cost extension through November 30, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will retain ownership over any intellectual property developed under the contract ("Project Result"). With respect to non-commercial use of any Project Result, the Company agreed to grant to CPRIT a nonexclusive, irrevocable, royalty-free, perpetual, worldwide license with right to sublicense any necessary additional intellectual property rights to exploit all Project Results by CPRIT, other governmental entities and agencies of the State of Texas, and private or independent institutions of higher education located in Texas, for education, research and other non-commercial purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is obligated to make revenue-sharing payments to CPRIT with respect to net sales of any product covered by the contract, up to a maximum repayment of certain percentage of the aggregate amount paid to the Company by CPRIT under the CPRIT contract. The payments are determined as a percentage of net sales, which may be reduced if the Company is required to obtain a license from a third party to sell any such product. In addition, upon meeting the foregoing limitation on revenue-sharing payments, the Company agreed to make continued revenue-sharing payments to CPRIT of less than 1% of net sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Lease Agreement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company presently leases office space under operating lease agreements on a month-to-month basis.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="ib62a51e0853048ae9069dab610776a5d_I20111231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180OS9mcmFnOjVjZGJkOTYzOWNiYjRlZjdhMTM3ZWZkMDY5Y2M1NDdmL3RleHRyZWdpb246NWNkYmQ5NjM5Y2JiNGVmN2ExMzdlZmQwNjljYzU0N2ZfMzYx_f89c88a0-7817-4a0d-829d-e1893a5d3e11"
      unitRef="number">0.02</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <flks:RevenueFromGrantsMaximumAward
      contextRef="i3a9d75c4f5bd48619d14c8ca1830a6c9_D20160601-20160630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180OS9mcmFnOjVjZGJkOTYzOWNiYjRlZjdhMTM3ZWZkMDY5Y2M1NDdmL3RleHRyZWdpb246NWNkYmQ5NjM5Y2JiNGVmN2ExMzdlZmQwNjljYzU0N2ZfNjA0NzMxMzk1Nzk1MA_f3a5f303-96a7-4be7-a28a-041a7afc7ab8"
      unitRef="usd">18700000</flks:RevenueFromGrantsMaximumAward>
    <flks:RevenueFromGrantsMaximumAward
      contextRef="i2e86d1fdb89f494eb9ee243d58ff09cd_D20160701-20160701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180OS9mcmFnOjVjZGJkOTYzOWNiYjRlZjdhMTM3ZWZkMDY5Y2M1NDdmL3RleHRyZWdpb246NWNkYmQ5NjM5Y2JiNGVmN2ExMzdlZmQwNjljYzU0N2ZfNjA0NzMxMzk1Nzk4MQ_ec206740-ff9c-4260-bc50-28e51749b0cb"
      unitRef="usd">16100000</flks:RevenueFromGrantsMaximumAward>
    <flks:RevenueFromGrantsAwardTerm
      contextRef="i3a9d75c4f5bd48619d14c8ca1830a6c9_D20160601-20160630"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180OS9mcmFnOjVjZGJkOTYzOWNiYjRlZjdhMTM3ZWZkMDY5Y2M1NDdmL3RleHRyZWdpb246NWNkYmQ5NjM5Y2JiNGVmN2ExMzdlZmQwNjljYzU0N2ZfMTA5OTUxMTYzMzA0Mg_b635d594-0748-4724-b3f6-f45401cab2f1">P3Y</flks:RevenueFromGrantsAwardTerm>
    <flks:RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales
      contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M180OS9mcmFnOjVjZGJkOTYzOWNiYjRlZjdhMTM3ZWZkMDY5Y2M1NDdmL3RleHRyZWdpb246NWNkYmQ5NjM5Y2JiNGVmN2ExMzdlZmQwNjljYzU0N2ZfNjA0NzMxMzk1ODAzMg_09ee84d6-73cd-459e-98a7-45473ab0c2cf"
      unitRef="number">0.01</flks:RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M181Mi9mcmFnOjNkZGYzYjk2OTE1ODQyODE4NmU0NTk0NmY2OWFkNDUyL3RleHRyZWdpb246M2RkZjNiOTY5MTU4NDI4MTg2ZTQ1OTQ2ZjY5YWQ0NTJfMTcwNA_82d7faba-57ea-4e23-b340-e9496ddf122e">FAIR VALUE OF FINANCIAL INSTRUMENTS &lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last is considered unobservable, are used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:76.5pt;text-align:justify;text-indent:-40.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 - Significant unobservable inputs including Salarius&#x2019; own assumptions in determining fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes the recorded values of its financial instruments, including cash and cash equivalents, accounts payable and note payable approximate their fair values due to the short-term nature of these instruments.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M181Mi9mcmFnOjNkZGYzYjk2OTE1ODQyODE4NmU0NTk0NmY2OWFkNDUyL3RleHRyZWdpb246M2RkZjNiOTY5MTU4NDI4MTg2ZTQ1OTQ2ZjY5YWQ0NTJfNTQ5NzU1ODE1NTk0_73a0ff38-243b-4064-8857-580240723e78">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last is considered unobservable, are used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:76.5pt;text-align:justify;text-indent:-40.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 - Significant unobservable inputs including Salarius&#x2019; own assumptions in determining fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes the recorded values of its financial instruments, including cash and cash equivalents, accounts payable and note payable approximate their fair values due to the short-term nature of these instruments.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M181NS9mcmFnOjc2NzhiZjQ2MGYyYjRmYmU4N2UxODRkMzljMWRhN2Q0L3RleHRyZWdpb246NzY3OGJmNDYwZjJiNGZiZTg3ZTE4NGQzOWMxZGE3ZDRfMzU5MA_324ce3d5-e900-46c8-9789-15bcdbdc84b2">STOCKHOLDERS' EQUITY&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Common Stock  Issuances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023, the Company sold 142,499 ATM shares under the Sales Agreement, with gross proceeds of  $0.3 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 12, 2022, the Company issued 40,000 shares of the Company's common stock, valued at $0.5 million to purchase in-process research and development technology SP-3164, please refer to NOTE 2 for further discussion. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants Exercised for Cash &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has five-year warrants outstanding that were issued in February 2020 and subsequently modified in December 2020 in connection with the issuance of additional inducement warrants. The warrants are exercisable at a price per share of $28.75. The inducement warrants expire on June 11, 2026, and are exercisable at a price per share of $29.55. The Company has 5.5 year warrants outstanding that were issued in April 2022, with an exercise price of $8.4975 per share. The warrants will be exercisable six months following the issuance date and will expire five and one-half years from the issuance date. &lt;/span&gt;&lt;/div&gt; As of March&#160;31, 2023 and 2022, approximately 597,512 and 317,329  warrants remain outstanding</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i5f25028dab374645ab8bd704715c06ac_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M181NS9mcmFnOjc2NzhiZjQ2MGYyYjRmYmU4N2UxODRkMzljMWRhN2Q0L3RleHRyZWdpb246NzY3OGJmNDYwZjJiNGZiZTg3ZTE4NGQzOWMxZGE3ZDRfODI0NjMzNzIxNTU4Mg_87031922-e027-490c-8464-7076c00177bc"
      unitRef="shares">142499</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5f25028dab374645ab8bd704715c06ac_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M181NS9mcmFnOjc2NzhiZjQ2MGYyYjRmYmU4N2UxODRkMzljMWRhN2Q0L3RleHRyZWdpb246NzY3OGJmNDYwZjJiNGZiZTg3ZTE4NGQzOWMxZGE3ZDRfODI0NjMzNzIxNTU4Ng_e8e72359-bd05-4202-a8d0-0460c0314489"
      unitRef="usd">300000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <flks:StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologySharesNewIssues
      contextRef="ie6b59e45b64342c89f3426880dc1103d_D20220112-20220112"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M181NS9mcmFnOjc2NzhiZjQ2MGYyYjRmYmU4N2UxODRkMzljMWRhN2Q0L3RleHRyZWdpb246NzY3OGJmNDYwZjJiNGZiZTg3ZTE4NGQzOWMxZGE3ZDRfNjA3_190f20b9-6f82-4400-a6a6-a89caf043a5d"
      unitRef="shares">40000</flks:StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologySharesNewIssues>
    <flks:StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues
      contextRef="ie6b59e45b64342c89f3426880dc1103d_D20220112-20220112"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M181NS9mcmFnOjc2NzhiZjQ2MGYyYjRmYmU4N2UxODRkMzljMWRhN2Q0L3RleHRyZWdpb246NzY3OGJmNDYwZjJiNGZiZTg3ZTE4NGQzOWMxZGE3ZDRfNjU4_245e7b0b-7c04-4336-b34e-6b5a511f5975"
      unitRef="usd">500000</flks:StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i0609f51e976346d69581a350de826fe9_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M181NS9mcmFnOjc2NzhiZjQ2MGYyYjRmYmU4N2UxODRkMzljMWRhN2Q0L3RleHRyZWdpb246NzY3OGJmNDYwZjJiNGZiZTg3ZTE4NGQzOWMxZGE3ZDRfMzU4NQ_4c203b81-3a23-43a0-b782-10008cc49498">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i750c9de36c044f428d626093ca2e218b_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M181NS9mcmFnOjc2NzhiZjQ2MGYyYjRmYmU4N2UxODRkMzljMWRhN2Q0L3RleHRyZWdpb246NzY3OGJmNDYwZjJiNGZiZTg3ZTE4NGQzOWMxZGE3ZDRfMjkxOQ_2b00b63a-e8a6-40fe-82ac-7ad131475c11"
      unitRef="usdPerShare">28.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i0609f51e976346d69581a350de826fe9_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M181NS9mcmFnOjc2NzhiZjQ2MGYyYjRmYmU4N2UxODRkMzljMWRhN2Q0L3RleHRyZWdpb246NzY3OGJmNDYwZjJiNGZiZTg3ZTE4NGQzOWMxZGE3ZDRfMzAxNg_13e24570-c01e-4c6b-b89b-24e03519f830"
      unitRef="usdPerShare">29.55</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i222ce181634a4cce9e9e36ac4ca82e0f_I20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M181NS9mcmFnOjc2NzhiZjQ2MGYyYjRmYmU4N2UxODRkMzljMWRhN2Q0L3RleHRyZWdpb246NzY3OGJmNDYwZjJiNGZiZTg3ZTE4NGQzOWMxZGE3ZDRfMzAzNg_f8bf928f-28f5-46c4-b227-d4f396d2b5ac">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ib762f099224741f2a7a409f28e07d108_I20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M181NS9mcmFnOjc2NzhiZjQ2MGYyYjRmYmU4N2UxODRkMzljMWRhN2Q0L3RleHRyZWdpb246NzY3OGJmNDYwZjJiNGZiZTg3ZTE4NGQzOWMxZGE3ZDRfMzExOQ_247ae3af-9512-4d3e-9fa7-53ef4d822000"
      unitRef="usdPerShare">8.4975</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <flks:WarrantsAndRightsExercisableTerm
      contextRef="i222ce181634a4cce9e9e36ac4ca82e0f_I20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M181NS9mcmFnOjc2NzhiZjQ2MGYyYjRmYmU4N2UxODRkMzljMWRhN2Q0L3RleHRyZWdpb246NzY3OGJmNDYwZjJiNGZiZTg3ZTE4NGQzOWMxZGE3ZDRfMzE2Ng_7cd87de0-3034-4414-b0be-f23dde496d35">P6M</flks:WarrantsAndRightsExercisableTerm>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M181NS9mcmFnOjc2NzhiZjQ2MGYyYjRmYmU4N2UxODRkMzljMWRhN2Q0L3RleHRyZWdpb246NzY3OGJmNDYwZjJiNGZiZTg3ZTE4NGQzOWMxZGE3ZDRfNzA3NQ_e5dab0a4-6c5c-4f43-b2ea-09da21f82338"
      unitRef="shares">597512</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ie5a306ceedd2446d93819bfd4e8afbe8_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M181NS9mcmFnOjc2NzhiZjQ2MGYyYjRmYmU4N2UxODRkMzljMWRhN2Q0L3RleHRyZWdpb246NzY3OGJmNDYwZjJiNGZiZTg3ZTE4NGQzOWMxZGE3ZDRfODI0NjMzNzIxNTM5OA_b68c59d6-9649-4a6d-bd25-24a1e6c282a2"
      unitRef="shares">317329</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfMjM3Mg_7ce09831-72c3-4c65-b2b0-c8f8dad4ec0e">EQUITY-BASED COMPENSATION &lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity Incentive Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has granted options to employees, directors, and consultants under the 2015 Equity Incentive Plan (the "2015 Plan"). The 2015 Plan provides for the grant of incentive stock options ("ISOs"), nonstatutory stock options, restricted stock awards, restricted stock units, stock appreciation rights, performance-based stock awards and other stock-based awards. Additionally, the 2015 Plan provides for the grant of performance-based cash awards. ISOs may be granted only to the Company's employees. All other awards may be granted to the Company's employees, including officers, and to non-employee directors and consultants. As of March&#160;31, 2023, there were approximately 55,365 shares remaining available for the grant of option awards under the 2015 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023, the Company awarded 12,220 restricted stock units to its employees and 36,640 restricted stock awards to its officers and directors, pursuant to the plan described above. Both the restricted stock units and restricted stock awards are valued at the closing price $1.57 of the Company's common stock on the grant date, and generally vest over &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfODI0NjMzNzIxMTc2Ng_92999dea-8fe6-44eb-b277-ca85e4d4df2d"&gt;one&lt;/span&gt; to four years. Total fair value of the restricted stock awards and restricted stock units awarded during the  three months periods ended March&#160;31, 2023 is $76,679. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three-month periods ended March&#160;31, 2023 and 2022, the Company awarded 0 and 50,160 stock options, to its employees and directors, pursuant to the plan described above. Stock options generally vest over &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfMTAyMQ_c80ce869-a2e6-4296-953f-d1a3e4d42122"&gt;one&lt;/span&gt; to four years and have a contractual term of ten years. Stock options are valued using the Black-Scholes option pricing model and compensation cost is recognized based on the resulting value over the service period. Expected volatilities utilized in the model are based on implied volatilities from traded stocks of peer companies. Similarly, the dividend yield is based on historical experience and the estimate of future dividend yields. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The expected term of the options is based on the average period the stock options are expected to remain outstanding. The fair value of the option grants awarded during the three months periods ended March&#160;31, 2022 was $0.5 million, which has been estimated with the following assumptions on the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.128%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.62%-1.70%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125.19% 126.42%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (years)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00-6.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for employees and non-employees for the three months ended March&#160;31, 2023 and 2022: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.755%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.04&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of both March&#160;31, 2023 and 2022, there was approximately $0.7 and $1.0 million of total unrecognized compensation cost related to unvested stock options,. Total unrecognized compensation cost will be adjusted for future changes in employee and non-employee forfeitures, if any. The Company expects to recognize that cost over a remaining weighted-average period of 1.9 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ic4da1d17c34948158531999f1b199116_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfNzMx_30221af4-bbb6-4e7c-9871-3a53e5ac0c66"
      unitRef="shares">55365</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i057e962232c1423ba944409a49a5dbbe_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfODI0NjMzNzIxMTU5MQ_ef75b123-8ddd-4982-8609-1f078f339a2c"
      unitRef="shares">12220</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i571227b74c3343649a8d063d182cb2fc_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfODI0NjMzNzIxMTYwOA_8d570bba-ccf3-4adf-8f02-78ea884d5052"
      unitRef="shares">36640</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0508e6c8ee6f431281f539250baa1ab9_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfODI0NjMzNzIxMTYxNg_de8bb705-0163-4c68-9918-49cf85ec1bf7"
      unitRef="usdPerShare">1.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i2ae8b02bb35841958964d4e4837cd194_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfODI0NjMzNzIxMTc4NQ_5ee748a0-f35e-4684-abe1-9535a0e10292">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i0508e6c8ee6f431281f539250baa1ab9_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfODI0NjMzNzIxMTU5OQ_94ac3c29-9acb-4db4-b720-44b1e5cef86d"
      unitRef="usd">76679</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfODc4_178060ce-2435-44fe-b491-9dd286246549"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfMTA5OTUxMTYzMTIxMQ_5804e9fc-3530-472e-84fb-b0f4cbb27571"
      unitRef="shares">50160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i576cab9bf4214c329f021a9b27484527_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfMTAyNw_cf93f03d-f28b-49f2-ac6f-e094e362e9ba">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i15eb79ec74594262ac1ee2bbbcb2dc8b_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfMTA2MQ_67d7a525-386e-4df0-a449-de8371444e1c">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfMTc3NA_3a4fb6fd-a47a-4954-85c5-63a7991c6378"
      unitRef="usd">500000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfMjM2NQ_97c75e52-5d6d-4ee9-bf98-2bd1df7f4d0a">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.128%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.62%-1.70%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125.19% 126.42%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (years)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00-6.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjczMzQ4MWQwMjg0ZjRmOGU4MWUxZWQ1NDA1MTRkMDk1L3RhYmxlcmFuZ2U6NzMzNDgxZDAyODRmNGY4ZTgxZTFlZDU0MDUxNGQwOTVfMi0xLTEtMS0zNjgyNS90ZXh0cmVnaW9uOjE0MTg0YmU2MzFiOTQ3MTI5NzQyMGNjYjQwMGI4NGYyXzQ_caf70a3b-2045-4c03-87fe-934ab09d748a"
      unitRef="number">0.0162</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjczMzQ4MWQwMjg0ZjRmOGU4MWUxZWQ1NDA1MTRkMDk1L3RhYmxlcmFuZ2U6NzMzNDgxZDAyODRmNGY4ZTgxZTFlZDU0MDUxNGQwOTVfMi0xLTEtMS0zNjgyNS90ZXh0cmVnaW9uOjE0MTg0YmU2MzFiOTQ3MTI5NzQyMGNjYjQwMGI4NGYyXzc_3c157b2e-a044-48ec-ac9b-523765276284"
      unitRef="number">0.0170</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjczMzQ4MWQwMjg0ZjRmOGU4MWUxZWQ1NDA1MTRkMDk1L3RhYmxlcmFuZ2U6NzMzNDgxZDAyODRmNGY4ZTgxZTFlZDU0MDUxNGQwOTVfMy0xLTEtMS0zNjgyNS90ZXh0cmVnaW9uOmM0MjdhZjhiNjYzYTQyNDE5ZDk3YTdkMzVlZjU1OWQ4XzQ_ae511a0e-40ad-4201-baa8-bca14893f428"
      unitRef="number">1.2519</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjczMzQ4MWQwMjg0ZjRmOGU4MWUxZWQ1NDA1MTRkMDk1L3RhYmxlcmFuZ2U6NzMzNDgxZDAyODRmNGY4ZTgxZTFlZDU0MDUxNGQwOTVfMy0xLTEtMS0zNjgyNS90ZXh0cmVnaW9uOmM0MjdhZjhiNjYzYTQyNDE5ZDk3YTdkMzVlZjU1OWQ4Xzc_f72b1c67-8a7a-478d-b06f-b8874879511d"
      unitRef="number">1.2642</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i63818b7d4b4049b2b5649dd59933606d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjczMzQ4MWQwMjg0ZjRmOGU4MWUxZWQ1NDA1MTRkMDk1L3RhYmxlcmFuZ2U6NzMzNDgxZDAyODRmNGY4ZTgxZTFlZDU0MDUxNGQwOTVfNC0xLTEtMS0zNjgyNS90ZXh0cmVnaW9uOjFlODZiOWIyNTZkMTRmOGQ5ZWM3NmI2ZmY5ODJhMmE4XzQ_fe678a6b-ba10-4e93-8b81-bfc14dd344a3">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i6ca10793f84f44ba8ea25c255a1b8295_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjczMzQ4MWQwMjg0ZjRmOGU4MWUxZWQ1NDA1MTRkMDk1L3RhYmxlcmFuZ2U6NzMzNDgxZDAyODRmNGY4ZTgxZTFlZDU0MDUxNGQwOTVfNC0xLTEtMS0zNjgyNS90ZXh0cmVnaW9uOjFlODZiOWIyNTZkMTRmOGQ5ZWM3NmI2ZmY5ODJhMmE4Xzc_63220191-fb5f-4aaf-9df2-ee6d010afec9">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjczMzQ4MWQwMjg0ZjRmOGU4MWUxZWQ1NDA1MTRkMDk1L3RhYmxlcmFuZ2U6NzMzNDgxZDAyODRmNGY4ZTgxZTFlZDU0MDUxNGQwOTVfNS0xLTEtMS0zNjgyNQ_4df3f292-d27b-4e4b-a482-93f884d71ca4"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfMjM2Ng_ac78d169-47af-4c7b-a5d4-c919463baeb6">&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for employees and non-employees for the three months ended March&#160;31, 2023 and 2022: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.755%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.04&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i9bb28550232b40a6a710d558583695ab_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfOS0xLTEtMS0zNjgyNQ_d688b2dc-fed4-4b10-92b0-aba4709719fc"
      unitRef="shares">63919</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i9bb28550232b40a6a710d558583695ab_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfOS0zLTEtMS0zNjgyNQ_0fec19b0-4379-43a4-b9bb-6df1cc4a357c"
      unitRef="usdPerShare">68.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ib8708a10429e4617bd4cd3efa5411eee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfOS01LTEtMS0zNjgyNQ_8465303d-1dd6-4b12-899c-bf041c8ba2f1">P8Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i9bb28550232b40a6a710d558583695ab_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfOS03LTEtMS0zNjgyNQ_22cd097a-83ee-4823-bef6-f28641a3e324"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTAtMS0xLTEtMzY4MjU_403ee475-90d5-4ff2-b036-600cdd1866b0"
      unitRef="shares">50160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTAtMy0xLTEtMzY4MjU_be478a31-4151-493c-8b84-0d7c2c84968f"
      unitRef="usdPerShare">12.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTEtMS0xLTEtMzY4MjU_adcfb4f5-99bb-4e3e-817e-8067f38cdd41"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTEtMy0xLTEtMzY5MDY_06280a48-1228-4663-bc5d-c242d19f89e1"
      unitRef="usdPerShare"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTItMS0xLTEtMzY4MjU_ba3fbe45-8b97-42a5-9440-333540157403"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTItMy0xLTEtMzY5MDg_4dd005ec-898a-4b91-a042-ebd3a2deb555"
      unitRef="usdPerShare"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTMtMS0xLTEtMzY4MjU_8e7901b4-7ecf-4d23-a351-dccb1105c887"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTMtMy0xLTEtMzY5MTA_a5bac9fb-559f-44cd-8acb-9be0cb2c66f6"
      unitRef="usdPerShare"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ie5a306ceedd2446d93819bfd4e8afbe8_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTQtMS0xLTEtMzY4MjU_d634954f-b89a-46b2-b11e-c75f2ddf7949"
      unitRef="shares">114079</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ie5a306ceedd2446d93819bfd4e8afbe8_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTQtMy0xLTEtMzY4MjU_764b5861-8ab5-41f6-9966-7dbc88c1d28b"
      unitRef="usdPerShare">43.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTQtNS0xLTEtMzY4MjU_af6e2997-97c3-4f8e-aa98-c33173145db9">P8Y11M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ie5a306ceedd2446d93819bfd4e8afbe8_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTQtNy0xLTEtMzY4MjU_cbc48583-a7a4-446c-b5db-b277f749ed06"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ie5a306ceedd2446d93819bfd4e8afbe8_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTUtMS0xLTEtMzY4MjU_1de4159a-b56f-4fb0-861a-4325e81532bf"
      unitRef="shares">30756</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ie5a306ceedd2446d93819bfd4e8afbe8_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTUtMy0xLTEtMzY4MjU_ada3b842-f1e5-4ac9-a565-cb2206492a79"
      unitRef="usdPerShare">111.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTUtNS0xLTEtMzY4MjU_b3b6543e-83aa-4bdf-9735-1817ca834891">P8Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ie5a306ceedd2446d93819bfd4e8afbe8_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTUtNy0xLTEtMzY4MjU_7a30506d-a89b-4e78-adad-97b3e85f3cd9"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i99580c61c8454190b396ed58334ece96_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfOS0xLTEtMS0zODY5OA_81cb637e-8121-499e-bb11-1282b45919be"
      unitRef="shares">107128</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i99580c61c8454190b396ed58334ece96_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfOS0zLTEtMS0zODY5OA_9341ee5c-40df-4c3f-967b-1cf902b0309f"
      unitRef="usdPerShare">23.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i9f0d7863d02d4527b559355b990c8aac_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfOS01LTEtMS0zODY5OA_3b397999-bc5e-4fa9-b3b7-621e8f0ecc6d">P8Y3M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i99580c61c8454190b396ed58334ece96_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfOS03LTEtMS0zODcxOA_5848f233-15d4-4b09-b278-1208f90a1265"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTAtMS0xLTEtMzg3MDg_dbaa1876-c2b0-4624-97c6-425650f2c645"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTAtMy0xLTEtMzg3MDg_d7b9d377-230f-4a2a-8580-4d9033b8a6dc"
      unitRef="usdPerShare"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTEtMS0xLTEtMzg3MDg_5c0ff0e1-c895-43d3-96aa-d22d8b783759"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTEtMy0xLTEtMzg3MDg_a753d084-e56e-469e-9d9d-2a12453bfb7a"
      unitRef="usdPerShare"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTItMS0xLTEtMzg3MDg_6224086d-2b81-49a0-b925-be0f9fa4c3b7"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTItMy0xLTEtMzg3MDg_bef44e12-2177-43cb-b4a5-0ac95227d4cd"
      unitRef="usdPerShare"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTMtMS0xLTEtMzg3MDg_3cfb4f6a-28df-45c7-a789-f804cbb7f37d"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTMtMy0xLTEtMzg3MDg_b5296253-d955-4e67-a6ec-015e6b7cb751"
      unitRef="usdPerShare"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTQtMS0xLTEtMzg3MDI_3a837d2f-bbe8-4020-b535-b978d681c506"
      unitRef="shares">107128</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTQtMy0xLTEtMzg3MDI_2b56327f-8187-4d70-bc09-16ecdd09cf13"
      unitRef="usdPerShare">23.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTQtNS0xLTEtMzg3MDI_177b4b3c-682a-4b93-86c2-95c1d63dc0e0">P8Y14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTQtNy0xLTEtMzg3MDY_1f02f320-7b8b-4197-aefe-55434743d2c0"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTUtMS0xLTEtMzg3MDI_25da84ec-dc72-44eb-a9b7-92f4991fec4e"
      unitRef="shares">59870</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTUtMy0xLTEtMzg3MDI_5949319b-5ca6-4801-a416-4628b203dc96"
      unitRef="usdPerShare">28.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTUtNS0xLTEtMzg3MDI_064e8e2c-8c9a-40cc-b1ae-91ab99124a50">P7Y9M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RhYmxlOjBhMWRmZTNiM2UwZTQzNmI4MTdiY2RkYjM5ODdkNDE3L3RhYmxlcmFuZ2U6MGExZGZlM2IzZTBlNDM2YjgxN2JjZGRiMzk4N2Q0MTdfMTUtNy0xLTEtMzg3MDY_6774884d-9364-4f2f-bc2d-a1e83a9e6178"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i21d8870425a246ecaa7e4fe2677a54c4_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfMTA5OTUxMTYzMTA3OQ_fe39487c-08a0-4d72-b729-ed6d16673a11"
      unitRef="usd">700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="ie5a306ceedd2446d93819bfd4e8afbe8_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfMjA2NA_cae0ae14-b8f0-4d17-9c9e-338f1e4b4d1a"
      unitRef="usd">1000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i25aebc31ca484ab3b3cbb46087a9333b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182MS9mcmFnOjZkYTk5OWYxMGJjMjQxNzBiY2M3NTU0ZjQwNmNkNmE4L3RleHRyZWdpb246NmRhOTk5ZjEwYmMyNDE3MGJjYzc1NTRmNDA2Y2Q2YThfMjM2MA_127f69c1-7e61-4712-897e-8ad6a2d7b5af">P1Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i66746fb43d0340e680dc791d2b399feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182Ny9mcmFnOmVjNjY0NGVmNjJmMzQ4OTU4NmE3MmQ4Njk2NzExZmRmL3RleHRyZWdpb246ZWM2NjQ0ZWY2MmYzNDg5NTg2YTcyZDg2OTY3MTFmZGZfMjQw_4b9fe734-3478-42f8-bdba-0c98021bac2e">SUBSEQUENT EVENTS&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 5, 2023, the Company was notified by FDA that they have completed the review of the Company's submission and have concluded that the clinical trial may be resumed. See Recent Developments for further discussion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;From April 4, 2023 to May 11, 2023, the Company sold 527,672 ATM shares of its common shares with gross proceeds of approximately $1.3&#160;million under the Sales Agreement.</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i1c04e18316394009b6153f59ba41f585_D20230404-20230511"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182Ny9mcmFnOmVjNjY0NGVmNjJmMzQ4OTU4NmE3MmQ4Njk2NzExZmRmL3RleHRyZWdpb246ZWM2NjQ0ZWY2MmYzNDg5NTg2YTcyZDg2OTY3MTFmZGZfODI0NjMzNzIxMDM0OA_b80f7dd0-71fe-45a9-aa61-57d209508be3"
      unitRef="shares">527672</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i1c04e18316394009b6153f59ba41f585_D20230404-20230511"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRiMTk5NTJhYzE3ZTQzYjU5MjNmYmVkZGRjNDI0MzkzL3NlYzpkYjE5OTUyYWMxN2U0M2I1OTIzZmJlZGRkYzQyNDM5M182Ny9mcmFnOmVjNjY0NGVmNjJmMzQ4OTU4NmE3MmQ4Njk2NzExZmRmL3RleHRyZWdpb246ZWM2NjQ0ZWY2MmYzNDg5NTg2YTcyZDg2OTY3MTFmZGZfODI0NjMzNzIxMDM1Nw_b3dbb691-d290-4f8b-a345-29f56642dde1"
      unitRef="usd">1300000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>39
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MOD^<GPBVSK9:7Y@0+,H.5Y3XE*L'Y/T%8^)PHOY!L5L__ ]02P,$%     @
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MQWH5*JI"N=Q_&B5T&$0Q+/K3)J&V':$$1V' &L,ML&$#-NP$^X?F@ PJ0RH
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MU^DU.OGU]Y$M87@5Q,Z:H2[KH;R>H7QTQZA<"G1#<Y(?^MN W;)[K^R7WF#
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M,Z\CQ&#FG_D](G8%T1VNB#TB\J)<2Y*_1T;X<S(,9OTR=C74'2Q9DV_ZL _
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M\&2F20!DENTW\"$376B_I 4@PVNR21*%S#GB:8AXL%VFD39H9=8U&[=J-E2
MJ,]:4I"(5N=\J"'!<ZS 1EV3CR$%H =:A]DAZV3:0Z7IB3L8)[0 CR1 )BS\
MDU5]L<AUFK/AJJP+/D$R0"M%[)L4:RIJ'^L1JPX+;B;3=KG0(0A4>-&(BD8H
M8LG&.NX12>P1(1!;?<\,@PLN%DVF&%HR^Q=@'):M(LX@HC'1QA1(M6W\R3BF
M'^;-UC3:9#,"*KD@9$FA=#LVK_OA<M,4V0;U)@I<W4;RU5QWY;70H :K0#1V
M$T^@1$UJ*4:RUC[PTZR!79I]=4I:9(8,C1Q+42#VQH2L8C3@%T[1@8Z=0O3(
MFD@_@>#6V&4@SF7L6.N->'3\D:6G)#65+F_MYNBO==D$BF!1Y'9JS(JXYV6U
M\#H9IY[!EQP@$LNQIQ\D_@D%R^(Y4HEBAM"I)E_7 [)6L#Y' Y_GL%^)):(4
M*MKO0-7/L,TUU!>9$_Y$F8!]E7%1F\3C2K,U+U%?0'[!:";3@3E'Y-+AG@P"
M:Z*)T![P'%QV8;@)$EI+0G]4"6$=HV43(TR!*2607#@3N@P:! :"!1Z*0B:F
MC0!$QGL.@+$4( M?L38.5=<'EP-T@05293='"$P)5&=$]+JM,UAF.4@Q:6OY
M +TX-VL*<C$06*%=SLR$D_"$\5?("K5]IU+*W.4*L9C*8![EY"*.5# *A?55
MSPAH-Y6X2;U)X.CHKSSWCS>-?3(%*A;(8T=YK*&(U @%UT-E$1LN#>J,GH=
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MSG7WD@X*%#+B"32AY1]!U*HHT<1P4PUST<J,EI.Z+O*(G/"=.<TII[%94P#
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M6Y/3B.!+3B<[,$Q7MX2PG+++K5=RMZ:0TLV]H?S1[]\VZ8 *U23BCK ;GFT
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M)I28,:S\G3Y_;3'<NES3Y4+;.:AN@W(#%L33!8O]J,9/'_=WEJ+9O,F2 E2
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MYXK380LL"!J'G\X"T.VL:@VK:C\?J$J:-GY9TGA'[0)HOU#*[@R7H/MAC/\
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M+W-H965T,3$N>&ULI5==;]LV%/TK%]XZ;(#CSS3MNB1 XJ2=AR8-DG1]&/9
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MD)VF]./@X\W9=/#3B".!TEP +H1V&"RWNG?=4,[5<&+VBB3\8<\W&C'DJD+
M.SNYH:3$W8FRNB@:2E51>RSA@P)"?=@MLTR&[D7(J>0\\.I#LER]^@L;.,!$
M6H]63"+]"\TCXKP-+*1[5W((451+.%I;H=FNE7=2UTA&+BQX09:[F@L>PEV
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MK+:)[22(YQ-Q2)^%"^W2&[JQJOH;>8'M;>?DD6H>4JW2Q.]K$E)AX<VB,I!
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M;TKC)\M32% "ZP,U#)28%AHLFHN"L+=[.WA#ZYX3H+'WUG< F@DHM'H0*3>
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MIMJ>%1O)4WA0GH[D*0HL_:T+'7?%[XZ4!@FR@EP[ *Y)L8W#=+$J.%877-6
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M+TOJF*A= L4+I>Q^XR[H>W#R&U!+ P04    " "\0ZM6FZN>@X(2  #S-@
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M$9S[++R3'E"@VM6=3E/!]J5IVD&WVC73:=-#'L.;3DR%W)%C$+BE5/]ZT'=
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M<@'V?"FEV1GN@GI:IW\!4$L#!!0    ( +Q#JU9[*'%> @4  +0:   9
M>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;,696V_B.!3'OXJ5':U:J=-<"%"Z
M%(F29(;5%%!I=Q]6^^ F!J(F=L9VH)7VPZ^=I(% 2&%E:?M0<O'YG6/_[>-+
M^AM"7]D*(0[>X@BS.VW%>7*KZ\Q?H1BR:Y(@+-XL"(TA%[=TJ;.$(AAD1G&D
M6X;1T6,88FW0SY[-Z*!/4AZ%&,TH8&D<0_I^CR*RN=-,[>/!8[A<<?E '_03
MN$1SQ)^3&15W>DD)PAAA%A(,*%K<:4/SUC-M:9"5^"-$&[9S#6157@AYE3?C
MX$XS9$0H0CZ7""A^UFB$HDB21!P_"ZA6^I2&N]<?="^KO*C,"V1H1*(_PX"O
M[K0;#01H =.(/Y+-=U14J"UY/HE8]A]LBK*&!OR4<1(7QB*".,3Y+WPK&F+'
MP&H?,; * VO?H'?$H%48M/8,[&,AV86!?:J'=F'0/K4.G<*@D[5]WEA92SN0
MPT&?D@V@LK2@R8M,KLQ:-'"(9<^:<RK>AL*.#^Z'\_$<3#TP>W3G[N1I^#2>
M3L!PXH#Y^-MD[(U'P\D3&(Y&T^?)TWCR#<RF/\:CL3L'%P[B,(S895_G(A")
MT_W"J9,[M8XX;8$'@OF* 1<'**C:ZZ("92VLCUK<6XW J<^O@6E? <NP+/ %
MZ("M($6L)K11,^EWB 7)*DC/<P=<?+D\3G.::0^07H.6F=%:)6T;WW&P>SKX
MA#"]9IJ#_!W:L>:K*-,J^U<K0[>.H,6(C^ +H5 F$#"D%.(E$IF) XB#ROV4
MKQ %? 4QJ!K]]4,PP9BCF/U=4[?[/ "[/@"9F6]9 GUTIXG4RQ!=(VWPZR]F
MQ_BMKG>HA#DJ8:Y*F*<(5ND2=MDE[":ZZ!)XC6@^-0F%29VF.<$T,H2<'=<#
MX]JP^_IZ5ZQ&/^>*I1+FJH1YBF 5L=JE6.U/Q(IC(928A_S7*Y! "M8P2A&X
M"#$(Y#"E(!'#-LL7E^"?YMQ[G_OJ5E4U#'-/U\:0SM7U-)^N2I_>ISXK6G1*
M+3J-6HSC!(8T2Y:^:.*EF#_( D0$+[]&(E$& #*&>&W#-X+/S9$J84X.Z^PV
MU9XRGY;P% 54$:5;BM)M%&6(>1B$49I-50SY*0UY*)1!;WZ4BM4-6% 2 Y_$
M2<IAMI@6FB%(<8B7;#MVL@&5#QPYC(X/H<9HSE52)<S)8>T=G;IFY\;>E_.P
MF-TR;:.[IZFBT"J:WI2:WC1KNEQ2M(0<B83W+L<; ZE8J5(PG(^&=:(TXLX5
MY>:@OXMMHORKMI"CTJFK$N8I@E6TZY7:]1JUFZ54)$>&0(B_)I3XB#$@O4#Q
M.%MS!F@M]M-)ED8Y\E>81&3Y7J=JHZ-S5>T=='NS7:=J[]-\>%BBEN0I"K^B
M@FEL]Y5&\V3%6 JQC[)T]S,-^?M.=KP"&/&Z)F^&GMOF!6VWJ6K;O*9<RQ2Y
M:W^-H#0Z3Q6M*M#.QM\\964WERN[6BD:S<^60B7-44ISE=(\5;2JK-965NO_
MWG 7$:CJ&2IICE*:JY3FJ:)5>\;V),9LW-6?D)%/7H0V>SJ[![0.EX1U6?JP
MF&E;=J^WGZ65GI2HHE5%VYZ5F,V')?]Q&E5Y_C!22G,*6F7]8N]+J/3\1!4M
MEU#?.6R/D=B%R\\B3.SP4LSS$^OR:?GI99A]<-A[[IBW;OX!98O)O^<\B,U]
MB!F(T$(@C>NNZ/,T_T22WW"29$?Z+X1S$F>7*P3%#D46$.\7A/"/&^F@_% U
M^!=02P,$%     @ O$.K5B4X3NSV @  3 L  !D   !X;"]W;W)K<VAE971S
M+W-H965T,C$N>&ULO59=;]HP%/TK5C9-G=0U(0F!,8@$A'9(;8?HQQZF/9CD
M E$3F]D&NG\_VTE3T@96IF@\D-CQ.<?GQ%QN=TO9 U\""/28)H3WC*40JXYI
M\G )*>9G= 5$/IE3EF(AAVQA\A4#'&E0FIBV97EFBF-B^%T]-V%^EZY%$A.8
M,,37:8K9[P$D=-LS&L;3Q#1>+(6:,/WN"B_@!L3=:L+DR"Q8HC@%PF-*$(-Y
MS^@W.D%;K=<+[F/8\IU[I)S,*'U0@W'4,RRU(4@@%(H!R\L&AI DBDANXU?.
M:122"KA[_\1^KKU++S/,84B3[W$DECVC;: (YGB=B"G=?H7<3U/QA33A^AMM
ML[6>5 S77- T!\MQ&I/LBA_S''8 DJ<:8.< ^R7 W0-P<H#S5H"; UR=3&9%
MYQ!@@?TNHUO$U&K)IFYTF!HM[<=$O?8;P>336.*$?S'M7]^BZ6@X&M_W!Y<C
M=#[]=H6&D^GX%IT$('"<\(_H$[J["=#)^X]=4TA1!37#7&"0"=A[!!QT18E8
M<C0B$41EO"DW6^S8?MKQP#Y(>(79&7(:I\BV;*=B/\.WP^T*>' 8'D"X#UYR
MXQ3Y.YK/V</7#T.Z)H*?HFLJ0%XN*28<81*A\YA@$L9D@:800KS!LP30CTM)
M@,8"4OZSZF5D:FZUFJHA';["(?0,620XL T8_H=W#<_Z4I5DG61!362EE-TB
M9?<0NW_!L,Q8EJDBQSFC:7;,JU+,V#S-I@KGQF\XEOQTS<UN/@=%C\VG0M-K
M6.[G9]&2]69AO7F<]2J_&45S5]MME[0SP\U7>WRQ(CBXF7]\RUYAU?N[U2I[
M!V''_BCJ) MJ(BO%U2KB:OW7TM.J,^4ZR8*:R$HIMXN4V[66GO;K,F!5E)Z#
MHL?F4Z'IE44SZ^9.GY$"6^A^C2-]C+(_\&*V: G[NA-Z,3]H=(999_=,D_69
M\N]Y$<M3F,!<4EIG+5E06-:[90-!5[J;F5$A>R-]NY3M+C"U0#Z?4WF8\X$2
M*!IH_P]02P,$%     @ O$.K5I^\^Q+I @  C <  !D   !X;"]W;W)K<VAE
M971S+W-H965T,C(N>&ULK55=;YLP%/TK%INF3LK*5R!IER"EA*E]6!N%=ILT
M[<&!F\2JP<QVDFZ_?C801!.:]F$O8.-[CL\]OKZ,=HP_BC6 1$\9S<786$M9
M7)JF2-:087'."LC5RI+Q#$LUY2M3%!QP6H(R:CJ6Y9L9)KD1C,IO,QZ,V$92
MDL.,(['),LS_7 %EN[%A&_L/<[):2_W!#$8%7D$,\J&8<34S&Y:49) +PG+$
M83DV)O9EZ.OX,N ;@9UHC9'.9,'8HY[<I&/#TH* 0B(U U:O+81 J292,G[7
MG$:SI0:VQWOV+V7N*I<%%A R^IVD<CTVA@9*88DW5,[9[AKJ?#S-ES JRB?:
MU;&6@9*-D"RKP4I!1O+JC9]J'UH N_\"P*D!SEL!;@UPRT0K965:4RQQ,.)L
MA[B.5FQZ4'I3HE4V)->G&$NN5HG"R6 VCV:3FRF*?LRBVSB*T>1VBN[NKZ,Y
M"A_F\^CV'DWB.+J/T2<4JQ)*-Q006Z(9AP*3%$5/JIX$"(3S%-W)-7 4;CB'
M7**)$" %.IN"Q(2*CXKA(9ZBL_<?1Z94TK4 ,ZEE7E4RG1=D?L7\'+EV#SF6
MXW; P]/P*20-W'D.-Y5AC6M.XYI3\KDO\BU!)9FBD DI>BC$!9&8DK^0]O;6
M]%J6U%9,B4@H$QL.Z.=D(2171?RKRXQJ]W[W[OIB7XH")S VU,T5P+=@!!_>
MV;[UN<N:_T3VS"BW,<H]Q1[LRR11"R3!%$E.U!/JJNG*O2+T2T+=@[:!;=M#
M;V1NVTF]%O5,;;]1VW^36I*K,\)Y EWZ*@JOM;/K#R]<^T#@<9CO]'W;Z5;H
M-0J]DPJK<BIJG;K DOJVX;+$N@1[1TILS_>LBP/!'6'^P!OXW8+]1K!_4O ]
M4_>B$0SM;L'*7%[7[Q\=M>?ZOG-8$<=A0\MU!^Z!?K/5*_5_2G66E3IO1&&I
M@-;Y0#G J]Y?320KRO:Y8%(UXW*X5K]+X#I K2\9D_N)[LC-#SCX!U!+ P04
M    " "\0ZM6HL88?+0#  #9#P  &0   'AL+W=O<FMS:&5E=',O<VAE970R
M,RYX;6S-5]^/XC80_E=&Z:FZDSB2\&MA"TB[)-=2'>QJV>T]5'TPB2'6)79J
MF^7X[V^<A!R<0KI(>>@+Q,E\W\Q\$X\SX[V07U5$J89O2<S5Q(JT3F]M6P41
M38AJBY1R?+(1,B$:EW)KJU12$F:@)+8[CC.P$\*X-1UG]Q[E="QV.F:</DI0
MNR0A\G!/8[&?6*YUO/'$MI$V-^SI."5;NJ+Z)7V4N+)+EI EE"LF.$BZF5AW
M[JT_,O:9P5^,[M7)-9A,UD)\-8MY.+$<$Q"-:: - \&_5SJC<6R(,(Q_"TZK
M=&F I]=']D]9[IC+FB@Z$_$7%NIH8@TM".F&[&+])/9_T"*?ON$+1*RR7]@7
MMHX%P4YID11@C"!A//\GWPH=3@!N[P*@4P Z/P/Z%P#= M!]JX=> >B]%= O
M %GJ=IY[)IQ'-)F.I=B#--;(9BXR]3,TZL6X>4]66N)3AC@]G3TL%O/GA;]\
M7L'=TH/9P_)YOOS=7\[F_@K>>U03%JL/\!%>5AZ\?_<!W@'CL&!QC'568UMC
M$(;*#@J'L]QAYX)#%Q:"ZTB!ST,:GN-M#+[,H'/,X+Y32_CG+FZ#X[:@X[B#
MJGC^"\[;T'4NPKUZ^()(A&?>.]T*N%\/]VAPA+MNC1C=LIS=C*][J9Q8$Q&S
MD)A=V(+/5"G0$>'P)1)Q?("'/:<AK'9KQ4*&?:$%CT12KK,'4D4LA3G75%*E
M6^!O-KB=%8@-S)!C2U4+EMBZ_OZ,7F&N::+^J4CY/@^Q5QVB:7RW*B4!G5C8
MV125K]2:_OJ+.W!^JZI>DV1>DV1^0V1G=>Z5=>[5L4_O]D2&0!*QX[JJ!#EZ
ME*'-4?$Z=0=M?,%>3Z6M,!JV;\Z-O-HXKI6L(;(SR?JE9/TW2(;O=E(E6"WV
MVG>V/I N'"B15:W3:S(*OR&R,[$'I=B#VARQ#VG&=]AK4G+ SPJ-K2.E,C"M
M!ML)QRZB2$RK1+BO9;ZV%$V2>3F9ZY[L&*?M_+2M_(9<GNE^4^I^4ZO["\?/
M+JF8/AB97S2)X F=$!E$\ F;17XP5*E>RWNMZDV2>4V2^0V1G15G6!9G^/\_
MG(=-UKE),J]),K\ALK,ZC\HZCVHWX8]R%2T/!RY8'X +'F!?E%ALQK<@C%E5
MB6K9KRU1DV1>DV3^J+*;=LINFFMOG\PV"97;;*A4$)@OGWS,*>^6<^M=-J[9
M/\SSH1>_U;>,*XCI!J%.^P9/2)D/DOE"BS2;E-9"X]R5748X>U-I#/#Y1@A]
M7!@'Y30__0Y02P,$%     @ O$.K5DD*]^F\!0  ABX  !D   !X;"]W;W)K
M<VAE971S+W-H965T,C0N>&ULM9IK;]LV%(;_"N$-6PNTMDA+OF2.@<22T&P-
MFM7MBF'8!T9F;*&2Z)%TD@+[\:,ND4Q'9JSA-!]BW<YS*+TB>?R:LP<NOLH-
M8PH]IDDFSWL;I;9G@X&,-BRELL^W+--G[KA(J=*[8CV06\'HJ@A*DP%QG-$@
MI7'6F\^*8S=B/N,[E<09NQ%([M*4BF^7+.$/YSW<>SKP,5YO5'Y@,)]MZ9HM
MF?J\O1%Z;U!35G'*,AGS# EV=]Z[P&<A\?* XHH_8O8@][91?BNWG'_-=ZY6
MYSTG;Q%+6*1R!-4?]VS!DB0GZ7;\4T%[=<X\<'_[B1X6-Z]OYI9*MN#)EWBE
M-N>]20^MV!W=)>HC?WC'JALJ&ACQ1!;_T4-UK=-#T4XJGE;!N@5IG)6?]+%Z
M$'L!V#T20*H <AC@'0D85@'#4S.X58![&# ^$N!5 =ZI&495P*AX]N7#*IZT
M3Q6=SP1_0"*_6M/RC4*N(EH_X#C+WZRE$OILK./4?/GIP^*W=Q_>^\''Y<\H
M^/WSU:<_T2N?*1HG\C5ZBSXO??3JQ]>S@=+9\IA!5)$7)9D<(0_1-<_41J(@
M6[&5&3_0K:R;2IZ:>DFLP%]IUD>8O$'$(:2M/?;P:RKZ:(B+\&%+N']Z>%OV
MP!Y^L<W#G:/AH3W<9U&=W;$\RV$M^[#@#8_P%@F5$O$[M%0\^HK^>J_/HRO%
M4OEW2^,N2YC;#LL'OS.YI1$[[^G133)QSWKSGW[ (^>7-ID@83XD+("$A4 P
M0UZWEM>UT>?+#=50%$NY8ZLWZ)XF.]:F:TD9%91\#KJ?>T[^-QO<[ROV_+(A
MQJ,)-B_SK6WJJ@4D+ 2"&5IXM1:>58L%3U,]A<JBHY6*(%T1H#A[NQ4\8KH?
MYDFIB#:(9BL]+=[K^7ZK9V^%%(LV&4_X^EN;>M:\77LE),SWGKTP[F0\/7RO
M LB<(1#,T'A4:SRR:OR%"D$S)0L!15[,Z,%UIZ32^W&V?J.%%&F;A%9L5PDA
M83XD++ _/0]]TZ^_1".4%A5#F[HG$2Q*CFLEQU92\,A$%$N&MB*.&'H59VC%
MDX0*M&6Z(,_'U;9:Z-)*[2HD),R'A 60L+"$3?9&"3+M>UX]2!@"3FH!)YV[
M(BM%I;<).]X5K=BN"D+"?$A88']ZMBX(U Q#U6FMZO0T5?=&U:)S%CU2MG9)
M*[&KH"7,VZ^4IF,/DX,2Z/EE0SP>DNG!Q ?9M! (9NB"G>;[HV-5YIH^QNFN
MM4?9([LJ $KS06D!*"V$HIF*[CD"&/*[846#4AF2YH/2 E!:"$4S52:-RN2[
M%#IV;&>Y(6D^*"T I845S:AV)OWQD6H'-T8.MAH)3U\OB[[:JA>H=P-*\T%I
M 2@MA**9LC8&#G9!!V%(NV0!2O-!:0$H+82BF2HWUA"V>T.&3_=2/5NQ]HM+
MM\6L:[D,N\2='M2@OKUIG64!]7*@:*8LC9N#[7;"J?:I'=.YUXV>N6;8/10-
MU)8!I850-%.TQKC!=N<&QF=]L1..3^N$H!;.:4D#T*0A%,V4L[%QL-V)^'ZV
M>97XQ5\][ WLK.'SK.ZA?I )0RB:J5]CV&"[8[.DB1Y"+]:"L4*3?]&+E2JH
M80-*\T%I 2@MA**9/\HW!A!Q("M5 FH*@=)\4%H 2@NA:*;*C2E$K'9$MTK5
MSNJL,3ZMH 7-&H#20BB:J5YC]A"[V7-J06O'=!:./%\WT#+1^J!9 U!:"$4S
MA6O<'6)W=VYVNKZADAD3:?5C2*N H&X/*,T'I06@M!"*9LK<N#T$U.TAH&X/
M*,T'I06@M!"*9JK<N#W$[O;\7\O=CNTL-^A*'U!:4-'&>S/&I.].]USR2DA0
M?VBPMWPV96)=+'26*.*[3)7+4^NC]6+JBV()\<'Q!3[SRR71#:9<H7U-Q3K.
M)$K8G48Z_;&^ 5$N>BYW%-\6BW1ON5(\+38WC*Z8R"_0Y^\X5T\[>8)ZZ?G\
M/U!+ P04    " "\0ZM6["=VR;P%  #^)   &0   'AL+W=O<FMS:&5E=',O
M<VAE970R-2YX;6S%FN]OXC88Q_\5BTU33VI+XO"C[0"II3VMTMJR<MPT37MA
M$@/1)3%G&RC3_OC93H@)!%,X5]R+*S%YOGZ>QWZ<#[%;"T*_L0G&'+S%4<+:
ME0GGTYMJE?D3'"-V2:8X$=^,"(T1%Y=T7&53BE&@C.*H"AVG48U1F%0Z+=76
MHYT6F?$H3'"/ C:+8T27=S@BBW;%K:P:7L/QA,N&:J<U16/<QWPP[5%Q5<U5
M@C#&"0M) B@>M2NW[DW7JTL#=<?7$"_8VF<@0QD2\DU>/ ;MBB,]PA'VN91
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MB17R<)7GX>K$2\R5S519$BNDZCI/U;5QRCPR-L/!.5BH![G( YIC*L D76-
M@#@&H[R@U8HS8P&8BF5)K3RE"T_:Y=7Z]+ZL-S=JP.C7D5&[CGZ>.^]<I.3R
MBN2@E]9$)E.HZ$:C>;T1C+FW8Z-9HQ/75N&#_\!3F(3Q+"X-U]C/H1/;EEHQ
M*U!G!9YX&<@<L)4N2VK%=&DN<XTLT_DJYDN8C&5MAR0H#=<LX((E1K0TLH^@
M*%=CE&OFJ /+ [WM+ ]C/P>/MR6U8E8TIKGU4Y>'5=BSI59,EX9"UTR%[R@/
MLT!-E4?94Z9KMCPV-(V-KID;'^)I1)889X7PHOBV-$*KB&A+K1BUAD3WU)3H
M6L5$6VK%=&E0=,VDV%__"7HN?@HEG"*?SU $.*;ERZ4EQLOB-_OG.F7U57QC
MHO$0FO%PWT_ [%O5LGM!V--)^KP$PO$X?>,#:P*XEZ4KA%GJR,&'&C"A&3!+
M5P@S2IH5#QU\6VK%^#5*PE.C)+2*DK;4BNG2* E_%"7W".Q&2;/AL9%IE(1F
ME-Q9"+NAT:QX\,A^!#1"#8WPU- (K4*C+;5BNC0TPA^%QCT"!F@T6QX;FH9&
M:(9&Z+AUT(M0*2B:;0\>Q(\ 1:A!$9X:%*%54+2E5DR7!D6X!Q35CH1 )+D]
M*B<_FJ,P0L,(@Q&AV8O%?$\C??6V;RLCZ[*P4U'W&O6-UW!FSXZ,W-/4Z)F!
M;O5PD&\1=KQ>.'OM#\I#-&L?O&WU$;SH:5[TW%-O\EG%2UMJQ71IO/2,/+8J
MF7?NZV5BZ\7@0@@W-YG,?1X;T]HVKQGA7D:CT,>4J9=M]Z'XQ<0)+:N,TA#M
M[N%^!#-ZFAF]VJF+P2IBVE(KIDLCIF?>/SZP&.I;Q> U&K6M8K#*@=6UDR0Q
MIF-UP(8!G\P2GA[,R%OS0SRWZNC*1ON=>]--C^)HF?1DT!.BXS!A(,(C(>E<
M-D4 -#ULDUYP,E7G58:$<Q*KCQ., DSE#>+[$2%\=2$[R(\\=?X'4$L#!!0
M   ( +Q#JU;W;Z*!*P,  !D+   9    >&PO=V]R:W-H965T<R]S:&5E=#(V
M+GAM;,56;6_:,!#^*U8F39TT2!P@E XB :4:TFA9:3M-TSX8<H!5)\YLAY=_
M/SN!P+0DJJI-_0*VXWN>Y\YGWW6W7#S+-8!"NY!%LF>ME8JO;%LNUA 26><Q
M1/K+DHN0*#T5*UO& DB0&H7,=AW'LT-"(\OOIFM3X7=YHAB-8"J03,*0B/T
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MA*+W;%4A$\V6BN;(0JL^RRAULR[6S96_#XXF$"FJZ^Y5E_'JUA6MX596-AH
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M5:"FKU5_EN99)%!SZ4ZEYQ>-)]:[/!^IOK"<5NEJ_QEI_PGL[B]02P,$%
M  @ O$.K5B\ @E1, 0  :Q$  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<\W8S8Z",!2&X5LAO0#+.2CJ1%S-QNW$&R!8?B)00CL9O?LAN,#/S&(V
MIF=%VH;3=_6$</@R;>X;V[NZ&5QTZ]K>9:KV?OC0VA6UZ7*WLH/IIY/2CEWN
MI^58Z2$OKGEE-,=QJL?G&>IX>)X9G>^#^<]$6Y9-83YM\=V9WO\Q6/_8\>IJ
M8[R*SOE8&9\I?6N7;:?G!ZVFR2HZ73(UGBZD=.@@AB .'Y1 4!(^: U!Z_!!
M&PC:A ]*(2@-'[2%H&WXH!T$[<('[2%H'SZ(8I0Q%I#T@K4 K0FY)@%>$X)-
M L0F))L$F$V(-@E0FY!M$N V(=PD0&Y"NDF W81XDP"]&?5F 7HSZLT"].:7
MCVT!>C/JS0+T9M2;!>C-J#<+T)M1;Q:@-Z/>+$!O1KWYG7H[?V^-6WH>:[S_
MG53[Z5VS7#\O'YLH83+CK.'?RO$74$L#!!0    ( +Q#JU8BX&C7>P$  #H2
M   3    6T-O;G1E;G1?5'EP97-=+GAM;,V8RT[#,!!%?R7*MFI<&R@/M=T
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M2P$"% ,4    " "\0ZM6!T%-8H$   "Q    $               @ $
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( +Q#JU8+'OBV[P   "L"   1
M              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M +Q#JU:97)PC$ 8  )PG   3              "  <T!  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ O$.K5B,CV]SO!0  N1\  !@
M     ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (
M +Q#JU:T</3%[@0  #H2   8              " @3,.  !X;"]W;W)K<VAE
M971S+W-H965T,BYX;6Q02P$"% ,4    " "\0ZM6HGO)_@4#  !?"@  &
M            @(%7$P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#
M%     @ O$.K5MK8PHQ?!   <P\  !@              ("!DA8  'AL+W=O
M<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( +Q#JU:0"$H%KP4  &@7
M   8              " @2<;  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q0
M2P$"% ,4    " "\0ZM6;JY3TI,%  ! 'P  &               @($,(0
M>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ O$.K5F&L6W9>
M"@  4!D  !@              ("!U28  'AL+W=O<FMS:&5E=',O<VAE970W
M+GAM;%!+ 0(4 Q0    ( +Q#JU947RGW$Q4   @\   8              "
M@6DQ  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " "\0ZM6
MC=H-P;\"   \!@  &               @(&R1@  >&PO=V]R:W-H965T<R]S
M:&5E=#DN>&UL4$L! A0#%     @ O$.K5L!D=$_U @  P@8  !D
M     ("!ITD  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +Q#JU95L:HY@P(  (\%   9              "
M@6QB  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ O$.K
M5INKGH."$@  \S8  !D              ("!)F4  'AL+W=O<FMS:&5E=',O
M<VAE970Q-BYX;6Q02P$"% ,4    " "\0ZM6&B<B.>H"  !N!@  &0
M        @('?=P  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0
M   ( +Q#JU:!'LG/MP,  +X(   9              " @0![  !X;"]W;W)K
M<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ O$.K5JQ:G.VD @  N04
M !D              ("![GX  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q0
M2P$"% ,4    " "\0ZM6>RAQ7@(%  "T&@  &0              @(')@0
M>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( +Q#JU8E.$[L
M]@(  $P+   9              " @0*'  !X;"]W;W)K<VAE971S+W-H965T
M,C$N>&UL4$L! A0#%     @ O$.K5I^\^Q+I @  C <  !D
M ("!+XH  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " "\
M0ZM6HL88?+0#  #9#P  &0              @(%/C0  >&PO=V]R:W-H965T
M<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( +Q#JU9)"O?IO 4  (8N   9
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M970R."YX;6Q02P$"% ,4    " "\0ZM6&W2$O3L#  #N$P  #0
M    @ $"J0  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( +Q#JU:7BKL<P
M !,"   +              "  6BL  !?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M +Q#JU8P56F<) ,  (83   /              "  5&M  !X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    " "\0ZM6+P""5$P!  !K$0  &@
M@ &BL   >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "\
M0ZM6(N!HUWL!   Z$@  $P              @ $FL@  6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     )  D +,)  #2LP     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>54</ContextCount>
  <ElementCount>164</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>18</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="flks-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - COVER PAGE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/COVERPAGE</Role>
      <ShortName>COVER PAGE</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="flks-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="flks-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="flks-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="flks-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="flks-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="flks-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - ORGANIZATION AND OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONS</Role>
      <ShortName>ORGANIZATION AND OPERATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="flks-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="flks-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - GRANT RECEIVABLE FROM CPRIT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/GRANTRECEIVABLEFROMCPRIT</Role>
      <ShortName>GRANT RECEIVABLE FROM CPRIT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="flks-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETS</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="flks-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="flks-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS</Role>
      <ShortName>FAIR VALUE OF FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="flks-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="flks-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - EQUITY-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATION</Role>
      <ShortName>EQUITY-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="flks-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="flks-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="flks-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSTables</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETS</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="flks-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - EQUITY-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONTables</Role>
      <ShortName>EQUITY-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATION</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="flks-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - ORGANIZATION AND OPERATIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONSDetails</Role>
      <ShortName>ORGANIZATION AND OPERATIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONS</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="flks-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails</Role>
      <ShortName>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="flks-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - GRANT RECEIVABLE FROM CPRIT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/GRANTRECEIVABLEFROMCPRITDetails</Role>
      <ShortName>GRANT RECEIVABLE FROM CPRIT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.flex-pharma.com/role/GRANTRECEIVABLEFROMCPRIT</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="flks-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS - Schedule of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS - Schedule of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="flks-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="flks-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - STOCKHOLDERS' EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.flex-pharma.com/role/STOCKHOLDERSEQUITY</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="flks-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - EQUITY-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>EQUITY-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="flks-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - EQUITY-BASED COMPENSATION - Schedule of Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails</Role>
      <ShortName>EQUITY-BASED COMPENSATION - Schedule of Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="flks-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - EQUITY-BASED COMPENSATION - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofStockOptionActivityDetails</Role>
      <ShortName>EQUITY-BASED COMPENSATION - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="flks-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/SUBSEQUENTEVENTSDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.flex-pharma.com/role/SUBSEQUENTEVENTS</ParentRole>
      <Position>28</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept ResearchAndDevelopmentInProcess in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. flks-20230331.htm 4</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 4 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:StockholdersEquityNoteStockSplitConversionRatio1, us-gaap:WarrantsAndRightsOutstandingTerm -  flks-20230331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="flks-20230331.htm">flks-20230331.htm</File>
    <File>flks-20230331.xsd</File>
    <File>flks-20230331_cal.xml</File>
    <File>flks-20230331_def.xml</File>
    <File>flks-20230331_lab.xml</File>
    <File>flks-20230331_pre.xml</File>
    <File>slrx20230331ex-311.htm</File>
    <File>slrx20230331ex-312.htm</File>
    <File>slrx20230331ex-321.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="264">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>45
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "flks-20230331.htm": {
   "axisCustom": 0,
   "axisStandard": 9,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 264,
    "http://xbrl.sec.gov/dei/2022": 30
   },
   "contextCount": 54,
   "dts": {
    "calculationLink": {
     "local": [
      "flks-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "flks-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "flks-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "flks-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "flks-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "flks-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 245,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 6,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 11
   },
   "keyCustom": 10,
   "keyStandard": 154,
   "memberCustom": 7,
   "memberStandard": 11,
   "nsprefix": "flks",
   "nsuri": "http://www.flex-pharma.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i66746fb43d0340e680dc791d2b399feb_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - COVER PAGE",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.flex-pharma.com/role/COVERPAGE",
     "shortName": "COVER PAGE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i66746fb43d0340e680dc791d2b399feb_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i66746fb43d0340e680dc791d2b399feb_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETS",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i66746fb43d0340e680dc791d2b399feb_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i66746fb43d0340e680dc791d2b399feb_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i66746fb43d0340e680dc791d2b399feb_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i66746fb43d0340e680dc791d2b399feb_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS",
     "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i66746fb43d0340e680dc791d2b399feb_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i66746fb43d0340e680dc791d2b399feb_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - STOCKHOLDERS' EQUITY",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITY",
     "shortName": "STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i66746fb43d0340e680dc791d2b399feb_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i66746fb43d0340e680dc791d2b399feb_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - EQUITY-BASED COMPENSATION",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATION",
     "shortName": "EQUITY-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i66746fb43d0340e680dc791d2b399feb_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i66746fb43d0340e680dc791d2b399feb_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - SUBSEQUENT EVENTS",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.flex-pharma.com/role/SUBSEQUENTEVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i66746fb43d0340e680dc791d2b399feb_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i66746fb43d0340e680dc791d2b399feb_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "menuCat": "Policies",
     "order": "16",
     "role": "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i66746fb43d0340e680dc791d2b399feb_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i66746fb43d0340e680dc791d2b399feb_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)",
     "menuCat": "Tables",
     "order": "17",
     "role": "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSTables",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i66746fb43d0340e680dc791d2b399feb_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i66746fb43d0340e680dc791d2b399feb_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - EQUITY-BASED COMPENSATION (Tables)",
     "menuCat": "Tables",
     "order": "18",
     "role": "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONTables",
     "shortName": "EQUITY-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i66746fb43d0340e680dc791d2b399feb_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i1c04e18316394009b6153f59ba41f585_D20230404-20230511",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - ORGANIZATION AND OPERATIONS (Details)",
     "menuCat": "Details",
     "order": "19",
     "role": "http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONSDetails",
     "shortName": "ORGANIZATION AND OPERATIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i21d8870425a246ecaa7e4fe2677a54c4_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i21d8870425a246ecaa7e4fe2677a54c4_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "ib514cd02604141cba330abbb11971983_I20221014",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "menuCat": "Details",
     "order": "20",
     "role": "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails",
     "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "ib514cd02604141cba330abbb11971983_I20221014",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i21d8870425a246ecaa7e4fe2677a54c4_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GrantsReceivableCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - GRANT RECEIVABLE FROM CPRIT (Details)",
     "menuCat": "Details",
     "order": "21",
     "role": "http://www.flex-pharma.com/role/GRANTRECEIVABLEFROMCPRITDetails",
     "shortName": "GRANT RECEIVABLE FROM CPRIT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i939615b57778416faf3eff53296b4db2_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:GrantsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i21d8870425a246ecaa7e4fe2677a54c4_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "flks:PrepaidClinicalTrialExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "menuCat": "Details",
     "order": "22",
     "role": "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i21d8870425a246ecaa7e4fe2677a54c4_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "flks:PrepaidClinicalTrialExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i2e86d1fdb89f494eb9ee243d58ff09cd_D20160701-20160701",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "flks:RevenueFromGrantsMaximumAward",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "menuCat": "Details",
     "order": "23",
     "role": "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i2e86d1fdb89f494eb9ee243d58ff09cd_D20160701-20160701",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "flks:RevenueFromGrantsMaximumAward",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i5a151b2cc8444c79aee3f783063d9279_D20220112-20220112",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - STOCKHOLDERS' EQUITY (Details)",
     "menuCat": "Details",
     "order": "24",
     "role": "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYDetails",
     "shortName": "STOCKHOLDERS' EQUITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i222ce181634a4cce9e9e36ac4ca82e0f_I20220430",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i66746fb43d0340e680dc791d2b399feb_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - EQUITY-BASED COMPENSATION - Narrative (Details)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails",
     "shortName": "EQUITY-BASED COMPENSATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i707f525a92ca4ce1a0db936dd13045d4_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i66746fb43d0340e680dc791d2b399feb_D20230101-20230331",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - EQUITY-BASED COMPENSATION - Schedule of Fair Value Assumptions (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails",
     "shortName": "EQUITY-BASED COMPENSATION - Schedule of Fair Value Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i66746fb43d0340e680dc791d2b399feb_D20230101-20230331",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i99580c61c8454190b396ed58334ece96_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - EQUITY-BASED COMPENSATION - Schedule of Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofStockOptionActivityDetails",
     "shortName": "EQUITY-BASED COMPENSATION - Schedule of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i66746fb43d0340e680dc791d2b399feb_D20230101-20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i1c04e18316394009b6153f59ba41f585_D20230404-20230511",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.flex-pharma.com/role/SUBSEQUENTEVENTSDetails",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i21d8870425a246ecaa7e4fe2677a54c4_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i21d8870425a246ecaa7e4fe2677a54c4_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i66746fb43d0340e680dc791d2b399feb_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i66746fb43d0340e680dc791d2b399feb_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i66746fb43d0340e680dc791d2b399feb_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i66746fb43d0340e680dc791d2b399feb_D20230101-20230331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i2bd45e30d3c0413c9f0cdd01c63fbe3a_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i2bd45e30d3c0413c9f0cdd01c63fbe3a_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i66746fb43d0340e680dc791d2b399feb_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - ORGANIZATION AND OPERATIONS",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONS",
     "shortName": "ORGANIZATION AND OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i66746fb43d0340e680dc791d2b399feb_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i66746fb43d0340e680dc791d2b399feb_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i66746fb43d0340e680dc791d2b399feb_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i66746fb43d0340e680dc791d2b399feb_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - GRANT RECEIVABLE FROM CPRIT",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.flex-pharma.com/role/GRANTRECEIVABLEFROMCPRIT",
     "shortName": "GRANT RECEIVABLE FROM CPRIT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20230331.htm",
      "contextRef": "i66746fb43d0340e680dc791d2b399feb_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 18,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "flks_AccruedExpensesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Expenses And Other Current Liabilities",
        "label": "Accrued Expenses And Other Current Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilities",
     "nsuri": "http://www.flex-pharma.com/20230331",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "flks_EmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees",
        "label": "Employees [Member]",
        "terseLabel": "Employees"
       }
      }
     },
     "localname": "EmployeesMember",
     "nsuri": "http://www.flex-pharma.com/20230331",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "flks_EquityIncentivePlan2015Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Incentive Plan 2015 [Member]",
        "label": "Equity Incentive Plan 2015 [Member]",
        "terseLabel": "2015 Plan"
       }
      }
     },
     "localname": "EquityIncentivePlan2015Member",
     "nsuri": "http://www.flex-pharma.com/20230331",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "flks_OfficersAndDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Officers and Directors",
        "label": "Officers and Directors [Member]",
        "terseLabel": "Officers and Directors"
       }
      }
     },
     "localname": "OfficersAndDirectorsMember",
     "nsuri": "http://www.flex-pharma.com/20230331",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "flks_PaymentsForAcquisitionAndStrategicCollaborationAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Acquisition And Strategic Collaboration Agreement",
        "label": "Payments For Acquisition And Strategic Collaboration Agreement",
        "terseLabel": "Aggregate payments under ASCA"
       }
      }
     },
     "localname": "PaymentsForAcquisitionAndStrategicCollaborationAgreement",
     "nsuri": "http://www.flex-pharma.com/20230331",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "flks_PrepaidClinicalTrialExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Clinical Trial Expense",
        "label": "Prepaid Clinical Trial Expense",
        "terseLabel": "Prepaid clinical trial expenses"
       }
      }
     },
     "localname": "PrepaidClinicalTrialExpense",
     "nsuri": "http://www.flex-pharma.com/20230331",
     "presentation": [
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "flks_PurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Agreement [Member]",
        "label": "Purchase Agreement [Member]",
        "terseLabel": "Purchase Agreement"
       }
      }
     },
     "localname": "PurchaseAgreementMember",
     "nsuri": "http://www.flex-pharma.com/20230331",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "flks_RestrictedStockAndRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock and Restricted Stock Units",
        "label": "Restricted Stock and Restricted Stock Units [Member]",
        "terseLabel": "Restricted Stock and Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockAndRestrictedStockUnitsMember",
     "nsuri": "http://www.flex-pharma.com/20230331",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "flks_RevenueFromGrantsAwardTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Grants, Award Term",
        "label": "Revenue From Grants, Award Term",
        "terseLabel": "Award term"
       }
      }
     },
     "localname": "RevenueFromGrantsAwardTerm",
     "nsuri": "http://www.flex-pharma.com/20230331",
     "presentation": [
      "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "flks_RevenueFromGrantsMaximumAward": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Grants, Maximum Award",
        "label": "Revenue From Grants, Maximum Award",
        "terseLabel": "Award amount"
       }
      }
     },
     "localname": "RevenueFromGrantsMaximumAward",
     "nsuri": "http://www.flex-pharma.com/20230331",
     "presentation": [
      "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Grants, Revenue-sharing Payments, Continued Payments, Percent of Net Sales",
        "label": "Revenue From Grants, Revenue-sharing Payments, Continued Payments, Percent of Net Sales",
        "terseLabel": "Continued payments, percent of net sales"
       }
      }
     },
     "localname": "RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales",
     "nsuri": "http://www.flex-pharma.com/20230331",
     "presentation": [
      "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "flks_SalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Agreement",
        "label": "Sales Agreement [Member]",
        "terseLabel": "Sales Agreement"
       }
      }
     },
     "localname": "SalesAgreementMember",
     "nsuri": "http://www.flex-pharma.com/20230331",
     "presentation": [
      "http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONSDetails",
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.flex-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "flks_StockIssuanceCostsAccruedAndAmortized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issuance Costs Accrued and Amortized",
        "label": "Stock Issuance Costs Accrued and Amortized",
        "terseLabel": "Accrued issuance costs for public offering"
       }
      }
     },
     "localname": "StockIssuanceCostsAccruedAndAmortized",
     "nsuri": "http://www.flex-pharma.com/20230331",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologySharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period For In-Process Research and Development Technology, Shares, New Issues",
        "label": "Stock Issued During Period For In-Process Research and Development Technology, Shares, New Issues",
        "terseLabel": "Common stock issued for in-process research and development technology (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologySharesNewIssues",
     "nsuri": "http://www.flex-pharma.com/20230331",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "flks_StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period For In-Process Research and Development Technology, Value, New Issues",
        "label": "Stock Issued During Period For In-Process Research and Development Technology, Value, New Issues",
        "terseLabel": "Common stock issued for in-process research and development technology"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodForInProcessResearchAndDevelopmentTechnologyValueNewIssues",
     "nsuri": "http://www.flex-pharma.com/20230331",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "flks_UniversityOfUtahResearchFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "University of Utah Research Foundation",
        "label": "University of Utah Research Foundation [Member]",
        "terseLabel": "University of Utah Research Foundation"
       }
      }
     },
     "localname": "UniversityOfUtahResearchFoundationMember",
     "nsuri": "http://www.flex-pharma.com/20230331",
     "presentation": [
      "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "flks_WarrantsAndRightsExercisableTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants and Rights Exercisable, Term",
        "label": "Warrants and Rights Exercisable, Term",
        "terseLabel": "Warrants and rights exercisable, term"
       }
      }
     },
     "localname": "WarrantsAndRightsExercisableTerm",
     "nsuri": "http://www.flex-pharma.com/20230331",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r160",
      "r191",
      "r263",
      "r267",
      "r274",
      "r275",
      "r285",
      "r287",
      "r292",
      "r317",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails",
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails",
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r160",
      "r191",
      "r263",
      "r267",
      "r274",
      "r275",
      "r285",
      "r287",
      "r292",
      "r317",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails",
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r150",
      "r264",
      "r286",
      "r291",
      "r312",
      "r313",
      "r318",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/GRANTRECEIVABLEFROMCPRITDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r150",
      "r264",
      "r286",
      "r291",
      "r312",
      "r313",
      "r318",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/GRANTRECEIVABLEFROMCPRITDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r160",
      "r190",
      "r191",
      "r220",
      "r221",
      "r222",
      "r262",
      "r263",
      "r267",
      "r274",
      "r275",
      "r285",
      "r287",
      "r292",
      "r311",
      "r317",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails",
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails",
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r160",
      "r190",
      "r191",
      "r220",
      "r221",
      "r222",
      "r262",
      "r263",
      "r267",
      "r274",
      "r275",
      "r285",
      "r287",
      "r292",
      "r311",
      "r317",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails",
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails",
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r307",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/GRANTRECEIVABLEFROMCPRITDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r8",
      "r290"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r3",
      "r290"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r228",
      "r229",
      "r230",
      "r304",
      "r305",
      "r306",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r75",
      "r80",
      "r91",
      "r107",
      "r141",
      "r144",
      "r148",
      "r153",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r241",
      "r243",
      "r250",
      "r290",
      "r315",
      "r316",
      "r352"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r88",
      "r96",
      "r107",
      "r153",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r241",
      "r243",
      "r250",
      "r290",
      "r315",
      "r316",
      "r352"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r23",
      "r89",
      "r276"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r18",
      "r23",
      "r28"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r18",
      "r74"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price (in dollar per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r10",
      "r77",
      "r83"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 5)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r40",
      "r155",
      "r156",
      "r273",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r304",
      "r305",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONSDetails",
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.flex-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollar per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r2",
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r2",
      "r290"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 100,000,000 shares authorized; 2,468,297 and 2,255,899 shares issued and outstanding at March\u00a031, 2023 and December\u00a031, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r79",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Financial Instruments and Credit Risks"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]",
        "terseLabel": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]"
       }
      }
     },
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable": {
     "auth_ref": [
      "r64",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning the effects of any changes in a parent's ownership interest in a subsidiary on the equity attributable to the parent which may have occurred during the period. The changes represented by this element did not result in the deconsolidation of the subsidiary.",
        "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]",
        "terseLabel": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]"
       }
      }
     },
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r63",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r21",
      "r140"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r67",
      "r68",
      "r69",
      "r70",
      "r71",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r194",
      "r224",
      "r225",
      "r227",
      "r232",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "EQUITY-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r103",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r122",
      "r124",
      "r126",
      "r127",
      "r128",
      "r130",
      "r247",
      "r248",
      "r265",
      "r266",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Loss per common share, basic ( in dollar per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r103",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r124",
      "r126",
      "r127",
      "r128",
      "r130",
      "r247",
      "r248",
      "r265",
      "r266",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Loss per common share, diluted ( in dollar per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r30",
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation cost, recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r346"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost, options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "verboseLabel": "Employee Stock Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r44",
      "r86",
      "r100",
      "r101",
      "r102",
      "r109",
      "r110",
      "r111",
      "r113",
      "r119",
      "r121",
      "r131",
      "r154",
      "r187",
      "r228",
      "r229",
      "r230",
      "r239",
      "r240",
      "r246",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r258",
      "r268",
      "r269",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONSDetails",
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.flex-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE OF FINANCIAL INSTRUMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r72",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Grant"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/GRANTRECEIVABLEFROMCPRITDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantsReceivableCurrent": {
     "auth_ref": [
      "r300"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Grants Receivable, Current",
        "terseLabel": "Grants receivable from CPRIT"
       }
      }
     },
     "localname": "GrantsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.flex-pharma.com/role/GRANTRECEIVABLEFROMCPRITDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r21",
      "r37",
      "r38"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment charges of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r36",
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "auth_ref": [
      "r14",
      "r22",
      "r62",
      "r114",
      "r115",
      "r116",
      "r117",
      "r125",
      "r128"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "totalLabel": "Loss from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r99",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "negatedTerseLabel": "Grants receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.flex-pharma.com/role/GRANTRECEIVABLEFROMCPRITDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest income, net and other"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r9",
      "r107",
      "r153",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r242",
      "r243",
      "r244",
      "r250",
      "r282",
      "r315",
      "r352",
      "r353"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r7",
      "r76",
      "r82",
      "r290",
      "r303",
      "r309",
      "r350"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.",
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "terseLabel": "GRANT RECEIVABLE FROM CPRIT"
       }
      }
     },
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/GRANTRECEIVABLEFROMCPRIT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Ownership percentage by noncontrolling owner"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r18",
      "r19",
      "r22"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r13",
      "r22",
      "r78",
      "r84",
      "r87",
      "r97",
      "r98",
      "r102",
      "r107",
      "r112",
      "r114",
      "r115",
      "r116",
      "r117",
      "r120",
      "r121",
      "r125",
      "r141",
      "r143",
      "r147",
      "r149",
      "r153",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r248",
      "r250",
      "r283",
      "r315"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Standard"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r141",
      "r143",
      "r147",
      "r149",
      "r283"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss before other income (expense)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "ORGANIZATION AND OPERATIONS"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r95",
      "r290"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other prepaid and current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other current assets.",
        "label": "Other Current Assets [Text Block]",
        "terseLabel": "PREPAID EXPENSES AND OTHER CURRENT ASSETS"
       }
      }
     },
     "localname": "OtherCurrentAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.",
        "label": "Payments to Acquire in Process Research and Development",
        "negatedTerseLabel": "Purchase in-process research and development technology",
        "terseLabel": "Purchase in-process research and development technology"
       }
      }
     },
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r1",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollar per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r1",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r1",
      "r290"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 10,000,000 shares authorized; 0 issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r301"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r277",
      "r284",
      "r310"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromOtherEquity": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from the issuance of equity classified as other.",
        "label": "Proceeds from Other Equity",
        "terseLabel": "Proceeds from issuance of equity securities, net"
       }
      }
     },
     "localname": "ProceedsFromOtherEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r61",
      "r85",
      "r360"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "In-process research and development technology"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r4",
      "r51",
      "r81",
      "r271",
      "r272",
      "r290"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r86",
      "r109",
      "r110",
      "r111",
      "r113",
      "r119",
      "r121",
      "r154",
      "r228",
      "r229",
      "r230",
      "r239",
      "r240",
      "r246",
      "r268",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r138",
      "r139",
      "r142",
      "r145",
      "r146",
      "r150",
      "r151",
      "r152",
      "r188",
      "r189",
      "r264"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Grant revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.",
        "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]",
        "terseLabel": "Revenue from contract with customer, product and service"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Grants Receivable and Revenue"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Proceeds from sale of stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONSDetails",
      "http://www.flex-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONSDetails",
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.flex-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONSDetails",
      "http://www.flex-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/GRANTRECEIVABLEFROMCPRITDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other current assets.",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r192",
      "r193",
      "r195",
      "r196",
      "r197",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails",
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r54",
      "r55",
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r41",
      "r42",
      "r43",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r92",
      "r93",
      "r94",
      "r132",
      "r170",
      "r171",
      "r172",
      "r174",
      "r178",
      "r183",
      "r185",
      "r285",
      "r299",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Equity-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "verboseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Shares granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Issued, weighted average grant date fair value (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r214"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of awards"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails",
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares remaining available for grant of stock awards (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted-Average Remaining Contractual Term (in years) and Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable, weighted-average exercise price (in dollar per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedTerseLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Number of stock options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails",
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r60"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r199",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r199",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-average exercise price, ending balance (in dollar per share)",
        "periodStartLabel": "Weighted-average exercise price, beginning balance (in dollar per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised, weighted-average exercise price (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired, weighted-average exercise price (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited, weighted-average exercise price (in dollar per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted, weighted-average exercise price (in dollar per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r198",
      "r217",
      "r218",
      "r219",
      "r220",
      "r223",
      "r231",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Equity-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Stock options, contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r60"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable, weighted-average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, weighted-average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r214"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r29",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r11",
      "r44",
      "r86",
      "r100",
      "r101",
      "r102",
      "r109",
      "r110",
      "r111",
      "r113",
      "r119",
      "r121",
      "r131",
      "r154",
      "r187",
      "r228",
      "r229",
      "r230",
      "r239",
      "r240",
      "r246",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r258",
      "r268",
      "r269",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONSDetails",
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.flex-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r131",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r25",
      "r26",
      "r27"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Common stock issued for in-process research and development technology"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r1",
      "r2",
      "r44",
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of equity securities, net (in shares)",
        "verboseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r1",
      "r2",
      "r44",
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Equity-based compensation expense (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r1",
      "r2",
      "r44",
      "r51",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r1",
      "r2",
      "r44",
      "r51"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of equity securities, net",
        "verboseLabel": "Shares issued, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r1",
      "r2",
      "r51",
      "r56"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Equity-based compensation expense"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r2",
      "r5",
      "r6",
      "r35",
      "r290",
      "r303",
      "r309",
      "r350"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r53",
      "r106",
      "r171",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r184",
      "r187",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r257",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONSDetails",
      "http://www.flex-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r257",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r257",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONSDetails",
      "http://www.flex-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r257",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONSDetails",
      "http://www.flex-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r259",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/SUBSEQUENTEVENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONSDetails",
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.flex-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r32",
      "r33",
      "r34",
      "r133",
      "r134",
      "r136",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrant"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrants and rights outstanding, term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r123",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average number of shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r122",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.13)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r293": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r294": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r295": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r296": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r297": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r298": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/subtopic&trid=2196772",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613673-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4M",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591554-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>46
<FILENAME>0001615219-23-000038-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001615219-23-000038-xbrl.zip
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MHRW"$,29:HY5I&*";1@*D)A(ADKG\D+F3U[(<^1E8@9<")Y$9)RSEG(>6<E
MI^G$ZS:5:"=&WN5\,,P$8CP#?R<UD+8\= Q;9C GS,@$&VLQ,9%?$\/4Z_'
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M-,)%4N"$@BVBE>3OD+BO[$>_"57!YD\<CD*JJ. V4<(0[(1SBN-(":M?;[W
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MN.<8W8<<"O @\;S-0+?W-[WJT!IK?WW:#.I;P7J]UMBL-6Z?9/PF]1>>=A@
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M%O&76QZ]3*3%B>8H3*CP%C%'*F(&)=(PXS1VDNNE558)P:F7^!TNQRP!Z!T
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M2)BV2/;S^):Q&(?Y2-Z@],D-RDZ=A#,WU5GFIXMSRT[OT!W+ ^JGK@_#ZG1
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MQ?)9>WLZS&ZQ9EZ' !5T,/2!==!*S!"O@C'(YQU <#9$K?K_W+QEZ<:;0V0
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MA.FAK1?\!O?2.$U_7WISM40+VP$RT^TT7/2O 3  W&00IA)F=0<V\J1\\MT
MB0>4!:#<_BOA=7&=UYW)$9CRN#EZHH LY 7\^A7M=SR1@QX(46_$RZYI%%>/
MW5D8NKW"K1O",0(I%]CAH%<^R=W@_ /H#G!T@C>/)L!;AG#?$($ZL8[-%0C!
ME>[FP87QAA5<V<&T0^27^,L%?N@)IBO5%Z3>6[[U1UX4#&5G9!RC'DM__O1@
MD@,O<,\>SQPQF7>Z"#WJ72%.WN-U,CAUM*$\;?BQSWA0EGE(' \#%G<A<9%0
M])ZZFR;XX%/X!L;8N< Y^BT #HO?P[#]N<&A?>JC 1 XU=1M:!=8,=J;,,*Y
M436"R[...O.:=.^BZ^[ 9P!G[A::,*XU\L5QP=+@6RPP'-G"4P]?=SM^$9!W
M%8/HHR<=!<UD.')Z1%[H$7XAELY=#QQQP12[$VT<:4F-I\-_[=U!R*L'Q1@5
M4.JP7'\<G./@3O240\.+AAH)%:<0R!XNY6C%Q?5YC,X&DZZ>D5ZY 7%7KN1W
M][HZ7I<=X*Y#!*<=SM(3^@/QM;A&\J(S]BS>3F!<'3?7D7'IMCC00DSA*I0
M-\5JP+S@+KRA8O!^]7 T!0?W,J+&GS<#5RN*<K&NRT3I7^[I"I^JY.BL'+=;
M_9JBDL.+8$2%>$3=QB#W7CPM[GL<G/D&(L<M$#[6K3W^@H__"@?6/=ZM5&X<
MA^BH#LZUOB"U SL^ QWH] S&;X(K6"5_HL<KJ.J_86P%3##RA#FA@]X7[0[U
M(!]+H-UE^U*\SU-^=SG<,-(]#@BX)LAAO ;X'$QYY/5#_X1R)%[%,#G2^@@L
MFF*%<6%Z$BBY.QIX00TR%G2J2W0U=V4^*%< 'CDR7:^C 0, 9C'NN[>YI:I4
MB:M-D*.7L%7#62T,%"T\9\CH.^4Y@Y$-W2(5FU;;#V OHY&=='&*GH%U.Z,S
MQYG@3IB)H[\N2*,[R>F_5CNT'E<B+DAR)Q'W#?IK@NWI6;NUR?.$DZF<E.XQ
M?R)]=M0M9O<!2 3/Q59A&0!A '-[W[%PV%^'VN+4K;U^L*?& ^RN&&6^N^(L
M:7\==(&_ Y]RQ\+9$7A^+N#@..[9'\))<HP4-=&QL[I /D5_4+!&<(& G&=T
M6<?=*T/%:44[ETC[(V#/@YYTA_;MSB&!2X9P@D[AC<57<"A@G*CV#F!5X+QC
MBHOG/VYH.(05@[N$F_6DD-A@8$D<2T>M>%'U! W#//,G&)]0"C@G_>!!H\FH
M8.^3?L7I<2= V0;&!WQBY"2_E^N_'7PZ:.[_OAE\ND"-R'SMP%C1:H#QNZ_<
MU.57V>DZF=CI^^@YW@NV6VU7"NF"/%(;$%\:QWH@K0$.NN^?"U?V.N.Q,6Z%
M\=[2AO7[TBCG6)DT7=0[E>E\=9M1W[+I;B$SK>3T]&,7%G$,=M)U8LG9L_#2
M#FS7V=4(Q(^$C?(X"VA.#_JHM")W1)NVNCSXM'FP&;P=#+P=M@VV4]#4/1@W
M,'6_$+^]W6[^CI*V#:J*ZPH:U<D6OBW6S<RJ&J5H#<!^[RO@SZ=#,*VG;R[I
M_*I.-9ZJ8"@-M]\HS*:#^8K:Y]@9SN6;"P&@ ]CY'*WWP7BJ#E4CN"VY%P<(
M"0]NOR@83K6-F&FQ&7P^ZZ  7?%]XQ8+4AV=)<=F=":=NM63SLY$H:2\%?#T
MU ,SJ>A^9I*X[,KH":AXE0BNS]0];G'SW%VC4>4(J$@!EPSY!*@L5]?^4=-#
M"2J/;!1:]'08)4^J=(XOL"?.2:7.<$\+U0X7 #0 =.IXZ\*E&>'+8.Q ?.,E
M>S"K7TE]YJP]I[&C:VKYG)R&.LD=!_#J'FARVFE/VA]"H#;8LB;8/UU??C95
M-1Y4^JP4JROE40L6*?9CFA5%E]Y6]OP7&*+;IX**K[R+Q^E2SCGB[9F2Q8+1
MY-?#>;H*X]E=[TTC/3T.LVRRW#+8'U J]>H8W.O38%!"H,6"65N!!\(!2Q?I
ML>E7HB6'7\#"VRL4[Z")+-.=V+G ZIPS_Z'6Y09_]URP_:4F.3R DI:M3FU8
M9RG\(ED*CW" ?O#)2T-W-X;BYD)W.HL$U8P)DR8\-%@Y0[D(8\XCS(MF3VT$
MO37Y<(+:GY<\T:SD<4?>26RG%]S,('^K!; .G >U^JX,9'E]X[T$W3V?#$]!
MRLMN3_;[P?^5O8N_X-6;LU&RZLKR 9L%MW;FP^P[%L1FZ6-#?XDI_%==$/S>
MT=/IN2_Q9R/PQ=:E%T)Y(3%R0J(^J^9A*_"5TZLFA,HQ:OM><3XMC3WG4-XL
M1EQ8/].'E?*V!X]!&8\3 '/M#"P"L/T*?08^[\I+,,Y,SZM".<ZI'%DAQWM^
M<TJW41E<1#O0@#+D]:]]#-'P*/Y-_OX;_[TRQJ9.J*;"1X!MS)BW 7IH;8%>
M77D%&V[>@\DXZ'9@?-);!-YM[F:A.T7TS(?-ZLZOMAQI^9]@J_"+>7IZ&8K8
M6Z0,IQX&W"MCN-"HFT71,N5LA(KXW2KX(Q5R$\')3U@&@\CR)(J9C;-<\LC&
M(BX23'C(?8))'-U8R@^KOF>=1M.>H'$(?[@W>_5FMW\(%M;(#^Y5Y*8_><K)
M'HRU?=ZZ;E_O7L'/J_;E"4T,Y[%51(22$LZQ6HXS1K)09I&-(@N";^--3--&
MDM*%)'-WMI?S%/^AXQJGP\%HY*T7H]V%+FSV#?9BC [9_[I#-<,]R8K$WZ&J
MK<*'[$[YOK-WC=Z[.UDEOS997;=/3W(N<FEL2#3GDO XED1F20Y+E8LH345N
M4KGQ)MI<!*3Q&9' ^[I("95ZLV"%/)T"L5PGNEG'F:P2X)N+TWF42, J#?%V
MF8T\K&<V/GG^(GWT_,4#6#'GP.N/FU7,^,.@B^&TT0O)2@Q;5?G2\?G1]7&W
M=:A8^]TG>GR^?]:F1W&[]S$^/H3SO+T;'Y]C>='9E_FS?-QKPV@^?6M?J_ 8
MSGS['8SS_ L]WNYVX3Q_:9UW>WOO=J*]=_NV=;C+]PY/3V(NC6%"$$NSC'"A
M,I)I)4B:1'D>2<-X'LVK_4*%.J,1:%"IX%H*R307+ 6V;)(LCLU\6N+?S8/=
M@V#O;?!A?^=@IWTXS4\\V'W7WGV[N]5L'P;-K:V]3^W#W?:[X,/>^]VMW9V;
MDQ;OF)IX\\!G)TJC+(TRHUABP/K)8F%U8C*NX'<*'"&JZO,>BW3_EJ/.:,_.
MD>V5__?7)MTO('N,DM8HDH.& +)'6)+GAI/,P.+*)!-2IO.D^-0LSFT@:D+U
M1.D[D/&+#CLNI.Y,RC3[NU0_>1]N;DQ_FN$#1AU&EP9H*Y:N_WNE^_RV\:[9
M_+ !YG;396:5@2M_\<A,Z[9JB4&G$QBVNPJ,0"-]ZH6[M\RUD1,P&H?.7H0Y
MX"O0O+0#EY[AQS$]NSB6OI9##>:6GD:4?MMH'FQM_.[L^247CX)/%RYK"Z_[
MM%&9MU6N_?*;_A[@BW[;>-L\^!NF_8JHJA[,YLN"V;;3Q=!ML(75V6X9G3>N
MB49]KTB0619F==$91YRS-[K<V(O"*3@-(!T8-30NE@C7.#*J/ OE']NF*R\Q
M-0W>Z+.#85@1 ;HE-':9>!@Z]FZ7$9#5N'S"0@38.^Z1! 93"+N:Q57WX&#0
M=QA\18C[[YM4'\S0&<X+K7<BKG1(DY!'/%*Y9"R4.4A[)^T$<X7B%,02O\%0
M][$'9U)]D,.]H5L7C[T_??7+,,&?04@U<6S?6H='8#/M7+4^GJA0:7A,2&RB
M# $+W**JE1!II>3,Q+GBH%&$FW"H%LN\7=*$HX<9!]Y^06,^_G. -#;-L?=)
MC#E(R9ZI9:\/%@\8L,5N-SCK 'T-7=C,O\F%B*OWEDF"P &[/DFB\(*AV\S%
M,8%]#X;C&D/W$5;OWBMN<_2_9-B;B^&HNN;WN'K63%G3+Z]=Q:W#CR=6R)B!
M\4@RA)GE,0/+/M:*Z"1*6)IF%GXLTZY>2 ;ZAZF.X",UT_U]1;(0-:R[J%)E
MCO"XT,S<>9V5.>Y0HP/O\FR >M/@$KWH]>(;SPQ&4ZO9Y8,.R^*8W$/?%FG/
M4Y]979$SZ$7OEU4+JK[Z-YSS%[(=RXFJ*B,-=G%%.KV:%K8[S?.Z38GOB]#7
M.\4L5J;<5PJ]RU\9U3[X_KW+57I\]]!KU)66-9QT"U*:%A!5).L2R6IQ'+QL
MYYM/QO&Y<3X3I*I!V]FJXE@8I5H<8RT;;],ISD-4M(IZK*N%5/MNUXVCGL.'
M8["#P=@;#$4NN(MF.?6_J ]Q^2O+P1[NMI)%OKU+7I'E:3J?]-6LLEH^:_E.
M8D+B(DA%F5+HDL5=0 P46N72\;QSML"TIN5Z:#C7(W/I,]O[<_4>S7Y_ J_=
M]RH C.TM+%D0A>1_"X5]JECO;.'W'C>;IF7BTJY_(M:=%74'/=F7IVX.W@"X
MY9*5BD:Y>_5BB=^*0B]<!7A#48XQ+8:I7?M[T#>8AH46 *@O[@6!E1W,N%JF
MPT_'4F:DH"T(+W$3G5E15I6,8$92U_/H6BI_N3.@7QD3@(X]/AL5.[3J85Z+
M.W3$ZM=F^:/Q5".)EW/#C&!,*E/>A"T.7GEOE>\V4+!"U;CL!);6=E"U=]3C
M7[R"> IY 91LS'A*2DA%0$0NI1?&ZVJKRH*%[U%S(\A!W=0#,UHXJKJJ-1_5
M0KN>VAL_<E3OYF]\1/WTT\CLV1T@6XRDC7Y%C73[TXE.I$HUUR14)@'[R:9$
MAD81"@IJ1".9L9B_8(WTDR_XJG;Q)6L)7FI7!6 K=,T']M%Y'P[:G_7\CB)G
M'OU80?-@JSS&HYIT0/;LDG5-N;9>Y(U&D]Y%61R%10O>18/N'\R$]M8JNEUJ
MU6\U'C*G(("6.W&RPK-&Y>2R[F!F2LFY!J/:&&Y6=+_K]GU*TGQLZUJ.SII]
MC3]VIK5M:S.[M7UT0E.E,EA5$IHL)YPGF@@K(\+RU.B$&9&IA;"4R*S$D)72
M0O"0RUR',K52JBR5*I8+9OE665[H?JEMP3WB:R^'7ZT(]=VT1M-:[[*D<.24
M",1O %95  ET^E]-J3LZ%C<8=D"(N)3R<6F6.*6IIJF!7M$M:A)RLU#3>:NL
M@%^%->R"#MT9XOKN#;<[(]"<97?/OA_T3]^C2MAT!=9K3M$Z/#KA"3>@_RA0
M?\*0<&9 _<F8((8FG,8Z#468SW.*7.2)Y7&2IIIQRTW&>99$L0A#9D6N%L*C
MT^U HL9M(&X? K\1W^<7WZT@>"5Y_@\*9AB%ZY3_7R_E_XXY*3?FF,P?Z51%
M)LTS.-**QVDH9:9H:#E-\YQI;58>A9<CFV_D2F\<Y^DZSE-B; S+2K "A*4S
M95679V!A? 4U'*%/QD[^E@5[:*1TAFJ"18S.:5WX.DQ5*M9!A*7AT/G%?$P5
M_1WH6LAK6!I=LQGL>M](=;4W&UR::[_ T3#??.JK0W<H# $8[L2AACE%P'8'
MEZZ^L#X!&.WPU*49X M/^[#"E8U4O 7,(!_.6S$$=^G,&)RC!MY0S*I^S3(5
MY-"Y]2[QGSNDZ:9A:F,: ZTJR96)9*CSC"5:1RSDL>9.!:"E"D!OT<BMIA',
MZP'_,EW]=C $0WHV/]=VOAE-KLUPL XW'Q[!F#]^:S5/8JK"-)>6P.X8PJG(
MB%2A(2'-J<QS.&[8BOWIVHBN]_KQ]CK7<2(E34BDHXSP-$E(GL"?*E;&QE9G
MTL0;;_J#)>CQ\WD&"VQI!E.GN\"8?]17_2,FS],[7AV$6;^ +=COC+YL#8V&
M$P*__7)4APX+=9)'0A@F. EEEA >*T4P@YBD:483S6+!5?[<69?UJ&P%).0]
M(&[[ MR_10?L:_!VO*V%,J=3<\I,A8K8O<)X_GF9;%-A10P"Y:<_A.E7D9.5
MX%-%5!;>TJG KS:]#\F!1#J#S"LJVO3*(..D\ U;HPNO+PQT@G$7/>BA3J3<
MR#OC2>&9'00(?M"#-7#CPD!@";K4&4W!..H5=V_]LX-M/X;:'5O33#Y,8\"2
MON*>*FVA2OFL1NLU)J\P+8S:U0,N*[&L+VT)  AKBD :N@35JW%._\YBU>[E
M''Y<CK>-P3AGDJ_]+C&(VI.,9:$-,TE2&5'"K<Q('F._EHA%1@C@ASQ[P6&G
MSPZ0YCNH72\@W%0>(VW&6!Z,R+5@TWEXX&+XM42(>?RF$I[P"@T_CT"'\$.U
M>V?OJ,$9SA6(5^&CY;93]3Q@MD:JLR*"Y,)="!=5(E.^1["T@ $WN)B4?N.:
M05I[< 7#6*53E+E>6_5<KPI.'4>R-PWFXY/1PO4),;./ABN+\4X7R,?II].$
M._!B;YKW!MITO:&=(Q!BPZ,)#<<-S-8H!(K#2YK&U>IA=@S+(P]T#-/S/)_Y
M? %LRD$SP7MP%'[1*Z2M;L<NK+"_!,4!L:A6NIP&&'<P+/%+E^_03*&[]_4X
M.WGVV4[8U<-WN!K#3L'VBPP'--EG47L<]-\4^6A0X@=]EUAJU%F4M!M,\K8K
M",C.^BYJCZV2(V YX:*2X& T/LL%H8 Z9EB^WGQ#A-J10UZ$I>Y,@[G."S M
M<BC&^=T34\ ZXMS13I@[-K!N#J'8'YM:1N"T%+C(R)\>H+Z'R/7H2KC%I$IZ
MK^LU15Y\L2GU1^<E5B?Z7F  EVXRQ5 <.3N\@7L&85\(#Z_@"0^'1<''< (V
M]2M+9)U/F+H8F@JFR0//UC&;"LQ?,RQ0SUP>0&>H'4N:TN(4$G90:U.!!3];
M^WLC7U;S!QZJ\N$^HM<YE8A&WIA]\6B"Y\+X5X-&.T$PWTF1,U2]<?J%RR*;
M?VT+7XM:[-=!1SE X^+DCDQM!IT:2@;:S-VK@J0G""L(J_RU@\KJ=/XPA]H%
ML#$&D<!QK.H,<6?U',08TH@_DB,SA<>M/0)]E [8?51*%H?D"J)F,JH8U!R.
M5LEY'=1:!=/E5]$_M)8IZ:%CZWE=N"7>#(-%FAEO112U%(ZA4Y<+7$3W=,<$
M0/GN.LCD,J\15'_EBG00U6UJ,)1@B_5W8I*I=!D=]<EZ>3"JK0%(-%-#GD6Q
M!H,JO*]%(LB2/2I>.4,2.,U.F2[BDT=<+FPM*7%UO=(-8,<H(;QOV8L#?%F!
M\3UOG9Q)C8#F]:SNVA!6>6-^BACSOD=$W_>N]76%A_?D[)R8Q')+4TTDK"?A
M(:<DHS'6?U,=Y<JF=+$B.L]5PD)%341S3A,&1E!F(BM2*6Q$TP5#Z)V7]QYD
MPXMH(.9B1X+7GG_B$/A6Q+AN6J@W\R#CH\%DJ$P=PA_/K4NB=PQ4!J=.H1P6
M@"7^TZT/^[N'F\&[XBM_XVP@"<-CP7^ 9<'*>#CV41%0J]P5!5\?%K?*T< #
MNL_A7V,I2F<F0]\/:9KNWT/DHRV/DEX?YJFG \?XOKH'^L++(NUZ873%# J(
M>DP&-$/?'\'/L&AA4$Y1CJIO;I[M/1-P'IM9>:;?[.L:YO:.Y_B>;_V*[.I0
MG40L-;GE@FB= [N*+26YIH*D)F49K#1/0OK<CN?]NLBN[1^(XM$2%\QK8&_[
MJ[00?["*>@JG,$[5DH*MH /!*T=X$E?J,VC2?2W\,5-_ I@'9*J9>Y5LF9VP
M&=PPQ-+1/7(,MW@(C N87-]T2>FC=1<WZ@C&UN"(\%]0V3ME[Y=YNZ/4 QN%
M!Z+H(E0T)A@@%C68S\5,L7A(JLK[!,<9E\R_PU5_.X,8=MP,7:\%?-J-$T3F
M5BQ^P>UKK.ZN5/6RJ7&KW-&*P+R5X1T'I$1.7DEJOVWL?MC?!K/0R;.BRX_L
MNN5VSJU"GW:(X9BSX4*@1?WR]]5QYXQ4OL;$FPX7'O/#RZ?"[NR?EN1^Y0,N
M@\G8Y80$A7TSX^MSDO0M?'V#'V-IZMW/A+_[L'EYT3HO[Q?+RUNNH]^42C=G
M_%C*&),V4TQ$'!2Z#!$*+8WCA$J;A/+1+5D'J>&Z%*%I#TS']UV]*)JQ[KI<
M!3BT'[#KS"^L+.Z>A%D4)IDVA"<:<0D5)YG,8Z*R5 D>Z0@^>49ET<FR'>=5
M)[[K5'U#7YN>Z%M?E^44/3 ?71<''S4@WN6H:O.;.N^G)J0NJVOGTA4O'9K1
MC+DW*A,9!ZKC-+=2 )>QFV75:IC&692VPK P<:%4W,I02OV-)79*IUZ]AM^6
M,MS?\S.I5PO!V,FH6.F_L;4@.5!G X>FX5L!SL4-'0)2X;I=$A#S ;E!48SG
M=MPK5=A=;W!5:K\>9-GUZVS6BO<F&#><IL2.3!FKG!H+531Q&F;$IC2J:)):
M$5P'NW3-7N:]T]BX4_MQ.O7]PIAAT0_6:>JP1QV-H;NKCNEZA\F*\"2,O6J6
MAG6#8#58TQF[(^%@='S:29G&W)\]&LX/+4<>CL!573OUO\S!\0LYEYA3ACO1
MHW_SVOK@AC^D&H.2M:VJA0><,=,=C(IB3E4=R5H7U7JT=>$TO]P4EQTY1(-A
M5()4K=W!K</3D]3F6MI4D(SIG'"0DT1(*8E(0.52*0?MZ-D3^]XCP#1LF\>9
M?Y5R$A$A5= W8Y<C5H/7PB!1C6-=>993AJJJ&V8;E]:/('91PBK&(@KE1X%'
M'"L83N$1#DS=L>.EN'(ST'-%@R&7<.!E77#0\8[@V:8$Z-(MIE+"7B!?PU+*
M(B@UM8.1C:*%J%?,WP7?$*Q,NDCE\G6:>WJCX)9>&(S*SJQX0=4E>A:KO#Y-
M;+X$UQ W+M"<;X].](HE_)009N9>K$^C].D5&"FSBU=+JOFM\_L<_91)0;]U
MX*LB^6<R5*Z7X#3]!KZ%KX<X*,P4'W?&77Q<2;[.U>)B!]-\$?BL>M!R&50,
M'27=;YVOOZ\2CUZMJP%5?2O@2*H8-4KCR;C*EBD)=I8(&[X?QPRZ_=W:)MRS
MF"*<EVE-6,=R(Z>(23O%]+ /Q-9T8GMV7@0V72'1J^BF\.0"LGW>#-O7K6\P
M7MJ^_ACM?3Q)%7,E:V!/8BQ"9C$1F=&$9IFF+$IBG20;;](H:0@>+M98()7>
MC5SN66>U)I=G(Q?:NCS)K0RE51EA2<8(1_A/J00C1J81C:UAG &Y<!8U>)@N
MDDO!>K^/)N5Q<N&ZB[(!\LN!+]KM U<UA_+;6M-N;>^><!,F/*<)B75H"<^E
M(E(J2T+)$J'#.(QB^8(SROUN!K"=WP$Q>GDIB,6PQSCLHIQXFGP]#TU8P0T=
M#B[@0*0\; 3U>7O4;OQ\HP+:+3+/?$E<E;'@W^<3PZLZ83RPM<1@U".D.IOV
M G. XYB_VIAY4%4,7;N]4Z7*%;GS>M:]YE.<'=AY;L:7J/3,.LFF.<AE=A^^
M:?II7D+8KWHY9N'570I^KC[567J<8'Q@A<O4E9<E(-.PE@?NT5)@+PHD;1?(
MG)W!:.&. F-[-O>QV@A9<U/Y)&%<!GDJ,<?8V1;+5G?21_26QKPS9-H]UCA7
MD (ML#-VV/#8V;[;^6*<DQ V&?,%JU:DRUY1=I$?&ND\6[/CQ["D\2,W>LE[
MBX3%A::GY?UERF+Q=%_^9/K&>@!RU(.7#.HOGP$$Q L36[YR54(2(JGGV.Z^
M\&)5H("S!>E+WO*:D.CG\FE]L1A.=](O,<1P8J7=.UJ%<>KH<52F315\ YL^
MF_[*1YEO8('-YMG/.<#Q^MJNSMY>I)1B(D&_1HOE]8[^EI+M E&6?$66B);8
M:;DHSID?QJT>BR=F[FB-C3KS*1VH?TPAB^MSPE=?&B2Q*6+3;$U#=4XP.;M(
M%:EC/Z!3^7L:U'+\RMD]T!WMYN,L2-<QKY90NVHO\>']P=1+[,HW^K+KV.?4
M%BUR#69XP7^C]P3U0%\-Z6UC3P73YQ4I[M-GULH..Y74PPSF,1K8K@EX]6D1
M/)GE0/"JJH(47CD .Z%?P')Z_Y+\ACS^'.R&D>YX^.?[ #L_J?[25#X"5*+Y
M'F!YMSD%,;\UZ!9I._A=U<=K#7/T_70*NDZG6*=3W"H]XD6+^[U^\(_LN_[!
M$5W&_!<:"-^5D<SVWCW8:M9Z=:"RL&W@O.]_:P3OWV^A#E;UEREK*J<V0XG&
M7W]B<?OTH1>3X6A2]"WR-DIQ">C 0U/4:+H6PJ7J7ZD[U?>5W[6"5"UJ$:O!
MHJ_=-<.IWN[+5YR#%U:P,^X:_X9*8G7\@F$ HY"8A6(\?4X]%?3@ V%1PAL+
M[\ '=A'L&PMR0,VZ@*==-1;PVEUA4$TH5L\#Q>"T@S1?5H Z\"A@4J<%DOCB
M+:>#@48]IU%ZL'U*JNST8*Z#0BT"XB@G5GF8BQG^!D3<+5TTGKZ*[?M0K'2)
MMC?=1^G5'J=9H7_'*1P.YL&X=LQ .F6W*2"J1GVK:NL[Z1D]6_Q<4\"&/3^3
MFMCWWO JXW_IN[S:T#P]Q<*JL9E2BP\9N[39:7],O,-YSN_2"3:641SE5"G!
M.5=IAF@C-A4L3)C.:)J5KL^(DO*7Y9U@;??+Z,\/\LHEA+P=#&O'M]G7U>&=
M.;O5T7T5'6&?WM=Y^#%N7W^*]K9W(O@]:C=/$L%$J&)&1*9RPK/4$OA/$Z/3
M3,4T52S4&V_HYJ);?+8C[&P0ZED(IG1?EC1S.&CZ_-[=_@>?:+R\6F--#IX<
M6.OT)**<:T5S(B/."<^QR"P,,V)9K&P>9C*R$38(CA?=WA4E8!+TA=^#2E!I
M@RA4OCG;W4(I)@'EQ_ X3SCC5(G,PH]$H%L[BD*F;R"/90W+,<#HFY-ON[#Y
M!Q>:]DW+0<EV7XW6T9*;20;NN3S)\Y32Q%!B1$*!@R2&9":1)./"1C*![1+Y
MQAL>-D )7!DL^6ZR4L.G.[GLIV?E+"LHQ[70JQ'.FIT@;="]CR<BBL,H3S2!
MQ4\)ESDG,K<),1SV(4UY)JG%'GJKV0F62(^+TIH5A218(O+B"D1NJ _!]CFR
MR#MLK%+EI0,!*VV :7Y,,:<*5*#DMJ.IANA2$7T8H0 \G>8AM:K[=KXZ*Z?6
MOJ&F*_H6IPMO'0ZN8'VOJG=N!LV@9\H,E66%\;ZW*9H*TYS&[FC@$GI]G%26
M95R%\5.9/7WG?BPR(UV6%4[%6E")JYZ>[M+-IXR/PE&OM7@>#OH#="7VIET2
MUG'3UG;K1+ HIH9)3$Z,L& ](CF/)$E8GDI#@0-'XF7&38M*2G33@=76U /7
M!65)X]Y7%!T!AO//!,X\B+G$<QP7-"T@>YH'GX+V8--]2R+6")9C,KHS3?\J
M<1G?>]B\WWS4E='D]S^#EH\K5BQOYDKL,[;LP65,MNH6@^/KS3X)K>HJEE@@
M(Q:X?1CDF49("\M]ZH]PV>)%EAIRP%%PYI+"QT6%01DZ=44-532VUEX57SOL
M^!BBYZOUXOI&D> ]+<-WAOD%/M8'. ;P;NE*0P\F^0CF6&M[C!M05MCC+E0[
ML&R+X$M!HJPQVY)ZMX<A*U.ADU3;L6H;R>RV%)@G^(*J45<!4N:="D,S;1!4
M00E4W;;[L^/&8"WVOO.I_[)L\UP6]8\]V"SZDK "Q18=+OT4?.NS$A[.5NZ0
M,<ZH*@W6)9*:&]T,)92C\HX.MWQ>UE3KCJ!A"S2?D9#?<U&+HS&SL.@!J^ 9
MW3S_9?2I2\;TCP/]Z'=//LLWJKR,QE7:0AG2^M$-<L!O?ND[932Z.E8%@'K1
M):5LM'2!2.Z#R0B6[G+8&<,.PK?6#7LN':#^]10!L-JV8LMJL6K/4OV)\=?C
MW J$SWN]WU- O2?\M*6RYQ=5/[Q1S=W9Z55YT!6189^HXKK<P/8YK=-%1:H@
M9!#%#4=([MD7DQP4 %CID4<^<EFSSH7GW8NN63@8&5TSK+&?JGQE,]B1V+90
MZJ)ZI^-R67LX-^W"HG+E[86/LIHWNN]F)UY7-@<U'WK9V!&7K7JSHR4,+Q8"
M;RZB6CEB'0YUZ8>$Z^N&W U=<!^^5MIK6S<%4#C;>'G0<>V]PYT -N&1-=CW
M QAC&QLM'J)L;/;U'KK"I[@_H^VJL=J+46.O2C7VZ+K5^T1;Y\?P3'C']4=0
M-]N=O</];OL:_CML\B.Z<WET?1HOJ+'GK:OCPZ.K=F__R_$VJ+3;7R[AG3&H
MPZ@21ZWML_.CP[_/][:[MG6]\^W$9(G1F>"$)[E%%).0Y"&-B:2":IZG6EH]
M7W=,LTBP-(T2F<(K8Y:)7%)M%.R.EEPM@B[M-]N'P?[.UL[NOYM_O]\)WN[O
MM3Q2T(V(2W?5-Y?W-+EQP+,33',91S)2V,,(#E,L:21B;D(A>)8K(9]4KRT@
MJZ;:';)$;ZB/E@ 5E1X$WQ;WH4"4G% M1#'F] Y\N8J=]'61,N*S:DQ_"K0D
MJP?.:J %.M3,E*9-O&&X=W&!90SSWO,X35/!H\1*RT :Q(QF2<YU3D]VEY4K
M+'J^_)"F_&'+:\$OQ]?UU,SA_/3Z)$UIF-B0$ATG(>&"*2*XB4DJ$Z%UPED:
M1NC=BE8[RU'ON,M^6CAG<4235*26TX@)F\/V62%32UG.,[>?H(>N]_-N^UFK
M HA:UTW>OCQA4L!&YI28/*:$JS@C>8)X>S*)$J73Q"J%H9!D]>ZBB0DL^>R.
M.6R;P?:TG,\UZBCY_G/D"P5W?/D#\/2;VI(\YW)X_;H2Q O:Z7-WZ[I9.-<2
M5+TDN@L#NF<A''(BS,&$WY94G: 4-G FW,_=_KQ.^LMRIST8:_N\==V^WKW<
MVSZ];#5/K !S/C*6Y!)8% @%23"23Z2Q,A-Q E0@;@C4U@ I;P.Q>%NS*KG9
MK)JF^]T)R/N[68*/98SQ1S?&')D7 MBG$KT4DZO=*>C\O!6VW^U>M;9W6.M=
MB[7./U[OO7O;.<:(7^\C!SK^=MS[>-WN'9_-TWGK^F-X=+Y[V3I4< X4/IL?
M??ZG"_1.C[?/NNWSM[WC[18][KT%K6J7GNA$20J2E@@C!<A=D1 11XJH6%/)
M;6KSA,U;)#JS:9A;2CG->6J,L+ '*DZD4AJ,F63>Y/JPO_.AN;L=[/Q_'W;:
M!SL'0;.]'>P=_FMG/]CZM+^_ _98\^!@Y_#@^P;84@9\XUCNFA;[R"!5ZLSH
M2=?LV25TB&SWUR7&UK>33%-C=0B*?0H4"1HWV/_&1B2.LM"F CY5B[5_3Z<"
M? #3$7/V*BS/*2AE&:<HR\#&=U1"RXPN4T$MV0%6%H%>^F<E''Q\H\J)'VHS
M))@P*2]&YL_RE[]T9W31E5=_=OIN!NZFOV8)'S/'OQHP@D' %TX+Y[_P7Q=)
MY5FVF88I:C[C(?RGRQ<7*>>;3BGZ8ZP7OTOB34;IRJ_!1%OYW?<>&_WX8[__
M7<S8XPSV=H_]PZVO7V/81=SK_W<#F&Y5&Z#1O?$GO?@61+.>IJZQ"QOI]_"I
M)+<K//"D7#'K8KYWFXHOTG@!DW'G-IBW?6XQJ1"GM/'JYU_%6$K6-+,$-]!J
M+M67T^%@TM>D&*52QEC[UTLBX@7F'M:9^UQ3CY+7SQ/"31,NV#/J%3#?P 5E
M@G+L]=4(@Y>[)O_U>+.NS];5"KR Z=[!,*>1!G4$3'ZP^'EBE)1@H%E#DS25
M,5=\N:<WG,VV]Q17]B]R[8L*+/O7D0[[@SKBV5'O6W?O'(SYZ[^[1[U/WUK;
MI_'QX7ZG#<9\:WL7_G[;W7NWWVM__J=W_+G=+>^!=TV.Z:<$C?/6NW_#\W?
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M6(@!/]59^.Q$&-A_7\U0GAKWY3;H?Q5RQ/H\^/. ,69M1)ZG84S"*'$. $%
MMQ7 E)45L5%1;K&O[6:\!*7UN[F7)=R UY,P8N U?,1W'[KRXJ] RQZ:<$:E
MP< /Z7PC9QVM3?_/7W1S%(9_,@KFAC826)0!)9:;G.0T38F2L#5<<VVIWG@S
MZ)M"PT3^\MVXG83=#FF>LUCP*(M%EL!3#!<L53K*^&V**W_T$+M__@U;7B7
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M(CM-GRT@H>&_KK+/]L^O5^LBCE5'U7RL0H]B2Y'$O!T0Z^6#&MH"E*&VJGL
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M=E8?M4/=X3$WW";-F'H6[L:QL^#HC?OF+J)#U<4U[IO=\*N/<^X;%DG.;%\
MEW)BT'T"0P>[1^C<,FWI,=LR@_C)*\MHN;:SHW+./6HN\=,DOB<\;N,Z]8/6
MM?;;1U-C6XV/9I><:SR;3"^LP..F'C-IZUR$OBYLQ];# "[9X;XI7'(\LUI#
MC,?#N7:DH^T9N>^KDV8Y32]STCS2*4;W1^ZS3IK "AR;8\6,)3 ),(IUW[5L
MG7G,#85G<<^G[C<&VX?N-XWBL(^*PQTZ:7;#7*:=-*SQTNR*F<S&=^#B;<.)
M=.'Y6(CG>CJH$Q%PE,"2GAU;8>3ONHO-#KTTY;M*Q+>)-^U+AG&SQGZN\4MD
M?M_2AKMQ^"UHMNW;GA$Z+/2XS9EO!);OR,CV+(L#]'Q'B<&FV?;AB;YZL^WS
MXT_V^=$7CX6!8V'-.3.Q0X@O]2!@3&>F9P;<]D$!DF U&VX+_K)'DJ_1VW]A
MO7U9?^RM&%>3E'48G.O'#.?R+<ZDM$.=&Q&.:K-BW7?<0&=A[!MF8%B&'S]Y
M95IMQWU\?&N?W'V[FN-YJ^//CXW(]1PK,LR(VZ8;V+9OV7;@^T;H"1'../Z:
MKM>/@>S9#-E;P-5=W_>Q98C4>2S@)RMP=<=DTHL-&89.A'X_TV_\?HW^L%[O
MZJWTAB8YZ]!8B35A)>%W8"6VQ[W8M"R=V31HR/ Q+0O;$AD>Z!""F8Z]QUZ_
MQ]WRIVE/O<P_L]5XZ(=M3]WPK!UTIKZRL/E)% C!/-?10YR)QAV38YJZHW/3
M=FPC-D.'[XYI/8YBE.V;!&Q%:G?;)*#IGGP/W9,+4G,#/[)<5X>;C74N3*%[
MH"GJ//+AI@-/.%'8]!EJHDV;-#'^=<-*=Z"V-)V,'[Z3L6*5=FC$L2&9'GJ^
MK<,=6[KO"*%'IAEY@>M9KKV7"11[T$?E46@E3=ODNVR;K&A,N#;<N,=U:3L2
M-']?ZG[D1[HIF,EM*X@#5S2-BYJVR9NT36Z\*/OC16EZ)]]'[V3%2QW3Y(;G
M /,,/$Q[$88>^*:M!]*(_5CPT I6=#]LO"B'KJ\TC9KOME&SHK) QIQ+9NHF
M<UVP"L) #[BP=4.$OFV:+DZM;APHC0-E_4;-C?MD?_25IEOS?71K5IS4HD%1
MCM!-#Y/=[-#5A>OY>NP9/ P"-[;<J/&O/&;_2M,:^BY;0Q?ZBFWZCFE;>N3;
MMLZE U3FR% WF"V=P T#UVX&4S6MH5>UAK::UM ;*#4FBSS/-;AI"Y,#I0GA
M2AY+TW%=8?.04^;=?>@R3:G1G;:&1O9Z\L42'J@I9JP'@?1T;IB&'MB6K0>^
MZT6.QT(;>Z'MJ-9H(Y)J6D,W+1YW586T'4]KJI .A:F-IYF:&=B.9;JQ[C'/
MU7GD E,+#5]G</519/AAS*P=E2$]#C_RP9<A;64>-F5(!T[W9S/*#'/=@ =6
MJ#N>24,(+=US0E/W[9!%CA6%AC2H_U#3)+K1(-:K0]I.<VCJD Z/ETSI$)^^
ML-@P8PO,(3?P ITSW]6%C*5NV]SB+@@:,S3V,1K]:S:)WL[%\[BC4WOCR&F:
M1-]ID^C"YK$CX7$9ZJ#XFCKG,M"%'[BZ;\;<]UDL0RZ?O++]%J#$XPM&-37?
MAZAK[;>WIFD2?==-HA7GLGWN6\P/=#L4CLX]L-$%9P[647J!:8#9YCM/7IE>
MVWJ$C.N7;!JS!]Z:IEOT W:+5G1O.%QZT@QU+\2II$88Z@$34O>9"$!C,;FP
MP<)RVY[5=(UI-(A[]]8TW:+WFIG,N&O@AKGG\4CW+8?K/,:(=FA&NF#2LX0O
M'>9Z^YB,1^Z:YT-$E5?S;"Y*KE_]7_J/VEDP>#YA?N6'Y3YK+_XZRH=)/+XO
M,C613(]R+8LU.%U'N6843$O_C"9Z$37W;6G#CAQ([4;DFNCW!]EWH,*A3,?:
M;W=.Z+H]2^EONOTT&TMY(0?7H,LO-AG.LMZUS%%#0!K/+[.A2.N?O\[RX5DV
M_"1A<V%VU0.@1?52YXJXG<,D[E3^Z\/X\]]1/P!8GW4_=,[AV<]?W]Q\ZIZ.
MD9AQC4\_0G9V^:%[=GQD?C+?FY\N.]C  ??V_?3RTP_XV3I__R66EL\]-]0-
M3V#7!M?4 ]?T=1DY$0.]T!*,/7EEM.<#LX1!F^#(=J,#&ARY9QSY>F2>'7T)
MA32$9%P/O!CQ@KFZ'_I2MRPO9I('\!?QY!5KSYN &G"P%%$!N,\0P0XX,:A@
M#"@QN03X)1]J YD"PXG@R_!-=6G (>$JM$S=1:NM7:ZST V\6 ND)B+DM_ 5
MD.U:/,(*)BWLH*Z0:TE/DP7^$ +#SO7J#_&DXJFE)3%\80RO[D@-,0=^T>3W
MO@R'.6ZUV@GP3S%4&\A M&@"/BHL%NVF,&5TH6P9K4]IR0B:5?88<%$9A!8+
M!?>X"*S "H. .X;G"M^RK'7LL3LC$I58_38;%'_"[STV4^PGB.?4/#WZPDPW
M=OR0Z2[H.3IWF:E[/O8/%Y$CS,@-;!$C\<RUW]009GE[6J7 [R!Z)+V14+G4
M-26C*P9724]72@Q(_FD;:%KO6*:OJ"L*F._;I@@92&XKL'W3 J8<15'(36[Y
MUA>'/UF@Y,R_?S<O<Y]LJFXMW<FNU2UWH;IU=G[Y1F/&2KK>A9]E%.3ROR,P
M<-Y<8TW$)2S^>PK,\H$I[6Q<4%KWKZ]G7S\99W_\U3W[^N_NZ8_W'-;@0%G6
M:?<]/_OZS3S[ ;9%]T-WEM(^_WUJGGU];WS^&^BR^^G'V?$5[/<**"L<?SZ^
M,L\OX427;[M@EP"EO;_YP@. FFMQW>*NIW,S]O0@"H1NA+YGF P,!;/P90/M
M )=#_N0Z;LQ,S_5#P^9N #+-#!PGEG%@A[9E@K8A0?+W95&D\NKBX^\7;]Y_
M?'-VJ;WY"_Y[L=3Y<3M"+B;-&?)6]WC[-J>/Q267+G<M!FH<%['MB]AC/#1-
M("C#BMU[-3W.>V!RC#5;F1ID850B%.V,7@9'3T! !V/M[?&1DJ#PI;'6 4%)
MDCV5I!+ @P-YG<@;TB8FR_PSU_)1T$WR'"&&@KQXLA>FHXB>5$MJ(6P/K3UM
MB.?2NK"O !?-X?JBMG8!8A\D&9"2=BRO99KUJ=2H4!T&:!MI49*'(WI3>=>[
M *59@I+6>9& [$W"-8#;UBJ,FQ,,Z^!@\2?,]O9628N=H<J&YUM,#[?B]PP]
M@$UA^*8O/8_'/(A=8+6&&?O8_1Y6\;PGK]X.LJYVU!\DJ<8+FQC4.L1;QA8A
M;IZED;99Q)^%!I?,LY@#1I9A^('#; OV'@C.8MNS"W[/#:[XO<UN#?V#37(>
MDZ&B0O?P"[U9M?@ZZ5T.X#+4YFZ)ZN^)@^N^!<<Y[/7LZ^F/LQ\GWT^/3XWS
MHR^!9\1N%!FZRV*I<UOXNA"@N-EN9!J^;7B!M)Z\LDVWY;CFO+US='FJJ>M'
M)I4 \P &U@7D*/YXDPP[VA4V?-7Z@PSM7_KB]LZ6GT2K>8NZAE6OP=Y*(JGJ
M*)$Q)M<R.M\<K1[:;'Y@M&)G-U\"*PH"QV=Z9/I@0L=>H N+V[KIQ[;C<#.*
M)$,KP%KB_BSMZ$5\?G=B:#V)OI@IW\YD1SW )6*CB&.Y=G0UD.2Q;\^?2IO3
MI+;4^]<6<;>L7$" FZH31#_+R=I]00X+H(N7-TDT[)11D=J#Q5Z,R2,B /$Q
M&BY_I+9'5$;DX/[#Q'31S)DQ/FO_7=]\<XW*?.M4DQ?[XDKJP4"*;[J(X80O
M1'HCQOF3Y]/7"1<W _AE,)N^>6_NXI>#,([7IQ!_#;@I% ,>F"G&^8+P'K\%
M>Q /NP&M,T"I\7_6N+4GKRXIFQ.D$P;;41'^O\_%JT48L8>H.\\_5NV00CP3
M@J4*2-AI*OJY?%'^\!)4_WXJQB^2'KV/'GHYC7>(H3,A)7J?^KA 7M]O<V8C
M_A:IP,6+"]1N$VK/Q+G49UZ;V][23XTV6_K9RE7]ML7-M9:])8%YG_*4YSPS
MQ#).AK*KF>TUDA3V_RRGHB=4R)M"I^[+7#NNK%.R@X]Z(AWG":F8;Y.>Z(5H
M]@(Y1R2)Z#L?P/I-A_25\WZAZ^53\)D.@VXF<E<[(1_ K"3"0S=^#&2=W:!C
M/IH&FBB!EG>R$9AYY"$0$48+0$7Y.NHIG9PT>51F1CTQBA(*,50@3GI*+R[7
MQ._ULB'P-PJP@FV9E,X)_#WIM30!QH%,4_PW&PVT^37S(5@'RB&A@A7UY5!Y
M$G!.VB8^?Z]J(0$5L VTMQ00JI\-AG?R_@VO60/HOX5[T)BA_R]Y<? >T*VN
MR1["?FZZ;0O@G<('U>5>O'F-JZAZ!C#ZR!> <2# CQK>%. G5Q&&3_0TR[XA
M;M4NC;Q02>\Z2Z\!HY+\F[I'P"?@)/#P,)%Y6SO'NZ>\-O)+I<5MXUZ&21>7
M!$+-92I#Q Y)?E]X/2)JE,0QG 6-2(0F&)(QNC6&G2S'^!9PJZ1/P35 $5@O
MEZMVBQD Q0[4&S%HE6HQ["T;8$2,\!<?4NOG<HC+ =B4FO_DG1@,M1--UXCE
MLB/XZ0,<6GNK5GA2@N\A4?918"Q"CUR3>14.0"R&J\FG\+A%B"337-Y0D@=A
M :#Q^Q'<%.B'XP(.]3V\IY G7F^%&2TM3;X!/J53'*E<;$!+M+2\#ZH]K 2K
MBKSTUT;P=?7S;:_5GHYZ8"(B[JNST:,)OB<"H0M(_$P=YT8J?!N*;\AAM2P
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MG7$$V@38$&"]=(O06+6@.B_I_3^4#Z8$<@5*H4X);P9;+>NB*J@,)=P?*FP
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MX8S#; F$XP\1;[L(7^$\+CM__Y63_[ZF__W6)IL+T9]PN?ST)U!+ P04
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M)5%SCIY3.056C)+$*4LZ:Y&J1SJ?*V'69^MVB; SE3 /GF&JG!FN^#@BI5'
MB0/Q'C21D6OP3',3JM<?/I'<D:7(LE3NR#)*VUBBP"*@GGKNR%**6RAC8!6I
M;ZYOE&/HM\22()%3L00X\58X(K+R@C&1%*W=5/:QY([49\(RPMY([@@$$54Y
M()/ $9#$7=RZX(EPSJ.-:&-TM6MA=C9W9"GES,T=64:R&\L=^>UD[^CLY&#_
MX/"?>[^^/7AS<OQN__W)X=D:"2+S'EDG"V0IX+<OT(LZTVR3,SQ(K[3GG+EL
M!4#*7'#9F??P-8]38BQQ\5$YJB[VR=L!&B&3_@3%!+FVHX6F2+%@"!H@0"1#
MM]];I(W(D0;FK6:^M@>S*+9U%Y[?T/ :WWCP_N5P6*)H1GM+G<]$64&+ZY"F
M%S0IK4"Z[('73K>8 67SBU KO+B]+M40? N)$7>;<A^/SV%XC1.]2LX==2[B
M;@OXQ3-.K)>&>!&"\\(!A?;O5KR-Z@=E265UM-HZY3N!--) J;SI]GT_=OL?
MKR%/_#L$)R.CMC0Z+V7-RI3>X)I0)60V ES0U0/@JT'=5.AG(X3:A+JV';L9
M#<>=]\-!NHSCX^$I##]WXZ24WJ84'"1'<E1H^46!LR1[1P+W1JGH@M(+;6KX
M@AM\PY^NN3;KW=N/S+2H[T%%N5=<HF[@*6.=(AI=U8TL &J9B,MBI+@+9+.1
MECHZNJOP2@+>F/;!4ZI]R(2:XE*:Q(DS(1)F4H@Z4&WM0I';W=+ZC*#*!I6^
MC%Q;L$8:JWKJYZ,[*5$9DFC*_<0P<DDXXJ463+%H(M3.LKSQ^LT9I!45<I^/
MLH(T-Q8UV3]^]^[P[-W!T=GIWM'K_>.FZ./@:,W*F@6>6B=VLBS\6^$3;Z)P
M&84O$L@8O35&9^ V TN!@^DL\/QUPY;]T:#734T&V%L8C<[.??_W\T&O]_7X
MSSZDZQ8"[WWQ;LLOAZ/S[J=#-/B&,!H?Y Q(V^.\?UZ.@D9'<..ZF7)CI3(R
M$&,->C::*E+NGR%,)9V5MLZ;^MUW6QS0NHO;NVY_,.R.OUZ]Z]O+WZ,]B&#\
M1_CU:W/(UA\CO_ Q'R<?Z41E0D:J$.]Y1FO.:1)*FVSJ5>0"?0<%M8\25@:[
MC0R176'Q[05X,QJO&$9J,D=/X#/T+Z&D)4^B7._\E^[%Y<5><XT;ETY*'46Y
M:P^]5YO0YN ^$_Q/6:]3-K<CBS,2>A]\S3.+JBNC=JN5.\@:2&<PO.C(X"W/
M21(K4KEL-I>[^1@CVOM DX]&&;4:1[Z]XYD@==50L=SE?EC37Y1LS)([-TT+
M1J&.N_CK=/6+Z<IXG%$Z33.:3J9:HC]3KKY.OESSR=%H1?,U!)Z<D<XGN5CW
MGFJ0GKFW526WT!"F#?E.\Z!49#QE13247EO"L.)R.:)<QM4Z:<-C_?NC6AK,
MYI(H=XWMN\6370C0?QM9$XC*W+,@6"!,@T&9BD2LL9X SXP!_DOI%G+UYH3C
MOGOIMD+R.\*!00U=5([7?@,R#5XM J5BC/[6ZS<?F5]#$?>I<PTIMJQ8E937
M@@N2N!?EPNM K!6!*&D]2TFBO;G0Z>\N*/2!H'L[^EQ&>+6=M@_];M/(8_SU
M.'\8^_.K(KPW@\O^9$6[ZOFHO 6TRH@(QI<[UA,)6AN2%.+#W9-:GQ:RNA=]
MXV8#[FOI9-"V0#<6@#\].][_K[\?OWU]<')Z\(\/AV?_6B/N/OMA=<+M"X*]
M'64/QDIP.7K/I [.@@G"4,X /0O@JC/[L6OZ%#T_&DW[M%Y;GPFX"]9DD@RH
MTH?"$I<%)5D;[TN<S]CJ0?'[@&RH3E8+&E.DF3#*:,G8C<0FRHFP'D<*.M#J
M#11WMDYV;3ZL6/"ZC Y::=^[2-TD\S8F#>CV"PFE)[4FCF5!?&89'3(=0ZY^
M-=&.%KQNBB=K:*!ZV^[[$;X9#.>T"SB#>-X?] 8?O]YFO0&=**[W)"M;.AAK
M()Y+3:SD&LTX23/E"QDP];$]9D[M@KIJQZHK#.=.%3AJ-:)U9R5%<[(DXMF(
MWRG!!#?X8]@<^7Z<]6P'E-5"[/EW/YR<V_332??C^7AT?#D>C7T_X=B:8QPJ
M;%8Y",*BD41R%8G77A-E([<:G)?5KU6:A^DQLZ@5N;?0"&DZXBG,XV$#\N +
M#&-W!.^'W0C?_CB:_G7$.N!%!I,2,4&&TCZ'(YG+S0_.4,:,0C](MN-?+ ?T
M1V!0^QJJV."H63SO<'Z*MDD<+YSG(),W$H4 #HU 7C)**4/I9. F1YF"62SL
M,^]-CUG_]4790I^A>\EY8XGK: _&&O DQV2)%&A[!4DU@:Q"XAY T>K=[>=@
M>LRD:$7NK78(:@;]Z]<&\.0 *N7DO/-H>@M:ZO*I)-YI1TP2C-)D#%6U\PP?
M@+.QX^;Z#G<E&6_[H/?;>&9>)9:$M;9T_W8BHNT<:;GXG0M"8X@Q)2V8K)W>
ML,-W/JZI[84O;UQ&ZMNYAF\1A,^7-ZZBSN7OXUM%%]MA38X,6#&-F2W]N;/-
MQ%F5$*FRU(+@2==V7A[=Y8TMDV49%6SF\D8>=(A<H1<N-)&0#)I+SI.H=7!)
MVBCH8@VD'\WEC4NI8/[EC4O(KW8EP?O+83SW([B-*8=LA1&1:!H8D89G$L!E
MHL%JZ4N),E_,RYSQ@A]+K36DV,9Z_F"++P9248>^C=#%RRF5ASZ:LF %I*!(
MUBI?_3QOIULK5C8.JTF_A8LN[F\#M@BHI]XC<2G%+=09;Q6I;ZY'HN5"6PV$
M:5]RL0T0!](3926H*)AFOO8J\5AZ)-9GPC+"WDB/1$H9\];B!N84)](#Q960
M6<27@B^M_B.UU6LC=K5'XC+*F=LC<1G)MI#R,PU^3L%$D,70-$1+3HD47I+@
M/6YX@5DNO9.4M71^^>.H>'6)5LX$/RDE"\T"932(P"6N30G?+V6(Q'/E",U:
M,Y8B#6&A\X,Y.>#?7OBC6'"K2[%B\L$W$%-&+0*C8J7&C5=OODIC1>'?5M\:
MDFMC3D[A.*=M,E20($RY) R!67")0'!<&@LES?TQ*/"!JHRZ^EM&8)7U-BWE
MGP()20IN<1F)TA:#+V=B/>[>0BN=')I^UB]TC]4<S7WWTLT67:PL]D$-F6VL
MJ&)21/#KWNG!Z_WC=^\/CDZ;2ZZ/RA9>[DU8H\1BT4?7*;A8:2"WRR]4BLJ@
M@4.MD,E(BZH.L?@T#'*6N;/H2]8,5I5TTU_]"%*QRG"1F5QZ=WV#Q:]?KS\R
M+5-O&BF\_78@+)U47+I > 3<ZW.T)*A$B56)%1U)':H?3JR->NT@WZH(CB[+
M!$6;J<GSW?N,.BP6TYO!L.D4T$D* (U70[A3)7A) QK#"0TR1A/C-%IO:M_:
MU]98MA!MWBR;[\0>=X$4;52JK#JNB;]WV!^-AY=-@XNFRW.I"S_^U-R),^F.
M<=B?Y"IW.%B?)&.$&I-*QC%N@\4Q%$K:$*6@F5>_=VA#8WN>#+M FC:.>S8T
MSM^A),Q!VOL,0_\1FC^^]F-XX[O#)G&_@W9BMC)H A#0ZD<[CW@?/:HL0KD\
M-'#W6&?/W,$_3Z]'0;L6SM16%D3SY9\P&G^KE6&=0 T(90UQH90VH,]% F6.
M),.E,$90!]73]BKB?YX%FU)^"_5.[<WH,DY(5S/Z;##VO>OI:Q*/FDE)M$B9
M2*H9\4K@;II=$ Z"UWEG'(ZU1OH\.7:/4"V4AZT\ZGNWO]^&@]&H$YE4BE+<
MTVP)I]D Q*>H2*(A6IYL4J%Z$7[]83Q/@ U3H6*5VG=#"O.'%.[,Z2^?NL/F
MPU.W25CJ65:4<$BB-$%%P7HGB9!:T8!B]^WXVC7 /TTF;USM+53?K3R0>W>>
M;YL.ZS GI (ET0MAO)Q[N9+^G8G(IE21>:&K9TRU-99G=F^#%"V4%!Y<?.H-
MO@),KRZY7\I'@_[G!G\SHE%C3-W\^_Y@-#X:C/\%XQ.(@X_][O]":A(NIH/O
M\.Q=RNBG2)H,D1XW(V>C1KYZ)8-G7LC:YR\;&=B3FP:[1Y>[<\+N[)SXUNYD
M^JOR.=;Q6FDN@R4ZED0DYC7QI4LER]9PD$SI^&@FQ[TC?)XENT.@N]/%5:Q*
MGR?VT2RY3U+R;! J.EEN3J&42)TE<=X*XB+G(7 50_UC^EK@-U7QOFT[:"O*
MWG8Q?<E>.NN.R[ /^ZG[N9LN?6^2QH:"4RA' L(&(HU/Q%,4K43SC5D*,IJ%
MHO%S,K_N??D.9-5ND@.#FKJHG YX!]#OW?'Y"?0:>91>Q6>#@_ZX._XZS2=?
M!&K%G-TEX6T^K[>"0A^B1PO:V#*!A%*F7!!$-(5R/Q#.(1?+;:+9@1%>NQMW
MU3]VXCR03[Q=WBRCA-H%]U<VYFB:3JMR (0AB.4QEEOG#'&4*Z*,ET"#]\K=
M*NF849=]Z\&;33-N50.#2N*K76I_G#-Z"</2CNQU=P@1/WH%2V?JI40FAU02
M%[Q"3SB(2(QQ,B:/6Z1S"VEU]CM^4 57$FH+V5CO>[Y?&@TT2U6PVCMF'0DX
M$N0= +$Z**)99KB$F>1D[:/MF^]_FB;DVIIH(4?H"LN4]XN@::G@_GLDVZFT
M7UTS,U2\AEA;7 *FJ!QS,N5@28KE!A,:96DKB/ZYEC'0H-& J7TPM DESZFA
M;TO'RTBSNE4V34LI5R1V/T-!QBE35T:&Q7>K%(FPS. @-45S@^*80S"21:NC
M6>PZS =?L_EPZSH*&+0BO18J#"9[#GYXRM>H9&2XV0#51%H32!#%Q5#19XE&
M"5>U.[!^!^!I;]RKZV(;29$S!7$]C'ZZLU'-'U-;31A;&,]VK(@U:+)LFM:F
M=+R-ZI!5QJ9<D@"Q:9$&1(;HB6-*$(-KMTC.)1[4D^7M',-HQVF[C&I;H.L)
MC,;#;AQ/<P8^H$)&)Z<?KEHFILBR]H%D3BV1)J&TC'=$T<"%U=GFVTWPU^;=
M@X!V\.R[=9T/VE)8"U;=+7!34-!<"*IE\4'0U.3:EGH]2Q@S6HO(F16U:VSN
M!?+,G@H*JNWCW4)4+I&XA^%70*,TRC)/0.E,I)>:A(P<IU)ZFQP/ '8AEV^9
MMSYAVK2KH3;Z;5[E"ETGP%UU)[*"><H022A%PXDJXC@'(A(P(01%Y[JVBSD3
MS!-F5%U%M=$';'+FF460P>&KDT,0RD?BK6<$@@90^$?F%HHA/J*6;EM*/EE-
MYA7+R.ZT,5L Q@_8 &X9X<]J +>"Y%IL .<C%Y)33V19HV0(N!65F+BBE@):
M-)(']Q@4N%@#N KZ6T9@M1O H:2NFYD!Y<PU%T-)7^YIIJ+<00^$>@O2^!RR
M7*A2;5X#N)LOW5X#N*7$/J@ALXJ>W]U.=-1&+5QD)'DEB622$@LZD4B9]HHS
MGA8KG7T<W?M65M[*,ILY\S;4O>_*9!CD;W57>Z/1Y<6DVJ1^2[_%WM=JG[\5
MAGRK^9](S $ "SQXB9/1!A E#TI'(4+485;SO\7>O/6.@,P'ALL/$).9(,AY
M3GQ9AD)2H"!QIWGMQM:/N"/@?:H\Z8[^>#,$..R/88CN]8D?PW2![V0N50B)
M$J^*:6UP@P\.5YM8(C761RKD0MFIFY#NDF/;04^X+MNK=2AHDS2[U$%PX7%.
M-M .]9YEK8%8QB.1UGO<@',DBF>#NXNQ]OIVRD<S.29C>YX<NT":7>H@>-\X
M#[Y\@A**_>>@I/WVNN.O-Y<!Z[E-(G,2A=1$>JM(*+=N>4E#$LDD<_O2N-V:
M'@^.[GF"[ 9Q=JG)WQ(CG2X&SIG &>Z4$'W Q8 YXM$;(S%0KB(HAN-]A%/D
M>0_9)>*TE2FW2A.5AT9Z!L,+ULDZ>I4ID&R%PI%93[PK)<Z2,5#!2F-WIK?.
MW-$\S2FP?6+L4JN_AT;VNM1.03^5J=WA1HLD(!*PWA(I2EITQ&TOY^B945SX
M^K=UMCVHISD!=H8F;30%K'9L*YC+K,QEQC@.!($3%SQN9%24 @$F0JS>%/ )
M-@E9B\U;4?8N- FY/MX,FF576O%$D4JG9D#1*9EPTAGO$L4_+^;&/IU\C*5T
M?6\^QC(R;_$8?Q$8/UX^QE+"GW&>OXKD6E1D JICTHD84WHS.I.)8\X2\$'9
M%+3"]?$Q*'"A?(P:^EM&8*WF8ZB@%!H[G+C$$Y$^"!*<T(12)E6VN5P\]^/D
M8RPE]IGY&,O(K-5\C*2BEBZ$PC]93 \@CC)D8J:X!W@+L-@-%X\C'V-EY:TL
MLXWE8YQ^^/7TX!\?#H[.#OZ)7T[72+68]:@Z610+ ;V5()&-X#;C.ADDDY$:
MYYW4-',!3##%66?60]=TI"[#"/Y]B:;3P6?\<FVP:ZXAB6B( 1,+C]!\2C'@
M]/76.,$#E=6#PC.PK.TL^F]7-G]_[=PA.KFEB_(9VI0C'XNN.S1%;;5G1#G(
M..Z0B1>EKXM5(%Q0R<3JQZE+X-M"**,&0^ZX=&VII(V3_&NL^P,T@?"IC2MR
M A&ZGR$=?P?64^LCB^AVY(SK+PV6>*<BT3YZ+FS4YG93AIK\F0_PQR-09:6T
M<=S]O00F_JEB0:!7BG L943F[(A-EJ-Z(0@/S*3J3<SOP[&Q&%(K+%A7L-L.
M\LP:R%6UMD63106;"?"$ _+&$1^EP/4OYYQLC*Y^-/Y^*%L+"*VMXCF<6474
M&U@C\)]-J\P6 =96[XY9H+;3@*.*ZN;380VY;Y0804$.U*.KQ[3"E5.BNT:=
M+KM:UCY;W/&J'UULEA!S.EMLE@_+B+M]'DP=]6RYXMPH$J1$4)H'8BW'E=!8
MYP,/6>N6.;"UBMXZBGI8_2M(N0T/!$%U4]</O]XP>QNFZZP92SA4*B(KZ0B)
M>.T<818LTY3:8-OPTN\%\T-9".N+NXV<P!M>L[_ ;V_X.%/N+X*P+6-A+KKM
M60T5U/E !*.B+MK8..8C=<Y%$9PG2I454WA&/'"#NV:VN)C&J%WU\J4ML64!
MDV(K9%E&!;5;T!1XH[V/0VB<VJMB=K!)&P:$ 0<BP=MB1 $Q J@57B"BQ5K-
MW/?T+9@+E54PJ"F_-FR&L1\W<"9=4$L.Q:!?LB8:,N.[03JJ2L]R363DF81L
M+,E94&^\M2)6O][W(4 _CNU03>PM)$S?PC2E_2*@6C(9[@6T)2NAGN)N=_JI
M)O46C(/[P7D692K;7) V$FDH)T'@2HAKH,!M4/% :WN5&Z3"/!-@PTQ81M@M
M, #A7 SZ-[OAT6!QA0N4V&P"D9PFXHK+ZZ&LA1:X3;6U?P?$Y@V$"LH9U)3L
M3)M@1EK%]-?E2ZEK^-M?_@]02P,$%     @ O$.K5C'S?X(S;P  .K0$ !4
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M\^X?^M#4WQKD!7BI(/;D6.8^ZG;:<IACV?71P?EN:$;\.LAC@X +L*0 K#D
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MZU.<."NEHW)[TC'[[?>J,HZ*MZL!CC_H[@ST*_N:ORQ>:I<VRC$G>L)"2E0
M2902<S>N+2Z<4D;#))&)5;&MO9:'9BG5X.Q]=K9Y:IZG9TG?\?RL<7ETY3LJ
M[1D>--OM]>8?<U",3>^7PP]X34QU,WE3Q7;JF-7]91S(..)8P5@@O0-":0 9
MDZ'>!DG-'@YBAIU"T=PA#&T>KZ#ZSDO5- QVJW2WY':L)D[DJ5K3OI:BD]OH
M]B1VF[JJ"< 04EA9$&29RLJFI78*\!>]8YG7"VJ<A4&:R!CR@'-S2IM!AD4
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MVTS-QK\7H]I=Q80#7@JM"XJ\]&V9R,_S&9NKIUQLY(_4OWB:J=+E9409ISS
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MA.]Q"].&-5];'*>^^]T"M:%E;XO4JI$S$G_PAL#J.JZ:'XFK_JLJYB;TL*[
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M.9"#PC82?%=GB&<,D>_CQ7.@M/0&G+Z\Y/-R0VQ\?*9EIB8U,7F:1IP(R47
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M<JX>?Z"ERYMX5G(QUC/^;OZL9E>+V<QX,12%TC/;I+%=+XMA'(19F"H8IDA
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M;_2<#+ZZG+F9:+.C+,]6E+$NC\]L4M=%+A-0%C>3J@C6**)9%O ,P2Q(M/7
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M]K@A_@4P! ## %A28(X;]:=RJI!8?]O?EN/VWEMC5]C?Q[:YY6!XVU*W[7\
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M2)VJEG<%=&@JMI[],V52")0^QDO$()O.P%-5?CNK\D[656;.B*OH:O@M]?0
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M_RCKX%,MDA?=95DN],2XG,@/^4R)_[>ZJ^MQ&\>R[_,K]+9IH A0(BE2^S!
M3=(9!%N;RJ;3:"SFP:#XD1CCV 7+E>[\^R4E^:ML2:1,JK1H=#IM6^*]A^(1
M/^X]U\"^3W,JH$*Z4 4H."P!ADJ  J$<F,F!)L(6'2'NDM#=[<QM".\MK5_Y
M!UL]-'AZ(.T?T &!BCRRKV,T?&+G!9:'7E$8T":2*_)\P/QDBH:1Z%4IZKE\
M.I&B81_.-(H<?CZ"&.^%V#XKV8H=5?L0J3;.\>&H2+'0F)4$JAQPQ9!9+5G&
MA)""+./(T*>9Z+C%+/@U.S?:; T_2+S53_>FCCH4C?&G,AX>#.'>$0[L&@7>
MR&2[1W9O=')_B.=L[4X>(B/K0<51$)Z(F0,A[<?8WH#U$KC[W:;C<V\/S^C=
M_VK_*-5W[?/U/\]\:\AR]?.S>MIL=XN"R5*0U,Q^2YS:@J5F\0JE !"7N2QL
M2K5T6KSVM#$W'M^;F1SL3!I#W4-2N]#LY^= &$4F8W]XO.)/!P 8%7G:=<_)
M8DX'G#J--AWZZ;@MJ2:NO66,0[((83EAE%  2YT!C+4$O! $I(@))@N%N/;2
M^;_:RMR&]_X]UJBK>:JI7<?1;9?J9G1BS[)J^PXY9%$28WHQ"+1Y=;V-2?>P
M>MU\N975_^,1"S<K]EC=?]VJ>H.LW4N 2$I%2@I48<N;91J!,B<E0%)(F<F2
MD,)]C7:MA;F-\]K&Y&"DQZK@*GX.2ZM;48F]&7T.R)B]JJO(>"R-;D5HHE60
MZZ/CM\SI<[YW17/UPND6+WUVGZU3>G_H7SGLLXT:JBN%Z@)C+CD#*<X,=Q59
M"0J;&*-S0:C2J.0*N]8,.]QU=GQEG^IJ5\NW_[?B-ONP&::>M5:/L/53UF@P
M)C@S&X&#5^6P"[]OJ!EVO-=DU<(NS#^M$W;YY<C4-%Y]L__:K(P?9F37R>YF
M<K(4.R7M%[98X-D')[]L LLO55K%ZME6#/_U+U$+'G_F._6KULK,H3.*",I%
M!I0-ML$:YZ!,N08D4TPHED&)]&)GI3G<UB+3FN]%)@<GX@VBCVJ7R-9L*W0L
MC']W]9^).KK95'L]@%!_[YF"-^U#XK;0FF_71Z;.MW4OVS^3$X_NDJ.S2?.3
M)I;K[,/S*QH4DBNRV7?) 8MD#T9BT4@:. +F*KY*-X9*A)S6^&FS+%^E8RY2
M.%_'BC"JQ"?"O*TN[P*ED.8("Y C10#F4 *&80$()8@H0@M)O2J\##<YMQGP
MJ5JQ#*%6? 5EMS=(6.PBL_ZEBO&;*[K/W:E;-TL:=Z,32=[X2H.O*G7<#<"0
M[''/E6,%)=;59K64]0[)@ZJJ+X;(_OBV6:U^V@+"TLJP+N62;W]^XG:_\5!5
MN*X*:.BRH;OJ4;<E2<Q,\L%8_&&GOE<+0DI$<88!K@NV9$B# E((1 $UR6&6
M<^E5_B"JM7.CMS-G[Q+K;K(S9B>-PTGM<7)TV<S":J>38_WLO=MW[62KLFE[
MK>MWB9WT_\NZG]3^>T;>QGUR'&?N<WD>8D_49_,HC% 0F:"+@JF1Q+1U8F63
M"6"_5$F9HM&QDFIO38M;OOJPENJO_U(_%X)F+$=0 T[SU+RA( -,*PVP, \&
MUP5-,?&34GO1PMQ>**T@6&ME4IN9&#M]I=-> MG/U4'@B<ROWLB,D$CK\/X&
M:;27=YQ8$JW#H4LIM*X?WI@MU<C_V,SQS=JNT>LS# IS6&JA@$29 EC*%'"I
M-2 IDB33A?G*:\;9V]KL!GA3<NIHI-=AD!O ;A.S8+#%'OB^B(W/N^I#(G0:
MUM6V7B<KJ\_MSB2MWHO&[JA5REQD=_G>J1]JM7FJ&VIB9)M\S@4J"8>094 3
MJ^\@;0YFIG)02)I#"'.=9D[GQAYMSHU"]B8WJ39'HQN]9-_MM6'(7??7@@(9
M?8.M \/6X&F$(CPP"[;M-MSBQ/MNSA!<;KRY7SJQUEE;1>+7O]16+"N;SOJ'
M6G[]9NM1_%!;_E6UWZA/VZ50"Z41TEQ:Z;., @R%!HP4#%!&6<Y3FGD*Q$YD
M]]R(\<3LN^3/UG# &\L3U9J>/%G;:P4T:9:]?)L\J6TCAC:5%IKGX^$XGYM?
MI\<.*[I=*:WU_2XY>W;V_B<M /MO55)#, /IM'%]]MI*:IY6__\05AO7%<%T
MUD8V/_*%*+XI^;Q2K:Q;G[U5E\&-"@@M$,XQYH SRJT:$P8E4QQ(,X\O28$S
MY:GV&<JRN;W4]HX=U!Q;,>4NPJN.C%=>,MY(!9=@W>[X*GN-SHS]LKKHQ_X7
M5]7[YHH@/A,:\U OFV!V3?LZ"0WGQ0LC> .CHQ-$O7EL&_V\K/[]=JOD<F?_
MMI HQ9E9V@#%RM2N:Q@H9<8!41SE2G#!<B^9K)ZVYD;;[Y=KOA;+^J2BVFV?
MOQ^"<QN;$VNTYV9-']3.A_$A (Q_E'ZTL@;J[A2U:?9F'* *=Z3=V=+4!])#
M+E\Y3AZ\)-+>2R>K'6;$3\O&KNK#N@D.[5UETSR3-,T+D"*. <YX!IA.95T>
M.L60XDS['4M-[,#<&+ VW]:C<-F)>:YDO&V8T$]*H/V85^S_&6S,],]OSW9F
M#C#8M)<&B#GMT43JQZDV:T*;/Z]=FTB=X[U]$\N.L?+Y33!7(\;='IE\W*PW
MAH.-$>NO'Y5-WV.IU(:WA109P"4GH-2B $5!$&0I9QDJ_*3TAQN=VTML;[-A
M'FOT7;)6NZ,(G*_0O@/H;N^6T%!&?A\<4&R5^-^T%O]REYP:7<>XAI3A=P<I
MF"2_0Y,3R_.[@W IU>]Q[7A]LO?+2O#5_RJ^?6\^J1:<%C O! <$20XPX0P4
M)%, ED+0-..J0$X3\9XVYD8S!P&NQL[$&IK4EOH+E+V$LY]1 H$4F4!&X#-*
MH:P#@9L4RE[><W*%L@ZGKBF4=?UTW"S#T(/-T?RTW?Q82B7_\?-W,_?YL'[<
MT\>]V"U_U"J'!]DM2:$L"-2 04H IB@S8U_E@&0Z2X5D4*9. =_C39@;-1Q,
M3?C!5K]YQXAN<)N%Q 4W,J78=)HZ27YOOEV/OK$>F+G>+\D1]J,74>33QH,8
M:,XRPH!)9S#C 7HYG[GA3OZSF[?+W<_[K>)O-U(M>,E*R@@!%",),$PIX*7.
M00G+$J64<RR<EE(O;SPWLK*V)=:XQ%KG/G<Y VMXPC(6@MCG%F[>>\U,KKDZ
M:CIR=J/)YB#7S#^=>%S]_L:DDX=#ABK#"N:\1"#%,@68(P[*7&! 4Y@6J,A*
MY3;LNIN8VP \J4[S,#9K^ J0CCO>-\$3>T_:#YGQ2207SH?.''EXG735;@<[
M<T0N?SEN:/]3K<TK>G6_EO?R^W*]K.H#QQ_[+8E%R=-"I1D"$*=FG,M2 JX5
M!829Y8+A .XYS@?:F]N@;\VM]R7YF<%^ W\(9C<6" A>9$HXQ>W<UGT:2#AZ
M<$0E$%<,M38I<3BZ_I)%7"^[13W]L.!E2!K^2'.@8)$#7&898%EI_C=/.:=:
M2XV\TLK.;S\WPFBL&R.3/DH??8:K_\:PB'KH48707U,!W4WZ_,8%]/YF?_!M
M7;36ZK[9P]#J\7E7[0Q?F]7Z%[7]OE!8E5(3 =(RTP"GS,SP=4Z!T$CF4!)N
M9OH^XW:HP;F-Y+V]C>QG;7&R.9I\EQ@COOL-]$',W89^2"0CD\$9B(VQR>,I
MB%_Z0/0F"%=D E'&8'.3DHBK\R]IQ?FZ&S</'O5ONXWX][?-REQ<-4GNAY>>
M$I*@K*0 2<T!A@39RDD49%CEJ! D95B/VD_H:W5NE'-<2-M,AA.S_R-II1H<
MWJHW=(+G7D0H:"?;GK@!U?&;%BXHA=['Z&WS=;8V7&#HW.UPNG@D/1U4N6Q!
MAK:A6NM%E*F$@C. A)8 YTP"#C,(H$94%(P2S;T.3#M;FAT-\3:7RAHX3D2G
M$U1'B@D!56Q:\4')GSZ&$ A%&9WM3$L30^Y>4,/@!2-*0?V^7OXPX\N0RZ/^
M?<>_[64PWF^>UXVL7UO$!Q.%<%I"H(E5E>"D!)Q*!G!)2B)I(5CA5 K.J]6Y
MT<31;CL,K.7)0?OE:+M'O21G^/M))!JHD0G%#<\QA:B<@?4H3A4#X(D*5MWX
MX/K5L?+%J;>VE?/-IJMWY>O?60TL[XN#1LNUB:17P[14;I"'M 10I01@EF-@
MIGQV'TQ*;O[!!?/2#?(W86YT?S U=+1<7S>X31?C@AN9]@>BY8ZPOTZTG .(
M<:/E^@R80[2< T".T7(N=PHI__AA;2P0JJH62L&,**V RBW',9J# FD&,I*F
M$'&-A?:LIM+;WMRH[<,:/#66V?I>1_5">:)>N%/BVWJSVGQU%(QVA=Z-X0("
M&IG..N4?;8)I8VULE<<+6*(J/!Y;FX&ZXX7K;LJ.EY>-XYE]H99/:ENG9#8J
M$E9$HM:06)"<%5BC% B4(3.7@APPE3.@2L484D2E#/KPS$![<^.9AXUA&&-K
MDYSMQR-#T+KQ2$# (O/(H3S3 :]IQ$D<$0I$*4.M34HICJZ_I!37R\875GV_
MVOSYT?A@_OIA_4-5=4;!6EZ9+[U;5F*UL55PCRNY JJ""+.(4ZS.M=:@*& )
MM( IT;DF%/I58;K1H+F1DO$#U*5.EWM/ZE>WOK+<^T__<J<W=9T;ITW9(9%)
MKUX'6E_J[.VZ5SZ<]<K5U>#1I2@+PU#X!JP5>I,YDU?_# '>M7J>0>X;4D)J
MD9<JS272 #%L")?D!6"IE* @&&G))"L1OUWH:6X,VIQ'MYJ@XE241PW$.OM@
MZWAR>C-BL8]-K^D2'<5<CL07/$Z\'YJHFD!S4.[I/$GM__5(%9SO3WRYK4,W
MMH9\GC857SWJA\WZZ\/RAY)-).O+)0RTY$$1!'D*%<!Y@0'+I0(9R@G*&$FU
MWY[[&"/FQBU''^Q9E;4=U,8G8P+-1_6*&^_$QCHR*YW"O$WV#ER%?)IEZ"UX
MAE+<&6/"M H\-X!TH<ASR[U&+FU7O*H>=1M_^[BMHV]/@F_-=*I :8H, Y:<
M&4(D!)0TXX Q3C0B&90H\UJZ#C0X-_([1(^?Q-W7FI:UEF7E*68Y"+?C<C,@
MB+&7D]942V*ML9;;:G/O3H/P ZX4':$)M1(<:F[:E9ZC\Q<K.=?KQLN ?3%W
MKI:UCK!ZVFQWBX+G!>5I <Q\BP.,;8D(RE*@L. 2PDQ"[G3>U]?(W,CD('1U
M-#1I+/47 KL M)\Z0L$4F2Y&(#1*"JP+@INTP"YN.KD86)=;U]3 .G_K/\@?
M#.:K3]\V:_7QN0[B$P*F*3>+)\)@"G FS(0A4QB@%*.293A'TEGD[^7-YS:H
M:_N2VL"DL=!],%\ -SR(;X$C\N#U0,)KT':Y/&JP7MQLLD':Y<;IX.S\39R*
M3G7(>JM1W&[5_JS+AAS7WDH(BH09P%1K C"T<3E0%R C0D->\D)D?BDH-YLT
M-P(XJ_U39V(TYN_/1SRC=0+TF>,^[:0]\=I[NHTC=X=.:6LLQ=DZ"0?M1'66
M' R:58$E=P!]*RMYW'D<)Q\$"1OA91N0LT"<LMPJH1:,4H!M81+&L$U"SF59
MXA(1N\NRV?&5&\E>:<.+-0\M10Y$*I7>;%4CM]Z*L"=OVA,KSZV5:["Z\>"-
M8$4FMJ-4Z5Y>W1K8#8XW5_6X'XA\KK4P*9OTN/B2'OI^.C;SX\][(3;/:WO7
M3]O-VOQ5-%4CFKW<EZ<=@G,N,R2 U-B209$!QGD&!$O+C$+*D5^I(E\#YC:_
M^JQL$:K5S^1>;I[JFC ';\Q\BZ\EWTK?+!#/+G$CDIA 1V898_HIK.?&3W/<
M-!:]8*D?GLU/G/@Q#IS+M(^1]QG'?75(MY+5>^/0HWW)-W$J"PJ+C&*: 2NJ
M C"%AN(H5$";3\U:4],BI3X4U]'.W)AL;V9B.SA95M4S-^C;=:-J5$ J)9ZW
M=;A478O&C]6ZP'8CKP 01N:H<_1J&UOUE' D-(!"(*[I:F522AEP]25S#/U\
M;*DJL55F"?9.-?^U62#JB2_E.Z75=JMD&X)UOY9UH\T9^$+0@O,4"Y"F!%E=
ME R4W!XC4:F$QADKLW2Q5E^YF2Y\\:EA-<8:IR%2-$/DPJ:8PZ4V?1\ 6!T+
M6R6&9+9V@X2/"> 9UV-N)!2Q Z:JA=48GKS9N_!+DW76]$5K?MT5#8$-Q%"-
M*(MU"X+!"F6-,F+BTEFW '593.NFNXTMSOW]>[MA5>]E56>!.Q)*A*@&F1(%
MP%PKP$C) .)*,BPQ5MPOYZ2GL;G-LQI;D\H:>]=&Z@0*X.F#W(WC0@$9F<E:
M#']K,&PLC16SXX!(L&K</4U-7(Y[V.G+>MP.UXP0G?JL?JCUL[)3NW_6T6[M
M![81NTYLSE.JMQN[;'P^5#BUZ7:BEL;[J'96 ZM:Y#BU]6\4H"D3 ,LT!86B
M!5 9):4010Z54U1/6+/FQT^MQ<E3:_*=K8\MVA!K6X6TLG9[Z"N%Z\)^%GN]
MCHG,=ZT+B74J:;RZ2]H/0=4XMC]9--\<N_#XV:=C%UI%E=]>K0L]-+1>I2LG
M$MF:NDO]5+F"(]\KVQ6NM>ETO8(C=";\%?[N76_>TP?FP?SM[W_;?V+^L"E[
M?__;_P%02P,$%     @ O$.K5E(9Z(6N1   \@D# !4   !F;&MS+3(P,C,P
M,S,Q7W!R92YX;6SM?5EW6TERYKM_14W-ZT17[DL?M^>P**J:QRI1)EG5ME]P
M<I4P#0%J %1)_O43"8#B!I!8\O(F9?NX)18(W1O+EY$1F;'\\__]\G'TP^<T
MG0TGX[_\2/]$?OPAC<,D#L?O__+C;Y>OP?SX?__EG_[IG_\7P+__?/[FAU>3
M</4QC><_'$^3FZ?XPQ_#^8<?_A;3[.\_Y.GDXP]_FTS_/OSL /YE\8^.)Y^^
M3H?O/\Q_8(3Q^[^=_IG[X FW%%QB!@11 JQ0$:R5TGGNJ<S^_[S_L^-,<<\S
MI$0U?BU+L)P*2(QI_%LR8?/BH:/A^.]_+G]X-TL_('/CV>(___+CA_G\TY]_
M^NF//_[XTQ<_'?UI,GW_$R.$_W3][1]77__RX/M_\,6WJ;7VI\5OOWUU-ESW
M17PL_>G??WUS$3ZDCPZ&X]G<C4-YP6SXY]GBPS>3X.8+F3])UP\;OU'^"ZZ_
M!N4CH PX_=.76?SQ7_[IAQ^6XIA.1ND\Y1_*W[^=G]YY91ZE+_#I@YM^='\*
MDX\_E>_\='SV^\GYNZ-?3I#BQ1/F7S^EO_PX&W[\-$K7GWV8IOR7'_/H[S,H
MJB5\^=[_??./?[HAX=,TS1 U"Y;?X >K9Y2W[4U.^C)/XYB6G%Z_:#0)=[XT
M*G*>3*__Y<CY-%I\.HAI.#B>(/2/_&P^=6$^$")I'Z. K&D"$:(&FR('+6*,
M3B$<#;G+?:%\AJ0OU#)+X4_O)Y]_P@>C>A@K/Q31L(58'KQN*9[]Z+Y>A9?X
MW8%2/B3B+1!) HB4-+@<$SBCH\_.6I/E063??MM=JF^K]6@:?IA,8YJB&;E^
MG9N&!RJ^"^'5-W[ZY*;X( @?AJ-X_:^+/:FAJ_FD@N26:D%R?_P!N<YI.DWQ
MS5(K&YE;<#9'XYH6WZRA\7^[<E-\XNCK>?HTF<X'D01*M,] G47[J6T"+ST'
M*4RVSE.3Y&&8W?#BK7# VL?!(?)L!!+OTG0XB2?C^ HWY($@EB:F"?B4&0C*
M%#B6'21E8PK99118%4#<>>U6<.#MPV%_638"ALNI&\^&1? K0'-%N78D@@N,
MH^<4,WC%T,&20OIH@W NU=D=[KUY*TB(]B%QD$1[1L7)>#Z<?WT]'*6W5Q]]
MF@ZTI,0+A2)P,H)PR8!W5@-/3A"NO//>'H2&^V_<"@6R710<),$FM'^>W@^+
M$,;SM^YC&CBD5B5K026-@G"!@",6K5O6,AF94TR'>8OKWKH5"E3K*#A DDT@
MX10#^RF:L(7@+U#^Z7AR-9Y/OQY/8AK(3 V5!CGQBS\P''<*T2TP\%8RL:P\
MJP",1XG8"B>Z=9S4DW,3L+ET7TXCBF^8A\LSBY4EC"[9Q!T!KC*2+U4 Y[@!
M:ZQ(5C.*_E(%P&QX_590,:U#I89LFP#)48RH@MGJKS?#<:*#0#VC CTCE9E&
MT2#(K28)E-/":A02(;$"0-:\>BMPV-;!<:A,&P4&&Q!B79#H0SE9?*A$?1&+
M T-Y]$1$CN+I!!ALN^,K\O*0L9M06T+&,?YX-KV<_#$>((03M8X#6\3;6GOP
MUB7@3@69I+1!UG!!'KQX.U0T?*I90Z M86+A-)U-WTTGGX?CD :AW 2%),$D
MHC#D]@X<)QRR$)S83(D,M!XP[KU].W0T?-993;0M0>3=9#9WH_\<?EHXU<(+
MX[Q2P(E$+G3.8!Q"/BFJ LI(DYSK >3.N[>#1\-GGY7$VC,XBM4[FB:WH)L+
MDZD0&M C0B^)>:2;8K1E1"+H3*LH[6&''+??MAT &C[IW%MT/:N\W*&/WGV8
MC*_/YK(E.ML0@:B(+A"B$Z.FQ(!IB^;,N^C985;@_ANW4WW#QYL'B;!G]5^D
M<#5%Z%+F+X?S41ID;1)C@8"EB[L[H< I+D!9(:0/ED=SV*J__\;MU-_PN>9!
M(NQ9_9=35[*4+KY^])/1@&EO!:$:O$;P"LH#&)\CA&!%ME$SHP_3_9W7;:?X
MA@\J]Q=>(XO^Y$OXX,;OT^(D/G#)4TP!E/"(6FHQ"/8!=R\I8O)62?RHRL*_
M_=;M,-#P">3!HFPB'#B^FA9Q+>]F"Z11!U>S@:><J40=**4%"([,F)PI*&UQ
M#XN6^.@J! 3KW[X=-)H_?ZP@VB8@<CK&IZ$XAI_3*S=W*[8&*MND)!*>G)8@
MC(G@*/ZD T4V)'54ABH77NO>OEW^5/,'D15$VP1$R@7_]-C-T_O)].M ),DB
M3PY]'^5+7J "8W$_))'[()S02=<XG[[STNT T?P9Y/Z"; ('%Q_=:/3SU6PX
M3K/9@"CB)/4:F./H%PE)P1%E(7N)A#L2J:UQPWGGI=OAH/G3QOT%V00.3CZF
MZ7O<\GZ93OZ8?SB>?/SDQE\'CGBT7CJ DTB\B )%XH4$0Y,BQB2KHJF A[4O
MWPX7S1\S'B[8)O!Q\2&-1M?41Y>SE48 UR: <$J"<U8"S=8GD82*50Z?;[]S
M.S0T?.9XH!B;  $2_K$D^$S"WR\^H-QF9U?S4NE3(NM!S,%PS<M%BG.X]?&,
M6U_PZ"6S9 07&%2+"J!XC(;M0-+PZ61E,;<!&I3<U(U.QS%]^=?T=9"5R)PA
M[9DY4?))";@L#>3$51"")1MKY&/>>^UVT&CXY/)P8?9]7[4,E5X/9\&-_B.Y
MZ771@8V$2(,B2$P01+1VX V*)4OEC2%!'WQWM>'-VV&BX4/-*B)MI([CAHG7
M^,EL8#FCBB4!*3AD(6=1(FH&VDNMK.'1L\,R(#:\>#M0-'S*64.@36%B6:*T
M9$)+G4Q)\I)48GPME$$/VGN(3 9/-5'T0%NQ\=7;X:+A(\XZ0NT9&4?(05QP
M,7+O!\$83:-@&#;I<HW#,( 2S$&B0DN:F/?A,#3<>=UV)7\-GV#N+[QJ6O_G
MGQX([PU^<%#I_MM7)V\O3E[A#Q=G;TY?'5V>O/KYZ,W1V^.3B[^>G%Q>W&5B
MVYK^)Y]:K]A_-P8.[ )P-8/WSGT:+-+B"AC.\NOAV(W#$(W"9%GW]PUIMIQA
M"9\@99U!**? 2!$AL."$UU(^WB @NYE? &+UTN4J2Z/Y[/J3F^6V"UW[6I#K
M=QS-9FD^^\:EEB*K;!4X$C$.]S2"S\J"X<E9YPTNL,?,R#Y<WJ6@GQX#G2'A
MVN94$'>/V\U=ZE>N]C<F(M72!V\@D7)M[&T ]*O3(HG,Q4 =;JJ=8.8>(?U"
MYQ#-K@7)(6)N "O';O;A:!S+7R?_N!I^=B-D9G8T/W;3Z=?A^/WO;G25!IP0
MHK.PN']+B]&94F!5.<PQE!K.F OBL5/U?;"S%6$M8.D@ $RZUD8#$/NEE./.
MSE-(R) ?I>L;Z$ L-<8$H)&4DR"3P5H463#($=?1<?I8VX-]0+6!E'XZI70'
MHQH2;P X[Z;IDQO&DR^?TGB6<%V<S3]@4'%;7(/,N(K!8>C')0<1>0 O,#"(
MN!0<_A'"HYV5]@'1%F3UTVNE.T#5UD0#X+I+/)66&*T\!*48",(].!TH&$^)
M%!Q%QA[+13O8.>JG$TMW@-E?NOM#8S)WHRK0N 7NMY-Q6#%AA;2,*J0Z.\1W
M*GG7/%BP+"AI-77,/W:\NP]$UA+2PF95Q7\^7,S-F)$!I]9E4]J+V(@N&>=(
M,/4$8DJ:<,45;KV=V(\6=IJ*T=1.@FS 5+P9.C\<#>?#-,-=<7$!_F$R0J'/
MBO\^__I---R%DIJ=@(I0RGPEBL82Y,L9J@5!T%M>&2#;TM:O0>G\+*<3%35@
M>6[Q=7_G%MQ8[S+NMR*BGX],X1+4&MFA5@3OG9*^.[ U==[3C?8W0^P0530
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MTFM<DB69L#SR;\/YA^.KV1Q?5\;BQ:LP+Y<1:?IY&-))$>QLZ$?IS7 V'X3
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MU_8+'J.GWQ9)'<&JF@(: --O,PPQ3F;SX4<,+&8#06GP/AL@RCH,6E@&(X(
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M!C>ZG [=:*6[@8N,>ZO1J.@R#4&A.VXSR>@\&YMX2!:ELUUVP.:7O.QQ0+N
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MKA2,$EZF&24@SB2A7?99Z HJO_/2-OH![*2R20WY]:WX.XT,B F*VT A.BE
M4$' )!4A$*J<9)1%OU5);?5&$)U<^591_-[R:\ C?7)/W+0EOOF6@2VLD R#
M06 A61 Y8"@H([(M(RU1D5#UDS,/IKK?JJXV3NV?6?<O&>UOK\KB7JEK=O39
M#4=%_*\GT\7DAT&4">T#T<"L+'U+B0>;8@*40J2,!.-T[=2'KGAI_."U,B9K
M+8F: 'G)"^7ZHGDVGUXMS-=B='V9U[*,G&?+22FGXV7I\X EXZ*@%(@N(30M
M?9A*[STNA?%!<)+95G[F<RR<'7EK_!RYT874)8#^&RVLOZ52RY;BT><T=>_3
MXI>OW#R]=L/IHH? P"2;C4 G-Z62:1@MAK<N.%1Q2!B?!,_L2UUY3S+?^'G[
M][$TZT+P):_=Q1^_I]G\6\L/.O!$)RZ-!NM+EP5O&7A"+43-!->:$YNJC[FI
M2'_C=P2-KJ!#@=!&:[;.[$>13(K7]N-R,G>C&V.A(PN*"@&*QPR"*(QY)<=]
M/UO/;?).Y69"K(,X[?EHXH4NK><#UTO>B=9NU+],)[/9(% A)2&X^YK2P=;X
M!"X&"9'X8%@T46YW\/L<ZVLS&_WVRWFIBZ<2+-K9GOS30O /+,B73\/IXLNK
MT)(;XFB6!%B*O P?1E4X*X +)8E'1;ENSB9J$-]O[Y\6UL&S0Z"5?6$?QM?N
MD=^V1SJ@E@N9I,!(C;+2(-^6R8 9>-:E(8[CJOH$HJYXZ;>)T4M=&34!TL!"
M^9;3E::?AR&MU\K;R?CS@M^%!&8+E_'V[TOSE+>3^7^D^7D*D_?CX7^M,A17
MPAJP[&S,&,L)$C4(A]NF-4$AUIT4WE''1>V;T6=A;*LE9+_3)=0>=+[G]?2M
M0^[JH_(].G!**B:\ 17*& ;J%#B5--!L-$N"2A5>S,):R^%VE[#D?Y;8<Z/I
MY77YN\XUF>1OV_71;';U<6EHZK?^V^Y]'?<#W(/I1IH$6L%I9A1R5.A'L=*6
MB&F"H8<,0>)OO:L]..5[:1+(J<W4< F4,E,:P#JP&*R!([S4MU/N0_5P_7^:
M!.Z(V>Z:!.ZB_A9RZY<US8IF6S:<P&.Y_$D$=TD1P02-_A_!7]^?*/\,I1@O
MH!G@3LI>6XJQB^1;@,MUI6\B*D050>L29UN=P5)K(#DO3?1*4ENCDV1CI1@[
M*6M#*<8NDNL[(_].*8'T4O(4&-C((H:"GH.W7 $A5,AL<AD[^'V68NRDLHVE
M&+O(KV_%WRDEB#(HC*!\P7H9Q.$36$(1]9F@?7,FI>U21%Y>*<;>BM];?@V<
MH50(NJGSE*%L0&?*"\<,7*D_\E$FF2*SBM4>G_-,I1@OH&_?/CY)3[I_R6A?
M%]"?#V=_?SU-Z72,!*;9_!S#EM4F,,A,2.\C 2=+A8RV$<U_B!!*TPKC N&B
M^BC29^+MQ9=J[(396DNF2P#]MUA8RTUV0)RC6:D$AK( PC@'GN8 DF5-&-?&
M5)\6_5R\O?C2C;87UAX ^MX6ULF73ZETM/E]4MI+CX;SK[=-CG',1)X9QKM"
M8<AB)'A#)>J0^,BCCGJ[8Z&^EM:CW+WXXHMF%E<]$/TW65XKPV.M]HSBCIZ"
M\VAX*#KIBEL(GC 9DJ0HGQ>XO';8NUJNS&A]>>T!HE:6USZ97X])I@Q>I(.L
M@I.9),@E^A7H$X.SY>9?4)JD-T*;9I(#G^3FQ5=?'+Q\^@=)*\NEMB%Y5>:*
MI'$L9F3 M.*1IP#)N#);LC1=#[@]YQP<U9)Q)SM9-5TR]>*K+YK;>_:&S$M.
M5+J5"7D4YBB!^=<N\Y0>>=VSI2EMRW(;64I"E-L4C"J4$1:$IJY,759@N7')
MR$!(J'W/T'.6TH&55;>&"I]/1J/7DVGYY<"[I!P)!*B0Y6A1)G!H9B!DK@GE
MQ+G[X[1ZK[E;S\F+SE_:!<VU2^XJ .,E>TL/I;!LI#0PCC#J.6Z_5#D4@/&X
M!SO\221GB65<J68.ES<Q\4*O9RHBL[O%L@=,]EXGGQ99XQ=S-YTWL5K6E>E2
M9XB0*(BDA5RZAMZ@]YI)$#E'ZW,TC:V7?:NWV[MW:7?%' J5%O:6XAF?8F2$
MP=#5]%OCE 7;L]LU4R=?TC0,40X#EF/.VB2()&,49[@#QT3Y0R;M>+8J5L\$
MWYG*%WH-TB'6NU5T"U ^4.@HY9R&<_1S;_K?"9^)#": ]F4JEL!UC7ZK )^R
MEYE&(MJYR]C,Q@N]M&C7\!\*E=U7BUVNEG%Z[Y:'OHTLFIN>#C>2(,I3@9L=
M,)XIB$PE>)LCN$!LI)Q*39OI);69C1=Z5='NHCD4*M_/HGD8:5E3DNA+HW%3
M1A!+RL 0'X!(B7)@DG#>VI+9+R!O[WJBW05S&$P.#,A/QK&)M;)R1TL.^$H(
M/ N=B2N]@D(&H40 1QT%Y@@GVB9GJO?]J,Y$OZ'X"S[1/0P.WT&4<LLHW&L!
M?!VXO9L.0RHV+*]LF'1,4<H4RJ54ZO"((9PG!I1VZ)1Z1ZAHIFYE;R[[#?A?
M\(KJ&%#_?9;<@&;C%+,)38\KI9!&@X\Z@$S$*IJU"Z:U'I];LO;=W+5T@O!^
M%N1.<'LYMS,;RP"WZ8)_5T \Q6S0/P9ET1\0*!,P1AB(RA#+M6$Y/?N^5X^]
M[^8VIXDUV1/L7L+N^)1HKKG?3CI.*VX217&@RP,B9O1RC") 2!;$L2RR5JTM
MRITX_&YNGE[$NNP.?-_#TEQS3_&H?+3U/EK47=0$39>+!*RS#F@TE+-,>9#/
M?K12F<?OYB[L12S/+@'X/2S0-7<BC\I'9"Y-0-%H4YIIDI*C[HF P-"6^4Q%
MC,^>TEJ9Q^_FWNU%+- N ?@2%FBE6%PXEXF."F3@*):4+.J08U2N'4O.,R9]
M,_/&.CCZ>0FW>DTLQQ[@]OW= SXJFAA)]B(M]%6B[VC!.Q& &A<E84FA&]'8
M2MR2M7X]UQ=\P]$%=+Z#O>THQD6+=C>ZT>V-PI*..3 O@">205@7P$2T,SP$
M36FV5JIF!MANPU"_;N4+7CWU8-+*FO%/"\/OO$&?IX]N.,;/CR?CA6BNW*C4
MYK.!,C*%;#7(&$LKBY# "14@Z\B<,DD+TDFQU?.R^;*O""N"O/),J*X1]QTL
MRLW[^R81T8''[5S@[@Y&!P6"<@_E(]!*!9L31\M*&UN4>[#YLN\(VUV472.N
ME459)Y0]14D,Q[-A6$X#SD99)D+I/%UFGF:GP/.<(6#8[4.F)JC6(K2-S+SL
MR[Z.%UCOZ&EE&=6Q-'<%00>!1R>BQDA5!H?B8*76"'^2T246A:(B=U*4W DW
M+_M:[D7L5(?@I^%^1Q>__7QQ\F^_G;R]//D=_[@XH)?1ID?5ZE.T%:F5>A!=
M7/E9^L<5TGKR^<Y9@G.1LQ@UZ*!MT7V9QZ<YL$QE",90EJIOOQMH.=BXWGWN
M<E" I)X+QG&#,.4*.6>+J\TPI"IY[A+5L7YYR!HZ>HZ':VC_@2TZ5-PM[,?W
M>,!_MIB!9- *2&\RH.E#7AP*QP7!P:%OD:,)P=;O%[B>E*: LX>.GP#-/@)O
M$S>O)B74&WB9LB<N@J9*XC8J,*XC5H%R(2N73:#U!R-N(J8M[.REZJ?ALX?<
MVP/0:HA2-DPRIB5X4;K%*.;!&(8K2QOK//-9U;]E64=(<\#91\F/0V</B3<"
MFV$<NNG7"[<8HU0ZM2Q6E<H8\484#>&!EI:_$7=R:X&:9*@BQ'A3O37))F)Z
M/F?L8L\Z7.@MH.>&_+?N(_YXB7'C#/U U,QJA5EK _<6PSY95AAW%##\TVBA
ML\'%%X*RU8MDGJ2J?W-40?WW0557%SVBJP3."W9F1^^G:7$*L3*N.IFH-$U
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MMJ-'VWY);-1O#X?//[G8X?/V:?<PL1V/1$ #>-N2%R\:_<8#2H][Y3V+M@]
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M>;O>?C;O^MVO#M._ %!+ 0(4 Q0    ( +Q#JU85!\&JZ^<  " B"  1
M          "  0    !F;&MS+3(P,C,P,S,Q+FAT;5!+ 0(4 Q0    ( +Q#
MJU9_,8%ZVP@  $E+   1              "  1KH  !F;&MS+3(P,C,P,S,Q
M+GAS9%!+ 0(4 Q0    ( +Q#JU80(2HQG P  #1E   5              "
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#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
